[0]: *** ERROR *** ERROR *** ERROR ***
[1]: *** ERROR *** ERROR *** ERROR ***
[2]: *** ERROR *** ERROR *** ERROR ***
[3]: *** ERROR *** ERROR *** ERROR ***
[4]: *** ERROR *** ERROR *** ERROR ***
[5]: *** ERROR *** ERROR *** ERROR ***
[6]: *** ERROR *** ERROR *** ERROR ***
[7]: *** ERROR *** ERROR *** ERROR ***
[8]: *** ERROR *** ERROR *** ERROR ***
[9]: *** ERROR *** ERROR *** ERROR ***
[10]: *** ERROR *** ERROR *** ERROR ***
[11]: *** ERROR *** ERROR *** ERROR ***
[12]: *** ERROR *** ERROR *** ERROR ***
[13]: *** ERROR *** ERROR *** ERROR ***
[14]: *** ERROR *** ERROR *** ERROR ***
[15]: *** ERROR *** ERROR *** ERROR ***
[16]: *** ERROR *** ERROR *** ERROR ***
[17]: *** ERROR *** ERROR *** ERROR ***
[18]: *** ERROR *** ERROR *** ERROR ***
[19]: *** ERROR *** ERROR *** ERROR ***
[20]: *** ERROR *** ERROR *** ERROR ***
[21]: *** ERROR *** ERROR *** ERROR ***
[22]: *** ERROR *** ERROR *** ERROR ***
[23]: *** ERROR *** ERROR *** ERROR ***
[24]: *** ERROR *** ERROR *** ERROR ***
[25]: *** ERROR *** ERROR *** ERROR ***
[26]: *** ERROR *** ERROR *** ERROR ***
[27]: *** ERROR *** ERROR *** ERROR ***
[28]: *** ERROR *** ERROR *** ERROR ***
[29]: *** ERROR *** ERROR *** ERROR ***
[30]: *** ERROR *** ERROR *** ERROR ***
[31]: *** ERROR *** ERROR *** ERROR ***
[32]: *** ERROR *** ERROR *** ERROR ***
[33]: *** ERROR *** ERROR *** ERROR ***
[34]: *** ERROR *** ERROR *** ERROR ***
[35]: *** ERROR *** ERROR *** ERROR ***
[36]: *** ERROR *** ERROR *** ERROR ***
[37]: *** ERROR *** ERROR *** ERROR ***
[38]: *** ERROR *** ERROR *** ERROR ***
[39]: *** ERROR *** ERROR *** ERROR ***
[40]: *** ERROR *** ERROR *** ERROR ***
[41]: *** ERROR *** ERROR *** ERROR ***
[42]: *** ERROR *** ERROR *** ERROR ***
[43]: *** ERROR *** ERROR *** ERROR ***
[44]: *** ERROR *** ERROR *** ERROR ***
[45]: *** ERROR *** ERROR *** ERROR ***
[46]: *** ERROR *** ERROR *** ERROR ***
[47]: *** ERROR *** ERROR *** ERROR ***
[48]: *** ERROR *** ERROR *** ERROR ***
[49]: *** ERROR *** ERROR *** ERROR ***
[50]: *** ERROR *** ERROR *** ERROR ***
[51]: *** ERROR *** ERROR *** ERROR ***
[52]: *** ERROR *** ERROR *** ERROR ***
[53]: *** ERROR *** ERROR *** ERROR ***
[54]: *** ERROR *** ERROR *** ERROR ***
[55]: *** ERROR *** ERROR *** ERROR ***
[56]: *** ERROR *** ERROR *** ERROR ***
[57]: *** ERROR *** ERROR *** ERROR ***
[58]: *** ERROR *** ERROR *** ERROR ***
[59]: *** ERROR *** ERROR *** ERROR ***
[60]: *** ERROR *** ERROR *** ERROR ***
[61]: *** ERROR *** ERROR *** ERROR ***
[62]: *** ERROR *** ERROR *** ERROR ***
[63]: *** ERROR *** ERROR *** ERROR ***
[64]: *** ERROR *** ERROR *** ERROR ***
[65]: *** ERROR *** ERROR *** ERROR ***
[66]: *** ERROR *** ERROR *** ERROR ***
SE|68||ti|1|text|15|92|Behavior of soluble and immobilized acid phosphatase in hydro-organic media.
SE|68||ti|1|entity|C0004927|Behavior|inbe|||Behavior|||0|1000|15|23
SE|68||ti|1|entity|C0001109|Acid Phosphatase|aapp,enzy|||acid phosphatase|||0|901|51|67
SE|68||ti|1|entity|C0747055|ORGANIC|qlco|||organic|||0|660|77|84

SE|68||ab|1|text|98|321|The hydrolysis of p-nitrophenyl phosphate by wheat germ acid phosphatase (orthophosphoric monoester phosphohydrolase, EC 3.1.3.2) has been investigated in mixtures of aqueous buffers with acetone, dioxane and acetonitrile.
SE|68||ab|1|entity|C0020291|Hydrolysis|npop|||hydrolysis|||0|1000|102|112
SE|68||ab|1|entity|C0134796|4-nitrophenylphosphate|opco|||p-nitrophenyl phosphate|||0|1000|116|139
SE|68||ab|1|entity|C0452688|Wheatgerm|food|||wheat germ|||0|901|143|153
SE|68||ab|1|entity|C0001109|Acid Phosphatase|aapp,enzy|||acid phosphatase|||0|901|154|170
SE|68||ab|1|entity|C0031678|Phosphoric Monoester Hydrolases|aapp,enzy|||phosphohydrolase|||0|793|198|214
SE|68||ab|1|entity|C0040676|Transferase|aapp,enzy|||EC 3.1.3.2|||0|897|216|226
SE|68||ab|1|entity|C0439962|Mixture|sbst|||mixtures|||0|966|253|261
SE|68||ab|1|entity|C0599956|Aqueous|qlco|||aqueous|||0|888|265|272
SE|68||ab|1|entity|C0006353|Buffers|bacs,irda|||buffers|||0|888|273|280
SE|68||ab|1|entity|C0001002|Acetone|orch,phsu|||acetone|||0|1000|286|293
SE|68||ab|1|entity|C0012501|Dioxanes|hops,orch|||dioxane|||0|1000|295|302
SE|68||ab|1|entity|C0050456|acetonitrile|orch|||acetonitrile|||0|1000|307|319
SE|68||ab|1|relation|0|0|C0001109|Acid Phosphatase|aapp,gngm,enzy|aapp|||acid phosphatase|||0|901|154|170|SPEC|ISA||154|214|0|0|C0031678|Phosphoric Monoester Hydrolases|aapp,gngm,enzy|aapp|||phosphohydrolase|||0|793|198|214

SE|68||ab|2|text|321|468|The enzyme was either in free solution or immobilized on a pellicular support which consisted of a porous carbonaceous layer on solid glass beads.
SE|68||ab|2|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|325|331
SE|68||ab|2|entity|C0037633|Solutions|sbst|||solution|||0|861|351|359
SE|68||ab|2|entity|C0080037|Porosity|qlco|||porous|||0|589|420|426
SE|68||ab|2|entity|C0205208|Solid|qlco|||solid|||0|851|449|454
SE|68||ab|2|entity|C0017596|Glass|mnob|||glass|||0|851|455|460
SE|68||ab|2|entity|C0991566|Beads|bodm|||beads|||0|851|461|466

SE|68||ab|3|text|468|615|The highest enzyme activity was obtained in acetone and acetonitrile mixed with citrate buffer over a wide range of organic solvent concentration.
SE|68||ab|3|entity|C1522410|Highest|qlco|||highest|||0|901|472|479
SE|68||ab|3|entity|C0243102|enzyme activity|moft|||enzyme activity|||0|901|480|495
SE|68||ab|3|entity|C0001002|Acetone|orch,phsu|||acetone|||0|1000|512|519
SE|68||ab|3|entity|C0050456|acetonitrile|orch|||acetonitrile|||0|1000|524|536
SE|68||ab|3|entity|C0008857|Citrates|orch|||citrate|||0|888|548|555
SE|68||ab|3|entity|C0006353|Buffers|bacs,irda|||buffer|||0|888|556|562
SE|68||ab|3|entity|C0205136|Over|spco|||over|||0|1000|563|567
SE|68||ab|3|entity|C0332464|Widening|spco|||wide|||0|888|570|574
SE|68||ab|3|entity|C1514721|Range|qnco|||range|||0|888|575|580
SE|68||ab|3|entity|C0747055|ORGANIC|qlco|||organic|||0|623|584|591
SE|68||ab|3|entity|C0037638|Solvents|irda|||solvent|||0|623|592|599

SE|68||ab|4|text|615|784|In 50% (v/v) acetone both V and Km of the immobilized enzyme were about half of the values in the neat aqueous buffer, but the Ki for inorganic phosphate was unchanged.
SE|68||ab|4|entity|C0001002|Acetone|orch,phsu|||acetone|||0|827|628|635
SE|68||ab|4|entity|C0014444|Enzymes, Immobilized|aapp,enzy,irda|||immobilized enzyme|||0|1000|657|675
SE|68||ab|4|entity|C0042295|Values|qlco|||values|||0|1000|699|705
SE|68||ab|4|entity|C0599956|Aqueous|qlco|||aqueous|||0|790|718|725
SE|68||ab|4|entity|C0006353|Buffers|bacs,irda|||buffer|||0|790|726|732
SE|68||ab|4|entity|C0031603|inorganic phosphate|inch|||inorganic phosphate|||0|1000|749|768
SE|68||ab|4|relation|5|2|C0014444|Enzymes, Immobilized|aapp,gngm,enzy,irda|aapp|||immobilized enzyme|||0|1000|657|675|PREP|COEXISTS_WITH||706|708|4|1|C0006353|Buffers|bacs,irda|bacs|||buffer|||0|790|726|732

SE|68||ab|5|text|784|1040|In 50% (v/v) mixtures of various solvents and citrate buffers of different pH, the enzymic activity was found to depend on the pH of the aqueous buffer component rather than the pH of the hydro-organic mixture as measured with the glass-calomel electrode.
SE|68||ab|5|entity|C0439962|Mixture|sbst|||mixtures|||0|793|797|805
SE|68||ab|5|entity|C0037638|Solvents|irda|||solvents|||0|861|817|825
SE|68||ab|5|entity|C0008857|Citrates|orch|||citrate|||0|1000|830|837
SE|68||ab|5|entity|C1547020|*Difference|qnco|||different|||0|853|849|858
SE|68||ab|5|entity|C0599956|Aqueous|qlco|||aqueous|||0|851|921|928
SE|68||ab|5|entity|C0006353|Buffers|bacs,irda|||buffer|||0|851|929|935
SE|68||ab|5|entity|C1524073|Component, LOINC Axis 1|clas|||component|||0|851|936|945
SE|68||ab|5|entity|C0747055|ORGANIC|qlco|||organic|||0|790|978|985
SE|68||ab|5|entity|C0439962|Mixture|sbst|||mixture|||0|790|986|993
SE|68||ab|5|entity|C0017596|Glass|mnob|||glass|||0|851|1015|1020
SE|68||ab|5|entity|C0025423|calomel|inch,phsu|||calomel|||0|851|1021|1028
SE|68||ab|5|entity|C0013812|electrode|mnob|||electrode|||0|851|1029|1038

SE|68||ab|6|text|1040|1236|The relatively high rates of p-nitrophenol liberation in the presence of glucose even at high organic solvent concentrations suggest that transphosphorylation is facilitated at low water activity.
SE|68||ab|6|entity|C0205250|High|qlco|||high|||0|773|1055|1059
SE|68||ab|6|entity|C1521828|Rate|qnco|||rates|||0|773|1060|1065
SE|68||ab|6|entity|C0048581|4-nitrophenol|hops,irda,orch|||p-nitrophenol|||0|734|1069|1082
SE|68||ab|6|entity|C0017725|Glucose|bacs,carb,phsu|||glucose|||0|861|1113|1120
SE|68||ab|6|entity|C0205250|High|qlco|||high|||0|833|1129|1133
SE|68||ab|6|entity|C0747055|ORGANIC|qlco|||organic|||0|833|1134|1141
SE|68||ab|6|entity|C0037638|Solvents|irda|||solvent|||0|833|1142|1149
SE|68||ab|6|entity|C0205251|low|qlco|||low|||0|851|1217|1220
SE|68||ab|6|entity|C0020311|Hydrotherapy|topp|||water|||0|851|1221|1226


SE|69||ti|1|text|15|128|Purification and some enzymatic properties of the chitosanase from Bacillus R-4 which lyses Rhizopus cell walls.
SE|69||ti|1|entity|C0243114|purification|lbpr,resa|||Purification|||0|1000|15|27
SE|69||ti|1|entity|C0014442|Enzymes|enzy,orch|||enzymatic|||0|836|37|46
SE|69||ti|1|entity|C0871161|Property|qlco|||properties|||0|836|47|57
SE|69||ti|1|entity|C0055320|chitosanase|aapp,enzy|||chitosanase|||0|1000|65|76
SE|69||ti|1|entity|C0035477|Rhizopus|fngs|||Rhizopus|||0|901|107|115
SE|69||ti|1|entity|C0007623|Cell Wall|celc|||cell walls|||0|901|116|126
SE|69||ti|1|relation|0|0|C0007623|Cell Wall|celc|celc|||cell walls|||0|901|116|126|MOD/HEAD|PART_OF||107|126|0|0|C0035477|Rhizopus|fngs|fngs|||Rhizopus|||0|901|107|115

SE|69||ab|1|text|134|274|A strain of Bacillus sp (Bacillus R-4) produces a protease and a carbohydrolase both of which have the ability to lyse Rhizopus cell walls.
SE|69||ab|1|entity|C0456178|Microbiology subtype strains|inpr|||strain|||0|861|136|142
SE|69||ab|1|entity|C1493473|Bacillus sp. R|bact|||sp (Bacillus R|||0|888|155|169
SE|69||ab|1|entity|C0030946|Endopeptidases|aapp,enzy,phsu|||protease|||0|1000|184|192
SE|69||ab|1|entity|C0085732|Ability|orga|||ability|||0|1000|237|244
SE|69||ab|1|entity|C0035477|Rhizopus|fngs|||Rhizopus|||0|901|253|261
SE|69||ab|1|entity|C0007623|Cell Wall|celc|||cell walls|||0|901|262|272
SE|69||ab|1|relation|0|0|C0007623|Cell Wall|celc|celc|||cell walls|||0|901|262|272|MOD/HEAD|PART_OF||253|272|0|0|C0035477|Rhizopus|fngs|fngs|||Rhizopus|||0|901|253|261

SE|69||ab|2|text|274|428|Of the enzymes, the carbohydrolase has been purified to an ultracentrifugally and electrophoretically homogeneous state, and identified as a chitosanase.
SE|69||ab|2|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|1000|281|288
SE|69||ab|2|entity|C1442792|State|ftcn|||state|||0|827|388|393
SE|69||ab|2|entity|C0055320|chitosanase|aapp,enzy|||chitosanase|||0|1000|415|426

SE|69||ab|3|text|428|490|The enzyme was active on glycol chitosan as well as chitosan.
SE|69||ab|3|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|432|438
SE|69||ab|3|entity|C0205177|Active|ftcn|||active|||0|1000|443|449
SE|69||ab|3|entity|C0766265|glycol-chitosan|carb|||glycol chitosan|||0|1000|453|468
SE|69||ab|3|entity|C0162969|Chitosan|carb,phsu|||chitosan|||0|1000|480|488

SE|69||ab|4|text|490|588|Molecular weight of the purified enzyme was estimated as 31 000 and isoelectric point as pH 8.30.
SE|69||ab|4|entity|C0026385|Molecular Weight|qnco|||Molecular weight|||0|1000|490|506
SE|69||ab|4|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|861|523|529
SE|69||ab|4|entity|C0022171|Isoelectric Point|qnco|||isoelectric point|||0|1000|558|575

SE|69||ab|5|text|588|779|The enzyme was most active at pH 5.6 and at 40 degrees C with either Rhizopus cell wall or glycol chitosan as substrate, and was stable over a range of pH 4.5 to 7.5 at 40 degrees C for 3 h.
SE|69||ab|5|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|592|598
SE|69||ab|5|entity|C0205393|Most|qnco|||most|||0|888|603|607
SE|69||ab|5|entity|C0205177|Active|ftcn|||active|||0|888|608|614
SE|69||ab|5|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|635|644
SE|69||ab|5|entity|C0035477|Rhizopus|fngs|||Rhizopus|||0|824|657|665
SE|69||ab|5|entity|C0007623|Cell Wall|celc|||cell wall|||0|824|666|675
SE|69||ab|5|entity|C0766265|glycol-chitosan|carb|||glycol chitosan|||0|1000|679|694
SE|69||ab|5|entity|C1514721|Range|qnco|||range|||0|1000|731|736
SE|69||ab|5|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|760|769
SE|69||ab|5|relation|0|0|C0007623|Cell Wall|celc|celc|||cell wall|||0|824|666|675|MOD/HEAD|PART_OF||657|675|0|0|C0035477|Rhizopus|fngs|fngs|||Rhizopus|||0|824|657|665

SE|69||ab|6|text|779|882|The activity was lost by sulfhydryl reagents and restored by either reduced glutathione of L-cysteine.
SE|69||ab|6|entity|C0038738|Sulfhydryl Reagents|irda,phsu|||sulfhydryl reagents|||0|1000|804|823
SE|69||ab|6|entity|C0034917|Reduced Glutathione|aapp,phsu|||reduced glutathione|||0|901|847|866
SE|69||ab|6|entity|C0010654|Cysteine|aapp,bacs|||L-cysteine|||0|1000|870|880

SE|69||ab|7|text|882|996|An abrupt decrease in viscosity of the reaction mixture suggested an endowise cleavage of chitosan by this enzyme.
SE|69||ab|7|entity|C0547047|Decrease|qnco|||decrease|||0|861|892|900
SE|69||ab|7|entity|C0042784|Viscosity|npop|||viscosity|||0|1000|904|913
SE|69||ab|7|entity|C0443286|Reaction|ftcn|||reaction|||0|888|921|929
SE|69||ab|7|entity|C0439962|Mixture|sbst|||mixture|||0|888|930|937
SE|69||ab|7|entity|C1330957|Cytokinesis of the fertilized ovum|celf|||cleavage|||0|861|960|968
SE|69||ab|7|entity|C0162969|Chitosan|carb,phsu|||chitosan|||0|1000|972|980
SE|69||ab|7|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|989|995


SE|70||ti|1|text|15|119|Specificity studies on alpha-mannosidases using oligosaccharides from mannosidosis urine as substrates.
SE|70||ti|1|entity|C0037791|Specificity|qnco|||Specificity|||0|1000|15|26
SE|70||ti|1|entity|C0051350|Alpha-mannosidase|aapp,enzy|||alpha-mannosidases|||0|983|38|56
SE|70||ti|1|entity|C0028959|Oligosaccharides|carb|||oligosaccharides|||0|1000|63|79
SE|70||ti|1|entity|C1257960|Mannosidase Deficiency Diseases|dsyn|||mannosidosis|||0|888|85|97
SE|70||ti|1|entity|C0042036|Urine|bdsu|||urine|||0|888|98|103

SE|70||ab|1|text|125|436|Oligosaccharides containing terminal non-reducing alpha(1 leads to 2)-, alpha(1 leads to 3)-, and alpha(1 leads to 6)-linked mannose residues, isolated from human and bovine mannosidosis urines were used as substrates to test the specificities of acidic alpha-mannosidases isolated from human and bovine liver.
SE|70||ab|1|entity|C0028959|Oligosaccharides|carb|||Oligosaccharides|||0|1000|125|141
SE|70||ab|1|entity|C0392756|Reduced|qlco|||reducing|||0|764|166|174
SE|70||ab|1|entity|C0439095|Alpha|inpr|||alpha|||0|764|175|180
SE|70||ab|1|entity|C0439095|Alpha|inpr|||alpha|||0|1000|197|202
SE|70||ab|1|entity|C0439095|Alpha|inpr|||alpha|||0|1000|223|228
SE|70||ab|1|entity|C0024742|Mannose|bacs,carb|||mannose|||0|748|250|257
SE|70||ab|1|entity|C0020114|Human|humn|||human|||0|1000|282|287
SE|70||ab|1|entity|C0007452|Cattle|mamm|||bovine|||0|840|292|298
SE|70||ab|1|entity|C1257960|Mannosidase Deficiency Diseases|dsyn|||mannosidosis|||0|840|299|311
SE|70||ab|1|entity|C0042036|Urine|bdsu|||urines|||0|840|312|318
SE|70||ab|1|entity|C0037791|Specificity|qnco|||specificities|||0|966|355|368
SE|70||ab|1|entity|C0001128|Acids|chem|||acidic|||0|866|372|378
SE|70||ab|1|entity|C0051350|Alpha-mannosidase|aapp,enzy|||alpha-mannosidases|||0|866|379|397
SE|70||ab|1|entity|C0020114|Human|humn|||human|||0|1000|412|417
SE|70||ab|1|entity|C0007452|Cattle|mamm|||bovine|||0|888|422|428
SE|70||ab|1|entity|C0023884|Liver|bpoc|||liver|||0|888|429|434
SE|70||ab|1|relation|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|888|429|434|MOD/HEAD|PART_OF||422|434|0|0|C0007452|Cattle|mamm|mamm|||bovine|||0|888|422|428

SE|70||ab|2|text|436|572|The enzymes released all the alpha-linked mannose residues from each oligosaccharide and were most effective on the smallest substrate.
SE|70||ab|2|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|1000|440|447
SE|70||ab|2|entity|C0439095|Alpha|inpr|||alpha|||0|747|465|470
SE|70||ab|2|entity|C0024742|Mannose|bacs,carb|||mannose|||0|747|478|485
SE|70||ab|2|entity|C0028959|Oligosaccharides|carb|||oligosaccharide|||0|1000|505|520
SE|70||ab|2|entity|C0205393|Most|qnco|||most|||0|888|530|534
SE|70||ab|2|entity|C0547044|Smaller|qlco|||smallest|||0|661|552|560

SE|70||ab|3|text|572|745|Enzyme A in each case was less active on the oligosaccharides than alpha-mannosidase B2, even though the apparent Km value for the substrates was the same with each enzyme.
SE|70||ab|3|entity|C0014442|Enzymes|enzy,orch|||Enzyme|||0|1000|572|578
SE|70||ab|3|entity|C0205177|Active|ftcn|||active|||0|861|603|609
SE|70||ab|3|entity|C0028959|Oligosaccharides|carb|||oligosaccharides|||0|1000|617|633
SE|70||ab|3|entity|C0051350|Alpha-mannosidase|aapp,enzy|||alpha-mannosidase|||0|901|639|656
SE|70||ab|3|entity|C0750489|APPARENT|idcn|||apparent|||0|623|677|685
SE|70||ab|3|entity|C0445247|Same|qlco|||same|||0|1000|722|726
SE|70||ab|3|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|737|743

SE|70||ab|4|text|745|888|The human acidic alpha-mannosidases were also found to be more active on substrates isolated from human rather than bovine mannosidosis urine.
SE|70||ab|4|entity|C0020114|Human|humn|||human|||0|834|749|754
SE|70||ab|4|entity|C0001128|Acids|chem|||acidic|||0|834|755|761
SE|70||ab|4|entity|C0051350|Alpha-mannosidase|aapp,enzy|||alpha-mannosidases|||0|834|762|780
SE|70||ab|4|entity|C0205172|More|ftcn|||more|||0|888|803|807
SE|70||ab|4|entity|C0205177|Active|ftcn|||active|||0|888|808|814
SE|70||ab|4|entity|C0020114|Human|humn|||human|||0|1000|843|848
SE|70||ab|4|entity|C0007452|Cattle|mamm|||bovine|||0|851|861|867
SE|70||ab|4|entity|C1257960|Mannosidase Deficiency Diseases|dsyn|||mannosidosis|||0|851|868|880
SE|70||ab|4|entity|C0042036|Urine|bdsu|||urine|||0|851|881|886

SE|70||ab|5|text|888|1091|Human alpha-mannosidase C, which has a neutral pH optimum when assayed with a synthetic substrate, did not hydrolyse any of the oligosaccharides at neutral pH, but was found to be active at an acidic pH.
SE|70||ab|5|entity|C0020114|Human|humn|||Human|||0|852|888|893
SE|70||ab|5|entity|C0051350|Alpha-mannosidase|aapp,enzy|||alpha-mannosidase|||0|852|894|911
SE|70||ab|5|entity|C1518422|Not|ftcn|||not|||0|1000|991|994
SE|70||ab|5|entity|C0028959|Oligosaccharides|carb|||oligosaccharides|||0|1000|1016|1032
SE|70||ab|5|entity|C0205177|Active|ftcn|||active|||0|1000|1068|1074
SE|70||ab|5|entity|C0001128|Acids|chem|||acidic|||0|853|1081|1087


SE|71||ti|1|text|15|120|Calcium-stimulated adenosine triphosphatase in the microsomal fraction of tooth germ from porcine fetus.
SE|71||ti|1|entity|C0001476|Ca(2+)-Transporting ATPase|aapp,enzy|||Calcium-stimulated adenosine triphosphatase|||0|923|15|58
SE|71||ti|1|entity|C0026029|Microsomes|celc|||microsomal|||0|623|66|76
SE|71||ti|1|entity|C0040442|Tooth Germ|tisu|||tooth germ|||0|1000|89|99
SE|71||ti|1|entity|C0039005|Family suidae|mamm|||porcine|||0|888|105|112
SE|71||ti|1|entity|C0015965|Fetus|emst|||fetus|||0|888|113|118
SE|71||ti|1|relation|0|0|C0015965|Fetus|emst|emst|||fetus|||0|888|113|118|MOD/HEAD|PART_OF||105|118|0|0|C0039005|Family suidae|mamm|mamm|||porcine|||0|888|105|112

SE|71||ab|1|text|126|271|The characterization and localization of a Ca(2+)-ATPase (ATP phosphohydrolase, EC 3.6.1.3) in the tooth germ of the porcine fetus are reported.
SE|71||ab|1|entity|C0475264|localization|ftcn|||localization|||0|1000|151|163
SE|71||ab|1|entity|C0001473|ATP phosphohydrolase|aapp,enzy|1769|DNAH8|ATPase|||0|1000|176|182
SE|71||ab|1|entity|C0001473|ATP phosphohydrolase|aapp,enzy|51761|ATP8A2|ATP phosphohydrolase|||0|1000|184|204
SE|71||ab|1|entity|C0040442|Tooth Germ|tisu|||tooth germ|||0|1000|225|235
SE|71||ab|1|entity|C0039005|Family suidae|mamm|||porcine|||0|888|243|250
SE|71||ab|1|entity|C0015965|Fetus|emst|||fetus|||0|888|251|256
SE|71||ab|1|relation|0|0|C0015965|Fetus|emst|emst|||fetus|||0|888|251|256|MOD/HEAD|PART_OF||243|256|0|0|C0039005|Family suidae|mamm|mamm|||porcine|||0|888|243|250
SE|71||ab|1|relation|2|1|C0040442|Tooth Germ|tisu|tisu|||tooth germ|||0|1000|225|235|PREP|LOCATION_OF||218|220|5|2|C0001473|ATP phosphohydrolase|aapp,gngm,enzy|aapp|1769|DNAH8|ATPase|||0|1000|176|182

SE|71||ab|2|text|271|345|This enzyme, a microsome fraction, is preferentially activated by Ca(2+).
SE|71||ab|2|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|276|282
SE|71||ab|2|entity|C0026029|Microsomes|celc|||microsome|||0|694|286|295

SE|71||ab|3|text|345|434|In the presence of 0.5 mM ATP, maximal enzyme activity is obtained at 0.5--1.0 mM CaCl2.
SE|71||ab|3|entity|C0444499|0/5|qnco|||0.5|||0|861|364|367
SE|71||ab|3|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|ATP|||0|861|371|374
SE|71||ab|3|entity|C0205289|Maximal|qlco|||maximal|||0|901|376|383
SE|71||ab|3|entity|C0243102|enzyme activity|moft|||enzyme activity|||0|901|384|399
SE|71||ab|3|entity|C0444499|0/5|qnco|||0.5|||0|1000|415|418

SE|71||ab|4|text|434|480|The maximal rate of ATP hydrolysis is approx.
SE|71||ab|4|entity|C0205289|Maximal|qlco|||maximal|||0|888|438|445
SE|71||ab|4|entity|C1521828|Rate|qnco|||rate|||0|888|446|450
SE|71||ab|4|entity|C1510699|ATP Hydrolysis|moft|||ATP hydrolysis|||0|1000|454|468

SE|71||ab|5|text|480|553|20 mumol per h per mg of protein as the enzyme preparation is used here.
SE|71||ab|5|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|505|512
SE|71||ab|5|entity|C0360722|Enzyme agent|aapp,enzy,phsu|||enzyme preparation|||0|1000|520|538

SE|71||ab|6|text|553|623|At optimal Ca(2+) concentration, the Mg(2+) has an inhibitory effect.
SE|71||ab|6|entity|C0243077|inhibitors|chvf|||inhibitory|||0|853|604|614
SE|71||ab|6|entity|C1280500|Effect|qlco|||effect|||0|853|615|621

SE|71||ab|7|text|623|691|The enzyme does not require Na+ or/and K+ for activation by Ca(2+).
SE|71||ab|7|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|627|633
SE|71||ab|7|entity|C1518422|Not|ftcn|||not|||0|1000|639|642

SE|71||ab|8|text|691|780|Other nucleotide triphosphates may serve as the substrate, but V for ATP is the highest.
SE|71||ab|8|entity|C0028630|Nucleotides|nnon|||nucleotide|||0|872|697|707
SE|71||ab|8|entity|C0146894|triphosphate|inch|||triphosphates|||0|872|708|721
SE|71||ab|8|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|ATP|||0|1000|760|763
SE|71||ab|8|entity|C1522410|Highest|qlco|||highest|||0|1000|771|778

SE|71||ab|9|text|780|815|The Km for ATP is 8.85 - 10(-5) M.
SE|71||ab|9|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|ATP|||0|1000|791|794

SE|71||ab|10|text|815|883|The optimal pH for Ca(2+) activation of the enzyme lies around 9.2.
SE|71||ab|10|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|859|865

SE|71||ab|11|text|883|1010|Well known inhibitors of (Na+ + K+)-ATPase, mitochondria ATPase and Ca(2+)-ATPase in the erthrocyte do not inhibit the enzyme.
SE|71||ab|11|entity|C0205170|Good|qlco|||Well|||0|851|883|887
SE|71||ab|11|entity|C0205309|Known|qlco|||known|||0|851|888|893
SE|71||ab|11|entity|C0243077|inhibitors|chvf|||inhibitors|||0|851|894|904
SE|71||ab|11|entity|C0001479|Na(+)-K(+)-Exchanging ATPase|aapp,enzy|||Na+ + K+)-ATPase|||0|1000|909|925
SE|71||ab|11|entity|C0026237|Mitochondria|celc|||mitochondria|||0|888|927|939
SE|71||ab|11|entity|C0001473|ATP phosphohydrolase|aapp,enzy|1769|DNAH8|ATPase|||0|888|940|946
SE|71||ab|11|entity|C0001473|ATP phosphohydrolase|aapp,enzy|1769|DNAH8|ATPase|||0|1000|958|964
SE|71||ab|11|entity|C1518422|Not|ftcn|||not|||0|1000|986|989
SE|71||ab|11|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|1002|1008
SE|71||ab|11|relation|0|0|C0001473|ATP phosphohydrolase|aapp,gngm,enzy|aapp|1769|DNAH8|ATPase|||0|888|940|946|MOD/HEAD|PART_OF||927|946|0|0|C0026237|Mitochondria|celc|celc|||mitochondria|||0|888|927|939
SE|71||ab|11|relation|6|2|C0001473|ATP phosphohydrolase|aapp,gngm,enzy|aapp|1769|DNAH8|ATPase|||0|1000|958|964|VERB|INHIBITS|negation|990|997|1|1|C0014442|Enzymes|enzy,orch|enzy|||enzyme|||0|1000|1002|1008

SE|71||ab|12|text|1010|1291|In the subcellular order the enzyme may be assumed to be localized in the smooth endoplasmic reticulum fraction containing cell and Golgi body membrane fragments and in the tissue order in the enamel organ containing an ameloblast layer, stratum intermedium and stellate reticulum.
SE|71||ab|12|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|1039|1045
SE|71||ab|12|entity|C0230789|Smooth Endoplasmic Reticulum|celc|||smooth endoplasmic reticulum|||0|804|1084|1112
SE|71||ab|12|entity|C0332256|Containing|ftcn|||containing|||0|804|1122|1132
SE|71||ab|12|entity|C0007634|Cells|cell|||cell|||0|804|1133|1137
SE|71||ab|12|entity|C0230764|Golgi membrane|celc|||Golgi body membrane|||0|824|1142|1161
SE|71||ab|12|entity|C0486805|FRAGMENTS|bdsu|||fragments|||0|824|1162|1171
SE|71||ab|12|entity|C0014032|Enamel Organ|tisu|||enamel organ|||0|1000|1203|1215
SE|71||ab|12|entity|C0002449|Ameloblasts|cell|||ameloblast|||0|694|1230|1240
SE|71||ab|12|entity|C1514987|Stratum Intermedium|tisu|||stratum intermedium|||0|1000|1248|1267
SE|71||ab|12|entity|C1514963|Stellate Reticulum|tisu|||stellate reticulum|||0|1000|1272|1290
SE|71||ab|12|relation|7|1|C0007634|Cells|cell|cell|||cell|||0|804|1133|1137|PREP|LOCATION_OF||1077|1079|2|1|C0014442|Enzymes|enzy,orch|orch|||enzyme|||0|1000|1039|1045
SE|71||ab|12|relation|7|1|C0486805|FRAGMENTS|bdsu|bdsu|||fragments|||0|824|1162|1171|PREP|LOCATION_OF||1077|1079|2|1|C0014442|Enzymes|enzy,orch|orch|||enzyme|||0|1000|1039|1045


SE|72||ti|1|text|15|109|Preparation and characterization of an enzymatically active immobilized derivative of myosin.
SE|72||ti|1|entity|C1521827|Preparation|ftcn|||Preparation|||0|1000|15|26
SE|72||ti|1|entity|C0205177|Active|ftcn|||active|||0|763|68|74
SE|72||ti|1|entity|C1527240|Derivative|ftcn|||derivative|||0|763|87|97
SE|72||ti|1|entity|||gngm|79784|MYH14|myosin|||0|1000|101|107

SE|72||ab|1|text|115|237|Purified skeletal muscle myosin (EC 3.6.1.3) has been covalently bound to Sepharose 4B by the cyanogen bromide procedure.
SE|72||ab|1|entity|C0949660|Skeletal Muscle Myosins|aapp,enzy|||skeletal muscle myosin|||0|906|124|146
SE|72||ab|1|entity|C0036682|Sepharose 4B|bodm,carb|||Sepharose 4B|||0|1000|189|201
SE|72||ab|1|entity|C0010511|Cyanogen Bromide|inch,irda|||cyanogen bromide|||0|901|209|225
SE|72||ab|1|entity|C0184661|Procedures|hlca|||procedure|||0|901|226|235
SE|72||ab|1|relation|1|1|C0949660|Skeletal Muscle Myosins|aapp,gngm,enzy|aapp|||skeletal muscle myosin|||0|906|124|146|VERB|INTERACTS_WITH||180|185|2|1|C0036682|Sepharose 4B|bodm,carb|bodm|||Sepharose 4B|||0|1000|189|201

SE|72||ab|2|text|237|373|The resulting complex, Sepharose-Myosin, possesses adenosine triphosphatase activity and is relatively stable for long periods of time.
SE|72||ab|2|entity|C1274040|result|ftcn|||resulting|||0|872|241|250
SE|72||ab|2|entity|C0439855|Complex|qlco|||complex|||0|872|251|258
SE|72||ab|2|entity|C0036681|Sepharose|bodm,carb|||Sepharose|||0|694|260|269
SE|72||ab|2|entity|||gngm|79784|MYH14|Myosin|||0|694|270|276
SE|72||ab|2|entity|C1148926|adenosinetriphosphatase activity|moft|||adenosine triphosphatase activity|||0|1000|288|321
SE|72||ab|2|entity|C0205166|Long|qlco|||long|||0|872|351|355
SE|72||ab|2|entity|C0439531|/period|tmco|||periods|||0|872|356|363
SE|72||ab|2|entity|C0040223|Time|tmco|||time|||0|1000|367|371

SE|72||ab|3|text|373|490|Under optimal binding conditions, approximately 33% of the specific ATPase activity of the bound myosin is retained.
SE|72||ab|3|entity|C0348080|Condition|qlco|||conditions|||0|793|395|405
SE|72||ab|3|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|861|407|420
SE|72||ab|3|entity|C1148926|adenosinetriphosphatase activity|moft|||ATPase activity|||0|901|441|456
SE|72||ab|3|entity|||gngm|79784|MYH14|myosin|||0|1000|470|476

SE|72||ab|4|text|490|852|Polyacrylamide gel electrophoresis of polypeptides released from denatured Sepharose-Myosin indicates that 85% of the myosin is attached to the agarose beads through the heavy chains and the remainder through the light chains, in agreement with predictions of binding and release based upon either the lysine contents or molecular weights of themyosin subunits.
SE|72||ab|4|entity|C0013862|Electrophoresis, Polyacrylamide Gel|lbpr|||Polyacrylamide gel electrophoresis|||0|1000|490|524
SE|72||ab|4|entity|C1305923|Polypeptides|aapp|||polypeptides|||0|1000|528|540
SE|72||ab|4|entity|C0036681|Sepharose|bodm,carb|||Sepharose|||0|660|565|574
SE|72||ab|4|entity|||gngm|79784|MYH14|Myosin|||0|660|575|581
SE|72||ab|4|entity|||gngm|79784|MYH14|myosin|||0|1000|608|614
SE|72||ab|4|entity|C0036681|Sepharose|bodm,carb|||agarose|||0|1000|634|641
SE|72||ab|4|entity|C0680240|Agreement|socb|||agreement|||0|1000|720|729
SE|72||ab|4|entity|C0681842|prediction|inpr|||predictions|||0|966|735|746
SE|72||ab|4|entity|C0024337|Lysine|aapp,bacs,phsu|||lysine|||0|888|792|798
SE|72||ab|4|entity|C0456205|Contents|sbst|||contents|||0|888|799|807
SE|72||ab|4|entity|C0026385|Molecular Weight|qnco|||molecular weights|||0|1000|811|828
SE|72||ab|4|relation|2|1|C1305923|Polypeptides|aapp,gngm|gngm|||polypeptides|||0|1000|528|540|VERB|PRODUCES||541|549|13|1|||gngm,aapp|aapp|79784|MYH14|Myosin|||0|660|575|581

SE|72||ab|5|text|852|1003|The adenosine triphosphatase of the immobilized myosin has been investigated under conditions of varying pH, ionic strength, and cation concentration.
SE|72||ab|5|entity|C0001473|ATP phosphohydrolase|aapp,enzy|||adenosine triphosphatase|||0|1000|856|880
SE|72||ab|5|entity|||gngm|79784|MYH14|myosin|||0|1000|900|906
SE|72||ab|5|entity|C0348080|Condition|qlco|||conditions|||0|966|935|945
SE|72||ab|5|entity|C1548673|Varies|inpr|||varying|||0|872|949|956
SE|72||ab|5|entity|C0086486|Ionic Strength|lbtr|||ionic strength|||0|1000|961|975
SE|72||ab|5|entity|C0007447|Cations|chvs|||cation|||0|694|981|987

SE|72||ab|6|text|1003|1127|The ATPase profiles of immobilized myosin are quite similar to those for free myosin, however subtle differences are found.
SE|72||ab|6|entity|C0001473|ATP phosphohydrolase|aapp,enzy|1769|DNAH8|ATPase|||0|694|1007|1013
SE|72||ab|6|entity|||gngm|79784|MYH14|myosin|||0|1000|1038|1044
SE|72||ab|6|entity|||gngm|79784|MYH14|myosin|||0|1000|1081|1087
SE|72||ab|6|entity|C1547020|*Difference|qnco|||differences|||0|793|1104|1115

SE|72||ab|7|text|1127|1296|The Sepharose-Myosin ATPase is not as sensitive as myosin to alterations in salt concentration and the apparent KM is approximately two-fold higher than that of myosin.
SE|72||ab|7|entity|C0036681|Sepharose|bodm,carb|||Sepharose|||0|901|1131|1140
SE|72||ab|7|entity|C0027096|Myosin ATPase|aapp,enzy|79784|MYH14|Myosin ATPase|||0|901|1141|1154
SE|72||ab|7|entity|C1518422|Not|ftcn|||not|||0|1000|1158|1161
SE|72||ab|7|entity|C0332324|Sensitive|ftcn|||sensitive|||0|1000|1165|1174
SE|72||ab|7|entity|||gngm|79784|MYH14|myosin|||0|1000|1178|1184
SE|72||ab|7|entity|C1515926|Alteration|idcn|||alterations|||0|966|1188|1199
SE|72||ab|7|entity|C0036140|Salts|chvs|||salt|||0|694|1203|1207
SE|72||ab|7|entity|C0750489|APPARENT|idcn|||apparent|||0|888|1230|1238
SE|72||ab|7|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|825|1245|1258
SE|72||ab|7|entity|C0205448|Two|qnco|||two|||0|825|1259|1262
SE|72||ab|7|entity|C0332462|Fold|spco|||fold|||0|825|1263|1267
SE|72||ab|7|entity|C0205250|High|qlco|||higher|||0|825|1268|1274
SE|72||ab|7|entity|||gngm|79784|MYH14|myosin|||0|1000|1288|1294
SE|72||ab|7|entity||<<sensitivity/sensitiveness>>||||sensitive|||||1165|1174
SE|72||ab|7|relation|1|1|||gngm,aapp|aapp|79784|MYH14|myosin|||0|1000|1178|1184|ADJ|INTERACTS_WITH|negation|1165|1174|6|3|C0036140|Salts|chvs|chvs|||salt|||0|694|1203|1207
SE|72||ab|7|relation|1|1|C0027096|Myosin ATPase|aapp,gngm,enzy|aapp|79784|MYH14|Myosin ATPase|||0|901|1141|1154|ADJ|INTERACTS_WITH|negation|1165|1174|6|3|C0036140|Salts|chvs|chvs|||salt|||0|694|1203|1207
SE|72||ab|7|relation|2|2|C0027096|Myosin ATPase|aapp,gngm,enzy|aapp|79784|MYH14|Myosin ATPase|||0|901|1141|1154|PREP|compared_with||1175|1177|6|1|||gngm,aapp|gngm|79784|MYH14|myosin|||0|1000|1178|1184
SE|72||ab|7|relation|2|2|C0027096|Myosin ATPase|aapp,gngm,enzy|aapp|79784|MYH14|Myosin ATPase|||0|901|1141|1154|PREP|lower_than||1175|1177|6|1|||gngm,aapp|gngm|79784|MYH14|myosin|||0|1000|1178|1184

SE|72||ab|8|text|1296|1497|These differences are probably due to chemical modification in the region of the attachment site(s) to the agarose beads and hydration and diffusion limitations imposed by the polymeric agarose matrix.
SE|72||ab|8|entity|C1547020|*Difference|qnco|||differences|||0|966|1302|1313
SE|72||ab|8|entity|C0332148|Probable diagnosis|qlco|||probably|||0|1000|1318|1326
SE|72||ab|8|entity|C0220806|Chemicals|chem|||chemical|||0|888|1334|1342
SE|72||ab|8|entity|C1522413|Modification|ftcn|||modification|||0|888|1343|1355
SE|72||ab|8|entity|C0205147|Region|spco|||region|||0|1000|1363|1369
SE|72||ab|8|entity|C0205675|Attachment site|spco|||attachment site|||0|1000|1377|1392
SE|72||ab|8|entity|C0036681|Sepharose|bodm,carb|||agarose|||0|888|1403|1410
SE|72||ab|8|entity|C0991566|Beads|bodm|||beads|||0|888|1411|1416
SE|72||ab|8|entity|C0012222|Diffusion|npop|||diffusion|||0|872|1435|1444
SE|72||ab|8|entity|C0449295|Limitation|ftcn|||limitations|||0|872|1445|1456
SE|72||ab|8|entity|C0032521|Polymers|bodm,chvs|||polymeric|||0|828|1472|1481
SE|72||ab|8|entity|C0036681|Sepharose|bodm,carb|||agarose|||0|828|1482|1489
SE|72||ab|8|entity|C0331858|Matrix|hcro|||matrix|||0|828|1490|1496


SE|73||ti|1|text|15|121|Radioactive labeling and location of specific thiol groups in myosin from fast, slow and cardiac muscles.
SE|73||ti|1|entity|C1514697|Radioactive|qlco|||Radioactive|||0|694|15|26
SE|73||ti|1|entity|C0450429|Location|spco|||location|||0|1000|40|48
SE|73||ti|1|entity|C0038734|Sulfhydryl Compounds|orch|||thiol|||0|861|61|66
SE|73||ti|1|entity|||gngm|79784|MYH14|myosin|||0|1000|77|83
SE|73||ti|1|entity|C0456962|Fast|qlco|||fast|||0|1000|89|93
SE|73||ti|1|entity|C0439834|Slow|qlco|||slow|||0|1000|95|99
SE|73||ti|1|entity|C0027061|Myocardium|tisu|||cardiac muscles|||0|1000|104|119
SE|73||ti|1|relation|3|1|C0038734|Sulfhydryl Compounds|orch|orch|||thiol|||0|861|61|66|PREP|COEXISTS_WITH||74|76|3|1|||gngm,aapp|gngm|79784|MYH14|myosin|||0|1000|77|83

SE|73||ab|1|text|127|130|1.

SE|73||ab|2|text|130|332|Based on incorporation of radioactively labeled N-ethylmaleimide, the readily reactive thiol groups of isolated myosin (EC 3.6.1.3) from fast, slow and cardiac muscles could be classified into 3 types.
SE|73||ab|2|entity|C0243126|incorporation|ftcn|||incorporation|||0|1000|139|152
SE|73||ab|2|entity|C0181496|Labels|mnob|||labeled|||0|753|170|177
SE|73||ab|2|entity|C0015101|Ethylmaleimide|irda,orch|||ethylmaleimide|||0|753|180|194
SE|73||ab|2|entity|C0205332|Reactive|qlco|||reactive|||0|790|208|216
SE|73||ab|2|entity|C0038734|Sulfhydryl Compounds|orch|||thiol|||0|790|217|222
SE|73||ab|2|entity|C0205409|Isolated|ftcn|||isolated|||0|694|233|241
SE|73||ab|2|entity|||gngm|79784|MYH14|myosin|||0|694|242|248
SE|73||ab|2|entity|C0456962|Fast|qlco|||fast|||0|1000|267|271
SE|73||ab|2|entity|C0439834|Slow|qlco|||slow|||0|1000|273|277
SE|73||ab|2|entity|C0027061|Myocardium|tisu|||cardiac muscles|||0|1000|282|297
SE|73||ab|2|entity|C0332307|Type - attribute|qlco|||types|||0|888|325|330

SE|73||ab|3|text|332|429|All 3 myosins contain 2 thiol-1, 2 thiol-2 and a variable number of thiol-3 groups per molecule.
SE|73||ab|3|entity|C0027096|Myosin ATPase|aapp,enzy|||myosins|||0|888|338|345
SE|73||ab|3|entity|C0038734|Sulfhydryl Compounds|orch|||thiol|||0|827|356|361
SE|73||ab|3|entity|C0038734|Sulfhydryl Compounds|orch|||thiol|||0|827|367|372
SE|73||ab|3|entity|C0439828|Variable|qlco|||variable|||0|888|381|389
SE|73||ab|3|entity|C0237753|Numbers|qnco|||number|||0|888|390|396
SE|73||ab|3|entity|C0038734|Sulfhydryl Compounds|orch|||thiol|||0|802|400|405
SE|73||ab|3|entity|C0441833|Groups|inpr|||groups|||0|802|408|414
SE|73||ab|3|entity|C0567416|Molecule|sbst|||molecule|||0|1000|419|427

SE|73||ab|4|text|429|581|Both thiol-1 and thiol-2 groups which are essential for functioning of the K+-stimulated ATPase, are located in the heavy chains in all 3 myosin types.
SE|73||ab|4|entity|C0038734|Sulfhydryl Compounds|orch|||thiol|||0|861|434|439
SE|73||ab|4|entity|C0038734|Sulfhydryl Compounds|orch|||thiol|||0|802|446|451
SE|73||ab|4|entity|C0441833|Groups|inpr|||groups|||0|802|454|460
SE|73||ab|4|entity|C0205224|Essential|qlco|||essential|||0|1000|471|480
SE|73||ab|4|entity|C0031843|physiological aspects|phsf|||functioning|||0|966|485|496
SE|73||ab|4|entity|C0064194|K ATPase|aapp,enzy|||K+-stimulated ATPase|||0|913|504|524
SE|73||ab|4|entity|||gngm|79784|MYH14|myosin|||0|802|567|573
SE|73||ab|4|entity|C0332307|Type - attribute|qlco|||types|||0|802|574|579

SE|73||ab|5|text|581|584|2.

SE|73||ab|6|text|584|819|The variation in the incorporation pattern of N-ethylmaleimide over the 3 thiol group classes under steady-state conditions of Mg(2+) - ATP hydrolysis allowed different conformations of some reaction intermediates to be characterized.
SE|73||ab|6|entity|C0205419|Variant|qlco|||variation|||0|1000|588|597
SE|73||ab|6|entity|C0243126|incorporation|ftcn|||incorporation|||0|888|605|618
SE|73||ab|6|entity|C0449774|Patterns|spco|||pattern|||0|888|619|626
SE|73||ab|6|entity|C0015101|Ethylmaleimide|irda,orch|||N-ethylmaleimide|||0|1000|630|646
SE|73||ab|6|entity|C0205136|Over|spco|||over|||0|1000|647|651
SE|73||ab|6|entity|C0038734|Sulfhydryl Compounds|orch|||thiol|||0|833|658|663
SE|73||ab|6|entity|C0441833|Groups|inpr|||group|||0|833|664|669
SE|73||ab|6|entity|C0456387|Class|inpr|||classes|||0|833|670|677
SE|73||ab|6|entity|C0678587|steady state|npop|||steady-state|||0|1000|684|696
SE|73||ab|6|entity|C1510699|ATP Hydrolysis|moft|||ATP hydrolysis|||0|1000|720|734
SE|73||ab|6|entity|C1547020|*Difference|qnco|||different|||0|623|743|752
SE|73||ab|6|entity|C0443286|Reaction|ftcn|||reaction|||0|872|775|783
SE|73||ab|6|entity|C0205103|Intermediate|spco|||intermediates|||0|872|784|797

SE|73||ab|7|text|819|942|In all 3 types of myosin the hydrolytic cycle of Mg(2+) - ATP was found to be controlled by the same step at 25 degrees C.
SE|73||ab|7|entity|C0332307|Type - attribute|qlco|||types|||0|888|828|833
SE|73||ab|7|entity|||gngm|79784|MYH14|myosin|||0|1000|837|843
SE|73||ab|7|entity|C0020291|Hydrolysis|npop|||hydrolytic|||0|853|848|858
SE|73||ab|7|entity|C0750729|Course|tmco|||cycle|||0|853|859|864
SE|73||ab|7|entity|||gngm|51761|ATP8A2|ATP|||0|1000|877|880
SE|73||ab|7|entity|C0445247|Same|qlco|||same|||0|888|915|919
SE|73||ab|7|entity|C1261552|Step|ftcn|||step|||0|888|920|924
SE|73||ab|7|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|931|940

SE|73||ab|8|text|942|1039|In all three cases, this rate-limiting step is changed in the same way by lowereing temperature.
SE|73||ab|8|entity|C0205449|Three|qnco|||three|||0|888|949|954
SE|73||ab|8|entity|C0868928|Case (situation)|ftcn|||cases|||0|888|955|960
SE|73||ab|8|entity|C1521828|Rate|qnco|||rate|||0|840|967|971
SE|73||ab|8|entity|C0439801|Limited|ftcn|||limiting|||0|840|972|980
SE|73||ab|8|entity|C1261552|Step|ftcn|||step|||0|840|981|985
SE|73||ab|8|entity|C0445247|Same|qlco|||same|||0|694|1004|1008
SE|73||ab|8|entity|C0039476|Temperature|qnco|||temperature|||0|861|1026|1037

SE|73||ab|9|text|1039|1042|3.

SE|73||ab|10|text|1042|1448|Using the chemically determined molecular weights for myosin light chains, their stoichiometry was found on the basis of sodium dodecyl sulfate electrophoresis to be 1.2 : 2.1 : 0.8 for light chain-1: light chain-2:light chain-3 per molecule of fast myosin, 2.0 : 1.9 for light chain-1:light chain-2 per molecule of slow myosin and 1.9 : 1.9 for light chain-1:light chain-2 per molecule of cardiac myosin.
SE|73||ab|10|entity|C0026385|Molecular Weight|qnco|||molecular weights|||0|1000|1074|1091
SE|73||ab|10|entity|C0027108|Myosin Light Chains|aapp,bacs|||myosin light chains|||0|1000|1096|1115
SE|73||ab|10|entity|C0597526|Stoichiometry|qnco|||stoichiometry|||0|1000|1123|1136
SE|73||ab|10|entity|C1527178|Basis|ftcn|||basis|||0|1000|1154|1159
SE|73||ab|10|entity|C0037506|Sodium Dodecyl Sulfate|bodm,lipd,phsu|||sodium dodecyl sulfate|||0|916|1163|1185
SE|73||ab|10|entity|C0013855|Electrophoresis|lbpr|||electrophoresis|||0|916|1186|1201
SE|73||ab|10|entity|C0580272|1/2|inpr|||1.2|||0|1000|1208|1211
SE|73||ab|10|entity|C0567416|Molecule|sbst|||molecule|||0|1000|1275|1283
SE|73||ab|10|entity|C0456962|Fast|qlco|||fast|||0|694|1287|1291
SE|73||ab|10|entity|||gngm|79784|MYH14|myosin|||0|694|1292|1298
SE|73||ab|10|entity|C0567416|Molecule|sbst|||molecule|||0|1000|1346|1354
SE|73||ab|10|entity|C0439834|Slow|qlco|||slow|||0|694|1358|1362
SE|73||ab|10|entity|||gngm|79784|MYH14|myosin|||0|694|1363|1369
SE|73||ab|10|entity|C0567416|Molecule|sbst|||molecule|||0|1000|1420|1428
SE|73||ab|10|entity|C0949656|Cardiac Myosins|aapp,enzy|||cardiac myosin|||0|1000|1432|1446
SE|73||ab|10|relation|0|0|C0013855|Electrophoresis|lbpr|lbpr|||electrophoresis|||0|916|1186|1201|MOD/HEAD|USES||1163|1201|0|0|C0037506|Sodium Dodecyl Sulfate|bodm,lipd,phsu|phsu|||sodium dodecyl sulfate|||0|916|1163|1185

SE|73||ab|11|text|1448|1740|This qualitative difference in light subunit composition between the fast and the two types of slow myosin is not reflected in the small variations of the characteristics exhibited by the isolated myosins, but rather seems to be connected with their respective myofibrillar ATPase activities.
SE|73||ab|11|entity|C0205556|Qualitative|qlco|||qualitative|||0|888|1453|1464
SE|73||ab|11|entity|C1547020|*Difference|qnco|||difference|||0|888|1465|1475
SE|73||ab|11|entity|C0486616|Composition|clna|||composition|||0|802|1493|1504
SE|73||ab|11|entity|C0456962|Fast|qlco|||fast|||0|1000|1517|1521
SE|73||ab|11|entity|C0205448|Two|qnco|||two|||0|888|1530|1533
SE|73||ab|11|entity|C0332307|Type - attribute|qlco|||types|||0|888|1534|1539
SE|73||ab|11|entity|C0439834|Slow|qlco|||slow|||0|694|1543|1547
SE|73||ab|11|entity|||gngm|79784|MYH14|myosin|||0|694|1548|1554
SE|73||ab|11|entity|C1518422|Not|ftcn|||not|||0|1000|1558|1561
SE|73||ab|11|entity|C0700321|Small|qnco|||small|||0|872|1579|1584
SE|73||ab|11|entity|C0205419|Variant|qlco|||variations|||0|872|1585|1595
SE|73||ab|11|entity|C1521970|Characteristics|grpa|||characteristics|||0|1000|1603|1618
SE|73||ab|11|entity|C0205409|Isolated|ftcn|||isolated|||0|888|1636|1644
SE|73||ab|11|entity|C0027096|Myosin ATPase|aapp,enzy|||myosins|||0|888|1645|1652
SE|73||ab|11|entity|C1148926|adenosinetriphosphatase activity|moft|||ATPase activities|||0|844|1722|1739


SE|74||ti|1|text|15|44|Yeast glutathione reductase.
SE|74||ti|1|entity|C0036025|Saccharomyces cerevisiae|fngs|||Yeast|||0|901|15|20
SE|74||ti|1|entity|C0017824|Glutathione Reductase|aapp,enzy|||glutathione reductase|||0|901|21|42
SE|74||ti|1|relation|0|0|C0017824|Glutathione Reductase|aapp,gngm,enzy|aapp|||glutathione reductase|||0|901|21|42|MOD/HEAD|PART_OF||15|42|0|0|C0036025|Saccharomyces cerevisiae|fngs|fngs|||Yeast|||0|901|15|20

SE|74||ti|2|text|44|140|Studies of the kinetics and stability of the enzyme as a function of pH and salt concentration.
SE|74||ti|2|entity|C0008972|Clinical Research|resa|||Studies|||0|966|44|51
SE|74||ti|2|entity|C0022702|Kinetics|idcn|||kinetics|||0|1000|59|67
SE|74||ti|2|entity|C1317741|STABILITY|qlco|||stability|||0|1000|72|81
SE|74||ti|2|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|89|95
SE|74||ti|2|entity|C0031843|physiological aspects|phsf|||function|||0|1000|101|109
SE|74||ti|2|entity|C0036140|Salts|chvs|||salt|||0|694|120|124

SE|74||ab|1|text|146|149|1.

SE|74||ab|2|text|149|394|The pH dependencies of the apparent Michaelis constant for oxidized glutathione and the apparent turnover number of yeast glutathione reductase (EC 1.6.4.2) have been determined at a fixed concentration of 0.1 mM NADPH in the range pH 4.5--8.0.
SE|74||ab|2|entity|C0750489|APPARENT|idcn|||apparent|||0|802|176|184
SE|74||ab|2|entity|C1547014|*Constant|qnco|||constant|||0|802|195|203
SE|74||ab|2|entity|C0061516|Glutathione Disulfide|aapp,bacs,phsu|||oxidized glutathione|||0|1000|208|228
SE|74||ab|2|entity|C0750489|APPARENT|idcn|||apparent|||0|802|237|245
SE|74||ab|2|entity|C0237753|Numbers|qnco|||number|||0|802|255|261
SE|74||ab|2|entity|C0036025|Saccharomyces cerevisiae|fngs|||yeast|||0|901|265|270
SE|74||ab|2|entity|C0017824|Glutathione Reductase|aapp,enzy|||glutathione reductase|||0|901|271|292
SE|74||ab|2|entity|C0040676|Transferase|aapp,enzy|||EC 1.6.4.2|||0|897|294|304
SE|74||ab|2|entity|C0443218|Fixed|qlco|||fixed|||0|694|332|337
SE|74||ab|2|entity|C0027303|NADP|bacs,nnon|||NADPH|||0|750|362|367
SE|74||ab|2|entity|C1514721|Range|qnco|||range|||0|750|375|380
SE|74||ab|2|relation|0|0|C0017824|Glutathione Reductase|aapp,gngm,enzy|aapp|||glutathione reductase|||0|901|271|292|MOD/HEAD|PART_OF||265|292|0|0|C0036025|Saccharomyces cerevisiae|fngs|fngs|||yeast|||0|901|265|270

SE|74||ab|3|text|394|468|Between pH 5.5 and 7.6, both of these parameters are relatively constant.
SE|74||ab|3|entity|C1547014|*Constant|qnco|||constant|||0|861|458|466

SE|74||ab|4|text|468|763|The principal effect of low pH on the kinetics of the enzyme-catalyzed reaction is the observation of a pH-dependent substrate inhibition by oxidized glutathione at pH less than or equal 7, which is shown to correlate with the binding of oxidized glutathione to the oxidized form of the enzyme.
SE|74||ab|4|entity|C0205225|Primary|qlco|||principal|||0|888|472|481
SE|74||ab|4|entity|C1280500|Effect|qlco|||effect|||0|888|482|488
SE|74||ab|4|entity|C0728725|Hydrogen ion increase|fndg|||low pH|||0|1000|492|498
SE|74||ab|4|entity|C0022702|Kinetics|idcn|||kinetics|||0|1000|506|514
SE|74||ab|4|entity|C0007382|Catalysis|npop|||catalyzed|||0|866|529|538
SE|74||ab|4|entity|C1511131|Biochemical Reaction|moft|||enzyme-catalyzed reaction|||0|866|522|547
SE|74||ab|4|entity|C0061516|Glutathione Disulfide|aapp,bacs,phsu|||oxidized glutathione|||0|1000|609|629
SE|74||ab|4|entity|C0205163|Equal|qlco|||equal|||0|861|649|654
SE|74||ab|4|entity|C0061516|Glutathione Disulfide|aapp,bacs,phsu|||oxidized glutathione|||0|1000|706|726
SE|74||ab|4|entity|C1522492|Formation|ftcn|||form|||0|861|743|747
SE|74||ab|4|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|755|761

SE|74||ab|5|text|763|766|2.

SE|74||ab|6|text|766|886|The catalytic activity of yeast glutathione reductase at pH 5.5 is affected by the sodium acetate buffer concentration.
SE|74||ab|6|entity|C0243102|enzyme activity|moft|||catalytic activity|||0|1000|770|788
SE|74||ab|6|entity|C0036025|Saccharomyces cerevisiae|fngs|||yeast|||0|901|792|797
SE|74||ab|6|entity|C0017824|Glutathione Reductase|aapp,enzy|||glutathione reductase|||0|901|798|819
SE|74||ab|6|entity|C0142785|Sodium Acetate|orch,phsu|||sodium acetate|||0|658|849|863
SE|74||ab|6|entity|C0006353|Buffers|bacs,irda|||buffer|||0|658|864|870
SE|74||ab|6|relation|0|0|C0017824|Glutathione Reductase|aapp,gngm,enzy|aapp|||glutathione reductase|||0|901|798|819|MOD/HEAD|PART_OF||792|819|0|0|C0036025|Saccharomyces cerevisiae|fngs|fngs|||yeast|||0|901|792|797
SE|74||ab|6|relation|0|0|C0142785|Sodium Acetate|orch,phsu|orch|||sodium acetate|||0|658|849|863|INFER|INTERACTS_WITH(SPEC)||849|870|0|0|C0017824|Glutathione Reductase|aapp,gngm,enzy|aapp|||glutathione reductase|||0|901|798|819
SE|74||ab|6|relation|0|0|C0142785|Sodium Acetate|orch,phsu|orch|||sodium acetate|||0|658|849|863|MOD/HEAD|ISA||849|870|0|0|C0006353|Buffers|bacs,irda|bacs|||buffer|||0|658|864|870
SE|74||ab|6|relation|1|1|C0006353|Buffers|bacs,irda|bacs|||buffer|||0|658|864|870|VERB|INTERACTS_WITH||833|841|2|1|C0017824|Glutathione Reductase|aapp,gngm,enzy|aapp|||glutathione reductase|||0|901|798|819

SE|74||ab|7|text|886|1073|The stability of the oxidized and reduced forms of the enzyme at pH 5.5 and 25 degrees C in the absence of bovine serum albumin was studied as a function of sodium acetate concentration.
SE|74||ab|7|entity|C1317741|STABILITY|qlco|||stability|||0|1000|890|899
SE|74||ab|7|entity|C0392756|Reduced|qlco|||reduced|||0|888|920|927
SE|74||ab|7|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|941|947
SE|74||ab|7|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|965|974
SE|74||ab|7|entity|C0036774|Serum Albumin, Bovine|aapp,bacs|||bovine serum albumin|||0|1000|993|1013
SE|74||ab|7|entity|C0031843|physiological aspects|phsf|||function|||0|1000|1031|1039
SE|74||ab|7|entity|C0142785|Sodium Acetate|orch,phsu|||sodium acetate|||0|734|1043|1057

SE|74||ab|8|text|1073|1259|The results show that activation of the catalytic activity of the enzyme at low sodium acetate concentration correlates with an effect of sodium acetate on a reduced form of the enzyme.
SE|74||ab|8|entity|C1274040|result|ftcn|||results|||0|966|1077|1084
SE|74||ab|8|entity|C0243102|enzyme activity|moft|||catalytic activity|||0|1000|1113|1131
SE|74||ab|8|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|1139|1145
SE|74||ab|8|entity|C1550571|low sodium|topp|||low sodium|||0|658|1149|1159
SE|74||ab|8|entity|C0000975|Acetate|orch,phsu|||acetate|||0|658|1160|1167
SE|74||ab|8|entity|C1280500|Effect|qlco|||effect|||0|1000|1201|1207
SE|74||ab|8|entity|C0142785|Sodium Acetate|orch,phsu|||sodium acetate|||0|1000|1211|1225
SE|74||ab|8|entity|C0392756|Reduced|qlco|||reduced|||0|888|1231|1238
SE|74||ab|8|entity|C1522492|Formation|ftcn|||form|||0|888|1239|1243
SE|74||ab|8|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|1251|1257
SE|74||ab|8|relation|5|1|C0000975|Acetate|orch,phsu|orch|||acetate|||0|658|1160|1167|NOM|INTERACTS_WITH||1201|1207|3|1|C0142785|Sodium Acetate|orch,phsu|orch|||sodium acetate|||0|1000|1211|1225

SE|74||ab|9|text|1259|1439|In contrast, inhibition of the catalytic activity of the enzyme at high sodium acetate concentration correlates with an effect of sodium acetate on the oxidized form of the enzyme.
SE|74||ab|9|entity|C0243102|enzyme activity|moft|||catalytic activity|||0|1000|1290|1308
SE|74||ab|9|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|1316|1322
SE|74||ab|9|entity|C0205250|High|qlco|||high|||0|658|1326|1330
SE|74||ab|9|entity|C0142785|Sodium Acetate|orch,phsu|||sodium acetate|||0|658|1331|1345
SE|74||ab|9|entity|C1280500|Effect|qlco|||effect|||0|1000|1379|1385
SE|74||ab|9|entity|C0142785|Sodium Acetate|orch,phsu|||sodium acetate|||0|1000|1389|1403
SE|74||ab|9|entity|C1522492|Formation|ftcn|||form|||0|861|1420|1424
SE|74||ab|9|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|1432|1438
SE|74||ab|9|relation|5|2|C0014442|Enzymes|enzy,orch|enzy|||enzyme|||0|1000|1316|1322|NOM|INTERACTS_WITH||1379|1385|3|1|C0142785|Sodium Acetate|orch,phsu|orch|||sodium acetate|||0|1000|1389|1403


SE|75||ti|1|text|15|162|Characteristics of the dephosphorylated form of phosphorylase purified from rat liver and measurement of its activity in crude liver preparations.
SE|75||ti|1|entity|C1521970|Characteristics|grpa|||Characteristics|||0|1000|15|30
SE|75||ti|1|entity|C1522492|Formation|ftcn|||form|||0|861|55|59
SE|75||ti|1|entity|C0917783|Glycogen Phosphorylase, Muscle Form|aapp,enzy|||phosphorylase|||0|1000|63|76
SE|75||ti|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|888|91|94
SE|75||ti|1|entity|C0023884|Liver|bpoc|||liver|||0|888|95|100
SE|75||ti|1|entity|C0242485|Measurement|ftcn|||measurement|||0|1000|105|116
SE|75||ti|1|entity|C0023899|Liver Extract|orch,phsu|||liver preparations|||0|884|142|160
SE|75||ti|1|relation|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|888|95|100|MOD/HEAD|PART_OF||91|100|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|888|91|94
SE|75||ti|1|relation|6|4|C0917783|Glycogen Phosphorylase, Muscle Form|aapp,gngm,enzy|aapp|||phosphorylase|||0|1000|63|76|PREP|COEXISTS_WITH||133|135|1|1|C0023899|Liver Extract|orch,phsu|orch|||liver preparations|||0|884|142|160

SE|75||ab|1|text|168|506|The phosphorylated form of liver glycogen phosphorylase (alpha-1,4-glucan : orthophosphate alpha-glucosyl-transferase, EC 2.4.1.1) (phosphorylase a) is active and easily measured while the dephosphorylated form (phosphorylase b), in contrast to the muscle enzyme, has been reported to be essentially inactive even in the presence of AMP.
SE|75||ab|1|entity|C1522492|Formation|ftcn|||form|||0|861|187|191
SE|75||ab|1|entity|C0023902|Liver Glycogen|bacs,carb|||liver glycogen|||0|901|195|209
SE|75||ab|1|entity|C0917783|Glycogen Phosphorylase, Muscle Form|aapp,enzy|||phosphorylase|||0|901|210|223
SE|75||ab|1|entity|C0439095|Alpha|inpr|||alpha|||0|861|225|230
SE|75||ab|1|entity|C0017696|Glucans|carb|||glucan|||0|861|235|241
SE|75||ab|1|entity|C0029356|Orthophosphate|inch|||orthophosphate|||0|851|244|258
SE|75||ab|1|entity|C0439095|Alpha|inpr|||alpha|||0|851|259|264
SE|75||ab|1|entity|C0119452|Glucosyltransferase|aapp,enzy|||-transferase|||0|851|273|285
SE|75||ab|1|entity|C0040676|Transferase|aapp,enzy|||EC 2|||0|840|287|291
SE|75||ab|1|entity|C0917783|Glycogen Phosphorylase, Muscle Form|aapp,enzy|||phosphorylase|||0|1000|300|313
SE|75||ab|1|entity|C0205177|Active|ftcn|||active|||0|1000|320|326
SE|75||ab|1|entity|C0332219|Easy|qlco|||easily|||0|1000|331|337
SE|75||ab|1|entity|C1522492|Formation|ftcn|||form|||0|861|374|378
SE|75||ab|1|entity|C0031711|Phosphorylase b|aapp,enzy|||phosphorylase b|||0|1000|380|395
SE|75||ab|1|entity|C1141895|Muscle enzyme|lbpr|||muscle enzyme|||0|1000|417|430
SE|75||ab|1|entity|C0205254|Sedentary|fndg|||inactive|||0|827|468|476
SE|75||ab|1|entity|C0457243|Ampere|qnco|||AMP|||0|966|501|504

SE|75||ab|2|text|506|607|We have purified both forms of phosphorylase from rat liver and studied the characteristics of each.
SE|75||ab|2|entity|C0917783|Glycogen Phosphorylase, Muscle Form|aapp,enzy|||phosphorylase|||0|1000|537|550
SE|75||ab|2|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|888|556|559
SE|75||ab|2|entity|C0023884|Liver|bpoc|||liver|||0|888|560|565
SE|75||ab|2|entity|C1521970|Characteristics|grpa|||characteristics|||0|1000|582|597
SE|75||ab|2|relation|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|888|560|565|MOD/HEAD|PART_OF||556|565|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|888|556|559
SE|75||ab|2|relation|2|1|C0023884|Liver|bpoc|bpoc|||liver|||0|888|560|565|PREP|LOCATION_OF||551|555|1|1|C0917783|Glycogen Phosphorylase, Muscle Form|aapp,gngm,enzy|aapp|||phosphorylase|||0|1000|537|550

SE|75||ab|3|text|607|675|Phosphorylase b activity can be measured with our assay conditions.
SE|75||ab|3|entity|C0031711|Phosphorylase b|aapp,enzy|||Phosphorylase b|||0|901|607|622
SE|75||ab|3|entity|C1510438|Assay|lbpr|||assay|||0|872|657|662
SE|75||ab|3|entity|C0348080|Condition|qlco|||conditions|||0|872|663|673

SE|75||ab|4|text|675|916|The phosphorylase b we obtained was stimulated by high concentrations of sulfate, and was a substrate for muscle phosphorylase kinase whereas phosphorylase a was inhibited by sulfate, and was a substrate for liver phosphorylase phosphatase.
SE|75||ab|4|entity|C0031711|Phosphorylase b|aapp,enzy|||phosphorylase b|||0|1000|679|694
SE|75||ab|4|entity|C0205250|High|qlco|||high|||0|888|725|729
SE|75||ab|4|entity|C0038720|Sulfates, Inorganic|inch|||sulfate|||0|1000|748|755
SE|75||ab|4|entity|C0544553|Phosphorylase kinase, muscle|aapp,enzy|||muscle phosphorylase kinase|||0|1000|781|808
SE|75||ab|4|entity|C0917783|Glycogen Phosphorylase, Muscle Form|aapp,enzy|||phosphorylase|||0|1000|817|830
SE|75||ab|4|entity|C0038720|Sulfates, Inorganic|inch|||sulfate|||0|1000|850|857
SE|75||ab|4|entity|C0023884|Liver|bpoc|||liver|||0|901|883|888
SE|75||ab|4|entity|C0031714|Phosphorylase Phosphatase|aapp,enzy|||phosphorylase phosphatase|||0|901|889|914
SE|75||ab|4|relation|0|0|C0031714|Phosphorylase Phosphatase|aapp,gngm,enzy|aapp|||phosphorylase phosphatase|||0|901|889|914|MOD/HEAD|PART_OF||883|914|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|901|883|888
SE|75||ab|4|relation|1|1|C0031711|Phosphorylase b|aapp,gngm,enzy|aapp|||phosphorylase b|||0|1000|679|694|VERB|STIMULATES||711|721|8|2|C0038720|Sulfates, Inorganic|inch|inch|||sulfate|||0|1000|748|755
SE|75||ab|4|relation|3|1|C0038720|Sulfates, Inorganic|inch|inch|||sulfate|||0|1000|850|857|VERB|INHIBITS||837|846|6|1|C0917783|Glycogen Phosphorylase, Muscle Form|aapp,gngm,enzy|gngm|||phosphorylase|||0|1000|817|830
SE|75||ab|4|relation|7|3|C0544553|Phosphorylase kinase, muscle|aapp,gngm,enzy|aapp|||muscle phosphorylase kinase|||0|1000|781|808|NOM|INTERACTS_WITH||869|878|1|1|C0031714|Phosphorylase Phosphatase|aapp,gngm,enzy|aapp|||phosphorylase phosphatase|||0|901|889|914

SE|75||ab|5|text|916|1084|Substrate binding to phosphorylase b was poor (KM glycogen = 2.5 mM, glucose-1-P = 250 mM) compared to phosphorylase a (KM glycogen = 1.8 mM, KM glucose-1-P = 0.7 mM).
SE|75||ab|5|entity|C0031711|Phosphorylase b|aapp,enzy|||phosphorylase b|||0|1000|937|952
SE|75||ab|5|entity|C0032854|Poverty|grpa|||poor|||0|1000|957|961
SE|75||ab|5|entity|C0017911|Glycogen|bacs,carb|||glycogen|||0|888|966|974
SE|75||ab|5|entity|C0450346|2/5|qnco|||2.5|||0|901|977|980
SE|75||ab|5|entity|C0017725|Glucose|bacs,carb,phsu|||glucose|||0|754|985|992
SE|75||ab|5|entity|C0917783|Glycogen Phosphorylase, Muscle Form|aapp,enzy|||phosphorylase|||0|1000|1019|1032
SE|75||ab|5|entity|C0017911|Glycogen|bacs,carb|||glycogen|||0|888|1039|1047
SE|75||ab|5|entity|C0017725|Glucose|bacs,carb,phsu|||glucose|||0|735|1061|1068
SE|75||ab|5|relation|6|3|C0017911|Glycogen|bacs,carb|bacs|||glycogen|||0|888|966|974|VERB|compared_with||1007|1015|4|1|C0917783|Glycogen Phosphorylase, Muscle Form|aapp,gngm,enzy|aapp|||phosphorylase|||0|1000|1019|1032

SE|75||ab|6|text|1084|1140|Liver phosphorylase b was active in the absence of AMP.
SE|75||ab|6|entity|C0023884|Liver|bpoc|||Liver|||0|901|1084|1089
SE|75||ab|6|entity|C0031711|Phosphorylase b|aapp,enzy|||phosphorylase b|||0|901|1090|1105
SE|75||ab|6|entity|C0205177|Active|ftcn|||active|||0|1000|1110|1116
SE|75||ab|6|entity|C0457243|Ampere|qnco|||AMP|||0|966|1135|1138
SE|75||ab|6|relation|0|0|C0031711|Phosphorylase b|aapp,gngm,enzy|aapp|||phosphorylase b|||0|901|1090|1105|MOD/HEAD|PART_OF||1084|1105|0|0|C0023884|Liver|bpoc|bpoc|||Liver|||0|901|1084|1089

SE|75||ab|7|text|1140|1282|However, AMP lowered the KM for glucose-1-P to 80 mM for purified phosphorylase b and to 60 mM for the enzyme in crude extract (Ka = 0.5 mM).
SE|75||ab|7|entity|C0457243|Ampere|qnco|||AMP|||0|966|1149|1152
SE|75||ab|7|entity|C0017725|Glucose|bacs,carb,phsu|||glucose|||0|802|1172|1179
SE|75||ab|7|entity|C0202178|Phosphorus measurement|lbpr|||1-P|||0|802|1180|1183
SE|75||ab|7|entity|C0031711|Phosphorylase b|aapp,enzy|||phosphorylase b|||0|901|1206|1221
SE|75||ab|7|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|1243|1249
SE|75||ab|7|entity|C1258023|Complex Extracts|chem|||crude extract|||0|983|1253|1266
SE|75||ab|7|entity|C0444499|0/5|qnco|||0.5|||0|901|1273|1276

SE|75||ab|8|text|1282|1483|Using appropriate substrate, buffer and AMP concentrations, assay conditions have been developed which allow determination of phosphorylase a and 90% of the phosphorylase b activity in liver extracts.
SE|75||ab|8|entity|C1548787|Appropriate|qlco|||appropriate|||0|694|1288|1299
SE|75||ab|8|entity|C0006353|Buffers|bacs,irda|||buffer|||0|1000|1311|1317
SE|75||ab|8|entity|C0457243|Ampere|qnco|||AMP|||0|872|1322|1325
SE|75||ab|8|entity|C1510438|Assay|lbpr|||assay|||0|872|1342|1347
SE|75||ab|8|entity|C0348080|Condition|qlco|||conditions|||0|872|1348|1358
SE|75||ab|8|entity|C0680730|Adjudication|gora|||determination|||0|1000|1391|1404
SE|75||ab|8|entity|C0917783|Glycogen Phosphorylase, Muscle Form|aapp,enzy|||phosphorylase|||0|1000|1408|1421
SE|75||ab|8|entity|C0439083|>90|qnco|||90|||0|1000|1428|1430
SE|75||ab|8|entity|C0031711|Phosphorylase b|aapp,enzy|||phosphorylase b|||0|901|1439|1454
SE|75||ab|8|entity|C0023899|Liver Extract|orch,phsu|||liver extracts|||0|1000|1467|1481
SE|75||ab|8|relation|7|1|C0031711|Phosphorylase b|aapp,gngm,enzy|aapp|||phosphorylase b|||0|901|1439|1454|PREP|COEXISTS_WITH||1464|1466|1|1|C0023899|Liver Extract|orch,phsu|orch|||liver extracts|||0|1000|1467|1481

SE|75||ab|9|text|1483|1621|Interconversion of the two forms can be demonstrated in vivo (under acute stimulation) and in vitro with little change in total activity.
SE|75||ab|9|entity|C0205448|Two|qnco|||two|||0|888|1506|1509
SE|75||ab|9|entity|C1515655|in vivo|spco|||in vivo|||0|1000|1536|1543
SE|75||ab|9|entity|C0205178|acute|tmco|||acute|||0|888|1551|1556
SE|75||ab|9|entity|C1533691|in vitro|qlco|||in vitro|||0|1000|1574|1582
SE|75||ab|9|entity|C0023882|Little's Disease|dsyn|||little|||0|888|1588|1594
SE|75||ab|9|entity|C0439175|% of total|qnco|||total|||0|888|1605|1610

SE|75||ab|10|text|1621|1725|A decrease in total phosphorylase activity has been observed after prolonged starvation and in diabetes.
SE|75||ab|10|entity|C0547047|Decrease|qnco|||decrease|||0|1000|1623|1631
SE|75||ab|10|entity|C0439175|% of total|qnco|||total|||0|901|1635|1640
SE|75||ab|10|entity|C1152161|phosphorylase activity|moft|||phosphorylase activity|||0|901|1641|1663
SE|75||ab|10|entity|C0439590|Prolonged|tmco|||prolonged|||0|888|1688|1697
SE|75||ab|10|entity|C0038187|Starvation|sosy|||starvation|||0|888|1698|1708
SE|75||ab|10|entity|C0011847|Diabetes|dsyn|||diabetes|||0|1000|1716|1724
SE|75||ab|10|relation|3|2|C1152161|phosphorylase activity|moft|moft|||phosphorylase activity|||0|901|1641|1663|PREP|COEXISTS_WITH||1713|1715|1|1|C0011847|Diabetes|dsyn|dsyn|||diabetes|||0|1000|1716|1724


SE|76||ti|1|text|15|73|Multiple forms of casein kinase from rabbit erythrocytes.
SE|76||ti|1|entity|C0439064|Numerous|qnco|||Multiple|||0|888|15|23
SE|76||ti|1|entity|C0054846|casein kinase|aapp,enzy|||casein kinase|||0|1000|33|46
SE|76||ti|1|entity|C0034493|Oryctolagus cuniculus|mamm|||rabbit|||0|888|52|58
SE|76||ti|1|entity|C0014792|Erythrocytes|cell|||erythrocytes|||0|888|59|71
SE|76||ti|1|relation|0|0|C0014792|Erythrocytes|cell|cell|||erythrocytes|||0|888|59|71|MOD/HEAD|PART_OF||52|71|0|0|C0034493|Oryctolagus cuniculus|mamm|mamm|||rabbit|||0|888|52|58
SE|76||ti|1|relation|1|1|C0014792|Erythrocytes|cell|cell|||erythrocytes|||0|888|59|71|PREP|LOCATION_OF||47|51|2|1|C0054846|casein kinase|aapp,gngm,enzy|aapp|||casein kinase|||0|1000|33|46

SE|76||ab|1|text|79|222|Two rabbit erythrocyte casein kinases, GTP:casein kinase I and GTP:casein kinase II, have been purified 29 000- and 47 000-fold, respectively.
SE|76||ab|1|entity|C0205448|Two|qnco|||Two|||0|840|79|82
SE|76||ab|1|entity|C0034493|Oryctolagus cuniculus|mamm|||rabbit|||0|840|83|89
SE|76||ab|1|entity|C0014792|Erythrocytes|cell|||erythrocyte|||0|840|90|101
SE|76||ab|1|entity|C0054846|casein kinase|aapp,enzy|||casein kinases|||0|840|102|116
SE|76||ab|1|entity|C0018353|Guanosine Triphosphate|bacs,nnon|||GTP|||0|1000|118|121
SE|76||ab|1|entity|C0054846|casein kinase|aapp,enzy|||casein kinase|||0|1000|122|135
SE|76||ab|1|entity|C0018353|Guanosine Triphosphate|bacs,nnon|||GTP|||0|1000|142|145
SE|76||ab|1|entity|C0108555|casein kinase II|aapp,enzy|||casein kinase II|||0|1000|146|162
SE|76||ab|1|entity|C0332462|Fold|spco|||fold|||0|827|202|206
SE|76||ab|1|relation|0|0|C0054846|casein kinase|aapp,gngm,enzy|aapp|||casein kinases|||0|840|102|116|MOD/HEAD|PART_OF||90|116|0|0|C0014792|Erythrocytes|cell|cell|||erythrocyte|||0|840|90|101

SE|76||ab|2|text|222|394|Studies employing sucrose density gradient centrifugation indicate that kinase I has a molecular weight of about 9.5 - 10(5) (25 S) and kinase II about 1.4 - 10(6) (32 S).
SE|76||ab|2|entity|C0008972|Clinical Research|resa|||Studies|||0|966|222|229
SE|76||ab|2|entity|C0038636|Sucrose|bacs,carb|||sucrose|||0|916|240|247
SE|76||ab|2|entity|C0007704|Centrifugation, Density Gradient|lbpr|||density gradient centrifugation|||0|916|248|279
SE|76||ab|2|entity|C0031727|Phosphotransferases|aapp,enzy|||kinase|||0|1000|294|300
SE|76||ab|2|entity|C0026385|Molecular Weight|qnco|||molecular weight|||0|1000|309|325
SE|76||ab|2|entity|C0031727|Phosphotransferases|aapp,enzy|||kinase|||0|694|358|364

SE|76||ab|3|text|394|463|These enzymes can utilize either ATP or GTP as the phosphoryl donor.
SE|76||ab|3|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|1000|400|407
SE|76||ab|3|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|ATP|||0|861|427|430
SE|76||ab|3|entity|C0018353|Guanosine Triphosphate|bacs,nnon|||GTP|||0|1000|434|437

SE|76||ab|4|text|463|668|Among various protein substrates examined, these kinases catalyze the phosphorylation of casein greater than 50% dephosphorylated phosvitin congruent to 50% dephosphorylated casein greater than phosvitin.
SE|76||ab|4|entity|C0033684|Proteins|aapp,bacs|||protein|||0|660|477|484
SE|76||ab|4|entity|C0031727|Phosphotransferases|aapp,enzy|||kinases|||0|1000|512|519
SE|76||ab|4|entity|C0031715|Phosphorylation|moft|||phosphorylation|||0|1000|533|548
SE|76||ab|4|entity|C0007332|Caseins|aapp,bacs|||casein|||0|1000|552|558
SE|76||ab|4|entity|C0443228|Largest|qnco|||greater|||0|1000|559|566
SE|76||ab|4|entity|C0031733|Phosvitin|aapp,bacs|||phosvitin|||0|827|593|602
SE|76||ab|4|entity|C0007332|Caseins|aapp,bacs|||casein|||0|827|637|643
SE|76||ab|4|entity|C0443228|Largest|qnco|||greater|||0|1000|644|651
SE|76||ab|4|entity|C0031733|Phosvitin|aapp,bacs|||phosvitin|||0|1000|657|666
SE|76||ab|4|entity||<<greatness>>||||greater|||||559|566
SE|76||ab|4|entity||<<greatness>>||||greater|||||644|651
SE|76||ab|4|relation|2|1|C0031727|Phosphotransferases|aapp,gngm,enzy|aapp|||kinases|||0|1000|512|519|VERB|AFFECTS||520|528|8|1|C0031715|Phosphorylation|moft|moft|||phosphorylation|||0|1000|533|548
SE|76||ab|4|relation|5|2|C0007332|Caseins|aapp,gngm,bacs|aapp|||casein|||0|1000|552|558|PREP|compared_with||567|571|5|1|C0031733|Phosvitin|aapp,gngm,bacs|aapp|||phosvitin|||0|827|593|602
SE|76||ab|4|relation|5|2|C0007332|Caseins|aapp,gngm,bacs|aapp|||casein|||0|1000|552|558|PREP|higher_than||567|571|5|1|C0031733|Phosvitin|aapp,gngm,bacs|aapp|||phosvitin|||0|827|593|602
SE|76||ab|4|relation|9|2|C0007332|Caseins|aapp,gngm,bacs|aapp|||casein|||0|827|637|643|PREP|compared_with||652|656|1|1|C0031733|Phosvitin|aapp,gngm,bacs|aapp|||phosvitin|||0|1000|657|666
SE|76||ab|4|relation|9|2|C0007332|Caseins|aapp,gngm,bacs|aapp|||casein|||0|827|637|643|PREP|higher_than||652|656|1|1|C0031733|Phosvitin|aapp,gngm,bacs|aapp|||phosvitin|||0|1000|657|666

SE|76||ab|5|text|668|744|Histones, protamine and bovine serum albumin are poor phosphoryl acceptors.
SE|76||ab|5|entity|C0019652|Histones|aapp,bacs|||Histones|||0|1000|668|676
SE|76||ab|5|entity|C0033603|Protamines|aapp,bacs,phsu|||protamine|||0|1000|678|687
SE|76||ab|5|entity|C0036774|Serum Albumin, Bovine|aapp,bacs|||bovine serum albumin|||0|1000|692|712
SE|76||ab|5|entity|C0032854|Poverty|grpa|||poor|||0|802|717|721
SE|76||ab|5|entity|C0000901|Acceptors|popg|||acceptors|||0|802|733|742

SE|76||ab|6|text|744|879|Kinetic data indicate that both enzymes are inhibited by high casein substrate concentrations which may be partially relieved by NaCl.
SE|76||ab|6|entity|C0022702|Kinetics|idcn|||Kinetic|||0|888|744|751
SE|76||ab|6|entity|C1511726|Data|idcn|||data|||0|888|752|756
SE|76||ab|6|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|1000|776|783
SE|76||ab|6|entity|C0205250|High|qlco|||high|||0|775|801|805
SE|76||ab|6|entity|C0007332|Caseins|aapp,bacs|||casein|||0|775|806|812
SE|76||ab|6|entity|C0037494|Sodium Chloride|bacs,inch,phsu|||NaCl|||0|1000|873|877
SE|76||ab|6|relation|2|1|C0014442|Enzymes|enzy,orch|enzy|||enzymes|||0|1000|776|783|NOM|INTERACTS_WITH||813|822|2|0|C0007332|Caseins|aapp,gngm,bacs|aapp|||casein|||0|775|806|812

SE|76||ab|7|text|879|968|Both phosphotransferases require Mg(2+) for activity and are optimally active at pH 9.0.
SE|76||ab|7|entity|C0031727|Phosphotransferases|aapp,enzy|||phosphotransferases|||0|1000|884|903
SE|76||ab|7|entity|C0205177|Active|ftcn|||active|||0|861|950|956

SE|76||ab|8|text|968|1084|The enzymes have apparent Km values of 2.5 - 10(-5) M for GTP, 2 - 10(-5) M for ATP, and 0.4--0.6 mg/ml for casein.
SE|76||ab|8|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|1000|972|979
SE|76||ab|8|entity|C0750489|APPARENT|idcn|||apparent|||0|851|985|993
SE|76||ab|8|entity|C0042295|Values|qlco|||values|||0|851|997|1003
SE|76||ab|8|entity|C0450346|2/5|qnco|||2.5|||0|901|1007|1010
SE|76||ab|8|entity|C0018353|Guanosine Triphosphate|bacs,nnon|||GTP|||0|1000|1026|1029
SE|76||ab|8|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|ATP|||0|1000|1048|1051
SE|76||ab|8|entity|C0007332|Caseins|aapp,bacs|||casein|||0|1000|1076|1082

SE|76||ab|9|text|1084|1341|The incorporation of the terminal phosphate of GTP into casein as catalyzed by these enzymes is inhibited to varying degrees by ATP, ITP, ADP, and GDP but not by UTP, CTP, GMP, adenosine 3':5'-cyclic monophosphate, and guanosine 3':5'-cyclic monophosphate.
SE|76||ab|9|entity|C0243126|incorporation|ftcn|||incorporation|||0|1000|1088|1101
SE|76||ab|9|entity|C0018353|Guanosine Triphosphate|bacs,nnon|||GTP|||0|1000|1131|1134
SE|76||ab|9|entity|C0007332|Caseins|aapp,bacs|||casein|||0|1000|1140|1146
SE|76||ab|9|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|1000|1169|1176
SE|76||ab|9|entity|C1548673|Varies|inpr|||varying|||0|661|1193|1200
SE|76||ab|9|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|ATP|||0|1000|1212|1215
SE|76||ab|9|entity|C0021540|Inosine Triphosphate|bacs,nnon|||ITP|||0|1000|1217|1220
SE|76||ab|9|entity|||gngm|23038|WDTC1|ADP|||0|1000|1222|1225
SE|76||ab|9|entity|C0018340|Guanosine Diphosphate|bacs,nnon|||GDP|||0|1000|1231|1234
SE|76||ab|9|entity|C1518422|Not|ftcn|||not|||0|1000|1239|1242
SE|76||ab|9|entity|C0042010|Uridine Triphosphate|bacs,nnon|||UTP|||0|1000|1246|1249
SE|76||ab|9|entity|C0010734|Cytidine Triphosphate|bacs,nnon|||CTP|||0|1000|1251|1254
SE|76||ab|9|entity|C0520462|GMP|bacs,nnon|||GMP|||0|1000|1256|1259
SE|76||ab|9|entity|C0001443|Adenosine|bacs,nnon,phsu|||adenosine|||0|861|1261|1270
SE|76||ab|9|entity|C0439596|Cyclical|tmco|||cyclic|||0|623|1277|1283
SE|76||ab|9|entity|C0018330|Guanosine|bacs,nnon,phsu|||guanosine|||0|861|1303|1312
SE|76||ab|9|entity|C0439596|Cyclical|tmco|||cyclic|||0|623|1319|1325
SE|76||ab|9|relation|0|0|C0010734|Cytidine Triphosphate|bacs,nnon|bacs|||CTP|||0|1000|1251|1254|SPEC|ISA||1251|1259|0|0|C0520462|GMP|bacs,nnon|bacs|||GMP|||0|1000|1256|1259
SE|76||ab|9|relation|11|1|C0014442|Enzymes|enzy,orch|enzy|||enzymes|||0|1000|1169|1176|VERB|INTERACTS_WITH||1150|1159|4|1|C0007332|Caseins|aapp,gngm,bacs|aapp|||casein|||0|1000|1140|1146

SE|76||ab|10|text|1341|1445|In addition, NaF and 2,3-diphosphoglyceric acid are also found to inhibit the activity of both kinases.
SE|76||ab|10|entity|C1366571|IL8 gene|gngm|3576|CXCL8|NaF|||0|1000|1354|1357
SE|76||ab|10|entity|C0012542|Diphosphoglyceric Acids|carb|||diphosphoglyceric acid|||0|901|1366|1388
SE|76||ab|10|entity|C0031727|Phosphotransferases|aapp,enzy|||kinases|||0|1000|1436|1443
SE|76||ab|10|relation|3|1|C0012542|Diphosphoglyceric Acids|carb|carb|||diphosphoglyceric acid|||0|901|1366|1388|VERB|INHIBITS||1407|1414|2|2|C0031727|Phosphotransferases|aapp,gngm,enzy|gngm|||kinases|||0|1000|1436|1443

SE|76||ab|11|text|1445|1602|The effect of 2,3-diphosphoglycerate is interesting and suggests that this metabolite may regulate the activity of the casein kinases in the red blood cells.
SE|76||ab|11|entity|C1280500|Effect|qlco|||effect|||0|1000|1449|1455
SE|76||ab|11|entity|C0178597|diphosphoglycerate|carb|||diphosphoglycerate|||0|888|1463|1481
SE|76||ab|11|entity|C0870883|Metabolites|bacs|||metabolite|||0|966|1520|1530
SE|76||ab|11|entity|C0054846|casein kinase|aapp,enzy|||casein kinases|||0|1000|1564|1578
SE|76||ab|11|entity|C0014792|Erythrocytes|cell|||red blood cells|||0|1000|1586|1601
SE|76||ab|11|relation|1|1|C0014792|Erythrocytes|cell|cell|||red blood cells|||0|1000|1586|1601|PREP|LOCATION_OF||1579|1581|5|1|C0054846|casein kinase|aapp,gngm,enzy|aapp|||casein kinases|||0|1000|1564|1578
SE|76||ab|11|relation|3|1|C0870883|Metabolites|bacs|bacs|||metabolite|||0|966|1520|1530|VERB|INTERACTS_WITH||1535|1543|3|2|C0054846|casein kinase|aapp,gngm,enzy|aapp|||casein kinases|||0|1000|1564|1578


SE|77||ti|1|text|15|135|Kinetic studies and effects of anions on creatine phosphokinase from skeletal muscle of rhesus monkey (Macaca mulatta).
SE|77||ti|1|entity|C0022702|Kinetics|idcn|||Kinetic|||0|872|15|22
SE|77||ti|1|entity|C0008972|Clinical Research|resa|||studies|||0|872|23|30
SE|77||ti|1|entity|C1280500|Effect|qlco|||effects|||0|966|35|42
SE|77||ti|1|entity|C0003075|Anions|elii|||anions|||0|1000|46|52
SE|77||ti|1|entity|C0010287|Creatine Kinase|aapp,enzy|||creatine phosphokinase|||0|1000|56|78
SE|77||ti|1|entity|C0242692|Skeletal muscle structure|bpoc|||skeletal muscle|||0|1000|84|99
SE|77||ti|1|entity|C0024400|Macaca mulatta|mamm|||rhesus monkey|||0|1000|103|116
SE|77||ti|1|entity|C0024400|Macaca mulatta|mamm|||Macaca mulatta|||0|1000|118|132
SE|77||ti|1|relation|3|1|C0242692|Skeletal muscle structure|bpoc|bpoc|||skeletal muscle|||0|1000|84|99|PREP|LOCATION_OF||79|83|4|1|C0010287|Creatine Kinase|aapp,gngm,enzy|aapp|||creatine phosphokinase|||0|1000|56|78
SE|77||ti|1|relation|5|1|C0003075|Anions|elii|elii|||anions|||0|1000|46|52|NOM|INTERACTS_WITH||35|42|5|2|C0010287|Creatine Kinase|aapp,gngm,enzy|aapp|||creatine phosphokinase|||0|1000|56|78
SE|77||ti|1|relation|5|1|C0242692|Skeletal muscle structure|bpoc|bpoc|||skeletal muscle|||0|1000|84|99|PREP|PART_OF||100|102|2|1|C0024400|Macaca mulatta|mamm|mamm|||rhesus monkey|||0|1000|103|116

SE|77||ab|1|text|141|300|A purification procedure for creatine kinase (EC 2.7.3.2) from muscle of the monke35--170 muequiv H+/mg protein per min at 30 degrees C and a yield of approx.
SE|77||ab|1|entity|C0243114|purification|lbpr,resa|||purification|||0|888|143|155
SE|77||ab|1|entity|C0184661|Procedures|hlca|||procedure|||0|888|156|165
SE|77||ab|1|entity|C0010287|Creatine Kinase|aapp,enzy|||creatine kinase|||0|1000|170|185
SE|77||ab|1|entity|C0040676|Transferase|aapp,enzy|||EC 2|||0|840|187|191
SE|77||ab|1|entity|C0026845|Muscle|tisu|||muscle|||0|1000|204|210
SE|77||ab|1|entity|C0033684|Proteins|aapp,bacs|||protein|||0|736|245|252
SE|77||ab|1|entity|C0439232|Minute of time|tmco|||min|||0|1000|257|260
SE|77||ab|1|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|267|276

SE|77||ab|2|text|300|317|0.5 g/kg muscle.
SE|77||ab|2|entity|C0444499|0/5|qnco|||0.5|||0|785|300|303
SE|77||ab|2|entity|C0026845|Muscle|tisu|||muscle|||0|785|309|315

SE|77||ab|3|text|317|454|Assuming equilibrium kinetics, synergistic binding of substrates at one catalytic site is found for both the forward and back reactions.
SE|77||ab|3|entity|C0014653|Equilibrium|orgf|||equilibrium|||0|790|326|337
SE|77||ab|3|entity|C0022702|Kinetics|idcn|||kinetics|||0|790|338|346
SE|77||ab|3|entity|C0205447|One|qnco|||one|||0|901|385|388
SE|77||ab|3|entity|C0600499|Catalytic Domain|amas|||catalytic site|||0|901|389|403
SE|77||ab|3|entity|C0439780|Forward|spco|||forward|||0|1000|426|433
SE|77||ab|3|entity|C0004600|Back|blor|||back|||0|872|438|442
SE|77||ab|3|entity|C0443286|Reaction|ftcn|||reactions|||0|872|443|452

SE|77||ab|4|text|454|643|Kinetic constants for the binding of each substrate to the free enzyme and the enzyme-second substrate complex are determined and are compared with those for the enzyme from other species.
SE|77||ab|4|entity|C0022702|Kinetics|idcn|||Kinetic|||0|872|454|461
SE|77||ab|4|entity|C1547014|*Constant|qnco|||constants|||0|872|462|471
SE|77||ab|4|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|861|518|524
SE|77||ab|4|entity|C0457385|seconds|tmco|||second|||0|916|540|546
SE|77||ab|4|entity|C0596529|enzyme substrate complex|enzy|||enzyme-second substrate complex|||0|916|533|564
SE|77||ab|4|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|861|616|622
SE|77||ab|4|entity|C1548151|Species|idcn|||species|||0|1000|634|641

SE|77||ab|5|text|643|754|Inhibition by small anions is determined in the presence of different combinations of substrates and products.
SE|77||ab|5|entity|C0700321|Small|qnco|||small|||0|888|657|662
SE|77||ab|5|entity|C0003075|Anions|elii|||anions|||0|888|663|669
SE|77||ab|5|entity|C1547020|*Difference|qnco|||different|||0|853|703|712
SE|77||ab|5|entity|C0453882|Combinations|mnob|||combinations|||0|853|713|725
SE|77||ab|5|entity|C1514468|product|qnco|||products|||0|966|744|752

SE|77||ab|6|text|754|874|SO4(2-) inhibits by simple competitive inhibition and probably binds at the site of the transferrable phosphoryl group.
SE|77||ab|6|entity|C0205352|Simple|qlco|||simple|||0|901|774|780
SE|77||ab|6|entity|C0301626|Competitive inhibition|phsf|||competitive inhibition|||0|901|781|803
SE|77||ab|6|entity|C0332148|Probable diagnosis|qlco|||probably|||0|1000|808|816
SE|77||ab|6|entity|C0205145|Site|spco|||site|||0|1000|830|834
SE|77||ab|6|entity|C0348011|Transfer procedure|ftcn|||transferrable|||0|760|842|855
SE|77||ab|6|entity|C0441833|Groups|inpr|||group|||0|760|867|872

SE|77||ab|7|text|874|1040|Inhibition by NO3-, NO2-, SCN- and Cl- is more complex and these ions are suggested to mimic the transferrable phosphoryl group in a planar transition-state complex.
SE|77||ab|7|entity|C0919442|NBL1 gene|gngm|4681|NBL1|NO3|||0|1000|888|891
SE|77||ab|7|entity|||gngm|6717|SRI|SCN|||0|1000|900|903
SE|77||ab|7|entity|C0205172|More|ftcn|||more|||0|888|916|920
SE|77||ab|7|entity|C0439855|Complex|qlco|||complex|||0|888|921|928
SE|77||ab|7|entity|C0022023|Ions|elii|||ions|||0|1000|939|943
SE|77||ab|7|entity|C0348011|Transfer procedure|ftcn|||transferrable|||0|760|971|984
SE|77||ab|7|entity|C0441833|Groups|inpr|||group|||0|760|996|1001
SE|77||ab|7|entity|C1442792|State|ftcn|||state|||0|750|1025|1030
SE|77||ab|7|entity|C0439855|Complex|qlco|||complex|||0|750|1031|1038

SE|77||ab|8|text|1040|1155|These anions stabilize the dead-end complex, enzyme-creatine-MgADP, which lacks the transferable phosphoryl group.
SE|77||ab|8|entity|C0003075|Anions|elii|||anions|||0|1000|1046|1052
SE|77||ab|8|entity|C1306577|Death (finding)|fndg|||dead|||0|851|1067|1071
SE|77||ab|8|entity|C0444930|End|spco|||end|||0|851|1072|1075
SE|77||ab|8|entity|C0439855|Complex|qlco|||complex|||0|851|1076|1083
SE|77||ab|8|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|851|1085|1091
SE|77||ab|8|entity|C0010286|Creatine|aapp,bacs|||creatine|||0|851|1092|1100
SE|77||ab|8|entity|C0024468|Magnesium ADP|bacs,nnon|||MgADP|||0|851|1101|1106
SE|77||ab|8|entity|C0348011|Transfer procedure|ftcn|||transferable|||0|766|1124|1136
SE|77||ab|8|entity|C0441833|Groups|inpr|||group|||0|766|1148|1153

SE|77||ab|9|text|1155|1303|The effects of these anions on the dissociation constants of the enzyme-substrate complexes is reported and is in accord with the above hypothesis.
SE|77||ab|9|entity|C1280500|Effect|qlco|||effects|||0|966|1159|1166
SE|77||ab|9|entity|C0003075|Anions|elii|||anions|||0|1000|1176|1182
SE|77||ab|9|entity|C0086168|Dissociation|mobd|||dissociation|||0|872|1190|1202
SE|77||ab|9|entity|C1547014|*Constant|qnco|||constants|||0|872|1203|1212
SE|77||ab|9|entity|C0596529|enzyme substrate complex|enzy|||enzyme-substrate complexes|||0|988|1220|1246
SE|77||ab|9|entity|C0680240|Agreement|socb|||accord|||0|1000|1269|1275
SE|77||ab|9|entity|C1282910|Upper|spco|||above|||0|888|1285|1290
SE|77||ab|9|entity|C1512571|Hypothesis|idcn|||hypothesis|||0|888|1291|1301

SE|77||ab|10|text|1303|1428|The dead-end complex in the absence of anion does not protect the essential thiol group against inhibition by iodoacetamide.
SE|77||ab|10|entity|C1306577|Death (finding)|fndg|||dead|||0|851|1307|1311
SE|77||ab|10|entity|C0444930|End|spco|||end|||0|851|1312|1315
SE|77||ab|10|entity|C0439855|Complex|qlco|||complex|||0|851|1316|1323
SE|77||ab|10|entity|C0003075|Anions|elii|||anion|||0|1000|1342|1347
SE|77||ab|10|entity|C1518422|Not|ftcn|||not|||0|1000|1353|1356
SE|77||ab|10|entity|C0205224|Essential|qlco|||essential|||0|851|1369|1378
SE|77||ab|10|entity|C0038734|Sulfhydryl Compounds|orch|||thiol|||0|851|1379|1384
SE|77||ab|10|entity|C0441833|Groups|inpr|||group|||0|851|1385|1390
SE|77||ab|10|entity|C0021973|Iodoacetamide|irda,orch|||iodoacetamide|||0|1000|1413|1426

SE|77||ab|11|text|1428|1545|Addition of NO3- or Cl- to the dead-end complex or a substrate equilibrium mixture without anion confers protection.
SE|77||ab|11|entity|C0442796|Additive|qlco|||Addition|||0|928|1428|1436
SE|77||ab|11|entity|C0919442|NBL1 gene|gngm|4681|NBL1|NO3|||0|1000|1440|1443
SE|77||ab|11|entity|C1306577|Death (finding)|fndg|||dead|||0|851|1459|1463
SE|77||ab|11|entity|C0444930|End|spco|||end|||0|851|1464|1467
SE|77||ab|11|entity|C0439855|Complex|qlco|||complex|||0|851|1468|1475
SE|77||ab|11|entity|C0014653|Equilibrium|orgf|||equilibrium|||0|790|1491|1502
SE|77||ab|11|entity|C0439962|Mixture|sbst|||mixture|||0|790|1503|1510
SE|77||ab|11|entity|C0003075|Anions|elii|||anion|||0|1000|1519|1524

SE|77||ab|12|text|1545|1697|The essential thiol group is inhibited by iodoacetamide at a rate which is essentially independent of pH over the normal stability range of the enzyme.
SE|77||ab|12|entity|C0205224|Essential|qlco|||essential|||0|851|1549|1558
SE|77||ab|12|entity|C0038734|Sulfhydryl Compounds|orch|||thiol|||0|851|1559|1564
SE|77||ab|12|entity|C0441833|Groups|inpr|||group|||0|851|1565|1570
SE|77||ab|12|entity|C0021973|Iodoacetamide|irda,orch|||iodoacetamide|||0|1000|1587|1600
SE|77||ab|12|entity|C1521828|Rate|qnco|||rate|||0|1000|1606|1610
SE|77||ab|12|entity|C0205136|Over|spco|||over|||0|1000|1650|1654
SE|77||ab|12|entity|C1317741|STABILITY|qlco|||stability|||0|901|1666|1675
SE|77||ab|12|entity|C0086715|Normal Range|qnco|||normal stability range|||0|901|1659|1681
SE|77||ab|12|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|1689|1695

SE|77||ab|13|text|1697|1914|Contrary to our previous report this pH independence is not altered by the presence of dead-end complex, creatine plus MgADP, in the presence or absence of anion or in the presence of a substrate equilibrium mixture.
SE|77||ab|13|entity|C0205156|Previous|tmco|||previous|||0|1000|1713|1721
SE|77||ab|13|entity|C0085862|INDEPENDENCE|idcn|||independence|||0|888|1737|1749
SE|77||ab|13|entity|C1518422|Not|ftcn|||not|||0|1000|1753|1756
SE|77||ab|13|entity|C1306577|Death (finding)|fndg|||dead|||0|851|1784|1788
SE|77||ab|13|entity|C0444930|End|spco|||end|||0|851|1789|1792
SE|77||ab|13|entity|C0439855|Complex|qlco|||complex|||0|851|1793|1800
SE|77||ab|13|entity|C0010286|Creatine|aapp,bacs|||creatine|||0|851|1802|1810
SE|77||ab|13|entity|C0332287|In addition to|ftcn|||plus|||0|851|1811|1815
SE|77||ab|13|entity|C0024468|Magnesium ADP|bacs,nnon|||MgADP|||0|851|1816|1821
SE|77||ab|13|entity|C0003075|Anions|elii|||anion|||0|1000|1853|1858
SE|77||ab|13|entity|C0014653|Equilibrium|orgf|||equilibrium|||0|790|1893|1904
SE|77||ab|13|entity|C0439962|Mixture|sbst|||mixture|||0|790|1905|1912

SE|77||ab|14|text|1914|2050|It is  inferred that the 'essential' thiol group of the monkey enzyme has essentially the same properties as that of the rabbit enzyme.
SE|77||ab|14|entity|C0205224|Essential|qlco|||essential|||0|851|1940|1949
SE|77||ab|14|entity|C0038734|Sulfhydryl Compounds|orch|||thiol|||0|851|1951|1956
SE|77||ab|14|entity|C0441833|Groups|inpr|||group|||0|851|1957|1962
SE|77||ab|14|entity|C0026447|Monkeys|mamm|||monkey|||0|888|1970|1976
SE|77||ab|14|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|888|1977|1983
SE|77||ab|14|entity|C0445247|Same|qlco|||same|||0|872|2004|2008
SE|77||ab|14|entity|C0871161|Property|qlco|||properties|||0|872|2009|2019
SE|77||ab|14|entity|C0034493|Oryctolagus cuniculus|mamm|||rabbit|||0|888|2035|2041
SE|77||ab|14|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|888|2042|2048

SE|77||ab|15|text|2050|2184|In consequence, the inferences made about the role of this group based on our previous work on the monkey enzyme are no longer valid.
SE|77||ab|15|entity|C0679201|inference|idcn|||inferences|||0|966|2070|2080
SE|77||ab|15|entity|C0035820|Role|socb|||role|||0|1000|2096|2100
SE|77||ab|15|entity|C0441833|Groups|inpr|||group|||0|1000|2109|2114
SE|77||ab|15|entity|C0205156|Previous|tmco|||previous|||0|888|2128|2136
SE|77||ab|15|entity|C0043227|Work|ocac|||work|||0|888|2137|2141
SE|77||ab|15|entity|C0026447|Monkeys|mamm|||monkey|||0|888|2149|2155
SE|77||ab|15|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|888|2156|2162
SE|77||ab|15|entity|C0205166|Long|qlco|||longer|||0|661|2170|2176

SE|77||ab|16|text|2184|2306|The present findings are compatible with the essential thiol group playing a conformational role in the catalytic process.
SE|77||ab|16|entity|C0150312|Present|qnco|||present|||0|888|2188|2195
SE|77||ab|16|entity|C0243095|Finding|ftcn|||findings|||0|888|2196|2204
SE|77||ab|16|entity|C1524057|Compatible|qlco|||compatible|||0|1000|2209|2219
SE|77||ab|16|entity|C0205224|Essential|qlco|||essential|||0|851|2229|2238
SE|77||ab|16|entity|C0038734|Sulfhydryl Compounds|orch|||thiol|||0|851|2239|2244
SE|77||ab|16|entity|C0441833|Groups|inpr|||group|||0|851|2245|2250
SE|77||ab|16|entity|C0035820|Role|socb|||role|||0|861|2276|2280
SE|77||ab|16|entity|C0007382|Catalysis|npop|||catalytic|||0|853|2288|2297
SE|77||ab|16|entity|C1522240|Process|phpr|||process|||0|853|2298|2305


SE|78||ti|1|text|15|62|Studies on rat renal cortical cell kallikrein.
SE|78||ti|1|entity|C0008972|Clinical Research|resa|||Studies|||0|966|15|22
SE|78||ti|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|828|26|29
SE|78||ti|1|entity|C1366490|ADRBK1 gene|gngm|156|GRK2|cortical|||0|828|36|44
SE|78||ti|1|entity|C0553257|Renal Cell|cell|||renal cortical cell|||0|828|30|49
SE|78||ti|1|entity|C0022478|Kininogenase|aapp,enzy,phsu|9622|KLK4|kallikrein|||0|828|50|60
SE|78||ti|1|relation|0|0|C0022478|Kininogenase|aapp,gngm,enzy,phsu|aapp|9622|KLK4|kallikrein|||0|828|50|60|MOD/HEAD|PART_OF||30|60|0|0|C0553257|Renal Cell|cell|cell|||renal cortical cell|||0|828|30|49

SE|78||ti|2|text|62|65|I.

SE|78||ti|3|text|65|93|Separation and measurement.
SE|78||ti|3|entity|C0036679|Diastasis|patf|||Separation|||0|1000|65|75
SE|78||ti|3|entity|C0242485|Measurement|ftcn|||measurement|||0|1000|80|91

SE|78||ab|1|text|99|238|A technique has been developed to separate and measure kallikrein in a heterogeneous population of rat renal cortical cells in suspension.
SE|78||ab|1|entity|C0449851|Techniques|ftcn|||technique|||0|1000|101|110
SE|78||ab|1|entity|C0079809|Measures|qnco|||measure|||0|888|146|153
SE|78||ab|1|entity|C0022478|Kininogenase|aapp,enzy,phsu|9622|KLK4|kallikrein|||0|888|154|164
SE|78||ab|1|entity|C1512425|Heterogeneous|qlco|||heterogeneous|||0|888|170|183
SE|78||ab|1|entity|C1257890|Population Group|popg|||population|||0|888|184|194
SE|78||ab|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|843|198|201
SE|78||ab|1|entity|C0022655|Structure of cortex of kidney|bpoc|||renal cortical|||0|843|202|216
SE|78||ab|1|entity|C0007634|Cells|cell|||cells|||0|843|217|222
SE|78||ab|1|entity|C0038960|Suspensions|bodm|||suspension|||0|1000|226|236
SE|78||ab|1|relation|0|0|C0007634|Cells|cell|cell|||cells|||0|843|217|222|MOD/HEAD|PART_OF||202|222|0|0|C0022655|Structure of cortex of kidney|bpoc|bpoc|||renal cortical|||0|843|202|216
SE|78||ab|1|relation|2|1|C0022478|Kininogenase|aapp,gngm,enzy,phsu|phsu|9622|KLK4|kallikrein|||0|888|154|164|PREP|TREATS||165|167|3|1|C1257890|Population Group|popg,humn|popg|||population|||0|888|184|194

SE|78||ab|2|text|238|358|After rat kidneys were perfused in situ in anaesthetized rats, viable, counted cortical cell suspensions were obtained.
SE|78||ab|2|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|888|244|247
SE|78||ab|2|entity|C0022646|Kidney|bpoc|||kidneys|||0|888|248|255
SE|78||ab|2|entity|C0444498|In situ|spco|||in situ|||0|1000|270|277
SE|78||ab|2|entity|C0034693|Rattus norvegicus|mamm|||rats|||0|861|295|299
SE|78||ab|2|entity|C0443348|Viable|qlco|||viable|||0|1000|301|307
SE|78||ab|2|entity|C1366490|ADRBK1 gene|gngm|156|GRK2|cortical|||0|833|317|325
SE|78||ab|2|entity|C0007634|Cells|cell|||cell|||0|833|326|330
SE|78||ab|2|entity|C0038960|Suspensions|bodm|||suspensions|||0|833|331|342
SE|78||ab|2|relation|0|0|C0022646|Kidney|bpoc|bpoc|||kidneys|||0|888|248|255|MOD/HEAD|PART_OF||244|255|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|888|244|247

SE|78||ab|3|text|358|505|Cells were suspended in a sucrose/Tris buffer containing 0.5% deoxycholate, homogenized, centrifuged, dialyzed, and gel filtered on Sephadex G-25.
SE|78||ab|3|entity|C0007634|Cells|cell|||Cells|||0|1000|358|363
SE|78||ab|3|entity|C0038636|Sucrose|bacs,carb|||sucrose|||0|901|384|391
SE|78||ab|3|entity|C0041175|Tromethamine|irda,orch,phsu|||Tris buffer|||0|901|392|403
SE|78||ab|3|entity|C0444499|0/5|qnco|||0.5|||0|901|415|418
SE|78||ab|3|entity|C0086123|Deoxycholate|bacs,phsu,strd|||deoxycholate|||0|901|420|432
SE|78||ab|3|entity|C0179834|Centrifuges|medd|||centrifuged|||0|966|447|458
SE|78||ab|3|entity|C0017243|Gel|bodm|||gel|||0|1000|474|477
SE|78||ab|3|entity|C0141992|sephadex G 25|irda,orch|||Sephadex G-25|||0|1000|490|503
SE|78||ab|3|relation|2|1|C0086123|Deoxycholate|bacs,phsu,strd|bacs|||deoxycholate|||0|901|420|432|VERB|PART_OF||404|414|2|2|C0007634|Cells|cell|cell|||Cells|||0|1000|358|363

SE|78||ab|4|text|505|645|Column chromatography on DEAE-cellulose resulted in a single peak of esterase activity between 0.20 to 0.25 M NaCl/sodium phosphate buffer.
SE|78||ab|4|entity|C0684296|Column Chromatography|lbpr|||Column chromatography|||0|1000|505|526
SE|78||ab|4|entity|C0011050|DEAE-Cellulose|bodm,carb|||DEAE-cellulose|||0|1000|530|544
SE|78||ab|4|entity|C0037179|Unmarried person|popg|||single|||0|694|559|565
SE|78||ab|4|entity|C1149811|esterase activity|moft|||esterase activity|||0|1000|574|591
SE|78||ab|4|entity|C0037494|Sodium Chloride|bacs,inch,phsu|||NaCl|||0|753|615|619
SE|78||ab|4|entity|C0074757|sodium phosphate|inch,phsu|||sodium phosphate|||0|753|620|636
SE|78||ab|4|entity|C0006353|Buffers|bacs,irda|||buffer|||0|753|637|643
SE|78||ab|4|relation|0|0|C0074757|sodium phosphate|inch,phsu|inch|||sodium phosphate|||0|753|620|636|MOD/HEAD|ISA||620|643|0|0|C0006353|Buffers|bacs,irda|bacs|||buffer|||0|753|637|643

SE|78||ab|5|text|645|861|Subsequent elution yielded an alkaline esterase which was identical to kallikrein isolated from rat urine, insofar as pH optimum, effects of inhibitors, bioassay activity and immunological properties were concerned.
SE|78||ab|5|entity|C0750530|SUBSEQUENT|idcn|||Subsequent|||0|888|645|655
SE|78||ab|5|entity|C1441565|ELUTION|lbpr|||elution|||0|888|656|663
SE|78||ab|5|entity|C0002055|Alkalies|inch|||alkaline|||0|853|675|683
SE|78||ab|5|entity|C0014894|ESTERASE|aapp,enzy|||esterase|||0|853|684|692
SE|78||ab|5|entity|C0205280|Identical|qlco|||identical|||0|1000|703|712
SE|78||ab|5|entity|C0022478|Kininogenase|aapp,enzy,phsu|9622|KLK4|kallikrein|||0|1000|716|726
SE|78||ab|5|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|888|741|744
SE|78||ab|5|entity|C0042036|Urine|bdsu|||urine|||0|888|745|750
SE|78||ab|5|entity|C1280500|Effect|qlco|||effects|||0|966|775|782
SE|78||ab|5|entity|C0243077|inhibitors|chvf|||inhibitors|||0|1000|786|796
SE|78||ab|5|entity|C0005507|Biological Assay|lbpr|||bioassay|||0|888|798|806
SE|78||ab|5|entity|C0205470|immunologic|ftcn|||immunological|||0|872|820|833
SE|78||ab|5|entity|C0871161|Property|qlco|||properties|||0|872|834|844
SE|78||ab|5|relation|0|0|C0022478|Kininogenase|aapp,gngm,enzy,phsu|aapp|9622|KLK4|kallikrein|||0|1000|716|726|SPEC|ISA||684|726|0|0|C0014894|ESTERASE|aapp,gngm,enzy|aapp|||esterase|||0|853|684|692
SE|78||ab|5|relation|6|3|C0022478|Kininogenase|aapp,gngm,enzy,phsu|enzy|9622|KLK4|kallikrein|||0|1000|716|726|NOM|INTERACTS_WITH||775|782|3|1|C0243077|inhibitors|chvf|chvf|||inhibitors|||0|1000|786|796

SE|78||ab|6|text|861|965|Calculated yields were about 70% of the total esterase activity present in the parent cell homogenates.
SE|78||ab|6|entity|C0439175|% of total|qnco|||total|||0|861|901|906
SE|78||ab|6|entity|C1149811|esterase activity|moft|||esterase activity|||0|861|907|924
SE|78||ab|6|entity|C0150312|Present|qnco|||present|||0|861|925|932
SE|78||ab|6|entity|C0030551|parent|famg|||parent|||0|623|940|946
SE|78||ab|6|entity|C0007634|Cells|cell|||cell|||0|623|947|951

SE|78||ab|7|text|965|1136|Recoveries of a purified rat urinary kallikrein added to the cell homogenates, the DEAE-cellulose columns, or the eluates from the columns ranged from 83-108% (mean 96%).
SE|78||ab|7|entity|C0237820|Recovery|orgf|||Recoveries|||0|966|965|975
SE|78||ab|7|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|824|990|993
SE|78||ab|7|entity|C0752224|Human Glandular Kallikrein 1|aapp,enzy|||urinary kallikrein|||0|824|994|1012
SE|78||ab|7|entity|C0007634|Cells|cell|||cell|||0|694|1026|1030
SE|78||ab|7|entity|C0011050|DEAE-Cellulose|bodm,carb|||DEAE-cellulose|||0|890|1048|1062
SE|78||ab|7|entity|C1185738|Column|bpoc|||columns|||0|890|1063|1070
SE|78||ab|7|entity|C1185738|Column|bpoc|||columns|||0|966|1096|1103
SE|78||ab|7|relation|0|0|C0752224|Human Glandular Kallikrein 1|aapp,gngm,enzy|aapp|||urinary kallikrein|||0|824|994|1012|MOD/HEAD|PART_OF||990|1012|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|824|990|993

SE|78||ab|8|text|1136|1379|Using this technique, it was found that the amount of kallikrein activity present in non-incubated renal cortical cells ranged from 0.6-10(-2) to 4.6 - 10(-2) alpha-N-tosyl-L-arginine methyl ester (Tos-Arg-OMe) esterase units per 10(8) cells.
SE|78||ab|8|entity|C0449851|Techniques|ftcn|||technique|||0|1000|1147|1156
SE|78||ab|8|entity|C1265611|Quantity|qnco|||amount|||0|1000|1180|1186
SE|78||ab|8|entity|C0022478|Kininogenase|aapp,enzy,phsu|9622|KLK4|kallikrein|||0|851|1190|1200
SE|78||ab|8|entity|C0150312|Present|qnco|||present|||0|851|1210|1217
SE|78||ab|8|entity|C1439852|Incubated|lbpr|||incubated|||0|781|1225|1234
SE|78||ab|8|entity|C0022655|Structure of cortex of kidney|bpoc|||renal cortical|||0|781|1235|1249
SE|78||ab|8|entity|C0007634|Cells|cell|||cells|||0|781|1250|1255
SE|78||ab|8|entity|C0470354|4+6|qnco|||4.6|||0|901|1282|1285
SE|78||ab|8|entity|C0439095|Alpha|inpr|||alpha|||0|759|1295|1300
SE|78||ab|8|entity|C0052335|arginine methyl ester|aapp|||arginine methyl ester|||0|759|1311|1332
SE|78||ab|8|entity|C0014894|ESTERASE|aapp,enzy|||esterase|||0|759|1347|1355
SE|78||ab|8|entity|C0439148|Unit|qnco|||units|||0|759|1356|1361
SE|78||ab|8|entity|C0007634|Cells|cell|||cells|||0|1000|1372|1377
SE|78||ab|8|relation|3|1|C0007634|Cells|cell|cell|||cells|||0|781|1250|1255|PREP|LOCATION_OF||1218|1220|3|1|C0022478|Kininogenase|aapp,gngm,enzy,phsu|aapp|9622|KLK4|kallikrein|||0|851|1190|1200

SE|78||ab|9|text|1379|1637|However, cells incubated in a nutrient medium at 37 degrees C for 3-8 h contained no measurable kallikrein activity, whereas the surrounding medium had kallikrein activity which could be significantly increased by aldosterone and decreased by spironolactone.
SE|78||ab|9|entity|C0007634|Cells|cell|||cells|||0|1000|1388|1393
SE|78||ab|9|entity|C0678695|Nutrients|food|||nutrient|||0|888|1409|1417
SE|78||ab|9|entity|C0439536|Medium|qlco|||medium|||0|888|1418|1424
SE|78||ab|9|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|1431|1440
SE|78||ab|9|entity|C1513040|Measurable|ftcn|||measurable|||0|851|1464|1474
SE|78||ab|9|entity|C0022478|Kininogenase|aapp,enzy,phsu|9622|KLK4|kallikrein|||0|851|1475|1485
SE|78||ab|9|entity|C1282914|Surrounding|spco|||surrounding|||0|888|1508|1519
SE|78||ab|9|entity|C0439536|Medium|qlco|||medium|||0|888|1520|1526
SE|78||ab|9|entity|C0022478|Kininogenase|aapp,enzy,phsu|9622|KLK4|kallikrein|||0|888|1531|1541
SE|78||ab|9|entity|C0002006|Aldosterone|horm,phsu,strd|||aldosterone|||0|1000|1593|1604
SE|78||ab|9|entity|C0037982|Spironolactone|phsu,strd|||spironolactone|||0|1000|1622|1636
SE|78||ab|9|relation|2|1|C0002006|Aldosterone|horm,phsu,strd|horm|||aldosterone|||0|1000|1593|1604|VERB|STIMULATES||1580|1589|7|1|C0022478|Kininogenase|aapp,gngm,enzy,phsu|gngm|9622|KLK4|kallikrein|||0|888|1531|1541
SE|78||ab|9|relation|5|1|C0022478|Kininogenase|aapp,gngm,enzy,phsu|aapp|9622|KLK4|kallikrein|||0|851|1475|1485|VERB|PART_OF||1451|1460|4|4|C0007634|Cells|cell|cell|||cells|||0|1000|1388|1393


SE|79||ti|1|text|15|87|Studies on electron transfer between mercury electrode and hemoprotein.
SE|79||ti|1|entity|C0008972|Clinical Research|resa|||Studies|||0|966|15|22
SE|79||ti|1|entity|C0013846|Electron Transport|moft|||electron transfer|||0|1000|26|43
SE|79||ti|1|entity|C0025424|Mercury|elii,hops|||mercury|||0|888|52|59
SE|79||ti|1|entity|C0013812|electrode|mnob|||electrode|||0|888|60|69
SE|79||ti|1|entity|C0018974|Hemeproteins|aapp,bacs|||hemoprotein|||0|1000|74|85

SE|79||ab|1|text|93|281|The electrochemical behaviour of ferricytochrome c, metmyoglobin and methemoglobin was studied using d.c., a.c. and differential pulse polarography, and controlled potential electrolysis.
SE|79||ab|1|entity|C0004927|Behavior|inbe|||behaviour|||0|861|113|122
SE|79||ab|1|entity|C0010749|CYTOCHROME C|aapp,enzy|||ferricytochrome c|||0|1000|126|143
SE|79||ab|1|entity|C0025852|Metmyoglobin|aapp,bacs|||metmyoglobin|||0|1000|145|157
SE|79||ab|1|entity|C0025635|Methemoglobin|aapp,bacs|||methemoglobin|||0|1000|162|175
SE|79||ab|1|entity|C0012358|Dilatation and Curettage|topp|||d.c|||0|1000|194|197
SE|79||ab|1|entity|C1136392|Pulse Polarography|lbpr|||pulse polarography|||0|901|222|240
SE|79||ab|1|entity|C0702113|Controlled|ftcn|||controlled|||0|851|246|256
SE|79||ab|1|entity|C0237399|Potential|qlco|||potential|||0|851|257|266
SE|79||ab|1|entity|C0013829|Electrolyses|phpr|||electrolysis|||0|851|267|279

SE|79||ab|2|text|281|284|1.

SE|79||ab|3|text|284|438|The three hemoproteins yield d.c. polarographic steps, and peaks in differential pulse polarograms, the height of which is proportional to concentration.
SE|79||ab|3|entity|C0205449|Three|qnco|||three|||0|888|288|293
SE|79||ab|3|entity|C0018974|Hemeproteins|aapp,bacs|||hemoproteins|||0|888|294|306
SE|79||ab|3|entity|C0012358|Dilatation and Curettage|topp|||d.c|||0|834|313|316
SE|79||ab|3|entity|C0032366|Polarography|lbpr|||polarographic|||0|834|318|331
SE|79||ab|3|entity|C1261552|Step|ftcn|||steps|||0|834|332|337
SE|79||ab|3|entity|C1136392|Pulse Polarography|lbpr|||pulse polarograms|||0|848|365|382
SE|79||ab|3|entity|C0487985|BODY HEIGHT:LENGTH:POINT IN TIME:^PATIENT:QUANTITATIVE|clna|||height|||0|1000|388|394
SE|79||ab|3|entity|C0205351|Proportional|qlco|||proportional|||0|1000|407|419

SE|79||ab|4|text|438|494|The charge transfer is influenced by strong adsorption.
SE|79||ab|4|entity|C0348011|Transfer procedure|ftcn|||transfer|||0|861|449|457
SE|79||ab|4|entity|C0442821|Strong|qlco|||strong|||0|888|475|481
SE|79||ab|4|entity|C0001674|Adsorption|lbpr|||adsorption|||0|888|482|492

SE|79||ab|5|text|494|497|2.

SE|79||ab|6|text|497|606|The concentration dependence of the a.c. polarograms indicates structural changes in the adsorbed molecules.
SE|79||ab|6|entity|C0439857|Dependence|mobd|||dependence|||0|861|515|525
SE|79||ab|6|entity|C0032366|Polarography|lbpr|||polarograms|||0|721|538|549
SE|79||ab|6|entity|C0567416|Molecule|sbst|||molecules|||0|827|595|604

SE|79||ab|7|text|606|609|3.

SE|79||ab|8|text|609|770|The reduction products of controlled potential electrolysis of metmyoglobin and methemoglobin have absorption spectra identical with the native control samples.
SE|79||ab|8|entity|C1514468|product|qnco|||products|||0|827|623|631
SE|79||ab|8|entity|C0702113|Controlled|ftcn|||controlled|||0|851|635|645
SE|79||ab|8|entity|C0237399|Potential|qlco|||potential|||0|851|646|655
SE|79||ab|8|entity|C0013829|Electrolyses|phpr|||electrolysis|||0|851|656|668
SE|79||ab|8|entity|C0025852|Metmyoglobin|aapp,bacs|||metmyoglobin|||0|1000|672|684
SE|79||ab|8|entity|C0025635|Methemoglobin|aapp,bacs|||methemoglobin|||0|1000|689|702
SE|79||ab|8|entity|C0205280|Identical|qlco|||identical|||0|1000|727|736
SE|79||ab|8|entity|C0302891|Native|ftcn|||native|||0|623|746|752
SE|79||ab|8|entity|C0243148|control|ftcn|||control|||0|623|753|760

SE|79||ab|9|text|770|881|The affinity for oxygen and the cooperativity in hemoglobin are not affected by the reaction at the electrode.
SE|79||ab|9|entity|C0030054|Oxygen|elii,phsu|||oxygen|||0|1000|787|793
SE|79||ab|9|entity|C0679729|cooperative|orgt|||cooperativity|||0|928|802|815
SE|79||ab|9|entity|C0019046|Hemoglobin|aapp,bacs|||hemoglobin|||0|1000|819|829
SE|79||ab|9|entity|C1518422|Not|ftcn|||not|||0|1000|834|837
SE|79||ab|9|entity|C0443286|Reaction|ftcn|||reaction|||0|1000|854|862
SE|79||ab|9|entity|C0013812|electrode|mnob|||electrode|||0|1000|870|879
SE|79||ab|9|relation|3|2|C0030054|Oxygen|elii,phsu|elii|||oxygen|||0|1000|787|793|PREP|COEXISTS_WITH||816|818|3|1|C0019046|Hemoglobin|aapp,gngm,bacs|aapp|||hemoglobin|||0|1000|819|829

SE|79||ab|10|text|881|884|4.

SE|79||ab|11|text|884|984|The charge transfer proceeds via adsorbed, already reduced, molecules to freely diffusible proteins.
SE|79||ab|11|entity|C0348011|Transfer procedure|ftcn|||transfer|||0|645|895|903
SE|79||ab|11|entity|C0567416|Molecule|sbst|||molecules|||0|966|944|953
SE|79||ab|11|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|827|975|983


SE|80||ti|1|text|15|76|The binding of organic phosphates to human methaemoglobin A.
SE|80||ti|1|entity|C0031701|Phosphoric Acid Esters|opco|||organic phosphates|||0|1000|30|48
SE|80||ti|1|entity|C0020114|Human|humn|||human|||0|888|52|57
SE|80||ti|1|entity|C0025635|Methemoglobin|aapp,bacs|||methaemoglobin|||0|888|58|72
SE|80||ti|1|relation|0|0|C0025635|Methemoglobin|aapp,gngm,bacs|aapp|||methaemoglobin|||0|888|58|72|MOD/HEAD|PART_OF||52|72|0|0|C0020114|Human|grup,humn|humn|||human|||0|888|52|57
SE|80||ti|1|relation|2|1|C0031701|Phosphoric Acid Esters|opco|opco|||organic phosphates|||0|1000|30|48|NOM|INTERACTS_WITH||19|26|2|2|C0025635|Methemoglobin|aapp,gngm,bacs|aapp|||methaemoglobin|||0|888|58|72

SE|80||ti|2|text|76|137|Perturbation of the polymerization of proteins by effectors.
SE|80||ti|2|entity|C0314672|Polymerization|phpr|||polymerization|||0|1000|96|110
SE|80||ti|2|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|114|122

SE|80||ab|1|text|143|265|Theory is presented relating to the binding of an effector to two states of a protein acceptor coexisting in equilibrium.
SE|80||ab|1|entity|C0871935|Theories|idcn|||Theory|||0|966|143|149
SE|80||ab|1|entity|C0205448|Two|qnco|||two|||0|872|205|208
SE|80||ab|1|entity|C1442792|State|ftcn|||states|||0|872|209|215
SE|80||ab|1|entity|C0033684|Proteins|aapp,bacs|||protein|||0|606|221|228
SE|80||ab|1|entity|C0000901|Acceptors|popg|||acceptor|||0|606|229|237
SE|80||ab|1|entity|C0014653|Equilibrium|orgf|||equilibrium|||0|1000|252|263

SE|80||ab|2|text|265|446|The problem is treated in terms of the four possible cases which specify relations between numbers of binding sites and intrinsic binding constants relevant to the acceptor states.
SE|80||ab|2|entity|C0205450|Four|qnco|||four|||0|851|304|308
SE|80||ab|2|entity|C0332149|Possible|qlco|||possible|||0|851|309|317
SE|80||ab|2|entity|C0868928|Case (situation)|ftcn|||cases|||0|851|318|323
SE|80||ab|2|entity|C0869014|Relations|socb|||relations|||0|1000|338|347
SE|80||ab|2|entity|C0237753|Numbers|qnco|||numbers|||0|1000|356|363
SE|80||ab|2|entity|C0005456|Binding Sites|rcpt|||binding sites|||0|1000|367|380
SE|80||ab|2|entity|C0205102|Intrinsic|spco|||intrinsic|||0|785|385|394
SE|80||ab|2|entity|C1547014|*Constant|qnco|||constants|||0|785|403|412
SE|80||ab|2|entity|C0000901|Acceptors|popg|||acceptor|||0|855|429|437
SE|80||ab|2|entity|C1442792|State|ftcn|||states|||0|855|438|444

SE|80||ab|3|text|446|716|It is shown that a distinction between these cases may be possible on the basis of the form of a plot of unbound effector concentration versus the constituent equilibrium coefficient which may be calculated from the sedimentation coefficient of the protein constituent.
SE|80||ab|3|entity|C0868928|Case (situation)|ftcn|||cases|||0|1000|491|496
SE|80||ab|3|entity|C0332149|Possible|qlco|||possible|||0|1000|504|512
SE|80||ab|3|entity|C1527178|Basis|ftcn|||basis|||0|1000|520|525
SE|80||ab|3|entity|C1522492|Formation|ftcn|||form|||0|1000|533|537
SE|80||ab|3|entity|C0729650|Constituents|sbst|||constituent|||0|840|593|604
SE|80||ab|3|entity|C0014653|Equilibrium|orgf|||equilibrium|||0|840|605|616
SE|80||ab|3|entity|C1547015|*Coefficient|qnco|||coefficient|||0|840|617|628
SE|80||ab|3|entity|C0920727|sedimentation coefficient|qnco|||sedimentation coefficient|||0|1000|662|687
SE|80||ab|3|entity|C0033684|Proteins|aapp,bacs|||protein|||0|872|695|702
SE|80||ab|3|entity|C0729650|Constituents|sbst|||constituent|||0|872|703|714

SE|80||ab|4|text|716|951|Particularly noteworthy in this respect is the finding that a turning point may exist in this plot for defined conditions with systems in which binding sites are not conserved (and binding affinities are altered) on polymer formation.
SE|80||ab|4|entity|C0679133|RESPECT|socb|||respect|||0|1000|748|755
SE|80||ab|4|entity|C0037088|Signs and Symptoms|sosy|||finding|||0|1000|763|770
SE|80||ab|4|entity|C0541749|Does turn|fndg|||turning|||0|661|778|785
SE|80||ab|4|entity|C0348080|Condition|qlco|||conditions|||0|827|827|837
SE|80||ab|4|entity|C0449913|System|ftcn|||systems|||0|1000|843|850
SE|80||ab|4|entity|C0005456|Binding Sites|rcpt|||binding sites|||0|1000|860|873
SE|80||ab|4|entity|C1518422|Not|ftcn|||not|||0|1000|878|881
SE|80||ab|4|entity|C0032521|Polymers|bodm,chvs|||polymer|||0|888|932|939
SE|80||ab|4|entity|C1522492|Formation|ftcn|||formation|||0|888|940|949

SE|80||ab|5|text|951|1057|The latter type of system is exemplified by studies on methaemoglobin A in 0.25 M sodium acetate, pH 5.4.
SE|80||ab|5|entity|C1547052|*Type|qnco|||type|||0|861|962|966
SE|80||ab|5|entity|C0449913|System|ftcn|||system|||0|1000|970|976
SE|80||ab|5|entity|C0008972|Clinical Research|resa|||studies|||0|966|995|1002
SE|80||ab|5|entity|C0025635|Methemoglobin|aapp,bacs|||methaemoglobin|||0|1000|1006|1020
SE|80||ab|5|entity|C0142785|Sodium Acetate|orch,phsu|||sodium acetate|||0|785|1033|1047
SE|80||ab|5|relation|4|1|C0025635|Methemoglobin|aapp,gngm,bacs|aapp|||methaemoglobin|||0|1000|1006|1020|PREP|COEXISTS_WITH||1023|1025|1|1|C0142785|Sodium Acetate|orch,phsu|orch|||sodium acetate|||0|785|1033|1047

SE|80||ab|6|text|1057|1267|In the absence of added organic phosphate effectors, a dimer-tetramer equilibrium operates governed by an association constant of 4.15 +/- 0.06 X 10(3) 1/mol, determined from sedimentation equilibrium results.
SE|80||ab|6|entity|C1524062|Additional|ftcn|||added|||0|641|1075|1080
SE|80||ab|6|entity|C0031701|Phosphoric Acid Esters|opco|||organic phosphate|||0|641|1081|1098
SE|80||ab|6|entity|C0596448|dimer|chvs|||dimer|||0|840|1112|1117
SE|80||ab|6|entity|C0039686|Tetrameres|invt|||tetramer|||0|840|1118|1126
SE|80||ab|6|entity|C0014653|Equilibrium|orgf|||equilibrium|||0|840|1127|1138
SE|80||ab|6|entity|C1547014|*Constant|qnco|||constant|||0|861|1175|1183
SE|80||ab|6|entity|C0027960|Nevus|neop|||mol|||0|861|1211|1214
SE|80||ab|6|entity|C0597429|sedimentation equilibrium|npop|||sedimentation equilibrium|||0|890|1232|1257
SE|80||ab|6|entity|C1274040|result|ftcn|||results|||0|890|1258|1265

SE|80||ab|7|text|1267|1592|Correlation of sedimentation velocity and equilibrium results shows that addition of adenosine 5'-triphosphate (ATP) results in its binding to one site on each of the dimeric (alpha beta) and tetrameric (alpha beta)2 species with intrinsic binding constants 1.03-10(3)-1.20-10(3) and 1.1-10(4)-2.1-10(4) 1/mol, respectively.
SE|80||ab|7|entity|C0597430|sedimentation velocity|qnco|||sedimentation velocity|||0|1000|1282|1304
SE|80||ab|7|entity|C0014653|Equilibrium|orgf|||equilibrium|||0|872|1309|1320
SE|80||ab|7|entity|C1274040|result|ftcn|||results|||0|872|1321|1328
SE|80||ab|7|entity|C0442796|Additive|qlco|||addition|||0|928|1340|1348
SE|80||ab|7|entity|C0001480|Adenosine Triphosphate|bacs,nnon,phsu|||adenosine 5'-triphosphate|||0|1000|1352|1377
SE|80||ab|7|entity|C0205447|One|qnco|||one|||0|888|1410|1413
SE|80||ab|7|entity|C0205145|Site|spco|||site|||0|888|1414|1418
SE|80||ab|7|entity|C0596448|dimer|chvs|||dimeric|||0|928|1434|1441
SE|80||ab|7|entity|C0439095|Alpha|inpr|||alpha|||0|861|1443|1448
SE|80||ab|7|entity|C0039686|Tetrameres|invt|||tetrameric|||0|928|1459|1469
SE|80||ab|7|entity|C0439095|Alpha|inpr|||alpha|||0|861|1471|1476
SE|80||ab|7|entity|C1548151|Species|idcn|||species|||0|861|1484|1491
SE|80||ab|7|entity|C0205102|Intrinsic|spco|||intrinsic|||0|711|1497|1506
SE|80||ab|7|entity|C1547014|*Constant|qnco|||constants|||0|711|1515|1524
SE|80||ab|7|entity|C0027960|Nevus|neop|||mol|||0|861|1573|1576

SE|80||ab|8|text|1592|1701|It is also shown that 2,3-diphosphoglycerate perturbs the dimer-tetramer equilibrium in a similar way to ATP.
SE|80||ab|8|entity|C0178597|diphosphoglycerate|carb|||diphosphoglycerate|||0|888|1618|1636
SE|80||ab|8|entity|C0596448|dimer|chvs|||dimer|||0|840|1650|1655
SE|80||ab|8|entity|C0039686|Tetrameres|invt|||tetramer|||0|840|1656|1664
SE|80||ab|8|entity|C0014653|Equilibrium|orgf|||equilibrium|||0|840|1665|1676
SE|80||ab|8|entity|C0001480|Adenosine Triphosphate|bacs,nnon,phsu|||ATP|||0|1000|1697|1700


SE|81||ti|1|text|15|86|N-terminal spin label studies of hemoglobin, Ligand and pH dependence.
SE|81||ti|1|entity|C0037914|Spin Labels|irda|||spin label|||0|838|26|36
SE|81||ti|1|entity|C0019046|Hemoglobin|aapp,bacs|||hemoglobin|||0|1000|48|58
SE|81||ti|1|entity|C0023688|Ligands|chem|||Ligand|||0|1000|60|66
SE|81||ti|1|entity|C0439857|Dependence|mobd|||dependence|||0|888|74|84

SE|81||ab|1|text|92|315|Human hemoglobin was spin labeled with 4-isothiocanato-2,2,6,6-tetramethyl-piperdinooxyl, which is known to bind specifically to the N-terminal alpha-amino groups of proteins and slightly to the reactive sulfhydryl groups.
SE|81||ab|1|entity|C0020114|Human|humn|||Human|||0|888|92|97
SE|81||ab|1|entity|C0019046|Hemoglobin|aapp,bacs|||hemoglobin|||0|888|98|108
SE|81||ab|1|entity|C0439095|Alpha|inpr|||alpha|||0|826|236|241
SE|81||ab|1|entity|C0596072|amino group|inch|||amino groups|||0|826|242|254
SE|81||ab|1|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|258|266
SE|81||ab|1|entity|C0750482|SLIGHTLY|idcn|||slightly|||0|1000|271|279
SE|81||ab|1|entity|C0205332|Reactive|qlco|||reactive|||0|890|287|295
SE|81||ab|1|entity|C0038734|Sulfhydryl Compounds|orch|||sulfhydryl groups|||0|890|296|313
SE|81||ab|1|relation|0|0|C0019046|Hemoglobin|aapp,gngm,bacs|aapp|||hemoglobin|||0|888|98|108|MOD/HEAD|PART_OF||92|108|0|0|C0020114|Human|grup,humn|humn|||Human|||0|888|92|97
SE|81||ab|1|relation|3|3|C0019046|Hemoglobin|aapp,gngm,bacs|aapp|||hemoglobin|||0|888|98|108|VERB|INTERACTS_WITH||200|204|3|1|C0596072|amino group|inch|inch|||amino groups|||0|826|242|254

SE|81||ab|2|text|315|485|Electron spin resonance (ESR) analysis indicated a partially resolved five-line spectrum, suggesting that the label was attached to at least two different binding sites.
SE|81||ab|2|entity|C0013852|Electrons|qnco|||Electron|||0|825|315|323
SE|81||ab|2|entity|C0858625|Spinning|sosy|||spin|||0|825|324|328
SE|81||ab|2|entity|C0459800|Vibration - physical agent|npop|||resonance|||0|825|329|338
SE|81||ab|2|entity|C0936012|Analysis|resa|||analysis|||0|825|345|353
SE|81||ab|2|entity|C0750521|RESOLVING|idcn|||resolved|||0|569|376|384
SE|81||ab|2|entity|C0205451|Five|qnco|||five|||0|569|385|389
SE|81||ab|2|entity|C0205132|Linear|spco|||line|||0|569|390|394
SE|81||ab|2|entity|C0181496|Labels|mnob|||label|||0|1000|425|430
SE|81||ab|2|entity|C0205448|Two|qnco|||two|||0|775|456|459
SE|81||ab|2|entity|C1547020|*Difference|qnco|||different|||0|775|460|469
SE|81||ab|2|entity|C0005456|Binding Sites|rcpt|||binding sites|||0|775|470|483

SE|81||ab|3|text|485|688|Using specific blocking reagents prior to spin labeling, the two binding sites were attributed to the sulfhydryl group of beta-93 (immobile) and the alpha-amino group of the N-terminal valines (mobile).
SE|81||ab|3|entity|C0332206|Blocking|ftcn|||blocking|||0|790|500|508
SE|81||ab|3|entity|C0034760|Reagents|irda|||reagents|||0|790|509|517
SE|81||ab|3|entity|C0205448|Two|qnco|||two|||0|901|546|549
SE|81||ab|3|entity|C0005456|Binding Sites|rcpt|||binding sites|||0|901|550|563
SE|81||ab|3|entity|C0038734|Sulfhydryl Compounds|orch|||sulfhydryl group|||0|1000|587|603
SE|81||ab|3|entity|C0231441|Immobile|fndg|||immobile|||0|1000|616|624
SE|81||ab|3|entity|C0439095|Alpha|inpr|||alpha|||0|901|634|639
SE|81||ab|3|entity|C0596072|amino group|inch|||amino group|||0|901|640|651
SE|81||ab|3|entity|C0042285|Valine|aapp,bacs,phsu|||valines|||0|829|670|677
SE|81||ab|3|entity|C0231435|Mobile|ftcn|||mobile|||0|1000|679|685

SE|81||ab|4|text|688|1117|The relative motion of the spin at one set of binding sites was restricted regardless of the state of ligation and pH, while the motion at the other site showed dependence on those parameters, e.g. the spin-labeled N-terminal ends of deoxyhemoglobin have restricted motion at all pH ranges studied, while those of oxyhemoglobin are relatively free to move at the basic pH range, but become more restricted in the acidic pH range.
SE|81||ab|4|entity|C0205345|Relative|qlco|||relative|||0|888|692|700
SE|81||ab|4|entity|C0026597|Motion|npop|||motion|||0|888|701|707
SE|81||ab|4|entity|C0205447|One|qnco|||one|||0|1000|723|726
SE|81||ab|4|entity|C0005456|Binding Sites|rcpt|||binding sites|||0|1000|734|747
SE|81||ab|4|entity|C1442792|State|ftcn|||state|||0|1000|781|786
SE|81||ab|4|entity|C0023690|Ligation|topp|||ligation|||0|1000|790|798
SE|81||ab|4|entity|C0026597|Motion|npop|||motion|||0|1000|817|823
SE|81||ab|4|entity|C0205145|Site|spco|||site|||0|1000|837|841
SE|81||ab|4|entity|C0439857|Dependence|mobd|||dependence|||0|1000|849|859
SE|81||ab|4|entity|C0037914|Spin Labels|irda|||spin-labeled|||0|820|890|902
SE|81||ab|4|entity|C0444930|End|spco|||ends|||0|820|914|918
SE|81||ab|4|entity|C0057437|deoxyhemoglobin|bacs,orch|||deoxyhemoglobin|||0|1000|922|937
SE|81||ab|4|entity|C0443288|Restricted|ftcn|||restricted|||0|888|943|953
SE|81||ab|4|entity|C0026597|Motion|npop|||motion|||0|888|954|960
SE|81||ab|4|entity|C1514721|Range|qnco|||ranges|||0|888|971|977
SE|81||ab|4|entity|C0030069|Oxyhemoglobin|aapp,bacs|||oxyhemoglobin|||0|1000|1002|1015
SE|81||ab|4|entity|C1514721|Range|qnco|||range|||0|828|1060|1065
SE|81||ab|4|entity|C0205172|More|ftcn|||more|||0|1000|1078|1082
SE|81||ab|4|entity|C0001128|Acids|chem|||acidic|||0|828|1101|1107
SE|81||ab|4|entity|C1514721|Range|qnco|||range|||0|828|1111|1116


SE|82||ti|1|text|15|93|The behavior of holo- and apo-forms of bovine superoxide dismutase at low pH.
SE|82||ti|1|entity|C0004927|Behavior|inbe|||behavior|||0|1000|19|27
SE|82||ti|1|entity|C0078040|doxorubicin/prednisone/vincristine protocol|topp|||apo|||0|888|41|44
SE|82||ti|1|entity|C0007452|Cattle|mamm|||bovine|||0|901|54|60
SE|82||ti|1|entity|C0038838|Superoxide Dismutase|aapp,enzy,phsu|||superoxide dismutase|||0|901|61|81
SE|82||ti|1|entity|C0728725|Hydrogen ion increase|fndg|||low pH|||0|1000|85|91
SE|82||ti|1|relation|0|0|C0038838|Superoxide Dismutase|aapp,gngm,enzy,phsu|aapp|||superoxide dismutase|||0|901|61|81|MOD/HEAD|PART_OF||54|81|0|0|C0007452|Cattle|mamm|mamm|||bovine|||0|901|54|60

SE|82||ab|1|text|99|102|1.

SE|82||ab|2|text|102|237|Holo-superoxide dismutase from bovine erythrocytes has been shown to undergo a reversible structural modification in the pH 3-5 range.
SE|82||ab|2|entity|C0038838|Superoxide Dismutase|aapp,enzy,phsu|||superoxide dismutase|||0|901|107|127
SE|82||ab|2|entity|C0007452|Cattle|mamm|||bovine|||0|888|133|139
SE|82||ab|2|entity|C0014792|Erythrocytes|cell|||erythrocytes|||0|888|140|152
SE|82||ab|2|entity|C0205343|Reversible|ftcn|||reversible|||0|901|181|191
SE|82||ab|2|entity|C0581602|Structural modification|topp|||structural modification|||0|901|192|215
SE|82||ab|2|entity|C0601906|PH.3|phsu|||pH 3|||0|824|223|227
SE|82||ab|2|entity|C1514721|Range|qnco|||range|||0|824|230|235
SE|82||ab|2|relation|0|0|C0014792|Erythrocytes|cell|cell|||erythrocytes|||0|888|140|152|MOD/HEAD|PART_OF||133|152|0|0|C0007452|Cattle|mamm|mamm|||bovine|||0|888|133|139
SE|82||ab|2|relation|3|1|C0014792|Erythrocytes|cell|cell|||erythrocytes|||0|888|140|152|PREP|LOCATION_OF||128|132|1|1|C0038838|Superoxide Dismutase|aapp,gngm,enzy,phsu|aapp|||superoxide dismutase|||0|901|107|127

SE|82||ab|3|text|237|240|2.

SE|82||ab|4|text|240|487|The spectral alterations observed on changing from neutrality to pH 2 were: a slight attenuation of the 680 nm absorbance; the loss of the 450 nm shoulder, apparent in the optical spectrum of the native protein; and a new band appeared at 330 nm.
SE|82||ab|4|entity|C1515926|Alteration|idcn|||alterations|||0|827|253|264
SE|82||ab|4|entity|C0392747|Changing|ftcn|||changing|||0|1000|277|285
SE|82||ab|4|entity|C0680444|neutrality|idcn|||neutrality|||0|1000|291|301
SE|82||ab|4|entity|C0547040|Minimal|qlco|||slight|||0|888|318|324
SE|82||ab|4|entity|C0599946|attenuation|genf|||attenuation|||0|888|325|336
SE|82||ab|4|entity|C1268822|Optical density function|clna|||absorbance|||0|827|351|361
SE|82||ab|4|entity|C1517945|Loss|qnco|||loss|||0|1000|367|371
SE|82||ab|4|entity|C0037004|Shoulder|bpoc|||shoulder|||0|827|386|394
SE|82||ab|4|entity|C0750489|APPARENT|idcn|||apparent|||0|1000|396|404
SE|82||ab|4|entity|C0042789|Vision|orgf|||optical|||0|638|412|419
SE|82||ab|4|entity|C0302891|Native|ftcn|||native|||0|888|436|442
SE|82||ab|4|entity|C0033684|Proteins|aapp,bacs|||protein|||0|888|443|450
SE|82||ab|4|entity|C0205314|New|tmco|||new|||0|888|458|461
SE|82||ab|4|entity|C0175723|Bands|medd|||band|||0|888|462|466

SE|82||ab|5|text|487|588|The circular dichroism at 600 nm was essentially lost while a weak negative band appeared at approx.
SE|82||ab|5|entity|C0008813|Circular Dichroism|lbpr,npop|||circular dichroism|||0|1000|491|509
SE|82||ab|5|entity|C0004093|Asthenia|sosy|||weak|||0|851|549|553
SE|82||ab|5|entity|C0205160|Negative|qlco|||negative|||0|851|554|562
SE|82||ab|5|entity|C0175723|Bands|medd|||band|||0|851|563|567

SE|82||ab|6|text|588|626|380 nm and a positive band at 310 nm.
SE|82||ab|6|entity|C1446409|Positive|qlco|||positive|||0|888|601|609
SE|82||ab|6|entity|C0175723|Bands|medd|||band|||0|888|610|614

SE|82||ab|7|text|626|629|3.

SE|82||ab|8|text|629|897|The EPR spectrum was also modified on changing from the native to the low pH form: A parallel increased from approximately 130 to approximately 150 G, g parallel remained unchanged at approximately 2.27, and gm decreased from approximately 2.09 to approximately 2.08.
SE|82||ab|8|entity|||gngm|2069|EREG|EPR|||0|1000|633|636
SE|82||ab|8|entity|C0392747|Changing|ftcn|||changing|||0|1000|667|675
SE|82||ab|8|entity|C0302891|Native|ftcn|||native|||0|1000|685|691
SE|82||ab|8|entity|C0728725|Hydrogen ion increase|fndg|||low pH|||0|901|699|705
SE|82||ab|8|entity|C1522492|Formation|ftcn|||form|||0|901|706|710
SE|82||ab|8|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|861|738|751
SE|82||ab|8|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|785|759|772
SE|82||ab|8|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|827|813|826
SE|82||ab|8|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|827|855|868
SE|82||ab|8|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|827|877|890

SE|82||ab|9|text|897|951|The apparent linewidth remained essentially constant.
SE|82||ab|9|entity|C0750489|APPARENT|idcn|||apparent|||0|694|901|909
SE|82||ab|9|entity|C1547014|*Constant|qnco|||constant|||0|861|941|949

SE|82||ab|10|text|951|954|4.

SE|82||ab|11|text|954|1100|High resolution (220 MHz) PMR spectra of holo- and apoproteins revealed that the metals influence the three-dimensional structure of the protein.
SE|82||ab|11|entity|C0205250|High|qlco|||High|||0|888|954|958
SE|82||ab|11|entity|C1514893|Resolution|ftcn|||resolution|||0|888|959|969
SE|82||ab|11|entity|C0556962|MHz|qnco|||MHz|||0|861|975|978
SE|82||ab|11|entity|C0003601|Apoproteins|aapp,bacs|||apoproteins|||0|1000|1005|1016
SE|82||ab|11|entity|C0025552|Metals|inch|||metals|||0|1000|1035|1041
SE|82||ab|11|entity|C0450363|Three-dimensional|spco|||three-dimensional|||0|901|1056|1073
SE|82||ab|11|entity|C0678594|Structure|spco|||structure|||0|901|1074|1083
SE|82||ab|11|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|1091|1098

SE|82||ab|12|text|1100|1103|5.

SE|82||ab|13|text|1103|1280|PMR studies indicated that at pH 3 the apoprotein existed almost entirely in a random coil form and that it assumed a compact well-ordered structure on returning to neutral pH.
SE|82||ab|13|entity|C0008972|Clinical Research|resa|||studies|||0|827|1107|1114
SE|82||ab|13|entity|C0601906|PH.3|phsu|||pH 3|||0|1000|1133|1137
SE|82||ab|13|entity|C0003601|Apoproteins|aapp,bacs|||apoprotein|||0|1000|1142|1152
SE|82||ab|13|entity|C0439605|Random|qlco|||random|||0|840|1182|1188
SE|82||ab|13|entity|C0444764|Coils|spco|||coil|||0|840|1189|1193
SE|82||ab|13|entity|C1522492|Formation|ftcn|||form|||0|840|1194|1198
SE|82||ab|13|entity|C0205170|Good|qlco|||well|||0|763|1229|1233
SE|82||ab|13|entity|C0678594|Structure|spco|||structure|||0|763|1242|1251

SE|82||ab|14|text|1280|1361|The holoprotein maintained a compact, apparently dimeric, structure even at pH 3.
SE|82||ab|14|entity|C0750541|APPARENTLY|idcn|||apparently|||0|754|1318|1328
SE|82||ab|14|entity|C0596448|dimer|chvs|||dimeric|||0|754|1329|1336
SE|82||ab|14|entity|C0601906|PH.3|phsu|||pH 3|||0|1000|1356|1360


SE|83||ti|1|text|15|60|Mechanical precipitation of hemoglobin koln.
SE|83||ti|1|entity|C0032931|Precipitation|npop|||precipitation|||0|861|26|39
SE|83||ti|1|entity|C0062371|hemoglobin Koln|aapp,bacs|||hemoglobin koln|||0|1000|43|58

SE|83||ab|1|text|66|161|Hb Koln (beta 98 Val leads to Met) was found to precipitate rapidly during mechanical shaking.
SE|83||ab|1|entity|C0062371|hemoglobin Koln|aapp,bacs|||Hb Koln|||0|1000|66|73
SE|83||ab|1|entity|C0718917|Beta-Val|orch,phsu|||beta 98 Val|||0|913|75|86
SE|83||ab|1|entity|C0040822|Tremor|sosy|||shaking|||0|861|152|159
SE|83||ab|1|relation|3|3|C0062371|hemoglobin Koln|aapp,gngm,bacs|gngm|||Hb Koln|||0|1000|66|73|VERB|CAUSES||114|125|1|1|C0040822|Tremor|sosy|sosy|||shaking|||0|861|152|159

SE|83||ab|2|text|161|237|The rate of precipitation of Hb Koln is 5-6 times faster than that of Hb S.
SE|83||ab|2|entity|C1521828|Rate|qnco|||rate|||0|1000|165|169
SE|83||ab|2|entity|C0032931|Precipitation|npop|||precipitation|||0|1000|173|186
SE|83||ab|2|entity|C0062371|hemoglobin Koln|aapp,bacs|||Hb Koln|||0|1000|190|197
SE|83||ab|2|entity|C0439084|>5|qnco|||5-6|||0|785|201|204
SE|83||ab|2|entity|C0040223|Time|tmco|||times|||0|785|205|210
SE|83||ab|2|entity|C0456962|Fast|qlco|||faster|||0|966|211|217

SE|83||ab|3|text|237|422|The kinetics of precipitation of the patient's hemolysate, which is a mixture of Hb Koln and Hb A, showed a biphasic curve indicating that Hb Koln precipitates independently from Hb A.
SE|83||ab|3|entity|C0022702|Kinetics|idcn|||kinetics|||0|1000|241|249
SE|83||ab|3|entity|C0032931|Precipitation|npop|||precipitation|||0|1000|253|266
SE|83||ab|3|entity|C0030705|Patients|podg|||patient's|||0|694|274|283
SE|83||ab|3|entity|C0439962|Mixture|sbst|||mixture|||0|1000|307|314
SE|83||ab|3|entity|C0062371|hemoglobin Koln|aapp,bacs|||Hb Koln|||0|1000|318|325
SE|83||ab|3|entity|C0205184|Biphasic|tmco|||biphasic|||0|853|345|353
SE|83||ab|3|entity|C0205134|Curved|spco|||curve|||0|853|354|359
SE|83||ab|3|entity|C0062371|hemoglobin Koln|aapp,bacs|||Hb Koln|||0|1000|376|383

SE|83||ab|4|text|422|521|The instability of Hb Koln may be attributed to the conformational change in the vicinity of heme.
SE|83||ab|4|entity|C1444783|Instability|fndg|||instability|||0|1000|426|437
SE|83||ab|4|entity|C0062371|hemoglobin Koln|aapp,bacs|||Hb Koln|||0|1000|441|448
SE|83||ab|4|entity|C0301641|Macromolecular alteration|moft|||conformational change|||0|1000|474|495
SE|83||ab|4|entity|C0018966|Heme|bacs,orch|||heme|||0|1000|515|519

SE|83||ab|5|text|521|653|The mechanical shaking may be used as a new method for detection and quantitation of hemoglobin Koln and other unstable hemoglobins.
SE|83||ab|5|entity|C0040822|Tremor|sosy|||shaking|||0|861|536|543
SE|83||ab|5|entity|C0205314|New|tmco|||new|||0|888|561|564
SE|83||ab|5|entity|C0025663|Methods|inpr|||method|||0|888|565|571
SE|83||ab|5|entity|C1511790|Detection|topp|||detection|||0|1000|576|585
SE|83||ab|5|entity|C0062371|hemoglobin Koln|aapp,bacs|||hemoglobin Koln|||0|1000|606|621
SE|83||ab|5|entity|C0347532|Unstable hemoglobin|aapp,bacs|||unstable hemoglobins|||0|983|632|652


SE|84||ti|1|text|15|84|Physical properties and subunits of Haemopis grandis erythrocruorin.
SE|84||ti|1|entity|C0597238|Physical Property|qnco|||Physical properties|||0|1000|15|34
SE|84||ti|1|entity|C1472275|Haemopis grandis|invt|||Haemopis grandis|||0|901|51|67
SE|84||ti|1|entity|C0082471|erythrocruorin|aapp|||erythrocruorin|||0|901|68|82
SE|84||ti|1|relation|0|0|C0082471|erythrocruorin|aapp,gngm|gngm|||erythrocruorin|||0|901|68|82|MOD/HEAD|PART_OF||51|82|0|0|C1472275|Haemopis grandis|invt|invt|||Haemopis grandis|||0|901|51|67

SE|84||ab|1|text|90|318|The erythrocruorin of the leech Haemopis grandis possessed an S20,w of 57 S at neutral pH, its isoelectric point at pH 6.0 and exhibited a slightly sigmoid oxygenation curve with n approximately 2.1 and P50 = 11.2 mm at pH 7.4.
SE|84||ab|1|entity|C0082471|erythrocruorin|aapp|||erythrocruorin|||0|1000|94|108
SE|84||ab|1|entity|C0023209|Leeches|invt|||leech|||0|901|116|121
SE|84||ab|1|entity|C1472275|Haemopis grandis|invt|||Haemopis grandis|||0|901|122|138
SE|84||ab|1|entity|||gngm|6224|RPS20|S20|||0|1000|152|155
SE|84||ab|1|entity|C0022171|Isoelectric Point|qnco|||isoelectric point|||0|1000|185|202
SE|84||ab|1|entity|C0750482|SLIGHTLY|idcn|||slightly|||0|751|229|237
SE|84||ab|1|entity|C0231940|Alveolar ventilation function|ortf|||oxygenation|||0|751|246|257
SE|84||ab|1|entity|C0205134|Curved|spco|||curve|||0|751|258|263
SE|84||ab|1|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|750|271|284
SE|84||ab|1|entity|C1367009|TNFRSF5 gene|gngm|958|CD40|P50|||0|1000|293|296
SE|84||ab|1|relation|0|0|C1472275|Haemopis grandis|invt|invt|||Haemopis grandis|||0|901|122|138|MOD/HEAD|ISA||116|138|0|0|C0023209|Leeches|invt|invt|||leech|||0|901|116|121
SE|84||ab|1|relation|1|1|C0082471|erythrocruorin|aapp,gngm|gngm|||erythrocruorin|||0|1000|94|108|PREP|PART_OF||109|111|9|1|C1472275|Haemopis grandis|invt|invt|||Haemopis grandis|||0|901|122|138

SE|84||ab|2|text|318|482|A minimum molecular weight of 24000 +/- 1500 per heme group was determined from the iron and heme contents, 0.22 +/- 0.01 and 2.73 +/- 0.14 weight %, respectively.
SE|84||ab|2|entity|C1524031|Minimum|qlco|||minimum|||0|901|320|327
SE|84||ab|2|entity|C0026385|Molecular Weight|qnco|||molecular weight|||0|901|328|344
SE|84||ab|2|entity|C0005810|Blood groups|inpr|||heme group|||0|950|367|377
SE|84||ab|2|entity|C0302583|Iron|bacs,elii,phsu|||iron|||0|1000|402|406
SE|84||ab|2|entity|C0018966|Heme|bacs,orch|||heme|||0|888|411|415
SE|84||ab|2|entity|C0456205|Contents|sbst|||contents|||0|888|416|424
SE|84||ab|2|entity|C0043100|Weight|qnco|||weight|||0|804|458|464

SE|84||ab|3|text|482|672|The subunit composition of the erythrocruorin was investigated using gel filtration in sodium dodecyl sulfate and polyacrylamide gel electrophoresis in sodium dodecyl sulfate at neutral pH.
SE|84||ab|3|entity|C0486616|Composition|clna|||composition|||0|861|494|505
SE|84||ab|3|entity|C0082471|erythrocruorin|aapp|||erythrocruorin|||0|1000|513|527
SE|84||ab|3|entity|C0008559|Chromatography, Gel|lbpr|||gel filtration|||0|1000|551|565
SE|84||ab|3|entity|C0037506|Sodium Dodecyl Sulfate|bodm,lipd,phsu|||sodium dodecyl sulfate|||0|1000|569|591
SE|84||ab|3|entity|C0013862|Electrophoresis, Polyacrylamide Gel|lbpr|||polyacrylamide gel electrophoresis|||0|1000|596|630
SE|84||ab|3|entity|C0037506|Sodium Dodecyl Sulfate|bodm,lipd,phsu|||sodium dodecyl sulfate|||0|1000|634|656
SE|84||ab|3|relation|3|2|C0082471|erythrocruorin|aapp,gngm|aapp|||erythrocruorin|||0|1000|513|527|PREP|COEXISTS_WITH||566|568|4|1|C0037506|Sodium Dodecyl Sulfate|bodm,lipd,phsu|lipd|||sodium dodecyl sulfate|||0|1000|569|591

SE|84||ab|4|text|672|866|Haemopis erythrocruorin dissociated in the presence of sodium dodecyl sulfate into four subunits (1 through 4) possessing molecular weights of about 27000, 23000, 21000 and 13500, respectively.
SE|84||ab|4|entity|C1007612|Haemopis|invt|||Haemopis|||0|888|672|680
SE|84||ab|4|entity|C0082471|erythrocruorin|aapp|||erythrocruorin|||0|888|681|695
SE|84||ab|4|entity|C0037506|Sodium Dodecyl Sulfate|bodm,lipd,phsu|||sodium dodecyl sulfate|||0|1000|727|749
SE|84||ab|4|entity|C0205450|Four|qnco|||four|||0|694|755|759
SE|84||ab|4|entity|C0026385|Molecular Weight|qnco|||molecular weights|||0|1000|794|811
SE|84||ab|4|relation|0|0|C0082471|erythrocruorin|aapp,gngm|gngm|||erythrocruorin|||0|888|681|695|MOD/HEAD|PART_OF||672|695|0|0|C1007612|Haemopis|invt|invt|||Haemopis|||0|888|672|680
SE|84||ab|4|relation|1|1|C0082471|erythrocruorin|aapp,gngm|aapp|||erythrocruorin|||0|888|681|695|NOM|COEXISTS_WITH||715|723|3|1|C0037506|Sodium Dodecyl Sulfate|bodm,lipd,phsu|lipd|||sodium dodecyl sulfate|||0|1000|727|749

SE|84||ab|5|text|866|1080|When the erythrocruorin was reduced with mercaptoethanol prior to sodium dodecyl sulfate electrophoresis, three subunits  were observed, possessing molecular weights of about 13000 (I), 16500 (II) and 28000 (III).
SE|84||ab|5|entity|C0082471|erythrocruorin|aapp|||erythrocruorin|||0|1000|875|889
SE|84||ab|5|entity|C0025402|2-Mercaptoethanol|orch|||mercaptoethanol|||0|1000|907|922
SE|84||ab|5|entity|C0037506|Sodium Dodecyl Sulfate|bodm,lipd,phsu|||sodium dodecyl sulfate|||0|916|932|954
SE|84||ab|5|entity|C0013855|Electrophoresis|lbpr|||electrophoresis|||0|916|955|970
SE|84||ab|5|entity|C0205449|Three|qnco|||three|||0|694|972|977
SE|84||ab|5|entity|C0026385|Molecular Weight|qnco|||molecular weights|||0|1000|1014|1031
SE|84||ab|5|entity|C0439070|III|inpr|||III|||0|1000|1074|1077
SE|84||ab|5|relation|0|0|C0013855|Electrophoresis|lbpr|lbpr|||electrophoresis|||0|916|955|970|MOD/HEAD|USES||932|970|0|0|C0037506|Sodium Dodecyl Sulfate|bodm,lipd,phsu|phsu|||sodium dodecyl sulfate|||0|916|932|954
SE|84||ab|5|relation|1|1|C0082471|erythrocruorin|aapp,gngm|aapp|||erythrocruorin|||0|1000|875|889|VERB|INHIBITS||894|901|6|1|C0025402|2-Mercaptoethanol|orch|orch|||mercaptoethanol|||0|1000|907|922
SE|84||ab|5|relation|1|1|C0082471|erythrocruorin|aapp,gngm|aapp|||erythrocruorin|||0|1000|875|889|VERB|INHIBITS||894|901|6|1|C0037506|Sodium Dodecyl Sulfate|bodm,lipd,phsu|lipd|||sodium dodecyl sulfate|||0|916|932|954

SE|84||ab|6|text|1080|1311|Sodium dodecyl sulfate electrophoresis of the isolated subunits 1 through 4 showed that subunit I was provided by subunits 1 and 4, subunit II was provided by subunit 1 and subunit III was provided by both subunit 2 and subunit 3.
SE|84||ab|6|entity|C0037506|Sodium Dodecyl Sulfate|bodm,lipd,phsu|||Sodium dodecyl sulfate|||0|916|1080|1102
SE|84||ab|6|entity|C0013855|Electrophoresis|lbpr|||electrophoresis|||0|916|1103|1118
SE|84||ab|6|entity|C0205409|Isolated|ftcn|||isolated|||0|827|1126|1134
SE|84||ab|6|entity|C0439070|III|inpr|||III|||0|861|1261|1264
SE|84||ab|6|relation|0|0|C0013855|Electrophoresis|lbpr|lbpr|||electrophoresis|||0|916|1103|1118|MOD/HEAD|USES||1080|1118|0|0|C0037506|Sodium Dodecyl Sulfate|bodm,lipd,phsu|phsu|||Sodium dodecyl sulfate|||0|916|1080|1102

SE|84||ab|7|text|1311|1407|Haemopis erythrocruorin thus appeared to consist of at least five different polypeptide chains.
SE|84||ab|7|entity|C1007612|Haemopis|invt|||Haemopis|||0|888|1311|1319
SE|84||ab|7|entity|C0082471|erythrocruorin|aapp|||erythrocruorin|||0|888|1320|1334
SE|84||ab|7|entity|C0205451|Five|qnco|||five|||0|545|1372|1376
SE|84||ab|7|entity|C1547020|*Difference|qnco|||different|||0|545|1377|1386
SE|84||ab|7|entity|C1305923|Polypeptides|aapp|||polypeptide|||0|545|1387|1398
SE|84||ab|7|relation|0|0|C0082471|erythrocruorin|aapp,gngm|gngm|||erythrocruorin|||0|888|1320|1334|MOD/HEAD|PART_OF||1311|1334|0|0|C1007612|Haemopis|invt|invt|||Haemopis|||0|888|1311|1319

SE|84||ab|8|text|1407|1511|It is likely that not all of the constituent polypeptide chains were associated each with a heme group.
SE|84||ab|8|entity|C1518422|Not|ftcn|||not|||0|1000|1425|1428
SE|84||ab|8|entity|C0729650|Constituents|sbst|||constituent|||0|606|1440|1451
SE|84||ab|8|entity|C1305923|Polypeptides|aapp|||polypeptide|||0|606|1452|1463
SE|84||ab|8|entity|C0005810|Blood groups|inpr|||heme group|||0|950|1499|1509

SE|84||ab|9|text|1511|1707|The shape of the Haemopis erythrocruorin observed by electron microscopy appeared to be consistent with the two-tiered hexagonal array characteristic of annelid erythrocruorins and chlorocruorins.
SE|84||ab|9|entity|C0332479|Shapes|spco|||shape|||0|1000|1515|1520
SE|84||ab|9|entity|C1007612|Haemopis|invt|||Haemopis|||0|888|1528|1536
SE|84||ab|9|entity|C0082471|erythrocruorin|aapp|||erythrocruorin|||0|888|1537|1551
SE|84||ab|9|entity|C0026019|Electron Microscopy|lbpr|||electron microscopy|||0|1000|1564|1583
SE|84||ab|9|entity|C0205448|Two|qnco|||two|||0|791|1619|1622
SE|84||ab|9|entity|C1510941|Array|spco|||array|||0|791|1640|1645
SE|84||ab|9|entity|C1521970|Characteristics|grpa|||characteristic|||0|966|1646|1660
SE|84||ab|9|entity|C0003096|Annelida|invt|||annelid|||0|888|1664|1671
SE|84||ab|9|entity|C0014764|Erythrocruorins|aapp,bacs|||erythrocruorins|||0|888|1672|1687
SE|84||ab|9|relation|0|0|C0014764|Erythrocruorins|aapp,gngm,bacs|gngm|||erythrocruorins|||0|888|1672|1687|MOD/HEAD|PART_OF||1664|1687|0|0|C0003096|Annelida|invt|invt|||annelid|||0|888|1664|1671
SE|84||ab|9|relation|0|0|C0082471|erythrocruorin|aapp,gngm|gngm|||erythrocruorin|||0|888|1537|1551|MOD/HEAD|PART_OF||1528|1551|0|0|C1007612|Haemopis|invt|invt|||Haemopis|||0|888|1528|1536


SE|85||ti|1|text|15|95|Myosin from arterial smooth muscle: isolation following actin depolymerization.
SE|85||ti|1|entity|||gngm|79784|MYH14|Myosin|||0|1000|15|21
SE|85||ti|1|entity|C0221464|Arterial|spco|||arterial|||0|901|27|35
SE|85||ti|1|entity|C1267092|Smooth muscle (tissue)|tisu|||smooth muscle|||0|901|36|49
SE|85||ti|1|entity|C0204727|Isolation procedure|topp|||isolation|||0|1000|51|60
SE|85||ti|1|entity|C1155980|actin filament depolymerization|celf|||actin depolymerization|||0|1000|71|93
SE|85||ti|1|relation|3|1|C1267092|Smooth muscle (tissue)|tisu|tisu|||smooth muscle|||0|901|36|49|PREP|LOCATION_OF||22|26|1|1|||gngm,aapp|aapp|79784|MYH14|Myosin|||0|1000|15|21

SE|85||ab|1|text|101|208|The contractile proteins from arterial smooth muscle are highly soluble, and can be extracted at I = 0.05.
SE|85||ab|1|entity|C0009915|Contractile Proteins|aapp,bacs|||contractile proteins|||0|1000|105|125
SE|85||ab|1|entity|C0221464|Arterial|spco|||arterial|||0|901|131|139
SE|85||ab|1|entity|C1267092|Smooth muscle (tissue)|tisu|||smooth muscle|||0|901|140|153
SE|85||ab|1|relation|2|1|C1267092|Smooth muscle (tissue)|tisu|tisu|||smooth muscle|||0|901|140|153|PREP|LOCATION_OF||126|130|1|1|C0009915|Contractile Proteins|aapp,gngm,bacs|aapp|||contractile proteins|||0|1000|105|125

SE|85||ab|2|text|208|348|However, they can be precipitated by a prolonged dialysis at pH 6 to give an actomyosin with a high, although variable, actin:myosin ratio.
SE|85||ab|2|entity|C0439590|Prolonged|tmco|||prolonged|||0|888|247|256
SE|85||ab|2|entity|C0011946|Dialysis procedure|topp|||dialysis|||0|888|257|265
SE|85||ab|2|entity|C0001291|Actomyosin|aapp,bacs|||actomyosin|||0|1000|285|295
SE|85||ab|2|entity|C0205250|High|qlco|||high|||0|1000|303|307
SE|85||ab|2|entity|C0439828|Variable|qlco|||variable|||0|1000|318|326
SE|85||ab|2|entity|C0001271|Actins|aapp,bacs|||actin|||0|1000|328|333
SE|85||ab|2|entity|||gngm|79784|MYH14|myosin|||0|861|334|340
SE|85||ab|2|entity|C0456603|Ratio|inpr|||ratio|||0|861|341|346

SE|85||ab|3|text|348|525|The sedimentation behavior of this actomyosin at high ionic strength was examined as a function of pH, protein concentration and composition by preparative ultracentrifugation.
SE|85||ab|3|entity|C0597428|Sedimentation procedure|lbpr|||sedimentation|||0|888|352|365
SE|85||ab|3|entity|C0004927|Behavior|inbe|||behavior|||0|888|366|374
SE|85||ab|3|entity|C0001291|Actomyosin|aapp,bacs|||actomyosin|||0|1000|383|393
SE|85||ab|3|entity|C0205250|High|qlco|||high|||0|901|397|401
SE|85||ab|3|entity|C0086486|Ionic Strength|lbtr|||ionic strength|||0|901|402|416
SE|85||ab|3|entity|C0031843|physiological aspects|phsf|||function|||0|1000|435|443
SE|85||ab|3|entity|C0427716|Protein concentration, test strip measurement|lbpr|||protein concentration|||0|1000|451|472
SE|85||ab|3|entity|C0486616|Composition|clna|||composition|||0|1000|477|488
SE|85||ab|3|entity|C0041609|Ultracentrifugation|lbpr|||ultracentrifugation|||0|861|504|523
SE|85||ab|3|relation|1|1|C0041609|Ultracentrifugation|lbpr|lbpr|||ultracentrifugation|||0|861|504|523|PREP|METHOD_OF||489|491|7|2|C0427716|Protein concentration, test strip measurement|lbpr|lbpr|||protein concentration|||0|1000|451|472

SE|85||ab|4|text|525|679|Comparisons with synthetic skeletal muscle actomyosins of similar composition demonstrated significant differences in the behaviors of these two systems.
SE|85||ab|4|entity|C0242692|Skeletal muscle structure|bpoc|||skeletal muscle|||0|824|552|567
SE|85||ab|4|entity|C0001291|Actomyosin|aapp,bacs|79784|MYH14|actomyosins|||0|824|568|579
SE|85||ab|4|entity|C0486616|Composition|clna|||composition|||0|853|591|602
SE|85||ab|4|entity|C0750502|Significant|idcn|||significant|||0|872|616|627
SE|85||ab|4|entity|C1547020|*Difference|qnco|||differences|||0|872|628|639
SE|85||ab|4|entity|C0004927|Behavior|inbe|||behaviors|||0|1000|647|656
SE|85||ab|4|entity|C0205448|Two|qnco|||two|||0|888|666|669
SE|85||ab|4|entity|C0449913|System|ftcn|||systems|||0|888|670|677
SE|85||ab|4|relation|0|0|C0001291|Actomyosin|aapp,gngm,bacs|aapp|79784|MYH14|actomyosins|||0|824|568|579|MOD/HEAD|PART_OF||552|579|0|0|C0242692|Skeletal muscle structure|bpoc|bpoc|||skeletal muscle|||0|824|552|567

SE|85||ab|5|text|679|832|It was found that much smooth muscle actomyosin is not dissociated by normally relaxing conditions, and that it sediments at a slower rate than F-actin.
SE|85||ab|5|entity|C1267092|Smooth muscle (tissue)|tisu|||smooth muscle|||0|901|702|715
SE|85||ab|5|entity|C0001291|Actomyosin|aapp,bacs|||actomyosin|||0|901|716|726
SE|85||ab|5|entity|C1518422|Not|ftcn|||not|||0|1000|730|733
SE|85||ab|5|entity|C0542193|Relaxed|qlco|||relaxing|||0|756|758|766
SE|85||ab|5|entity|C0348080|Condition|qlco|||conditions|||0|756|767|777
SE|85||ab|5|entity|C0439834|Slow|qlco|||slower|||0|872|806|812
SE|85||ab|5|entity|C1521828|Rate|qnco|||rate|||0|872|813|817
SE|85||ab|5|entity|C0025979|Microfilaments|celc|||F-actin|||0|1000|823|830
SE|85||ab|5|relation|0|0|C0001291|Actomyosin|aapp,gngm,bacs|aapp|||actomyosin|||0|901|716|726|MOD/HEAD|PART_OF||702|726|0|0|C1267092|Smooth muscle (tissue)|tisu|tisu|||smooth muscle|||0|901|702|715

SE|85||ab|6|text|832|968|The solubility of the supernatant protein (a myosin-enriched actomyosin) in 0.2 M K Cl (pH 7) depended on the pH during centrifugation.
SE|85||ab|6|entity|C0037628|Solubility|qnco|||solubility|||0|1000|836|846
SE|85||ab|6|entity|C1550101|Supernatant|bdsu|||supernatant|||0|738|854|865
SE|85||ab|6|entity|C0033684|Proteins|aapp,bacs|||protein|||0|738|866|873
SE|85||ab|6|entity|||gngm|79784|MYH14|myosin|||0|738|877|883
SE|85||ab|6|entity|C0359583|Enrich|food|||enriched|||0|738|884|892
SE|85||ab|6|entity|C0001291|Actomyosin|aapp,bacs|||actomyosin|||0|738|893|903
SE|85||ab|6|entity|C0007703|Centrifugation|lbpr|||centrifugation|||0|1000|952|966

SE|85||ab|7|text|968|1112|A lower solubility was associated only with a higher actin concentration in the supernatant, suggesting a dependence on actin repolymerization.
SE|85||ab|7|entity|C0441994|Lower|ftcn|||lower|||0|888|970|975
SE|85||ab|7|entity|C0037628|Solubility|qnco|||solubility|||0|888|976|986
SE|85||ab|7|entity|C0205250|High|qlco|||higher|||0|606|1014|1020
SE|85||ab|7|entity|C0001271|Actins|aapp,bacs|||actin|||0|606|1021|1026
SE|85||ab|7|entity|C1550101|Supernatant|bdsu|||supernatant|||0|1000|1048|1059
SE|85||ab|7|entity|C0439857|Dependence|mobd|||dependence|||0|1000|1074|1084
SE|85||ab|7|entity|C0001271|Actins|aapp,bacs|||actin|||0|694|1088|1093
SE|85||ab|7|relation|3|1|C1550101|Supernatant|bdsu|bdsu|||supernatant|||0|1000|1048|1059|PREP|LOCATION_OF||1041|1043|2|1|C0001271|Actins|aapp,gngm,bacs|aapp|||actin|||0|606|1021|1026

SE|85||ab|8|text|1112|1264|Pure myosin was selectively precipitated from the supernatant by polyethylene glycol-6000, but only when the protein was soluble at low ionic strength.
SE|85||ab|8|entity|||gngm|79784|MYH14|myosin|||0|1000|1117|1123
SE|85||ab|8|entity|C1550101|Supernatant|bdsu|||supernatant|||0|1000|1162|1173
SE|85||ab|8|entity|C0030775|Polyethylene Glycol 6000|orch,phsu|||polyethylene glycol-6000|||0|1000|1177|1201
SE|85||ab|8|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|1221|1228
SE|85||ab|8|entity|C0205251|low|qlco|||low|||0|901|1244|1247
SE|85||ab|8|entity|C0086486|Ionic Strength|lbtr|||ionic strength|||0|901|1248|1262

SE|85||ab|9|text|1264|1351|The solubility of purified myosin was similar to that of myosin from striated muscles.
SE|85||ab|9|entity|C0037628|Solubility|qnco|||solubility|||0|1000|1268|1278
SE|85||ab|9|entity|||gngm|79784|MYH14|myosin|||0|1000|1291|1297
SE|85||ab|9|entity|||gngm|79784|MYH14|myosin|||0|1000|1321|1327
SE|85||ab|9|entity|C1331262|Muscle, Striated|tisu|||striated muscles|||0|1000|1333|1349
SE|85||ab|9|relation|1|1|C1331262|Muscle, Striated|tisu|tisu|||striated muscles|||0|1000|1333|1349|PREP|LOCATION_OF||1328|1332|4|1|||gngm,aapp|aapp|79784|MYH14|myosin|||0|1000|1321|1327

SE|85||ab|10|text|1351|1485|A relationship between the presence of depolymerized actin and the high solubility of smooth muscle contractile proteins is suggested.
SE|85||ab|10|entity|C0439849|Relationships|qlco|||relationship|||0|1000|1353|1365
SE|85||ab|10|entity|C0001271|Actins|aapp,bacs|||actin|||0|861|1404|1409
SE|85||ab|10|entity|C0205250|High|qlco|||high|||0|888|1418|1422
SE|85||ab|10|entity|C0037628|Solubility|qnco|||solubility|||0|888|1423|1433
SE|85||ab|10|entity|C1155937|smooth muscle contraction|ortf|||smooth muscle contractile|||0|892|1437|1462
SE|85||ab|10|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|892|1463|1471


SE|86||ti|1|text|15|89|Hybrids of chemical derivatives of Escherichia coli alkaline phosphatase.
SE|86||ti|1|entity|C0020205|Hybrids|orgm|||Hybrids|||0|1000|15|22
SE|86||ti|1|entity|C0220806|Chemicals|chem|||chemical|||0|888|26|34
SE|86||ti|1|entity|C0243072|derivatives|chvs|||derivatives|||0|888|35|46
SE|86||ti|1|entity|C0014834|Escherichia coli|bact|||Escherichia coli|||0|888|50|66
SE|86||ti|1|entity|C0002059|Alkaline Phosphatase|aapp,enzy|||alkaline phosphatase|||0|888|67|87
SE|86||ti|1|relation|0|0|C0002059|Alkaline Phosphatase|aapp,gngm,enzy|aapp|||alkaline phosphatase|||0|888|67|87|MOD/HEAD|PART_OF||50|87|0|0|C0014834|Escherichia coli|bact|bact|||Escherichia coli|||0|888|50|66

SE|86||ab|1|text|95|219|The activities of hybrid dimers of alkaline phosphatase containing two chemically modified subunits have been investigated.
SE|86||ab|1|entity|C0441655|Activities|acty|||activities|||0|1000|99|109
SE|86||ab|1|entity|C0007597|Cell hybridization|lbpr|||hybrid|||0|872|113|119
SE|86||ab|1|entity|C0596448|dimer|chvs|||dimers|||0|872|120|126
SE|86||ab|1|entity|C0002059|Alkaline Phosphatase|aapp,enzy|||alkaline phosphatase|||0|584|130|150
SE|86||ab|1|entity|C0332256|Containing|ftcn|||containing|||0|584|151|161
SE|86||ab|1|entity|C0205448|Two|qnco|||two|||0|584|162|165
SE|86||ab|1|entity|C0205349|Altered|ftcn|||modified|||0|584|177|185

SE|86||ab|2|text|219|431|One hybrid species was prepared by dissociation and reconstitution of a mixture of two variants produced by chemical modification of the native enzyme with succinic anhydride and tetranitromethane, respectively.
SE|86||ab|2|entity|C0205447|One|qnco|||One|||0|851|219|222
SE|86||ab|2|entity|C0007597|Cell hybridization|lbpr|||hybrid|||0|851|223|229
SE|86||ab|2|entity|C1548151|Species|idcn|||species|||0|851|230|237
SE|86||ab|2|entity|C0086168|Dissociation|mobd|||dissociation|||0|1000|254|266
SE|86||ab|2|entity|C0439962|Mixture|sbst|||mixture|||0|1000|291|298
SE|86||ab|2|entity|C0205448|Two|qnco|||two|||0|872|302|305
SE|86||ab|2|entity|C0205419|Variant|qlco|||variants|||0|872|306|314
SE|86||ab|2|entity|C0220806|Chemicals|chem|||chemical|||0|888|327|335
SE|86||ab|2|entity|C1522413|Modification|ftcn|||modification|||0|888|336|348
SE|86||ab|2|entity|C0302891|Native|ftcn|||native|||0|888|356|362
SE|86||ab|2|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|888|363|369
SE|86||ab|2|entity|C0075430|succinic anhydride|orch|||succinic anhydride|||0|1000|375|393
SE|86||ab|2|entity|C0039694|Tetranitromethane|hops,irda,orch|||tetranitromethane|||0|1000|398|415
SE|86||ab|2|relation|3|2|C0039694|Tetranitromethane|hops,irda,orch|orch|||tetranitromethane|||0|1000|398|415|NOM|INTERACTS_WITH||336|348|5|0|C0220806|Chemicals|chem|chem|||chemical|||0|888|327|335
SE|86||ab|2|relation|3|2|C0075430|succinic anhydride|orch|orch|||succinic anhydride|||0|1000|375|393|NOM|INTERACTS_WITH||336|348|5|0|C0220806|Chemicals|chem|chem|||chemical|||0|888|327|335

SE|86||ab|3|text|431|675|The succinyl-nitrotyrosyl hybrid was separated from the other members of the hybrid set by DEAE-Sephadex chromatography and then converted to a succinyl-aminotyrosyl hybrid by reduction of the modified tyrosine residues with sodium dithionite.
SE|86||ab|3|entity|C0007597|Cell hybridization|lbpr|||hybrid|||0|827|457|463
SE|86||ab|3|entity|C0680022|member|popg|||members|||0|966|493|500
SE|86||ab|3|entity|C0007597|Cell hybridization|lbpr|||hybrid|||0|1000|508|514
SE|86||ab|3|entity|C0074343|sephadex|irda,orch|||Sephadex|||0|901|527|535
SE|86||ab|3|entity|C0598730|diethylaminoethyl cellulose chromatography|lbpr|||DEAE-Sephadex chromatography|||0|901|522|550
SE|86||ab|3|entity|C0007597|Cell hybridization|lbpr|||hybrid|||0|827|597|603
SE|86||ab|3|entity|C0205349|Altered|ftcn|||modified|||0|824|624|632
SE|86||ab|3|entity|C0041485|Tyrosine|aapp,bacs,phsu|||tyrosine|||0|824|633|641
SE|86||ab|3|entity|C0037505|Sodium Dithionite|inch|||sodium dithionite|||0|1000|656|673
SE|86||ab|3|relation|0|0|C0598730|diethylaminoethyl cellulose chromatography|lbpr|lbpr|||DEAE-Sephadex chromatography|||0|901|522|550|MOD/HEAD|USES||527|550|0|0|C0074343|sephadex|irda,orch|irda|||Sephadex|||0|901|527|535
SE|86||ab|3|relation|5|1|C0598730|diethylaminoethyl cellulose chromatography|lbpr|lbpr|||DEAE-Sephadex chromatography|||0|901|522|550|PREP|METHOD_OF||519|521|3|1|C0007597|Cell hybridization|lbpr|lbpr|||hybrid|||0|1000|508|514

SE|86||ab|4|text|675|1052|A comparison of the activities of these two hybrids with the activities of the succinyl, nitrotyrosyl and aminotyrosyl derivatives has shown that either the subunits of alkaline phosphatase function independently or if the subunits turnover alternately in a reciprocating mechanism, then the intrinsic activity of each subunit must be strongly dependent on its partner subunit.
SE|86||ab|4|entity|C0441655|Activities|acty|||activities|||0|1000|695|705
SE|86||ab|4|entity|C0599647|Yeast One/Two-Hybrid System|mbrt|||two hybrids|||0|983|715|726
SE|86||ab|4|entity|C0441655|Activities|acty|||activities|||0|1000|736|746
SE|86||ab|4|entity|C0243072|derivatives|chvs|||derivatives|||0|861|794|805
SE|86||ab|4|entity|C0002059|Alkaline Phosphatase|aapp,enzy|||alkaline phosphatase|||0|1000|844|864
SE|86||ab|4|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|861|947|956
SE|86||ab|4|entity|C0205102|Intrinsic|spco|||intrinsic|||0|888|967|976


SE|87||ti|1|text|15|114|Some physicochemical properties of hemoglobin-manitoba (alpha2 102Ser replaced by Arg (G9) beta2).
SE|87||ti|1|entity|C0871161|Property|qlco|||properties|||0|827|36|46
SE|87||ti|1|entity|C0062395|hemoglobin Manitoba|aapp,bacs|||hemoglobin-manitoba|||0|1000|50|69
SE|87||ti|1|entity|||gngm|27,473|ABL2,RERE|Arg|||0|1000|97|100
SE|87||ti|1|entity|||gngm|4760,10383|NEUROD1,TUBB4B|beta2|||0|1000|106|111

SE|87||ab|1|text|120|199|Hb-Manitoba was discovered in 1970 [1] in a Canadian family of British origin.
SE|87||ab|1|entity|C0062395|hemoglobin Manitoba|aapp,bacs|||Hb-Manitoba|||0|1000|120|131
SE|87||ab|1|entity|C0238884|CANADIAN|fndg|||Canadian|||0|888|164|172
SE|87||ab|1|entity|C0015576|Family|famg|||family|||0|888|173|179
SE|87||ab|1|entity|C0596227|British|popg|||British|||0|888|183|190
SE|87||ab|1|entity|C0439659|Beginning|tmco|||origin|||0|888|191|197
SE|87||ab|1|relation|0|0|C0238884|CANADIAN|fndg|fndg|||Canadian|||0|888|164|172|MOD/HEAD|PROCESS_OF||164|179|0|0|C0015576|Family|famg,humn|humn|||family|||0|888|173|179
SE|87||ab|1|relation|2|1|C0015576|Family|famg,humn|humn|||family|||0|888|173|179|PREP|LOCATION_OF||159|161|1|1|C0062395|hemoglobin Manitoba|aapp,gngm,bacs|aapp|||Hb-Manitoba|||0|1000|120|131

SE|87||ab|2|text|199|500|Recently we observed the same variant in a second family, and found that the oxy-derivative of Hb-Manitoba is slightly unstable at 65 degrees C, dissociates less readily at alkaline pH than does Hb-A, and forms asymmetric hybrids with other hemoglobins which are readily detectable by electrophoresis.
SE|87||ab|2|entity|C0332185|Recent|tmco|||Recently|||0|1000|199|207
SE|87||ab|2|entity|C0445247|Same|qlco|||same|||0|888|224|228
SE|87||ab|2|entity|C0205419|Variant|qlco|||variant|||0|888|229|236
SE|87||ab|2|entity|C0457385|seconds|tmco|||second|||0|888|242|248
SE|87||ab|2|entity|C0015576|Family|famg|||family|||0|888|249|255
SE|87||ab|2|entity|C1527240|Derivative|ftcn|||derivative|||0|861|280|290
SE|87||ab|2|entity|C0062395|hemoglobin Manitoba|aapp,bacs|||Hb-Manitoba|||0|1000|294|305
SE|87||ab|2|entity|C0750482|SLIGHTLY|idcn|||slightly|||0|694|309|317
SE|87||ab|2|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|333|342
SE|87||ab|2|entity|C0002055|Alkalies|inch|||alkaline|||0|853|372|380
SE|87||ab|2|entity|C0332514|Asymmetry|spco|||asymmetric|||0|888|410|420
SE|87||ab|2|entity|C0020205|Hybrids|orgm|||hybrids|||0|888|421|428
SE|87||ab|2|entity|C0019046|Hemoglobin|aapp,bacs|||hemoglobins|||0|1000|440|451
SE|87||ab|2|entity|C0013855|Electrophoresis|lbpr|||electrophoresis|||0|1000|484|499
SE|87||ab|2|entity||<<readily>>||||pH|||||381|383
SE|87||ab|2|relation|3|1|C0019046|Hemoglobin|aapp,gngm,bacs|aapp|||hemoglobins|||0|1000|440|451|PREP|PART_OF||429|433|9|1|C0020205|Hybrids|orgm|orgm|||hybrids|||0|888|421|428
SE|87||ab|2|relation|3|1|C0062395|hemoglobin Manitoba|aapp,gngm,bacs|aapp|||Hb-Manitoba|||0|1000|294|305|PREP|PART_OF||429|433|9|1|C0020205|Hybrids|orgm|orgm|||hybrids|||0|888|421|428
SE|87||ab|2|relation|7|4|C0062395|hemoglobin Manitoba|aapp,gngm,bacs|aapp|||Hb-Manitoba|||0|1000|294|305|PREP|compared_with||384|388|6|4|C0019046|Hemoglobin|aapp,gngm,bacs|aapp|||hemoglobins|||0|1000|440|451
SE|87||ab|2|relation|7|4|C0062395|hemoglobin Manitoba|aapp,gngm,bacs|aapp|||Hb-Manitoba|||0|1000|294|305|PREP|lower_than||384|388|6|4|C0019046|Hemoglobin|aapp,gngm,bacs|aapp|||hemoglobins|||0|1000|440|451


SE|88||ti|1|text|15|95|The oxygen affinity of haemoglobin Tak, a variant with an elongated beta chain.
SE|88||ti|1|entity|C0369765|Oxygen affinity|moft|||oxygen affinity|||0|1000|19|34
SE|88||ti|1|entity|C0313469|hemoglobin Tak|aapp,bacs|1025|CDK9|haemoglobin Tak|||0|1000|38|53
SE|88||ti|1|entity|C0205419|Variant|qlco|||variant|||0|1000|57|64

SE|88||ab|1|text|101|214|The oxygen affinity was investigated of purified Hb Tak, a human haemoglobin variant with elongated beta-chains.
SE|88||ab|1|entity|C0369765|Oxygen affinity|moft|||oxygen affinity|||0|1000|105|120
SE|88||ab|1|entity|C0313469|hemoglobin Tak|aapp,bacs|2944|GSTM1|Hb Tak|||0|901|150|156
SE|88||ab|1|entity|C0020114|Human|humn|||human|||0|851|160|165
SE|88||ab|1|entity|C0019046|Hemoglobin|aapp,bacs|||haemoglobin|||0|851|166|177
SE|88||ab|1|entity|C0205419|Variant|qlco|||variant|||0|851|178|185
SE|88||ab|1|relation|0|0|C0019046|Hemoglobin|aapp,gngm,bacs|aapp|||haemoglobin|||0|851|166|177|MOD/HEAD|PART_OF||160|177|0|0|C0020114|Human|grup,humn|humn|||human|||0|851|160|165

SE|88||ab|2|text|214|313|A very low P50 value was found which was not influenced by the addition of 2,3 diphosphoglycerate.
SE|88||ab|2|entity|C1367009|TNFRSF5 gene|gngm|958|CD40|P50|||0|658|225|228
SE|88||ab|2|entity|C1518422|Not|ftcn|||not|||0|1000|255|258
SE|88||ab|2|entity|C0442796|Additive|qlco|||addition|||0|928|277|285
SE|88||ab|2|entity|C0178597|diphosphoglycerate|carb|||diphosphoglycerate|||0|888|293|311

SE|88||ab|3|text|313|362|The n value was 1, indicating non-cooperativity.
SE|88||ab|3|entity|C0679729|cooperative|orgt|||cooperativity|||0|789|347|360

SE|88||ab|4|text|362|641|The oxygen equilibrium curve of the whole blood haemolysate containing Hbs A and Tak was close to that of Hb A at the top of the curve, while the bottom of the curve greatly deviated from the latter, indicative of small if any interaction between Hb A and Tak during oxygenation.
SE|88||ab|4|entity|C0030054|Oxygen|elii,phsu|||oxygen|||0|828|366|372
SE|88||ab|4|entity|C0014653|Equilibrium|orgf|||equilibrium|||0|828|373|384
SE|88||ab|4|entity|C0205134|Curved|spco|||curve|||0|828|385|390
SE|88||ab|4|entity|C0370231|whole blood|bdsu|||whole blood|||0|785|398|409
SE|88||ab|4|entity|C0332256|Containing|ftcn|||containing|||0|785|422|432
SE|88||ab|4|entity|C0019043|Sickle Hemoglobin|aapp,bacs|2944|GSTM1|Hbs|||0|785|433|436
SE|88||ab|4|entity|||gngm|1025|CDK9|Tak|||0|1000|443|446
SE|88||ab|4|entity|C0205134|Curved|spco|||curve|||0|928|491|496
SE|88||ab|4|entity|C1511276|Bottom|spco|||bottom|||0|1000|508|514
SE|88||ab|4|entity|C0205134|Curved|spco|||curve|||0|928|522|527
SE|88||ab|4|entity|C0700321|Small|qnco|||small|||0|1000|576|581
SE|88||ab|4|entity|||gngm|1025|CDK9|Tak|||0|1000|618|621
SE|88||ab|4|entity|C0231940|Alveolar ventilation function|ortf|||oxygenation|||0|1000|629|640


SE|89||ti|1|text|15|136|Effects of membrane ribonuclease and 3'-nucleotidase on the digestion of polyuridylic acid by rat liver plasma membrane.
SE|89||ti|1|entity|C1280500|Effect|qlco|||Effects|||0|966|15|22
SE|89||ti|1|entity|C0596901|Membrane|celc|||membrane|||0|888|26|34
SE|89||ti|1|entity|C0035542|Ribonucleases|aapp,enzy|||ribonuclease|||0|888|35|47
SE|89||ti|1|entity|C0046834|3'-Nucleotidase|aapp,enzy|||3'-nucleotidase|||0|1000|52|67
SE|89||ti|1|entity|C0012238|Digestion|orgf|||digestion|||0|1000|75|84
SE|89||ti|1|entity|C0032417|Poly U|nnon|||polyuridylic acid|||0|983|88|105
SE|89||ti|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|861|109|112
SE|89||ti|1|entity|C0023884|Liver|bpoc|||liver|||0|861|113|118
SE|89||ti|1|entity|C0007603|Cell membrane|celc|||plasma membrane|||0|861|119|134
SE|89||ti|1|relation|0|0|C0007603|Cell membrane|celc|celc|||plasma membrane|||0|861|119|134|MOD/HEAD|PART_OF||113|134|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|861|113|118
SE|89||ti|1|relation|0|0|C0035542|Ribonucleases|aapp,gngm,enzy|aapp|||ribonuclease|||0|888|35|47|MOD/HEAD|PART_OF||26|47|0|0|C0596901|Membrane|celc|celc|||membrane|||0|888|26|34

SE|89||ab|1|text|142|145|1.

SE|89||ab|2|text|145|412|Fragments of isolated rat liver plasma membrane possess a ribonuclease activity which at pH 7.8 in the presence of 10 mM EDTA can digest polyuridylic acid (poly(U)) and polycytidylic acid (poly(C)) but not polyadenylic acid (poly(A)) and polyguanylic acid (poly(G)).
SE|89||ab|2|entity|C0486805|FRAGMENTS|bdsu|||Fragments|||0|1000|145|154
SE|89||ab|2|entity|C0205409|Isolated|ftcn|||isolated|||0|840|158|166
SE|89||ab|2|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|840|167|170
SE|89||ab|2|entity|C0023884|Liver|bpoc|||liver|||0|840|171|176
SE|89||ab|2|entity|C0007603|Cell membrane|celc|||plasma membrane|||0|840|177|192
SE|89||ab|2|entity|C1148840|ribonuclease activity|genf|||ribonuclease activity|||0|1000|203|224
SE|89||ab|2|entity|C0013618|Edetic Acid|irda,orch,phsu|||EDTA|||0|790|266|270
SE|89||ab|2|entity|C0032417|Poly U|nnon|||polyuridylic acid|||0|983|282|299
SE|89||ab|2|entity|C0747726|POLY|cnce|||poly|||0|1000|301|305
SE|89||ab|2|entity|C0032408|Poly C|nnon|||polycytidylic acid|||0|966|314|332
SE|89||ab|2|entity|C0747726|POLY|cnce|||poly|||0|1000|334|338
SE|89||ab|2|entity|C1518422|Not|ftcn|||not|||0|884|347|350
SE|89||ab|2|entity|C0085746|Adenine Polynucleotides|nnon|||polyadenylic acid|||0|884|351|368
SE|89||ab|2|entity|C0032400|Poly A|nnon|||poly(A|||0|1000|370|376
SE|89||ab|2|entity|C0032411|Poly G|nnon|||polyguanylic acid|||0|983|383|400
SE|89||ab|2|entity|C0747726|POLY|cnce|||poly|||0|1000|402|406
SE|89||ab|2|relation|0|0|C0007603|Cell membrane|celc|celc|||plasma membrane|||0|840|177|192|MOD/HEAD|PART_OF||171|192|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|840|171|176
SE|89||ab|2|relation|0|0|C0032400|Poly A|nnon|nnon|||poly(A|||0|1000|370|376|SPEC|ISA||351|376|0|0|C0085746|Adenine Polynucleotides|nnon|nnon|||polyadenylic acid|||0|884|351|368

SE|89||ab|3|text|412|503|Under these conditions, the membrane preparation does not degrade native or denatured DNA.
SE|89||ab|3|entity|C0348080|Condition|qlco|||conditions|||0|966|424|434
SE|89||ab|3|entity|C0596901|Membrane|celc|||membrane|||0|888|440|448
SE|89||ab|3|entity|C1521827|Preparation|ftcn|||preparation|||0|888|449|460
SE|89||ab|3|entity|C1518422|Not|ftcn|||not|||0|1000|466|469
SE|89||ab|3|entity|C0302891|Native|ftcn|||native|||0|1000|478|484
SE|89||ab|3|entity|C0012854|DNA|bacs,nnon|||DNA|||0|861|498|501

SE|89||ab|4|text|503|506|2.

SE|89||ab|5|text|506|653|The products of the reaction with poly(U) (10 mM EDTA present) can be separated on DEAE-Sephadex into oligonucleotides of increasing chain length.
SE|89||ab|5|entity|C1514468|product|qnco|||products|||0|966|510|518
SE|89||ab|5|entity|C0443286|Reaction|ftcn|||reaction|||0|1000|526|534
SE|89||ab|5|entity|C0747726|POLY|cnce|||poly|||0|1000|540|544
SE|89||ab|5|entity|C0013618|Edetic Acid|irda,orch,phsu|||EDTA|||0|775|555|559
SE|89||ab|5|entity|C0150312|Present|qnco|||present|||0|775|560|567
SE|89||ab|5|entity|C0917886|DEAE Sephadex|carb,irda|||DEAE-Sephadex|||0|1000|589|602
SE|89||ab|5|entity|C0028953|Oligonucleotides|nnon|||oligonucleotides|||0|1000|608|624
SE|89||ab|5|entity|C0442808|Increasing|ftcn|||increasing|||0|802|628|638
SE|89||ab|5|entity|C1444754|Length|qnco|||length|||0|802|645|651

SE|89||ab|6|text|653|746|Most of the products are di- to hexa-nucleotides which contain terminal 3'-phosphate groups.
SE|89||ab|6|entity|C0205393|Most|qnco|||Most|||0|1000|653|657
SE|89||ab|6|entity|C1514468|product|qnco|||products|||0|966|665|673
SE|89||ab|6|entity|||gngm|3073|HEXA|hexa|||0|861|685|689
SE|89||ab|6|entity|C0028630|Nucleotides|nnon|||nucleotides|||0|861|690|701
SE|89||ab|6|entity|C0441833|Groups|inpr|||groups|||0|791|738|744

SE|89||ab|7|text|746|749|3.

SE|89||ab|8|text|749|857|When EDTA is not present (pH 7.8 or 8.8) the plasma membrane preparation degrades both poly(A) and poly(U).
SE|89||ab|8|entity|C0013618|Edetic Acid|irda,orch,phsu|||EDTA|||0|1000|754|758
SE|89||ab|8|entity|C1518422|Not|ftcn|||not|||0|1000|762|765
SE|89||ab|8|entity|C0007603|Cell membrane|celc|||plasma membrane|||0|901|794|809
SE|89||ab|8|entity|C1521827|Preparation|ftcn|||preparation|||0|901|810|821
SE|89||ab|8|entity|C0032400|Poly A|nnon|||poly(A|||0|1000|836|842
SE|89||ab|8|entity|C0747726|POLY|cnce|||poly|||0|1000|848|852

SE|89||ab|9|text|857|1012|With poly(A) the product is all nucleoside while with poly(U) as substrate most of the product is nucleoside, but also some oligonucleotides are produced.
SE|89||ab|9|entity|C0032400|Poly A|nnon|||poly(A|||0|1000|862|868
SE|89||ab|9|entity|C1514468|product|qnco|||product|||0|1000|874|881
SE|89||ab|9|entity|C0028621|Nucleosides|nnon|||nucleoside|||0|1000|889|899
SE|89||ab|9|entity|C0747726|POLY|cnce|||poly|||0|1000|911|915
SE|89||ab|9|entity|C1514468|product|qnco|||product|||0|1000|944|951
SE|89||ab|9|entity|C0028621|Nucleosides|nnon|||nucleoside|||0|1000|955|965
SE|89||ab|9|entity|C0028953|Oligonucleotides|nnon|||oligonucleotides|||0|1000|981|997
SE|89||ab|9|relation|0|0|C0032400|Poly A|nnon|nnon|||poly(A|||0|1000|862|868|SPEC|ISA||862|899|0|0|C0028621|Nucleosides|nnon|nnon|||nucleoside|||0|1000|889|899

SE|89||ab|10|text|1012|1015|4.

SE|89||ab|11|text|1015|1120|The ribonuclease releases acid soluble products very slowly from high concentrations of poly(U) (mg/ml).
SE|89||ab|11|entity|C0035542|Ribonucleases|aapp,enzy|||ribonuclease|||0|1000|1019|1031
SE|89||ab|11|entity|C0001128|Acids|chem|||acid|||0|729|1041|1045
SE|89||ab|11|entity|C1514468|product|qnco|||products|||0|729|1054|1062
SE|89||ab|11|entity|C0442824|Very|qlco|||very|||0|729|1063|1067
SE|89||ab|11|entity|C0205250|High|qlco|||high|||0|888|1080|1084
SE|89||ab|11|entity|C0747726|POLY|cnce|||poly|||0|1000|1103|1107

SE|89||ab|12|text|1120|1123|5.

SE|89||ab|13|text|1123|1234|Uridine trinucleotide with and without a terminal 3'-phosphate group is degraded by rat liver plasma membrane.
SE|89||ab|13|entity|C0041984|Uridine|bacs,nnon|||Uridine|||0|694|1123|1130
SE|89||ab|13|entity|C0441833|Groups|inpr|||group|||0|791|1186|1191
SE|89||ab|13|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|861|1207|1210
SE|89||ab|13|entity|C0023884|Liver|bpoc|||liver|||0|861|1211|1216
SE|89||ab|13|entity|C0007603|Cell membrane|celc|||plasma membrane|||0|861|1217|1232
SE|89||ab|13|relation|0|0|C0007603|Cell membrane|celc|celc|||plasma membrane|||0|861|1217|1232|MOD/HEAD|PART_OF||1211|1232|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|861|1211|1216

SE|89||ab|14|text|1234|1405|The trinucleotide diphosphate is rapidly hydrolyzed to nucleoside while the trinucleotide itself is slowly digested and yields intermediate products, including nucleoside.
SE|89||ab|14|entity|C0034320|Diphosphates|inch|||diphosphate|||0|861|1252|1263
SE|89||ab|14|entity|C0028621|Nucleosides|nnon|||nucleoside|||0|1000|1289|1299
SE|89||ab|14|entity|C0205103|Intermediate|spco|||intermediate|||0|872|1361|1373
SE|89||ab|14|entity|C1514468|product|qnco|||products|||0|872|1374|1382
SE|89||ab|14|entity|C0028621|Nucleosides|nnon|||nucleoside|||0|1000|1394|1404
SE|89||ab|14|relation|1|1|C0034320|Diphosphates|inch|inch|||diphosphate|||0|861|1252|1263|VERB|INTERACTS_WITH||1275|1285|4|1|C0028621|Nucleosides|nnon|nnon|||nucleoside|||0|1000|1289|1299


SE|90||ti|1|text|15|102|Alterations in phospholipid-dependent (Na+ +K+)-ATPase activity due to lipid fluidity.
SE|90||ti|1|entity|C1515926|Alteration|idcn|||Alterations|||0|966|15|26
SE|90||ti|1|entity|C0031676|Phospholipids|bacs,lipd|||phospholipid|||0|888|30|42
SE|90||ti|1|entity|C0001479|Na(+)-K(+)-Exchanging ATPase|aapp,enzy|||Na+ +K+)-ATPase|||0|916|54|69
SE|90||ti|1|entity|C0023779|Lipids|lipd|||lipid|||0|888|86|91
SE|90||ti|1|entity|C0596579|fluidity|qnco|||fluidity|||0|888|92|100

SE|90||ti|2|text|102|135|Effects of cholesterol and Mg2+.
SE|90||ti|2|entity|C1280500|Effect|qlco|||Effects|||0|966|102|109
SE|90||ti|2|entity|C0008377|Cholesterol|bacs,strd|||cholesterol|||0|1000|113|124
SE|90||ti|2|entity|||gngm|4589,57192|MUC7,MCOLN1|Mg2|||0|1000|129|132

SE|90||ab|1|text|141|333|The (Na+ +K+)-activated, Mg2+-dependent ATPase from rabbit kidney outer medulla was prepared in a partially inactivated, soluble form depleted of endogenous phospholipids, using deoxycholate.
SE|90||ab|1|entity|C0337443|Sodium measurement|lbpr|||Na|||0|846|146|148
SE|90||ab|1|entity|C0202194|Potassium measurement|lbpr|||K|||0|846|151|152
SE|90||ab|1|entity|C1515877|Activate|ftcn|||activated|||0|846|155|164
SE|90||ab|1|entity|C0001477|Ca(2+) Mg(2+)-ATPase|aapp,enzy|4589,57192|MUC7,MCOLN1|Mg2+-dependent ATPase|||0|846|166|187
SE|90||ab|1|entity|C0034493|Oryctolagus cuniculus|mamm|||rabbit|||0|833|193|199
SE|90||ab|1|entity|C0022646|Kidney|bpoc|||kidney|||0|833|200|206
SE|90||ab|1|entity|C0205101|Extrinsic|spco|||outer|||0|833|207|212
SE|90||ab|1|entity|C1305694|Medulla|bpoc|||medulla|||0|833|213|220
SE|90||ab|1|entity|C1522492|Formation|ftcn|||form|||0|861|270|274
SE|90||ab|1|entity|C0205227|Endogenous|ftcn|||endogenous|||0|888|287|297
SE|90||ab|1|entity|C0031676|Phospholipids|bacs,lipd|||phospholipids|||0|888|298|311
SE|90||ab|1|entity|C0086123|Deoxycholate|bacs,phsu,strd|||deoxycholate|||0|1000|319|331
SE|90||ab|1|relation|3|3|C0001477|Ca(2+) Mg(2+)-ATPase|aapp,gngm,enzy|aapp|4589,57192|MUC7,MCOLN1|Mg2+-dependent ATPase|||0|846|166|187|VERB|INHIBITS||275|283|2|1|C0031676|Phospholipids|bacs,lipd|bacs|||phospholipids|||0|888|298|311
SE|90||ab|1|relation|4|1|C1305694|Medulla|bpoc|bpoc|||medulla|||0|833|213|220|PREP|LOCATION_OF||188|192|1|1|C0001477|Ca(2+) Mg(2+)-ATPase|aapp,gngm,enzy|aapp|4589,57192|MUC7,MCOLN1|Mg2+-dependent ATPase|||0|846|166|187

SE|90||ab|2|text|333|524|This preparation was reactivated 10 to 50-fold by sonicated liposomes of phosphatidylserine, but not by non-sonicated phosphatidylserine liposomes or sonicated phosphatidylcholine liposomes.
SE|90||ab|2|entity|C1521827|Preparation|ftcn|||preparation|||0|1000|338|349
SE|90||ab|2|entity|C0332462|Fold|spco|||fold|||0|861|375|379
SE|90||ab|2|entity|C0023828|Liposomes|celc,lipd|||liposomes|||0|861|393|402
SE|90||ab|2|entity|C0031623|Phosphatidylserines|lipd|||phosphatidylserine|||0|1000|406|424
SE|90||ab|2|entity|C1518422|Not|ftcn|||not|||0|1000|430|433
SE|90||ab|2|entity|C0031623|Phosphatidylserines|lipd|||phosphatidylserine|||0|750|451|469
SE|90||ab|2|entity|C0023828|Liposomes|celc,lipd|||liposomes|||0|750|470|479
SE|90||ab|2|entity|C0031617|Lecithin|bacs,lipd,phsu|||phosphatidylcholine|||0|790|493|512
SE|90||ab|2|entity|C0023828|Liposomes|celc,lipd|||liposomes|||0|790|513|522

SE|90||ab|3|text|524|745|The reconstituted enzyme resembled native membrane preparations of (Na+ +K+)-ATPase in its pH optimum being around 7.0, showing optimal activity at Mg2+:ATP mol ratios of approximately 1 and a Km value for ATP of 0.4 mM.
SE|90||ab|3|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|861|542|548
SE|90||ab|3|entity|C0302891|Native|ftcn|||native|||0|840|559|565
SE|90||ab|3|entity|C0596901|Membrane|celc|||membrane|||0|840|566|574
SE|90||ab|3|entity|C1521827|Preparation|ftcn|||preparations|||0|840|575|587
SE|90||ab|3|entity|C0001479|Na(+)-K(+)-Exchanging ATPase|aapp,enzy|||Na+ +K+)-ATPase|||0|1000|592|607
SE|90||ab|3|entity|||gngm|4589,57192|MUC7,MCOLN1|Mg2|||0|1000|672|675
SE|90||ab|3|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|ATP|||0|851|677|680
SE|90||ab|3|entity|C0027960|Nevus|neop|||mol|||0|851|681|684
SE|90||ab|3|entity|C0456603|Ratio|inpr|||ratios|||0|851|685|691
SE|90||ab|3|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|861|695|708
SE|90||ab|3|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|ATP|||0|1000|730|733

SE|90||ab|4|text|745|1013|Arrhenius plots of this reactivated activity at a constant pH of 7.0 and an Mg2+: ATP mol ratio of 1:1 showed a discontinuity (sharp change of slope) at 17 degrees C, with activation energy (Ea) values of 13-15 kcal/mol above this temperature and 30-35 kcal below it.
SE|90||ab|4|entity|C0521123|Reactivated|ftcn|||reactivated|||0|888|769|780
SE|90||ab|4|entity|C1547014|*Constant|qnco|||constant|||0|888|795|803
SE|90||ab|4|entity|||gngm|4589,57192|MUC7,MCOLN1|Mg2|||0|1000|821|824
SE|90||ab|4|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|ATP|||0|851|827|830
SE|90||ab|4|entity|C0027960|Nevus|neop|||mol|||0|851|831|834
SE|90||ab|4|entity|C0456603|Ratio|inpr|||ratio|||0|851|835|840
SE|90||ab|4|entity|C0439599|Discontinuous|tmco|||discontinuity|||0|928|857|870
SE|90||ab|4|entity|C0807955|SLOPE|fndg|||slope|||0|1000|888|893
SE|90||ab|4|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|901|910
SE|90||ab|4|entity|C0424589|Vitality|fndg|||energy|||0|861|928|934
SE|90||ab|4|entity|C0042295|Values|qlco|||values|||0|1000|940|946
SE|90||ab|4|entity|C0439259|Calories|qnco|||kcal|||0|750|956|960
SE|90||ab|4|entity|C0027960|Nevus|neop|||mol|||0|750|961|964
SE|90||ab|4|entity|C0039476|Temperature|qnco|||temperature|||0|1000|976|987
SE|90||ab|4|entity|C0439259|Calories|qnco|||kcal|||0|812|998|1002

SE|90||ab|5|text|1013|1134|A further discontinuity was also found at 8.0 degrees C and the Ea below this was very high (greater than 100 kcal/mol).
SE|90||ab|5|entity|C1517331|Further|spco|||further|||0|853|1015|1022
SE|90||ab|5|entity|C0439599|Discontinuous|tmco|||discontinuity|||0|853|1023|1036
SE|90||ab|5|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|861|1059|1068
SE|90||ab|5|entity|C0442804|Very high|fndg|||very high|||0|1000|1095|1104
SE|90||ab|5|entity|C0443228|Largest|qnco|||greater|||0|1000|1106|1113
SE|90||ab|5|entity|C0439259|Calories|qnco|||kcal|||0|790|1123|1127
SE|90||ab|5|entity|C0027960|Nevus|neop|||mol|||0|790|1128|1131

SE|90||ab|6|text|1134|1303|Increased Mg2+ concentrations at Mg2+:ATP ratios in excess of 1:1 inhibited the (Na+ +K+)-ATPase activity and also abolished the discontinuities in the Arrhenius plots.
SE|90||ab|6|entity|C0205217|Increased|qnco|||Increased|||0|802|1134|1143
SE|90||ab|6|entity|||gngm|4589,57192|MUC7,MCOLN1|Mg2|||0|802|1144|1147
SE|90||ab|6|entity|||gngm|4589,57192|MUC7,MCOLN1|Mg2|||0|1000|1167|1170
SE|90||ab|6|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|ATP|||0|888|1172|1175
SE|90||ab|6|entity|C0456603|Ratio|inpr|||ratios|||0|888|1176|1182
SE|90||ab|6|entity|C0442802|Excessive|qlco|||excess|||0|928|1186|1192
SE|90||ab|6|entity|C0001479|Na(+)-K(+)-Exchanging ATPase|aapp,enzy|||Na+ +K+)-ATPase|||0|916|1215|1230
SE|90||ab|6|entity|C0439599|Discontinuous|tmco|||discontinuities|||0|916|1263|1278

SE|90||ab|7|text|1303|1423|The addition of cholesterol to phosphatidylserine at a 1:1 mol ratio partially inhibited (Na+ +K+)-ATPase reactivation.
SE|90||ab|7|entity|C0442796|Additive|qlco|||addition|||0|928|1307|1315
SE|90||ab|7|entity|C0008377|Cholesterol|bacs,strd|||cholesterol|||0|1000|1319|1330
SE|90||ab|7|entity|C0031623|Phosphatidylserines|lipd|||phosphatidylserine|||0|1000|1334|1352
SE|90||ab|7|entity|C0027960|Nevus|neop|||mol|||0|790|1362|1365
SE|90||ab|7|entity|C0456603|Ratio|inpr|||ratio|||0|790|1366|1371
SE|90||ab|7|entity|C0001479|Na(+)-K(+)-Exchanging ATPase|aapp,enzy|||Na+ +K+)-ATPase|||0|756|1393|1408

SE|90||ab|8|text|1423|1591|Arrhenius plots under these conditions showed a single discontinuity at 20 degrees C and Ea values of 22 and 68 kcal/mol above and below this temperature respectively.
SE|90||ab|8|entity|C0348080|Condition|qlco|||conditions|||0|966|1451|1461
SE|90||ab|8|entity|C0037179|Unmarried person|popg|||single|||0|853|1471|1477
SE|90||ab|8|entity|C0439599|Discontinuous|tmco|||discontinuity|||0|853|1478|1491
SE|90||ab|8|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|1498|1507
SE|90||ab|8|entity|C0042295|Values|qlco|||values|||0|861|1515|1521
SE|90||ab|8|entity|C0439259|Calories|qnco|||kcal|||0|790|1535|1539
SE|90||ab|8|entity|C0027960|Nevus|neop|||mol|||0|790|1540|1543
SE|90||ab|8|entity|C0542339|Inferior|spco|||below|||0|1000|1554|1559
SE|90||ab|8|entity|C0039476|Temperature|qnco|||temperature|||0|861|1565|1576

SE|90||ab|9|text|1591|1693|The ouabain-insensitive Mg2+-ATPase normally showed a linear Arrhenius plot with an Ea of 8 kcal/mol.
SE|90||ab|9|entity|C0029904|Ouabain|carb,phsu,strd|||ouabain|||0|843|1595|1602
SE|90||ab|9|entity|C0237677|Insensitivity|menp|||insensitive|||0|843|1603|1614
SE|90||ab|9|entity|C0001477|Ca(2+) Mg(2+)-ATPase|aapp,enzy|4589,57192|MUC7,MCOLN1|Mg2+-ATPase|||0|843|1615|1626
SE|90||ab|9|entity|C0205132|Linear|spco|||linear|||0|660|1645|1651
SE|90||ab|9|entity|C0439259|Calories|qnco|||kcal|||0|790|1683|1687
SE|90||ab|9|entity|C0027960|Nevus|neop|||mol|||0|790|1688|1691

SE|90||ab|10|text|1693|1929|The cholesterol-phosphatidylserine mixed liposomes stimulated the Mg2+-ATPase activity, which now also showed a discontinuity at 20 degrees C with, however, an increased value of 14 kcal/mol above this temperature and 6 kcal/mol below.
SE|90||ab|10|entity|C0008377|Cholesterol|bacs,strd|||cholesterol|||0|833|1697|1708
SE|90||ab|10|entity|C0031623|Phosphatidylserines|lipd|||phosphatidylserine|||0|833|1709|1727
SE|90||ab|10|entity|C0205430|Mixed|ftcn|||mixed|||0|833|1728|1733
SE|90||ab|10|entity|C0023828|Liposomes|celc,lipd|||liposomes|||0|833|1734|1743
SE|90||ab|10|entity|||gngm|4589,57192|MUC7,MCOLN1|Mg2|||0|901|1759|1762
SE|90||ab|10|entity|C1148926|adenosinetriphosphatase activity|moft|||ATPase activity|||0|901|1764|1779
SE|90||ab|10|entity|C0439599|Discontinuous|tmco|||discontinuity|||0|928|1805|1818
SE|90||ab|10|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|1825|1834
SE|90||ab|10|entity|C0205217|Increased|qnco|||increased|||0|694|1853|1862
SE|90||ab|10|entity|C0439259|Calories|qnco|||kcal|||0|790|1875|1879
SE|90||ab|10|entity|C0027960|Nevus|neop|||mol|||0|790|1880|1883
SE|90||ab|10|entity|C0039476|Temperature|qnco|||temperature|||0|1000|1895|1906
SE|90||ab|10|entity|C0439259|Calories|qnco|||kcal|||0|750|1913|1917
SE|90||ab|10|entity|C0027960|Nevus|neop|||mol|||0|750|1918|1921

SE|90||ab|11|text|1929|2021|Kinetic studies showed that cholesterol had no significant effect on the Km values for ATP.
SE|90||ab|11|entity|C0022702|Kinetics|idcn|||Kinetic|||0|872|1929|1936
SE|90||ab|11|entity|C0008972|Clinical Research|resa|||studies|||0|872|1937|1944
SE|90||ab|11|entity|C0008377|Cholesterol|bacs,strd|||cholesterol|||0|1000|1957|1968
SE|90||ab|11|entity|C0750502|Significant|idcn|||significant|||0|888|1976|1987
SE|90||ab|11|entity|C1280500|Effect|qlco|||effect|||0|888|1988|1994
SE|90||ab|11|entity|C0042295|Values|qlco|||values|||0|888|2005|2011
SE|90||ab|11|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|ATP|||0|1000|2016|2019

SE|90||ab|12|text|2021|2181|Since both cholesterol and Mg2+ are known to alter the effects of temperature on the fluidity of phospholipids, the above results are discussed in this context.
SE|90||ab|12|entity|C0008377|Cholesterol|bacs,strd|||cholesterol|||0|1000|2032|2043
SE|90||ab|12|entity|||gngm|4589,57192|MUC7,MCOLN1|Mg2|||0|1000|2048|2051
SE|90||ab|12|entity|C1280500|Effect|qlco|||effects|||0|966|2076|2083
SE|90||ab|12|entity|C0039476|Temperature|qnco|||temperature|||0|1000|2087|2098
SE|90||ab|12|entity|C0596579|fluidity|qnco|||fluidity|||0|1000|2106|2114
SE|90||ab|12|entity|C0031676|Phospholipids|bacs,lipd|||phospholipids|||0|1000|2118|2131
SE|90||ab|12|entity|C1282910|Upper|spco|||above|||0|872|2137|2142
SE|90||ab|12|entity|C1274040|result|ftcn|||results|||0|872|2143|2150


SE|91||ti|1|text|15|150|Conformational and molecular responses to pH variation of the purified membrane adenosine triphosphatase of Micrococcus lysodeikticus.
SE|91||ti|1|entity|C1521991|Molecular|qlco|||molecular|||0|888|34|43
SE|91||ti|1|entity|C0871261|response|clna|||responses|||0|888|44|53
SE|91||ti|1|entity|C0205419|Variant|qlco|||variation|||0|888|60|69
SE|91||ti|1|entity|C0596901|Membrane|celc|||membrane|||0|812|86|94
SE|91||ti|1|entity|C0001473|ATP phosphohydrolase|aapp,enzy|||adenosine triphosphatase|||0|812|95|119
SE|91||ti|1|entity|C0085493|Micrococcus luteus|bact|||Micrococcus lysodeikticus|||0|1000|123|148
SE|91||ti|1|relation|0|0|C0001473|ATP phosphohydrolase|aapp,gngm,enzy|aapp|||adenosine triphosphatase|||0|812|95|119|MOD/HEAD|PART_OF||86|119|0|0|C0596901|Membrane|celc|celc|||membrane|||0|812|86|94
SE|91||ti|1|relation|4|1|C0001473|ATP phosphohydrolase|aapp,gngm,enzy|aapp|||adenosine triphosphatase|||0|812|95|119|PREP|PART_OF||120|122|1|1|C0085493|Micrococcus luteus|bact|bact|||Micrococcus lysodeikticus|||0|1000|123|148

SE|91||ab|1|text|156|337|A preparation of ATPase from the membranes of Micrococcus lysodeikticus, solubilized and more than 95% pure, showed two main bands in analytical polyacrylamide gel electrophoresis.
SE|91||ab|1|entity|C1521827|Preparation|ftcn|||preparation|||0|1000|158|169
SE|91||ab|1|entity|C0001473|ATP phosphohydrolase|aapp,enzy|||ATPase|||0|1000|173|179
SE|91||ab|1|entity|C0025255|Tissue membrane|tisu|||membranes|||0|1000|189|198
SE|91||ab|1|entity|C0085493|Micrococcus luteus|bact|||Micrococcus lysodeikticus|||0|1000|202|227
SE|91||ab|1|entity|C0205172|More|ftcn|||more|||0|1000|245|249
SE|91||ab|1|entity|C0205448|Two|qnco|||two|||0|851|272|275
SE|91||ab|1|entity|C0205225|Primary|qlco|||main|||0|851|276|280
SE|91||ab|1|entity|C0175723|Bands|medd|||bands|||0|851|281|286
SE|91||ab|1|entity|C0013862|Electrophoresis, Polyacrylamide Gel|lbpr|||polyacrylamide gel electrophoresis|||0|923|301|335
SE|91||ab|1|relation|3|1|C0025255|Tissue membrane|tisu|tisu|||membranes|||0|1000|189|198|PREP|PART_OF||199|201|4|1|C0085493|Micrococcus luteus|bact|bact|||Micrococcus lysodeikticus|||0|1000|202|227
SE|91||ab|1|relation|5|1|C0025255|Tissue membrane|tisu|tisu|||membranes|||0|1000|189|198|PREP|LOCATION_OF||180|184|2|1|C0001473|ATP phosphohydrolase|aapp,gngm,enzy|aapp|||ATPase|||0|1000|173|179

SE|91||ab|2|text|337|469|They did not correspond to isoenzymes because one band could be converted into the other by exposure to a mildly alkaline pH value.
SE|91||ab|2|entity|C1518422|Not|ftcn|||not|||0|1000|346|349
SE|91||ab|2|entity|C0022173|Isoenzymes|aapp,enzy|||isoenzymes|||0|1000|364|374
SE|91||ab|2|entity|C0205447|One|qnco|||one|||0|888|383|386
SE|91||ab|2|entity|C0175723|Bands|medd|||band|||0|888|387|391
SE|91||ab|2|entity|C0750532|MILDLY|idcn|||mildly|||0|584|443|449
SE|91||ab|2|entity|C0002055|Alkalies|inch|||alkaline|||0|584|450|458

SE|91||ab|3|text|469|576|The conversion was paralleled by changes in molecular weight, circular dichroism and catalytic properties.
SE|91||ab|3|entity|C0439836|Conversions|spco|||conversion|||0|966|473|483
SE|91||ab|3|entity|C0026385|Molecular Weight|qnco|||molecular weight|||0|1000|513|529
SE|91||ab|3|entity|C0008813|Circular Dichroism|lbpr,npop|||circular dichroism|||0|1000|531|549
SE|91||ab|3|entity|C0007382|Catalysis|npop|||catalytic|||0|836|554|563
SE|91||ab|3|entity|C0871161|Property|qlco|||properties|||0|836|564|574

SE|91||ab|4|text|576|716|Denaturation by pH at 25 degrees C was followed by means of circular dichroism, ultracentrifugation and polyacrylamide gel electrophoresis.
SE|91||ab|4|entity|C0301642|Denaturation|moft|||Denaturation|||0|1000|576|588
SE|91||ab|4|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|601|610
SE|91||ab|4|entity|C0008813|Circular Dichroism|lbpr,npop|||circular dichroism|||0|1000|636|654
SE|91||ab|4|entity|C0041609|Ultracentrifugation|lbpr|||ultracentrifugation|||0|1000|656|675
SE|91||ab|4|entity|C0013862|Electrophoresis, Polyacrylamide Gel|lbpr|||polyacrylamide gel electrophoresis|||0|1000|680|714

SE|91||ab|5|text|716|866|A large conformational transition took place in the acid range with midpoints at about pH = 3.6 (I = 10(-4) M), 4.3 (I = 0.03 M) and 5.3 (I = 0.1 M).
SE|91||ab|5|entity|C0549177|Large|qnco|||large|||0|660|718|723
SE|91||ab|5|entity|C0442504|Place|spco|||place|||0|1000|755|760
SE|91||ab|5|entity|C0001128|Acids|chem|||acid|||0|888|768|772
SE|91||ab|5|entity|C1514721|Range|qnco|||range|||0|888|773|778
SE|91||ab|5|entity|C0601906|PH.3|phsu|||pH = 3|||0|861|803|809

SE|91||ab|6|text|866|899|The transition was irreversible.

SE|91||ab|7|text|899|963|Strong aggregation of the protein occurred in this range of pH.
SE|91||ab|7|entity|C0442821|Strong|qlco|||Strong|||0|888|899|905
SE|91||ab|7|entity|C0332621|Aggregation|ftcn|||aggregation|||0|888|906|917
SE|91||ab|7|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|925|932
SE|91||ab|7|entity|C1514721|Range|qnco|||range|||0|1000|950|955

SE|91||ab|8|text|963|1081|The final product was largely random coil, but even at pH 1.5 dissociation into individual subunits was not complete.
SE|91||ab|8|entity|C0205088|End-stage|tmco|||final|||0|888|967|972
SE|91||ab|8|entity|C1514468|product|qnco|||product|||0|888|973|980
SE|91||ab|8|entity|C0439605|Random|qlco|||random|||0|773|993|999
SE|91||ab|8|entity|C0444764|Coils|spco|||coil|||0|773|1000|1004
SE|91||ab|8|entity|C0086168|Dissociation|mobd|||dissociation|||0|791|1025|1037
SE|91||ab|8|entity|C0237401|Individual|humn|||individual|||0|694|1043|1053
SE|91||ab|8|entity|C1518422|Not|ftcn|||not|||0|1000|1067|1070

SE|91||ab|9|text|1081|1145|However, partial dissociation took place at pH 5 (I = 0.028 M).
SE|91||ab|9|entity|C0728938|Partial|qnco|||partial|||0|888|1090|1097
SE|91||ab|9|entity|C0086168|Dissociation|mobd|||dissociation|||0|888|1098|1110
SE|91||ab|9|entity|C0442504|Place|spco|||place|||0|1000|1116|1121

SE|91||ab|10|text|1145|1266|At this pH value the enzyme was inactive, but 20-30% of the activity could be recovered when the pH was returned to 7.5.
SE|91||ab|10|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|1166|1172
SE|91||ab|10|entity|C0205254|Sedentary|fndg|||inactive|||0|1000|1177|1185

SE|91||ab|11|text|1266|1357|In the alkaline region the midpoint of the transition occurred near pH = 11 (I = 0.028 M).
SE|91||ab|11|entity|C0002055|Alkalies|inch|||alkaline|||0|853|1273|1281
SE|91||ab|11|entity|C0205147|Region|spco|||region|||0|853|1282|1288
SE|91||ab|11|entity|C0475806|1/3 meter|fndg|||near|||0|790|1329|1333
SE|91||ab|11|entity|C0020283|Hydrogen-Ion Concentration|qnco|||pH|||0|790|1334|1336

SE|91||ab|12|text|1357|1428|The pK of most of the tyrosine residues of the protein was about 10.9.
SE|91||ab|12|entity|C0205393|Most|qnco|||most|||0|1000|1367|1371
SE|91||ab|12|entity|C0041485|Tyrosine|aapp,bacs,phsu|||tyrosine|||0|847|1379|1387
SE|91||ab|12|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|1404|1411

SE|91||ab|13|text|1428|1650|The unfolding was irreversible and the protein was soon converted into peptide species with molecular weights lower than those determined for the subunits by gel electrophoresis in the presence of sodium dodecyl sulphate.
SE|91||ab|13|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|1467|1474
SE|91||ab|13|entity|C0030956|Peptides|aapp|||peptide|||0|888|1499|1506
SE|91||ab|13|entity|C1548151|Species|idcn|||species|||0|888|1507|1514
SE|91||ab|13|entity|C0026385|Molecular Weight|qnco|||molecular weights|||0|1000|1520|1537
SE|91||ab|13|entity|C0441994|Lower|ftcn|||lower|||0|1000|1538|1543
SE|91||ab|13|entity|C0596607|Gel Electrophoresis|lbpr|||gel electrophoresis|||0|1000|1586|1605
SE|91||ab|13|entity|C0037506|Sodium Dodecyl Sulfate|bodm,lipd,phsu|||sodium dodecyl sulphate|||0|1000|1625|1648
SE|91||ab|13|relation|8|6|C0033684|Proteins|aapp,gngm,bacs|aapp|||protein|||0|1000|1467|1474|NOM|COEXISTS_WITH||1613|1621|1|1|C0037506|Sodium Dodecyl Sulfate|bodm,lipd,phsu|lipd|||sodium dodecyl sulphate|||0|1000|1625|1648

SE|91||ab|14|text|1650|1714|Conventional proteolysis did not account for the transformation.
SE|91||ab|14|entity|C0439858|Conventional|qlco|||Conventional|||0|888|1650|1662
SE|91||ab|14|entity|C0597304|Proteolysis|moft|||proteolysis|||0|888|1663|1674
SE|91||ab|14|entity|C1518422|Not|ftcn|||not|||0|1000|1679|1682


SE|92||ti|1|text|15|39|Membrane-bound enzymes.
SE|92||ti|1|entity|C0596901|Membrane|celc|||Membrane|||0|802|15|23
SE|92||ti|1|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|802|30|37

SE|92||ti|2|text|39|44|III.
SE|92||ti|2|entity|C0439070|III|inpr|||III|||0|1000|39|42

SE|92||ti|3|text|44|114|Protease activity in leucocytes in relation to erythrocyte membranes.
SE|92||ti|3|entity|C0030946|Endopeptidases|aapp,enzy,phsu|449619,619465,100616101,100616102,100616103,100775105,100862683,100862684,100862685|ERVK-7,ERVK-8,ERVK-10,ERVK-9,ERVK-21,ERVK-18,ERVK-25,ERVK-24,ERVK-19|Protease|||0|888|44|52
SE|92||ti|3|entity|C0023516|Leukocytes|cell|||leucocytes|||0|1000|65|75
SE|92||ti|3|entity|C0014780|Erythrocyte Membrane|celc|||erythrocyte membranes|||0|1000|91|112
SE|92||ti|3|relation|2|1|C0023516|Leukocytes|cell|cell|||leucocytes|||0|1000|65|75|PREP|LOCATION_OF||62|64|1|1|C0030946|Endopeptidases|aapp,gngm,enzy,phsu|aapp|449619,619465,100616101,100616102,100616103,100775105,100862683,100862684,100862685|ERVK-7,ERVK-8,ERVK-10,ERVK-9,ERVK-21,ERVK-18,ERVK-25,ERVK-24,ERVK-19|Protease|||0|888|44|52

SE|92||ab|1|text|120|290|Protease activity was detected in membranes of human bovine erythrocytes prepared by the conventional procedures which include washing and removal of the  "buffy layer".
SE|92||ab|1|entity|C0030946|Endopeptidases|aapp,enzy,phsu|449619,619465,100616101,100616102,100616103,100775105,100862683,100862684,100862685|ERVK-7,ERVK-8,ERVK-10,ERVK-9,ERVK-21,ERVK-18,ERVK-25,ERVK-24,ERVK-19|Protease|||0|888|120|128
SE|92||ab|1|entity|C0025255|Tissue membrane|tisu|||membranes|||0|1000|154|163
SE|92||ab|1|entity|C0020114|Human|humn|||human|||0|851|167|172
SE|92||ab|1|entity|C0007452|Cattle|mamm|||bovine|||0|851|173|179
SE|92||ab|1|entity|C0014792|Erythrocytes|cell|||erythrocytes|||0|851|180|192
SE|92||ab|1|entity|C0439858|Conventional|qlco|||conventional|||0|888|209|221
SE|92||ab|1|entity|C0025664|Methodology|inpr|||procedures|||0|888|222|232
SE|92||ab|1|entity|C0441648|Washing|hlca|||washing|||0|1000|247|254
SE|92||ab|1|entity|C0728940|Excision|topp|||removal|||0|1000|259|266
SE|92||ab|1|relation|0|0|C0014792|Erythrocytes|cell|cell|||erythrocytes|||0|851|180|192|MOD/HEAD|PART_OF||173|192|0|0|C0007452|Cattle|mamm|mamm|||bovine|||0|851|173|179
SE|92||ab|1|relation|6|1|C0025255|Tissue membrane|tisu|tisu|||membranes|||0|1000|154|163|PREP|LOCATION_OF||151|153|1|1|C0030946|Endopeptidases|aapp,gngm,enzy,phsu|aapp|449619,619465,100616101,100616102,100616103,100775105,100862683,100862684,100862685|ERVK-7,ERVK-8,ERVK-10,ERVK-9,ERVK-21,ERVK-18,ERVK-25,ERVK-24,ERVK-19|Protease|||0|888|120|128

SE|92||ab|2|text|290|396|The enzyme was extracted by 0.75 M KCNS or (NH4)2SO4 and was activated by 0.4 to 0.5 M of the same salts.
SE|92||ab|2|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|294|300
SE|92||ab|2|entity|C0444499|0/5|qnco|||0.5|||0|901|371|374
SE|92||ab|2|entity|C0445247|Same|qlco|||same|||0|888|384|388
SE|92||ab|2|entity|C0036140|Salts|chvs|||salts|||0|888|389|394

SE|92||ab|3|text|396|574|Colored, particulate hide powder-azure, membrane fractions and soluble proteins such as hemoglobin, casein or albumin were susceptible to hydrolysis by the membraneous protease.
SE|92||ab|3|entity|C0457784|Particulate|qlco|||particulate|||0|916|405|416
SE|92||ab|3|entity|C0244681|hide powder azure|irda|||hide powder-azure|||0|916|417|434
SE|92||ab|3|entity|C1166621|membrane fraction|celc|||membrane fractions|||0|983|436|454
SE|92||ab|3|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|861|467|475
SE|92||ab|3|entity|C0019046|Hemoglobin|aapp,bacs|||hemoglobin|||0|1000|484|494
SE|92||ab|3|entity|C0007332|Caseins|aapp,bacs|||casein|||0|1000|496|502
SE|92||ab|3|entity|C0001924|Albumins|aapp,bacs|||albumin|||0|1000|506|513
SE|92||ab|3|entity|C0231204|Susceptible|ftcn|||susceptible|||0|1000|519|530
SE|92||ab|3|entity|C0020291|Hydrolysis|npop|||hydrolysis|||0|1000|534|544
SE|92||ab|3|entity|C0205287|Membranous|qlco|||membraneous|||0|888|552|563
SE|92||ab|3|entity|C0030946|Endopeptidases|aapp,enzy,phsu|449619,619465,100616101,100616102,100616103,100775105,100862683,100862684,100862685|ERVK-7,ERVK-8,ERVK-10,ERVK-9,ERVK-21,ERVK-18,ERVK-25,ERVK-24,ERVK-19|protease|||0|888|564|572

SE|92||ab|4|text|574|769|Partial purification of the enzyme was accomplished through disc-gel electrophoresis on polyacrylamide in the presence of 0.25% positively charged detergents like cetyltrimethylammonium bromide.
SE|92||ab|4|entity|C0728938|Partial|qnco|||Partial|||0|888|574|581
SE|92||ab|4|entity|C0243114|purification|lbpr,resa|||purification|||0|888|582|594
SE|92||ab|4|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|602|608
SE|92||ab|4|entity|C0013859|Electrophoresis, Disc|lbpr|||disc-gel electrophoresis|||0|1000|634|658
SE|92||ab|4|entity|C0071499|polyacrylamide|bodm,orch|||polyacrylamide|||0|1000|662|676
SE|92||ab|4|entity|C0007961|charge amounts|qnco|||charged|||0|712|713|720
SE|92||ab|4|entity|C0011740|Detergents|chvf|||detergents|||0|712|721|731
SE|92||ab|4|entity|C0951233|CETRIMONIUM BROMIDE|orch,phsu|||cetyltrimethylammonium bromide|||0|1000|737|767
SE|92||ab|4|relation|2|2|C0243114|purification|lbpr,resa|lbpr|||purification|||0|888|582|594|PREP|METHOD_OF||626|633|5|1|C0013859|Electrophoresis, Disc|lbpr|lbpr|||disc-gel electrophoresis|||0|1000|634|658

SE|92||ab|5|text|769|883|An alkaline protease (pH 7.4) with properties similar to those of the erythrocyte enzyme was found in leucocytes.
SE|92||ab|5|entity|C1563389|alkaline protease|aapp,enzy|||alkaline protease|||0|1000|772|789
SE|92||ab|5|entity|C0871161|Property|qlco|||properties|||0|966|804|814
SE|92||ab|5|entity|C0014792|Erythrocytes|cell|||erythrocyte|||0|888|839|850
SE|92||ab|5|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|888|851|857
SE|92||ab|5|entity|C0023516|Leukocytes|cell|||leucocytes|||0|1000|871|881
SE|92||ab|5|relation|1|1|C0023516|Leukocytes|cell|cell|||leucocytes|||0|1000|871|881|VERB|LOCATION_OF||862|867|4|4|C1563389|alkaline protease|aapp,gngm,enzy|aapp|||alkaline protease|||0|1000|772|789

SE|92||ab|6|text|883|1218|The similarity between the properties of the leucocytic and erythrocytic proteases and the correlation of the activity in erythrocyte membranes with content of white cells in these preparations, suggest that enzymatic activities in the contaminating leucocytes are responsible for the activity of membraneous proteases in erythrocytes.
SE|92||ab|6|entity|C0871364|Simile|inpr|||similarity|||0|900|887|897
SE|92||ab|6|entity|C0871161|Property|qlco|||properties|||0|966|910|920
SE|92||ab|6|entity|C0023516|Leukocytes|cell|||leucocytic|||0|1000|928|938
SE|92||ab|6|entity|C0014792|Erythrocytes|cell|||erythrocytic|||0|888|943|955
SE|92||ab|6|entity|C0030940|Peptide Hydrolases|aapp,enzy|||proteases|||0|888|956|965
SE|92||ab|6|entity|C0014780|Erythrocyte Membrane|celc|||erythrocyte membranes|||0|1000|1005|1026
SE|92||ab|6|entity|C0023508|White Blood Cell Count procedure|lbpr|||white cells|||0|1000|1043|1054
SE|92||ab|6|entity|C1521827|Preparation|ftcn|||preparations|||0|966|1064|1076
SE|92||ab|6|entity|C0243102|enzyme activity|moft|||enzymatic activities|||0|947|1091|1111
SE|92||ab|6|entity|C0205279|Contaminated|ftcn|||contaminating|||0|872|1119|1132
SE|92||ab|6|entity|C0023516|Leukocytes|cell|||leucocytes|||0|872|1133|1143
SE|92||ab|6|entity|C0205287|Membranous|qlco|||membraneous|||0|888|1180|1191
SE|92||ab|6|entity|C0030940|Peptide Hydrolases|aapp,enzy|||proteases|||0|888|1192|1201
SE|92||ab|6|entity|C0014792|Erythrocytes|cell|||erythrocytes|||0|1000|1205|1217
SE|92||ab|6|relation|0|0|C0030940|Peptide Hydrolases|aapp,gngm,enzy|aapp|||proteases|||0|888|956|965|MOD/HEAD|PART_OF||943|965|0|0|C0014792|Erythrocytes|cell|cell|||erythrocytic|||0|888|943|955
SE|92||ab|6|relation|10|1|C0014780|Erythrocyte Membrane|celc|celc|||erythrocyte membranes|||0|1000|1005|1026|PREP|LOCATION_OF||1002|1004|6|3|C0030940|Peptide Hydrolases|aapp,gngm,enzy|aapp|||proteases|||0|888|956|965
SE|92||ab|6|relation|11|1|C0243102|enzyme activity|moft|moft|||enzymatic activities|||0|947|1091|1111|PREP|PROCESS_OF||1112|1114|5|1|C0023516|Leukocytes|cell|cell|||leucocytes|||0|872|1133|1143
SE|92||ab|6|relation|15|5|C0243102|enzyme activity|moft|moft|||enzymatic activities|||0|947|1091|1111|PREP|PROCESS_OF||1202|1204|1|1|C0014792|Erythrocytes|cell|cell|||erythrocytes|||0|1000|1205|1217


SE|93||ti|1|text|15|103|[Structure formation in interphase adsorption layers of lysozyme at liquid boundaries].
SE|93||ti|1|entity|C0678594|Structure|spco|||Structure|||0|888|16|25
SE|93||ti|1|entity|C1522492|Formation|ftcn|||formation|||0|888|26|35
SE|93||ti|1|entity|C0021798|Interphase|tmco|||interphase|||0|623|39|49
SE|93||ti|1|entity|C0001674|Adsorption|lbpr|||adsorption|||0|623|50|60
SE|93||ti|1|entity|C0026794|Muramidase|aapp,enzy,phsu|||lysozyme|||0|1000|71|79

SE|93||ab|1|text|109|428|In connection with the modelling of biomembranes regularities of the formation and development of interphase adsorption layers of lysozyme at liquid borders under different conditions and depending on the nature of carbohydrate phase were investigated by the determination of mechanical characteristics of such layers.
SE|93||ab|1|entity|C0449379|Connection|inpr|||connection|||0|1000|112|122
SE|93||ab|1|entity|C0870071|Modeling|inpr,resa|||modelling|||0|1000|132|141
SE|93||ab|1|entity|C0449581|Regularity|qlco|||regularities|||0|827|158|170
SE|93||ab|1|entity|C1522492|Formation|ftcn|||formation|||0|1000|178|187
SE|93||ab|1|entity|C1527148|Development|ftcn|||development|||0|1000|192|203
SE|93||ab|1|entity|C0021798|Interphase|tmco|||interphase|||0|623|207|217
SE|93||ab|1|entity|C0001674|Adsorption|lbpr|||adsorption|||0|623|218|228
SE|93||ab|1|entity|C0026794|Muramidase|aapp,enzy,phsu|||lysozyme|||0|1000|239|247
SE|93||ab|1|entity|C0205284|Marginal|spco|||borders|||0|827|258|265
SE|93||ab|1|entity|C1547020|*Difference|qnco|||different|||0|836|272|281
SE|93||ab|1|entity|C0348080|Condition|qlco|||conditions|||0|836|282|292
SE|93||ab|1|entity|C0349590|Nature|idcn|||nature|||0|1000|314|320
SE|93||ab|1|entity|C0007004|Carbohydrates|carb|||carbohydrate|||0|888|324|336
SE|93||ab|1|entity|C0205390|Phase|tmco|||phase|||0|888|337|342
SE|93||ab|1|entity|C0680730|Adjudication|gora|||determination|||0|1000|368|381
SE|93||ab|1|entity|C1521970|Characteristics|grpa|||characteristics|||0|861|396|411

SE|93||ab|2|text|428|714|The investigations carried out showed that the most solid layers appeared under the conditions which assured the formation of the maximum number of intermolecular bonds (which in a common case is performed with maximum disorderlinesss of the macromolecules which get at the interphase).
SE|93||ab|2|entity|C0439787|Out|spco|||out|||0|1000|455|458
SE|93||ab|2|entity|C0205393|Most|qnco|||most|||0|623|475|479
SE|93||ab|2|entity|C0205208|Solid|qlco|||solid|||0|623|480|485
SE|93||ab|2|entity|C0348080|Condition|qlco|||conditions|||0|966|512|522
SE|93||ab|2|entity|C1522492|Formation|ftcn|||formation|||0|1000|541|550
SE|93||ab|2|entity|C0806909|Maximum|fndg|||maximum|||0|888|558|565
SE|93||ab|2|entity|C0237753|Numbers|qnco|||number|||0|888|566|572
SE|93||ab|2|entity|C0205214|Common|qnco|||common|||0|694|609|615
SE|93||ab|2|entity|C0806909|Maximum|fndg|||maximum|||0|694|639|646
SE|93||ab|2|entity|C0178735|macromolecule|chvs|||macromolecules|||0|966|670|684
SE|93||ab|2|entity|C0021798|Interphase|tmco|||interphase|||0|1000|702|712


SE|94||ti|1|text|15|155|[Relation between fluorescence and circular dichroism of the complex of the fluorescence probe 4-dimethylaminochalcone with serum albumin].
SE|94||ti|1|entity|C0869014|Relations|socb|||Relation|||0|966|16|24
SE|94||ti|1|entity|C0016315|Fluorescence|npop|||fluorescence|||0|1000|33|45
SE|94||ti|1|entity|C0008813|Circular Dichroism|lbpr,npop|||circular dichroism|||0|1000|50|68
SE|94||ti|1|entity|C0439855|Complex|qlco|||complex|||0|1000|76|83
SE|94||ti|1|entity|C0016321|Fluorescent Probes|irda|||fluorescence probe|||0|801|91|109
SE|94||ti|1|entity|C0058249|dimethylaminochalcone|orch|||dimethylaminochalcone|||0|801|112|133
SE|94||ti|1|entity|C0036773|Serum Albumin|aapp|||serum albumin|||0|1000|139|152

SE|94||ab|1|text|161|269|The fluorescence probe(4-dimethylaminochalcone; DMH) was noncovalently linked to human serum albumin (HSA).
SE|94||ab|1|entity|C0016321|Fluorescent Probes|irda|||fluorescence probe|||0|964|165|183
SE|94||ab|1|entity|C1434228|4-dimethylaminochalcone|orch|||4-dimethylaminochalcone|||0|1000|184|207
SE|94||ab|1|entity|C1455846|Domestic medium-haired cat|mamm|||DMH|||0|1000|209|212
SE|94||ab|1|entity|C0304925|Human serum albumin|aapp,bacs,phsu|||human serum albumin|||0|1000|242|261

SE|94||ab|2|text|269|408|The variation of pH was due to serum albumin structural changes, which was determined in terms of DMH and HSA fluorescence and CD spectra.
SE|94||ab|2|entity|C0205419|Variant|qlco|||variation|||0|1000|273|282
SE|94||ab|2|entity|C0036773|Serum Albumin|aapp|||serum albumin|||0|813|300|313
SE|94||ab|2|entity|C1455846|Domestic medium-haired cat|mamm|||DMH|||0|1000|367|370
SE|94||ab|2|entity|C0304925|Human serum albumin|aapp,bacs,phsu|||HSA|||0|916|375|378
SE|94||ab|2|entity|C0016315|Fluorescence|npop|||fluorescence|||0|916|379|391

SE|94||ab|3|text|408|564|Considerable changes of fluorescence and CD spectra were observed at pH 8 and 10, where there is ionization of two more recently titrated tyrosin residues.
SE|94||ab|3|entity|C0016315|Fluorescence|npop|||fluorescence|||0|1000|432|444
SE|94||ab|3|entity|C0596801|ionization|phpr|||ionization|||0|1000|505|515
SE|94||ab|3|entity|C0205448|Two|qnco|||two|||0|722|519|522
SE|94||ab|3|entity|C0332185|Recent|tmco|||recently|||0|722|528|536

SE|94||ab|4|text|564|687|It is assumed that these two tyrosine residues are in binding region and quench the fluorescence of DMH between pH 4 to 8.
SE|94||ab|4|entity|C0205448|Two|qnco|||two|||0|824|589|592
SE|94||ab|4|entity|C0041485|Tyrosine|aapp,bacs,phsu|||tyrosine|||0|824|593|601
SE|94||ab|4|entity|C0205147|Region|spco|||region|||0|861|626|632
SE|94||ab|4|entity|C0016315|Fluorescence|npop|||fluorescence|||0|1000|648|660
SE|94||ab|4|entity|C1455846|Domestic medium-haired cat|mamm|||DMH|||0|1000|664|667

SE|94||ab|5|text|687|823|Quenching disappears if these residues are ionized (pH greater than 8) or if the protein undergoes the N -F transition (pH less than 4).
SE|94||ab|5|entity|C0443228|Largest|qnco|||greater|||0|1000|742|749
SE|94||ab|5|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|768|775
SE|94||ab|5|entity|C0441922|N+|inpr|||N -F|||0|660|790|794


SE|95||ti|1|text|15|108|[Luminescence study of the effect of temperature on the conformational state of fibrinogen].
SE|95||ti|1|entity|C1450275|luminescence|npop|||Luminescence|||0|888|16|28
SE|95||ti|1|entity|C0008972|Clinical Research|resa|||study|||0|888|29|34
SE|95||ti|1|entity|C1280500|Effect|qlco|||effect|||0|1000|42|48
SE|95||ti|1|entity|C0039476|Temperature|qnco|||temperature|||0|1000|52|63
SE|95||ti|1|entity|C1442792|State|ftcn|||state|||0|861|86|91
SE|95||ti|1|entity|C0016006|Fibrinogen|aapp,bacs|||fibrinogen|||0|1000|95|105

SE|95||ab|1|text|114|257|Results are presented of measuring fibrinogen fluorescence parameters in temperature range of 20-80 degrees C at different pH of the solution.
SE|95||ab|1|entity|C1274040|result|ftcn|||Results|||0|966|114|121
SE|95||ab|1|entity|C0079809|Measures|qnco|||measuring|||0|825|139|148
SE|95||ab|1|entity|C0016006|Fibrinogen|aapp,bacs|||fibrinogen|||0|825|149|159
SE|95||ab|1|entity|C0016315|Fluorescence|npop|||fluorescence|||0|825|160|172
SE|95||ab|1|entity|C0039476|Temperature|qnco|||temperature|||0|888|187|198
SE|95||ab|1|entity|C1514721|Range|qnco|||range|||0|888|199|204
SE|95||ab|1|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|861|214|223
SE|95||ab|1|entity|C1547020|*Difference|qnco|||different|||0|853|227|236
SE|95||ab|1|entity|C0037633|Solutions|sbst|||solution|||0|1000|247|255

SE|95||ab|2|text|257|438|It was found that the temperature increase from 20 to 40 degrees C for solutions with pH of 4,5-9,3 were not accompanied by the conformational changes of fibrinogen macromolecules.
SE|95||ab|2|entity|C0015967|Fever|fndg|||temperature increase|||0|1000|279|299
SE|95||ab|2|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|314|323
SE|95||ab|2|entity|C0037633|Solutions|sbst|||solutions|||0|1000|328|337
SE|95||ab|2|entity|C0439084|>5|qnco|||5-9|||0|861|351|354
SE|95||ab|2|entity|C1518422|Not|ftcn|||not|||0|1000|362|365
SE|95||ab|2|entity|C0301641|Macromolecular alteration|moft|||conformational changes|||0|983|385|407
SE|95||ab|2|entity|C0016006|Fibrinogen|aapp,bacs|||fibrinogen|||0|872|411|421
SE|95||ab|2|entity|C0178735|macromolecule|chvs|||macromolecules|||0|872|422|436

SE|95||ab|3|text|438|585|In the temperature range of 40-50 degrees C for neutral solutions conformational reconstruction of fibrinogen of undenatured character took place.
SE|95||ab|3|entity|C0039476|Temperature|qnco|||temperature|||0|888|445|456
SE|95||ab|3|entity|C1514721|Range|qnco|||range|||0|888|457|462
SE|95||ab|3|entity|C0457176|Greater than 50 degrees C|qnco|||50 degrees C|||0|916|469|481
SE|95||ab|3|entity|C0037633|Solutions|sbst|||solutions|||0|763|494|503
SE|95||ab|3|entity|C0524865|Reconstructive Surgical Procedures|topp|||reconstruction|||0|763|519|533
SE|95||ab|3|entity|C0016006|Fibrinogen|aapp,bacs|||fibrinogen|||0|1000|537|547
SE|95||ab|3|entity|C0442504|Place|spco|||place|||0|1000|578|583

SE|95||ab|4|text|585|728|Temperature increase above 50-55 degrees C brings about significant structural changes of fibrinogen molecule which are of denaturation nature.
SE|95||ab|4|entity|C0015967|Fever|fndg|||Temperature increase|||0|1000|585|605
SE|95||ab|4|entity|C0457176|Greater than 50 degrees C|qnco|||50-55 degrees C|||0|923|612|627
SE|95||ab|4|entity|C0750502|Significant|idcn|||significant|||0|785|641|652
SE|95||ab|4|entity|C0016006|Fibrinogen|aapp,bacs|||fibrinogen|||0|888|675|685
SE|95||ab|4|entity|C0567416|Molecule|sbst|||molecule|||0|888|686|694
SE|95||ab|4|entity|C0301642|Denaturation|moft|||denaturation|||0|888|708|720
SE|95||ab|4|entity|C0349590|Nature|idcn|||nature|||0|888|721|727


SE|96||ti|1|text|15|138|Polymer concentration dependence of the helix to random coil transition of a charged polypeptide in aqueous salt solution.
SE|96||ti|1|entity|C0032521|Polymers|bodm,chvs|||Polymer|||0|802|15|22
SE|96||ti|1|entity|C0439857|Dependence|mobd|||dependence|||0|802|37|47
SE|96||ti|1|entity|C0439605|Random|qlco|||random|||0|606|64|70
SE|96||ti|1|entity|C0444764|Coils|spco|||coil|||0|606|71|75
SE|96||ti|1|entity|C0007961|charge amounts|qnco|||charged|||0|872|92|99
SE|96||ti|1|entity|C1305923|Polypeptides|aapp|||polypeptide|||0|872|100|111
SE|96||ti|1|entity|C0599956|Aqueous|qlco|||aqueous|||0|851|115|122
SE|96||ti|1|entity|C0036140|Salts|chvs|||salt|||0|851|123|127
SE|96||ti|1|entity|C0037633|Solutions|sbst|||solution|||0|851|128|136

SE|96||ab|1|text|144|343|The helix to coil transition of poly(L-glutamic acid) was investigated in 0.05 and 0.005 M aqueous potassium chloride solutions by use of potentiometric titration and circular dichroism measurement.
SE|96||ab|1|entity|C0747726|POLY|cnce|||poly|||0|1000|176|180
SE|96||ab|1|entity|C0061472|Glutamic Acid|aapp,bacs,phsu|||L-glutamic acid|||0|1000|181|196
SE|96||ab|1|entity|C0599956|Aqueous|qlco|||aqueous|||0|753|235|242
SE|96||ab|1|entity|C0032825|Potassium Chloride|inch,phsu|||potassium chloride|||0|753|243|261
SE|96||ab|1|entity|C0037633|Solutions|sbst|||solutions|||0|753|262|271
SE|96||ab|1|entity|C0597842|potentiometric titration|inpr|||potentiometric titration|||0|1000|282|306
SE|96||ab|1|entity|C0008813|Circular Dichroism|lbpr,npop|||circular dichroism|||0|901|311|329
SE|96||ab|1|entity|C0242485|Measurement|ftcn|||measurement|||0|901|330|341

SE|96||ab|2|text|343|474|Polymer concentration dependence of the transition was observed in the range from 0.006 to 0.04 monomol/e in 0.005 M KG1 solution.
SE|96||ab|2|entity|C0032521|Polymers|bodm,chvs|||Polymer|||0|802|343|350
SE|96||ab|2|entity|C0439857|Dependence|mobd|||dependence|||0|802|365|375
SE|96||ab|2|entity|C1514721|Range|qnco|||range|||0|1000|414|419
SE|96||ab|2|entity|C0037633|Solutions|sbst|||solution|||0|742|464|472

SE|96||ab|3|text|474|710|The polymer concentration dependence can be interpreted by current theories of the transition of charged polypeptides and of titration curves of linear weak polyelectrolytes taking the effect of polymer concentration into consideration.
SE|96||ab|3|entity|C0032521|Polymers|bodm,chvs|||polymer|||0|802|478|485
SE|96||ab|3|entity|C0439857|Dependence|mobd|||dependence|||0|802|500|510
SE|96||ab|3|entity|C0521116|Current|tmco|||current|||0|888|533|540
SE|96||ab|3|entity|C0871935|Theories|idcn|||theories|||0|888|541|549
SE|96||ab|3|entity|C0007961|charge amounts|qnco|||charged|||0|872|571|578
SE|96||ab|3|entity|C1305923|Polypeptides|aapp|||polypeptides|||0|872|579|591
SE|96||ab|3|entity|C0162621|Titration|lbpr|||titration|||0|1000|599|608
SE|96||ab|3|entity|C0205132|Linear|spco|||linear|||0|623|619|625
SE|96||ab|3|entity|C0004093|Asthenia|sosy|||weak|||0|623|626|630
SE|96||ab|3|entity|C1280500|Effect|qlco|||effect|||0|1000|659|665
SE|96||ab|3|entity|C0032521|Polymers|bodm,chvs|||polymer|||0|694|669|676
SE|96||ab|3|relation|6|3|C1305923|Polypeptides|aapp,gngm|aapp|||polypeptides|||0|872|579|591|NOM|INTERACTS_WITH||659|665|2|1|C0032521|Polymers|bodm,chvs|bodm|||polymer|||0|694|669|676


[96]: *** ERROR *** ERROR *** ERROR ***
[97]: *** ERROR *** ERROR *** ERROR ***
[98]: *** ERROR *** ERROR *** ERROR ***
[99]: *** ERROR *** ERROR *** ERROR ***
[100]: *** ERROR *** ERROR *** ERROR ***
[101]: *** ERROR *** ERROR *** ERROR ***
SE|103||ti|1|text|16|113|[Combined effects of hypoxia and hypercapnia on the functional state of the respiratory center].
SE|103||ti|1|entity|C0205195|Combined|qlco|||Combined|||0|872|17|25
SE|103||ti|1|entity|C1280500|Effect|qlco|||effects|||0|872|26|33
SE|103||ti|1|entity|C0242184|Hypoxia|patf|||hypoxia|||0|1000|37|44
SE|103||ti|1|entity|C0020440|Hypercapnia|sosy|||hypercapnia|||0|1000|49|60
SE|103||ti|1|entity|C0205245|Functional|ftcn|||functional|||0|888|68|78
SE|103||ti|1|entity|C1442792|State|ftcn|||state|||0|888|79|84
SE|103||ti|1|entity|C0035216|Respiratory Center|bpoc|||respiratory center|||0|1000|92|110

SE|103||ab|1|text|119|427|Experiments were conducted on cats under nembutal anesthesia; a study was made of pulse activity of bulbar respiratory neurons, electrical activity of the diaphragm and of the intercostal muscles; pO2, pCO2, pH, arterial blood oxygen saturation were determined in combined action of hypoxia and hypercapnia.
SE|103||ab|1|entity|C0681814|research study|resa|||Experiments|||0|1000|119|130
SE|103||ab|1|entity|C0007450|Felis catus|mamm|||cats|||0|1000|149|153
SE|103||ab|1|entity|C0702208|Nembutal|orch,phsu|||nembutal|||0|888|160|168
SE|103||ab|1|entity|C0002903|Anesthesia procedures|topp|||anesthesia|||0|888|169|179
SE|103||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|183|188
SE|103||ab|1|entity|C0025148|Medulla Oblongata|bpoc|||bulbar|||0|828|219|225
SE|103||ab|1|entity|C0521346|respiratory|ftcn|||respiratory|||0|828|226|237
SE|103||ab|1|entity|C0027882|Neurons|cell|||neurons|||0|828|238|245
SE|103||ab|1|entity|C0442828|Electrical|ftcn|||electrical|||0|888|247|257
SE|103||ab|1|entity|C1279038|Entire diaphragm|bpoc|||diaphragm|||0|1000|274|283
SE|103||ab|1|entity|C0021724|Structure of intercostal muscle|bpoc|||intercostal muscles|||0|1000|295|314
SE|103||ab|1|entity|C0391839|Carbon dioxide, partial pressure|lbtr|||pCO2|||0|1000|321|325
SE|103||ab|1|entity|C0221464|Arterial|spco|||arterial|||0|916|331|339
SE|103||ab|1|entity|C0428174|Hemoglobin saturation with oxygen|ortf|||blood oxygen saturation|||0|916|340|363
SE|103||ab|1|entity|C0205195|Combined|qlco|||combined|||0|694|383|391
SE|103||ab|1|entity|C0242184|Hypoxia|patf|||hypoxia|||0|1000|402|409
SE|103||ab|1|entity|C0020440|Hypercapnia|sosy|||hypercapnia|||0|1000|414|425
SE|103||ab|1|relation|0|0|C0002903|Anesthesia procedures|topp|topp|||anesthesia|||0|888|169|179|MOD/HEAD|USES||160|179|0|0|C0702208|Nembutal|orch,phsu|phsu|||nembutal|||0|888|160|168

SE|103||ab|2|text|427|657|When hypoxic gaseous mixture was given for respiration the developing hypocapnia disturbed the discharge rhythmic activity of the respiratory neurons, the respiration acquiring a pathological character of the Cheyne--Stokes type.
SE|103||ab|2|entity|C0068879|nitrox|inch|||hypoxic gaseous mixture|||0|976|432|455
SE|103||ab|2|entity|C0035203|Respiration|phsf|||respiration|||0|1000|470|481
SE|103||ab|2|entity|C0085383|Hypocapnia|sosy|||hypocapnia|||0|861|497|507
SE|103||ab|2|entity|C0012621|Discharge, Body Substance|bdsu|||discharge|||0|828|522|531
SE|103||ab|2|entity|C0031084|Periodicity|tmco|||rhythmic|||0|828|532|540
SE|103||ab|2|entity|C0521346|respiratory|ftcn|||respiratory|||0|888|557|568
SE|103||ab|2|entity|C0027882|Neurons|cell|||neurons|||0|888|569|576
SE|103||ab|2|entity|C0035203|Respiration|phsf|||respiration|||0|872|582|593
SE|103||ab|2|entity|C0439661|Acquired|tmco|||acquiring|||0|872|594|603
SE|103||ab|2|entity|C1521733|Pathologic|ftcn|||pathological|||0|694|606|618
SE|103||ab|2|entity|C1551086|Stokes|qnco|||Stokes|||0|888|644|650
SE|103||ab|2|entity|C1547052|*Type|qnco|||type|||0|888|651|655

SE|103||ab|3|text|657|921|After addition to the hypoxic gaseous mixture of 2% CO2 the gaseous composition of the arterial blood approached the initial values; this addition prevented the development of hypercapnia and disturbances of rhythmic discharge activity of the respiratory neurons.
SE|103||ab|3|entity|C0442796|Additive|qlco|||addition|||0|928|663|671
SE|103||ab|3|entity|C0068879|nitrox|inch|||hypoxic gaseous mixture|||0|976|679|702
SE|103||ab|3|entity|C0007012|Carbon Dioxide|bacs,inch|||CO2|||0|861|709|712
SE|103||ab|3|entity|C0017110|Gases|chvs|||gaseous|||0|853|717|724
SE|103||ab|3|entity|C0486616|Composition|clna|||composition|||0|853|725|736
SE|103||ab|3|entity|C0229665|Blood arterial|tisu|||arterial blood|||0|1000|744|758
SE|103||ab|3|entity|C0205265|Initially|tmco|||initial|||0|888|774|781
SE|103||ab|3|entity|C0042295|Values|qlco|||values|||0|888|782|788
SE|103||ab|3|entity|C0442796|Additive|qlco|||addition|||0|928|795|803
SE|103||ab|3|entity|C1527148|Development|ftcn|||development|||0|1000|818|829
SE|103||ab|3|entity|C0020440|Hypercapnia|sosy|||hypercapnia|||0|1000|833|844
SE|103||ab|3|entity|C0031084|Periodicity|tmco|||rhythmic|||0|828|865|873
SE|103||ab|3|entity|C0012621|Discharge, Body Substance|bdsu|||discharge|||0|828|874|883
SE|103||ab|3|entity|C0521346|respiratory|ftcn|||respiratory|||0|888|900|911
SE|103||ab|3|entity|C0027882|Neurons|cell|||neurons|||0|888|912|919
SE|103||ab|3|relation|11|1|C0012621|Discharge, Body Substance|bdsu|bdsu|||discharge|||0|828|874|883|PREP|PART_OF||893|895|1|1|C0027882|Neurons|cell|cell|||neurons|||0|888|912|919

SE|103||ab|4|text|921|1154|Addition of 5% CO2 to the hypoxic gaseous mixture produced a negative effect: at first it intensified and then depressed the pulse activity of the respiratory neurons, caused metabolic and respiratory acidosis, and promoted asphyxia.
SE|103||ab|4|entity|C0442796|Additive|qlco|||Addition|||0|928|921|929
SE|103||ab|4|entity|C0007012|Carbon Dioxide|bacs,inch|||CO2|||0|888|936|939
SE|103||ab|4|entity|C0068879|nitrox|inch|||hypoxic gaseous mixture|||0|976|947|970
SE|103||ab|4|entity|C0205160|Negative|qlco|||negative|||0|888|982|990
SE|103||ab|4|entity|C1280500|Effect|qlco|||effect|||0|888|991|997
SE|103||ab|4|entity|C1279901|Firstly|qlco|||first|||0|1000|1002|1007
SE|103||ab|4|entity|C0521346|respiratory|ftcn|||respiratory|||0|888|1068|1079
SE|103||ab|4|entity|C0027882|Neurons|cell|||neurons|||0|888|1080|1087
SE|103||ab|4|entity|C0311400|Metabolic|ftcn|||metabolic|||0|1000|1096|1105
SE|103||ab|4|entity|C0001127|Acidosis, Respiratory|dsyn|||respiratory acidosis|||0|1000|1110|1130
SE|103||ab|4|entity|C0004044|Asphyxia|patf|||asphyxia|||0|861|1145|1153
SE|103||ab|4|relation|4|2|C0068879|nitrox|inch|inch|||hypoxic gaseous mixture|||0|976|947|970|VERB|AFFECTS||1032|1041|5|2|C0027882|Neurons|cell|cell|||neurons|||0|888|1080|1087


SE|104||ti|1|text|16|115|[Level of nicotinamide coenzymes in the liver and myocardium of rats poisoned with dichlorethane].
SE|104||ti|1|entity|C0028027|Niacinamide|orch,phsu,vita|||nicotinamide|||0|888|26|38
SE|104||ti|1|entity|C0009235|Coenzymes|bacs,orch|||coenzymes|||0|888|39|48
SE|104||ti|1|entity|C0023884|Liver|bpoc|||liver|||0|1000|56|61
SE|104||ti|1|entity|C0027061|Myocardium|tisu|||myocardium|||0|1000|66|76
SE|104||ti|1|entity|C0034693|Rattus norvegicus|mamm|||rats|||0|1000|80|84
SE|104||ti|1|relation|4|1|C0023884|Liver|bpoc|bpoc|||liver|||0|1000|56|61|PREP|LOCATION_OF||49|51|2|1|C0009235|Coenzymes|bacs,orch|bacs|||coenzymes|||0|888|39|48
SE|104||ti|1|relation|4|1|C0023884|Liver|bpoc|bpoc|||liver|||0|1000|56|61|PREP|PART_OF||77|79|2|1|C0034693|Rattus norvegicus|mamm|mamm|||rats|||0|1000|80|84
SE|104||ti|1|relation|4|1|C0027061|Myocardium|tisu|tisu|||myocardium|||0|1000|66|76|PREP|LOCATION_OF||49|51|2|1|C0009235|Coenzymes|bacs,orch|bacs|||coenzymes|||0|888|39|48
SE|104||ti|1|relation|4|1|C0027061|Myocardium|tisu|tisu|||myocardium|||0|1000|66|76|PREP|PART_OF||77|79|2|1|C0034693|Rattus norvegicus|mamm|mamm|||rats|||0|1000|80|84

SE|104||ab|1|text|121|162|Experiments were conducted on male rats.
SE|104||ab|1|entity|C0681814|research study|resa|||Experiments|||0|1000|121|132
SE|104||ab|1|entity|C0034693|Rattus norvegicus|mamm|||rats|||0|861|156|160

SE|104||ab|2|text|162|328|A study was made of the content of nicotinamide coenzymes in the liver and myocardium 24 hours after the administration of 0.5 ml of dichloroethane into the stomach.
SE|104||ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|164|169
SE|104||ab|2|entity|C0028027|Niacinamide|orch,phsu,vita|||nicotinamide|||0|888|197|209
SE|104||ab|2|entity|C0009235|Coenzymes|bacs,orch|||coenzymes|||0|888|210|219
SE|104||ab|2|entity|C0023884|Liver|bpoc|||liver|||0|1000|227|232
SE|104||ab|2|entity|C0027061|Myocardium|tisu|||myocardium|||0|901|237|247
SE|104||ab|2|entity|C0439584|24 hour time frame|tmco|||24 hours|||0|901|248|256
SE|104||ab|2|entity|C0444499|0/5|qnco|||0.5|||0|901|285|288
SE|104||ab|2|entity|C0015082|Ethylene Dichlorides|hops,irda,orch|||dichloroethane|||0|1000|295|309
SE|104||ab|2|entity|C0038351|Stomach|bpoc|||stomach|||0|1000|319|326
SE|104||ab|2|relation|6|1|C0023884|Liver|bpoc|bpoc|||liver|||0|1000|227|232|PREP|LOCATION_OF||220|222|3|1|C0009235|Coenzymes|bacs,orch|bacs|||coenzymes|||0|888|210|219
SE|104||ab|2|relation|6|1|C0027061|Myocardium|tisu|tisu|||myocardium|||0|901|237|247|PREP|LOCATION_OF||220|222|3|1|C0009235|Coenzymes|bacs,orch|bacs|||coenzymes|||0|888|210|219

SE|104||ab|3|text|328|648|In parallel with disturbance of the morphological structure of the liver and of the myocardium, increase in the activity of alanine and aspargic aminotranspherases in the blood serum, dichloroethane reduced the content of nicotinamide coenzymes and deranged the ratio of their oxidized and reduced forms in these organs.
SE|104||ab|3|entity|C0543482|morphological|spco|||morphological|||0|888|364|377
SE|104||ab|3|entity|C0678594|Structure|spco|||structure|||0|888|378|387
SE|104||ab|3|entity|C0023884|Liver|bpoc|||liver|||0|1000|395|400
SE|104||ab|3|entity|C0027061|Myocardium|tisu|||myocardium|||0|1000|412|422
SE|104||ab|3|entity|C0442805|Increase|ftcn|||increase|||0|1000|424|432
SE|104||ab|3|entity|C0001898|Alanine|aapp,bacs|||alanine|||0|1000|452|459
SE|104||ab|3|entity|C0229671|Serum|bdsu|||blood serum|||0|1000|499|510
SE|104||ab|3|entity|C0015082|Ethylene Dichlorides|hops,irda,orch|||dichloroethane|||0|1000|512|526
SE|104||ab|3|entity|C0028027|Niacinamide|orch,phsu,vita|||nicotinamide|||0|888|550|562
SE|104||ab|3|entity|C0009235|Coenzymes|bacs,orch|||coenzymes|||0|888|563|572
SE|104||ab|3|entity|C0456603|Ratio|inpr|||ratio|||0|1000|590|595
SE|104||ab|3|entity|C0392756|Reduced|qlco|||reduced|||0|888|618|625
SE|104||ab|3|entity|C0178784|Organ|bpoc|||organs|||0|966|641|647
SE|104||ab|3|relation|8|1|C0229671|Serum|bdsu|bdsu|||blood serum|||0|1000|499|510|PREP|LOCATION_OF||492|494|9|2|C0001898|Alanine|aapp,gngm,bacs|aapp|||alanine|||0|1000|452|459
SE|104||ab|3|relation|11|1|C0015082|Ethylene Dichlorides|hops,irda,orch|hops|||dichloroethane|||0|1000|512|526|VERB|INHIBITS||527|534|6|2|C0009235|Coenzymes|bacs,orch|bacs|||coenzymes|||0|888|563|572


SE|105||ti|1|text|16|71|[Effect of carbidine on conditioned defense reflexes].
SE|105||ti|1|entity|C1280500|Effect|qlco|||Effect|||0|1000|17|23
SE|105||ti|1|entity|C0057820|dicarbine|orch,phsu|||carbidine|||0|1000|27|36
SE|105||ti|1|entity|C0679190|defensiveness|inbe|||defense|||0|856|52|59
SE|105||ti|1|entity|C0034936|Reflex, Conditioned|menp|||conditioned defense reflexes|||0|856|40|68

SE|105||ab|1|text|77|282|Chronic experiments were conducted on rats and rabbits; a study was made of the effect of carbidine on the conditioned defence reflexes in stimulation of the mesencephalic part of the reticular formation.
SE|105||ab|1|entity|C0205191|chronic|tmco|||Chronic|||0|888|77|84
SE|105||ab|1|entity|C0681814|research study|resa|||experiments|||0|888|85|96
SE|105||ab|1|entity|C0034693|Rattus norvegicus|mamm|||rats|||0|1000|115|119
SE|105||ab|1|entity|C0034493|Oryctolagus cuniculus|mamm|||rabbits|||0|1000|124|131
SE|105||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|135|140
SE|105||ab|1|entity|C1280500|Effect|qlco|||effect|||0|1000|157|163
SE|105||ab|1|entity|C0057820|dicarbine|orch,phsu|||carbidine|||0|1000|167|176
SE|105||ab|1|entity|C0679190|defensiveness|inbe|||defence|||0|854|196|203
SE|105||ab|1|entity|C0034936|Reflex, Conditioned|menp|||conditioned defence reflexes|||0|854|184|212
SE|105||ab|1|entity|C0025462|Midbrain structure|bpoc|||mesencephalic|||0|888|235|248
SE|105||ab|1|entity|C0449719|Part|spco|||part|||0|888|249|253
SE|105||ab|1|entity|C0035284|Reticular Formation|bpoc|||reticular formation|||0|1000|261|280
SE|105||ab|1|relation|8|0|C0025462|Midbrain structure|bpoc|bpoc|||mesencephalic|||0|888|235|248|NOM|PART_OF||249|253|1|1|C0035284|Reticular Formation|bpoc|bpoc|||reticular formation|||0|1000|261|280

SE|105||ab|2|text|282|432|Carbidine prevented the depression of the conditioned defence reflexes caused by stimulation of the mesencephalic portion of the reticular formation.
SE|105||ab|2|entity|C0057820|dicarbine|orch,phsu|||Carbidine|||0|1000|282|291
SE|105||ab|2|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|306|316
SE|105||ab|2|entity|C0679190|defensiveness|inbe|||defence|||0|854|336|343
SE|105||ab|2|entity|C0034936|Reflex, Conditioned|menp|||conditioned defence reflexes|||0|854|324|352
SE|105||ab|2|entity|C0025462|Midbrain structure|bpoc|||mesencephalic|||0|694|382|395
SE|105||ab|2|entity|C0035284|Reticular Formation|bpoc|||reticular formation|||0|1000|411|430
SE|105||ab|2|relation|1|1|C0057820|dicarbine|orch,phsu|orch|||Carbidine|||0|1000|282|291|VERB|PREVENTS||292|301|5|1|C0011581|Depressive disorder|mobd|mobd|||depression|||0|1000|306|316
SE|105||ab|2|relation|4|0|C0025462|Midbrain structure|bpoc|bpoc|||mesencephalic|||0|694|382|395|NOM|PART_OF||396|403|1|1|C0035284|Reticular Formation|bpoc|bpoc|||reticular formation|||0|1000|411|430

SE|105||ab|3|text|432|655|This pointed to its depressive influence on the mentioned structures, and was confirmed by experiments on rabbits in recording changes in biocurrents under conditions of stimulation of the mesencephalic reticular formation.
SE|105||ab|3|entity|C0678594|Structure|spco|||structures|||0|827|490|500
SE|105||ab|3|entity|C0681814|research study|resa|||experiments|||0|1000|523|534
SE|105||ab|3|entity|C0034493|Oryctolagus cuniculus|mamm|||rabbits|||0|1000|538|545
SE|105||ab|3|entity|C0034869|Records|inpr|||recording|||0|855|549|558
SE|105||ab|3|entity|C0348080|Condition|qlco|||conditions|||0|966|588|598
SE|105||ab|3|entity|C0025462|Midbrain structure|bpoc|||mesencephalic|||0|901|621|634
SE|105||ab|3|entity|C0035284|Reticular Formation|bpoc|||reticular formation|||0|901|635|654
SE|105||ab|3|relation|0|0|C0035284|Reticular Formation|bpoc|bpoc|||reticular formation|||0|901|635|654|MOD/HEAD|PART_OF||621|654|0|0|C0025462|Midbrain structure|bpoc|bpoc|||mesencephalic|||0|901|621|634


SE|106||ti|1|text|16|172|[Level of nicotinamide coenzymes in the myocardium of rats during the effects of methylxanthines (theophylline, theobromine, caffeine) and catecholamines].
SE|106||ti|1|entity|C0028027|Niacinamide|orch,phsu,vita|||nicotinamide|||0|888|26|38
SE|106||ti|1|entity|C0009235|Coenzymes|bacs,orch|||coenzymes|||0|888|39|48
SE|106||ti|1|entity|C0027061|Myocardium|tisu|||myocardium|||0|1000|56|66
SE|106||ti|1|entity|C0034693|Rattus norvegicus|mamm|||rats|||0|1000|70|74
SE|106||ti|1|entity|C1280500|Effect|qlco|||effects|||0|966|86|93
SE|106||ti|1|entity|C0066447|methylxanthine|bacs,nnon|||methylxanthines|||0|1000|97|112
SE|106||ti|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline|||0|1000|114|126
SE|106||ti|1|entity|C0039763|Theobromine|bacs,orch,phsu|||theobromine|||0|1000|128|139
SE|106||ti|1|entity|C0006644|Caffeine|orch,phsu|||caffeine|||0|1000|141|149
SE|106||ti|1|entity|C0007412|Catecholamines|nsba,orch|||catecholamines|||0|1000|155|169
SE|106||ti|1|relation|3|1|C0027061|Myocardium|tisu|tisu|||myocardium|||0|1000|56|66|PREP|PART_OF||67|69|7|1|C0034693|Rattus norvegicus|mamm|mamm|||rats|||0|1000|70|74
SE|106||ti|1|relation|4|3|C0009235|Coenzymes|bacs,orch|bacs|||coenzymes|||0|888|39|48|NOM|INTERACTS_WITH||86|93|5|1|C0066447|methylxanthine|bacs,nnon|bacs|||methylxanthines|||0|1000|97|112
SE|106||ti|1|relation|8|1|C0027061|Myocardium|tisu|tisu|||myocardium|||0|1000|56|66|PREP|LOCATION_OF||49|51|2|1|C0009235|Coenzymes|bacs,orch|orch|||coenzymes|||0|888|39|48

SE|106||ab|1|text|178|465|It was shown in acute experiments on rats that one hour after an intraperitoneal injection of theophylline (50 mg/kg) there was a decrease in the NAD + NADP content by 19.4%, a tendency to a fall of NAD.H2 + NADP.H2 was expressed, and the total nicotinamide coferment level was reduced.
SE|106||ab|1|entity|C0205178|acute|tmco|||acute|||0|888|194|199
SE|106||ab|1|entity|C0681814|research study|resa|||experiments|||0|888|200|211
SE|106||ab|1|entity|C0034693|Rattus norvegicus|mamm|||rats|||0|1000|215|219
SE|106||ab|1|entity|C0205447|One|qnco|||one|||0|888|225|228
SE|106||ab|1|entity|C0439227|Hour|tmco|||hour|||0|888|229|233
SE|106||ab|1|entity|C0021493|Injections, Intraperitoneal|topp|||intraperitoneal injection|||0|1000|243|268
SE|106||ab|1|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline|||0|1000|272|284
SE|106||ab|1|entity|C0547047|Decrease|qnco|||decrease|||0|1000|308|316
SE|106||ab|1|entity|C0027270|Nicotinamide adenine dinucleotide (NAD)|bacs,nnon|||NAD|||0|623|324|327
SE|106||ab|1|entity|C0027303|NADP|bacs,nnon|||NADP|||0|623|330|334
SE|106||ab|1|entity|C0085639|Falls|fndg|||fall|||0|1000|369|373
SE|106||ab|1|entity|C0027270|Nicotinamide adenine dinucleotide (NAD)|bacs,nnon|||NAD|||0|597|377|380
SE|106||ab|1|entity|C0027303|NADP|bacs,nnon|||NADP|||0|597|386|390
SE|106||ab|1|entity|C0439175|% of total|qnco|||total|||0|888|417|422
SE|106||ab|1|entity|C0028027|Niacinamide|orch,phsu,vita|||nicotinamide|||0|888|423|435
SE|106||ab|1|relation|6|5|C0028027|Niacinamide|orch,phsu,vita|orch|||nicotinamide|||0|888|423|435|NOM|INHIBITS||308|316|6|1|C0027303|NADP|bacs,nnon|bacs|||NADP|||0|623|330|334

SE|106||ab|2|text|465|579|A tendency to decrease NAD + NADP and the total pyridine nucleotide level was seen after caffeine administration.
SE|106||ab|2|entity|C0027270|Nicotinamide adenine dinucleotide (NAD)|bacs,nnon|||NAD|||0|888|488|491
SE|106||ab|2|entity|C0027303|NADP|bacs,nnon|||NADP|||0|888|494|498
SE|106||ab|2|entity|C0439175|% of total|qnco|||total|||0|658|507|512
SE|106||ab|2|entity|C0597331|pyridine nucleotide|nnon|||pyridine nucleotide|||0|658|513|532
SE|106||ab|2|entity|C0006644|Caffeine|orch,phsu|||caffeine|||0|888|554|562

SE|106||ab|3|text|579|642|The action of catecholamines and methylxanthines was compared.
SE|106||ab|3|entity|C0007412|Catecholamines|nsba,orch|||catecholamines|||0|1000|593|607
SE|106||ab|3|entity|C0066447|methylxanthine|bacs,nnon|||methylxanthines|||0|1000|612|627

SE|106||ab|4|text|642|713|Theobromine produced no significant effect on the indices under study.
SE|106||ab|4|entity|C0039763|Theobromine|bacs,orch,phsu|||Theobromine|||0|1000|642|653
SE|106||ab|4|entity|C0750502|Significant|idcn|||significant|||0|888|666|677
SE|106||ab|4|entity|C1280500|Effect|qlco|||effect|||0|888|678|684
SE|106||ab|4|entity|C0918012|Index|inpr|||indices|||0|1000|692|699
SE|106||ab|4|entity|C0008972|Clinical Research|resa|||study|||0|1000|706|711

SE|106||ab|5|text|713|906|It was shown that isadrine decreased the NAD + NADP level; adrenaline (25 mkg/kg) increased the content of both the oxidized (by 24%) and of the reduced (by 48%) forms of pyridine nucleotides.
SE|106||ab|5|entity|C0701455|Isadrine|orch,phsu|||isadrine|||0|1000|731|739
SE|106||ab|5|entity|C0027270|Nicotinamide adenine dinucleotide (NAD)|bacs,nnon|||NAD|||0|623|754|757
SE|106||ab|5|entity|C0027303|NADP|bacs,nnon|||NADP|||0|623|760|764
SE|106||ab|5|entity|C0014563|Epinephrine|horm,nsba,orch,phsu|||adrenaline|||0|1000|772|782
SE|106||ab|5|entity|C0392756|Reduced|qlco|||reduced|||0|1000|858|865
SE|106||ab|5|entity|C0597331|pyridine nucleotide|nnon|||pyridine nucleotides|||0|983|884|904
SE|106||ab|5|relation|1|1|C0701455|Isadrine|orch,phsu|orch|||isadrine|||0|1000|731|739|VERB|INHIBITS||740|749|7|1|C0027303|NADP|bacs,nnon|bacs|||NADP|||0|623|760|764

SE|106||ab|6|text|906|1069|An increase of adrenaline dose to 1000 mkg/kg was accompanied by reduction of the oxidized forms (by 22.2%) and of the total nicotinamide coferment level (by 18%).
SE|106||ab|6|entity|C0442805|Increase|ftcn|||increase|||0|1000|909|917
SE|106||ab|6|entity|C0014563|Epinephrine|horm,nsba,orch,phsu|||adrenaline|||0|888|921|931
SE|106||ab|6|entity|C1446466|Dose|qnco|||dose|||0|888|932|936
SE|106||ab|6|entity|C0439175|% of total|qnco|||total|||0|888|1025|1030
SE|106||ab|6|entity|C0028027|Niacinamide|orch,phsu,vita|||nicotinamide|||0|888|1031|1043


SE|107||ti|1|text|16|66|Potable water quality in rural Georgetown County.
SE|107||ti|1|entity|C0597680|water quality|qnco|||water quality|||0|901|24|37
SE|107||ti|1|entity|C0079170|Counties|geoa|||County|||0|802|58|64

SE|107||ab|1|text|72|206|Drinking water supplies of 161 rural communities, in Georgetown County, South Carolina, were randomly selected for sample collection.
SE|107||ab|1|entity|C0001948|Alcohol consumption|inbe|||Drinking|||0|901|72|80
SE|107||ab|1|entity|C0043062|Water Supply|qnco|||water supplies|||0|901|81|95
SE|107||ab|1|entity|C0086944|Rural Communities|popg|||rural communities|||0|901|103|120
SE|107||ab|1|entity|C0079170|Counties|geoa|||County|||0|861|136|142
SE|107||ab|1|entity|C0037716|South Carolina|geoa|||South Carolina|||0|1000|144|158
SE|107||ab|1|entity|C0200345|Specimen collection|lbpr|||sample collection|||0|1000|187|204

SE|107||ab|2|text|206|272|The analysis showed that most of the waters were slightly acidic.
SE|107||ab|2|entity|C0936012|Analysis|resa|||analysis|||0|1000|210|218
SE|107||ab|2|entity|C0205393|Most|qnco|||most|||0|1000|231|235
SE|107||ab|2|entity|C0043047|Water|inch,phsu|||waters|||0|1000|243|249
SE|107||ab|2|entity|C0750482|SLIGHTLY|idcn|||slightly|||0|853|255|263
SE|107||ab|2|entity|C0001128|Acids|chem|||acidic|||0|853|264|270

SE|107||ab|3|text|272|389|Low, but acceptable concentrations of chloride, copper, fluoride, sodium, cadmium, nitrate and phosphate were found.
SE|107||ab|3|entity|C0205251|low|qlco|||Low|||0|1000|272|275
SE|107||ab|3|entity|C0814633|acceptability|qlco|||acceptable|||0|853|281|291
SE|107||ab|3|entity|C0008203|Chlorides|inch|||chloride|||0|1000|310|318
SE|107||ab|3|entity|C0009968|Copper|bacs,elii,phsu|||copper|||0|1000|320|326
SE|107||ab|3|entity|C0016327|Fluorides|inch,phsu|||fluoride|||0|1000|328|336
SE|107||ab|3|entity|C0037473|Sodium|bacs,elii|||sodium|||0|1000|338|344
SE|107||ab|3|entity|C0006632|Cadmium|elii,hops|||cadmium|||0|1000|346|353
SE|107||ab|3|entity|C0699857|Nitrate|inch|||nitrate|||0|1000|355|362

SE|107||ab|4|text|389|483|A few water samples showed higher then recommended levels of arsenic, mercury, zinc and lead.
SE|107||ab|4|entity|C0205388|Few|qnco|||few|||0|890|391|394
SE|107||ab|4|entity|C1550678|Water Specimen|inch|||water samples|||0|890|395|408
SE|107||ab|4|entity|C0205250|High|qlco|||higher|||0|775|416|422
SE|107||ab|4|entity|C0441889|Levels|inpr|||levels|||0|775|440|446
SE|107||ab|4|entity|C0003818|Arsenic|elii,hops|||arsenic|||0|1000|450|457
SE|107||ab|4|entity|C0025424|Mercury|elii,hops|||mercury|||0|1000|459|466
SE|107||ab|4|entity|C0043481|Zinc|bacs,elii,phsu|||zinc|||0|1000|468|472

SE|107||ab|5|text|483|617|Although only 2% of the samples exceeded the mandatory limit of 0.05 ppm for arsenic, 72% exceeded the recommended level of 0.01 ppm.
SE|107||ab|5|entity|C1549649|Limit|idcn|||limit|||0|861|538|543
SE|107||ab|5|entity|C0439187|ppm|qnco|||ppm|||0|827|552|555
SE|107||ab|5|entity|C0003818|Arsenic|elii,hops|||arsenic|||0|1000|560|567
SE|107||ab|5|entity|C0439187|ppm|qnco|||ppm|||0|827|612|615

SE|107||ab|6|text|617|724|The mandatory limit for manganese was exceeded in 37% of the waters while 88% exceeded the limit for iron.
SE|107||ab|6|entity|C1549649|Limit|idcn|||limit|||0|861|631|636
SE|107||ab|6|entity|C0024706|Manganese|bacs,elii|||manganese|||0|1000|641|650
SE|107||ab|6|entity|C0043047|Water|inch,phsu|||waters|||0|1000|678|684
SE|107||ab|6|entity|C1549649|Limit|idcn|||limit|||0|1000|708|713
SE|107||ab|6|entity|C0302583|Iron|bacs,elii,phsu|||iron|||0|1000|718|722

SE|107||ab|7|text|724|824|The high iron content was generally responsible for the high turbidity found in 45% of the samples.
SE|107||ab|7|entity|C0205250|High|qlco|||high|||0|623|728|732
SE|107||ab|7|entity|C0302583|Iron|bacs,elii,phsu|||iron|||0|623|733|737
SE|107||ab|7|entity|C0205250|High|qlco|||high|||0|888|780|784
SE|107||ab|7|entity|C0301633|Turbidity|qlco|||turbidity|||0|888|785|794

SE|107||ab|8|text|824|898|The well depth and the consumer income had some bearing on water quality.
SE|107||ab|8|entity|C0205170|Good|qlco|||well|||0|888|828|832
SE|107||ab|8|entity|C0205125|Depth|spco|||depth|||0|888|833|838
SE|107||ab|8|entity|C0021162|Income|qnco|||income|||0|861|856|862
SE|107||ab|8|entity|C0597680|water quality|qnco|||water quality|||0|1000|883|896

SE|107||ab|9|text|898|1062|Statistical evidence suggested that septic tank seepage was partially responsible for nitrate, phosphate, iron and arsenic contamination of shallow water supplies.
SE|107||ab|9|entity|C0220917|statistical|inpr|||Statistical|||0|694|898|909
SE|107||ab|9|entity|C0333534|Septic|ftcn|||septic|||0|623|934|940
SE|107||ab|9|entity|C0336821|Tank|mnob|||tank|||0|623|941|945
SE|107||ab|9|entity|C0699857|Nitrate|inch|||nitrate|||0|1000|984|991
SE|107||ab|9|entity|C0302583|Iron|bacs,elii,phsu|||iron|||0|1000|1004|1008
SE|107||ab|9|entity|C0003818|Arsenic|elii,hops|||arsenic|||0|888|1013|1020
SE|107||ab|9|entity|C0259846|adulteration|hcpp|||contamination|||0|888|1021|1034
SE|107||ab|9|entity|C0043062|Water Supply|qnco|||water supplies|||0|901|1046|1060

SE|107||ab|10|text|1062|1153|Lead concentrations appear to vary according to the plumbing used and the pH of the waters.
SE|107||ab|10|entity|C0032248|Plumbing|ocdi|||plumbing|||0|1000|1114|1122
SE|107||ab|10|entity|C0043047|Water|inch,phsu|||waters|||0|1000|1146|1152


[107]: *** ERROR *** ERROR *** ERROR ***
[108]: *** ERROR *** ERROR *** ERROR ***
[109]: *** ERROR *** ERROR *** ERROR ***
[110]: *** ERROR *** ERROR *** ERROR ***
[111]: *** ERROR *** ERROR *** ERROR ***
[112]: *** ERROR *** ERROR *** ERROR ***
[113]: *** ERROR *** ERROR *** ERROR ***
[114]: *** ERROR *** ERROR *** ERROR ***
[115]: *** ERROR *** ERROR *** ERROR ***
[116]: *** ERROR *** ERROR *** ERROR ***
[117]: *** ERROR *** ERROR *** ERROR ***
[118]: *** ERROR *** ERROR *** ERROR ***
[119]: *** ERROR *** ERROR *** ERROR ***
[120]: *** ERROR *** ERROR *** ERROR ***
[121]: *** ERROR *** ERROR *** ERROR ***
SE|123||ti|1|text|16|143|The importance of an innervated and intact antrum and pylorus in preventing postoperative duodenogastric reflux and gastritis.
SE|123||ti|1|entity|C0205266|Intact|qlco|||intact|||0|888|52|58
SE|123||ti|1|entity|C1549092|Antrum|bpoc|||antrum|||0|888|59|65
SE|123||ti|1|entity|C0034196|Pylorus|bpoc|||pylorus|||0|1000|70|77
SE|123||ti|1|entity|C0013299|Duodenogastric Reflux|dsyn|||duodenogastric reflux|||0|808|106|127
SE|123||ti|1|entity|C0017152|Gastritis|dsyn|||gastritis|||0|1000|132|141

SE|123||ab|1|text|149|325|This study has investigated the relationship between duodenogastric reflux, gastritis and certain symptoms 6-12 months after three operations for uncomplicated duodenal ulcer.
SE|123||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|154|159
SE|123||ab|1|entity|C0439849|Relationships|qlco|||relationship|||0|1000|181|193
SE|123||ab|1|entity|C0013299|Duodenogastric Reflux|dsyn|||duodenogastric reflux|||0|1000|202|223
SE|123||ab|1|entity|C0017152|Gastritis|dsyn|||gastritis|||0|1000|225|234
SE|123||ab|1|entity|C1457887|Symptoms|sosy|||symptoms|||0|762|247|255
SE|123||ab|1|entity|C0439231|month|tmco|||months|||0|762|261|267
SE|123||ab|1|entity|C0205449|Three|qnco|||three|||0|888|274|279
SE|123||ab|1|entity|C0038895|Surgical aspects|ftcn|||operations|||0|888|280|290
SE|123||ab|1|entity|C0443334|Uncomplicated|qlco|||uncomplicated|||0|901|295|308
SE|123||ab|1|entity|C0013295|Duodenal Ulcer|dsyn|||duodenal ulcer|||0|901|309|323

SE|123||ab|2|text|325|501|The operations studied were proximal gastric vagotomy (PGV, 20 cases), truncal vagotomy and pyloroplasty (TV+P, 22 cases) and truncal vagotomy and antrectomy (TV+A, 21 cases).
SE|123||ab|2|entity|C0038895|Surgical aspects|ftcn|||operations|||0|1000|329|339
SE|123||ab|2|entity|C0042273|Proximal Gastric Vagotomy|topp|||proximal gastric vagotomy|||0|1000|353|378
SE|123||ab|2|entity|C0868928|Case (situation)|ftcn|||cases|||0|861|388|393
SE|123||ab|2|entity|C0042275|Vagotomy, Truncal|topp|||truncal vagotomy|||0|1000|396|412
SE|123||ab|2|entity|C0192489|Pyloroplasty|topp|||pyloroplasty|||0|1000|417|429
SE|123||ab|2|entity|C0868928|Case (situation)|ftcn|||cases|||0|861|440|445
SE|123||ab|2|entity|C0042275|Vagotomy, Truncal|topp|||truncal vagotomy|||0|1000|451|467
SE|123||ab|2|entity|C0599482|antrectomy|topp|||antrectomy|||0|1000|472|482
SE|123||ab|2|entity|C0868928|Case (situation)|ftcn|||cases|||0|861|493|498

SE|123||ab|3|text|501|669|Duodenogastric reflux was assessed both by a radiological technique and by measuring the concentration of bilirubin in the gastric aspirate before and after operation.
SE|123||ab|3|entity|C0013299|Duodenogastric Reflux|dsyn|||Duodenogastric reflux|||0|1000|501|522
SE|123||ab|3|entity|C0457276|Radiographic imaging|diap|||radiological technique|||0|947|546|568
SE|123||ab|3|entity|C0079809|Measures|qnco|||measuring|||0|966|576|585
SE|123||ab|3|entity|C0005437|Bilirubin|bacs,orch|||bilirubin|||0|1000|607|616
SE|123||ab|3|entity|C1546644|Aspirate, Gastric|inpr|||gastric aspirate|||0|1000|624|640
SE|123||ab|3|entity|C0543467|Operative Surgical Procedures|topp|||operation|||0|1000|658|667
SE|123||ab|3|relation|1|1|C0543467|Operative Surgical Procedures|topp|topp|||operation|||0|1000|658|667|PREP|PRECEDES||652|657|6|5|C0457276|Radiographic imaging|diap|diap|||radiological technique|||0|947|546|568

SE|123||ab|4|text|669|757|Incidence and severity of postoperative gastritis were determined by endoscopic biopsy.
SE|123||ab|4|entity|C0021149|Incidence|qnco|||Incidence|||0|1000|669|678
SE|123||ab|4|entity|C0439793|Severities|qlco|||severity|||0|1000|683|691
SE|123||ab|4|entity|C0017152|Gastritis|dsyn|||gastritis|||0|861|709|718
SE|123||ab|4|entity|C0184980|Endoscopic biopsy|diap|||endoscopic biopsy|||0|1000|738|755
SE|123||ab|4|relation|1|1|C0184980|Endoscopic biopsy|diap|diap|||endoscopic biopsy|||0|1000|738|755|VERB|MEASURES||724|734|3|1|C0017152|Gastritis|dsyn|dsyn|||gastritis|||0|861|709|718

SE|123||ab|5|text|757|821|Symptoms were assessed by symptomatic score and Visick grading.
SE|123||ab|5|entity|C1457887|Symptoms|sosy|||Symptoms|||0|1000|757|765
SE|123||ab|5|entity|C0231220|Symptomatic|ftcn|||symptomatic|||0|888|783|794
SE|123||ab|5|entity|C0449820|Score|qnco|||score|||0|888|795|800

SE|123||ab|6|text|821|986|There was a significant correlation between duodenal reflux and histological evidence of both severe superficial gastritis and glandular atrophy (P less than 0-01).
SE|123||ab|6|entity|C0750502|Significant|idcn|||significant|||0|694|833|844
SE|123||ab|6|entity|C0013299|Duodenogastric Reflux|dsyn|||duodenal reflux|||0|1000|865|880
SE|123||ab|6|entity|C0205462|Histologic|ftcn|||histological|||0|694|885|897
SE|123||ab|6|entity|C0205082|Severe|qlco|||severe|||0|901|915|921
SE|123||ab|6|entity|C0267159|Superficial gastritis|dsyn|||superficial gastritis|||0|901|922|943
SE|123||ab|6|entity|C0225353|Glandular|qlco|||glandular|||0|888|948|957
SE|123||ab|6|entity|C0333641|Atrophic|patf|||atrophy|||0|888|958|965

SE|123||ab|7|text|986|1139|There was also a close association between the degree of reflux and the presence of severe heartburn, epigastric pain and bile vomiting after operation.
SE|123||ab|7|entity|C0232483|Reflux|patf|||reflux|||0|1000|1043|1049
SE|123||ab|7|entity|C0205082|Severe|qlco|||severe|||0|888|1070|1076
SE|123||ab|7|entity|C0018834|Heartburn|sosy|||heartburn|||0|888|1077|1086
SE|123||ab|7|entity|C0232493|[D]Epigastric pain|sosy|||epigastric pain|||0|1000|1088|1103
SE|123||ab|7|entity|C0042963|Vomiting|sosy|||vomiting|||0|861|1113|1121
SE|123||ab|7|entity|C0543467|Operative Surgical Procedures|topp|||operation|||0|1000|1128|1137

SE|123||ab|8|text|1139|1193|The amount of reflux did not differ before operation.
SE|123||ab|8|entity|C1265611|Quantity|qnco|||amount|||0|1000|1143|1149
SE|123||ab|8|entity|C0232483|Reflux|patf|||reflux|||0|1000|1153|1159
SE|123||ab|8|entity|C1518422|Not|ftcn|||not|||0|1000|1164|1167
SE|123||ab|8|entity|C0543467|Operative Surgical Procedures|topp|||operation|||0|1000|1182|1191

SE|123||ab|9|text|1193|1315|There was significantly less reflux following PGV than after either TV+P (P less than 0-025) or TV+A (P less than 0-001).
SE|123||ab|9|entity|C0232483|Reflux|patf|||reflux|||0|827|1222|1228

SE|123||ab|10|text|1315|1495|The results indicate that an operation which preserves an innervated and intact antrum and pylorus will protect against postoperative duodenogastric reflux, gastritis and symptoms.
SE|123||ab|10|entity|C1274040|result|ftcn|||results|||0|966|1319|1326
SE|123||ab|10|entity|C0543467|Operative Surgical Procedures|topp|||operation|||0|1000|1344|1353
SE|123||ab|10|entity|C0205266|Intact|qlco|||intact|||0|888|1388|1394
SE|123||ab|10|entity|C1549092|Antrum|bpoc|||antrum|||0|888|1395|1401
SE|123||ab|10|entity|C0034196|Pylorus|bpoc|||pylorus|||0|1000|1406|1413
SE|123||ab|10|entity|C0013299|Duodenogastric Reflux|dsyn|||duodenogastric reflux|||0|901|1449|1470
SE|123||ab|10|entity|C0017152|Gastritis|dsyn|||gastritis|||0|1000|1472|1481
SE|123||ab|10|entity|C1457887|Symptoms|sosy|||symptoms|||0|1000|1486|1494
SE|123||ab|10|relation|5|4|C0543467|Operative Surgical Procedures|topp|topp|||operation|||0|1000|1344|1353|VERB|PREVENTS||1419|1426|3|1|C0013299|Duodenogastric Reflux|dsyn|dsyn|||duodenogastric reflux|||0|901|1449|1470
SE|123||ab|10|relation|5|4|C0543467|Operative Surgical Procedures|topp|topp|||operation|||0|1000|1344|1353|VERB|PREVENTS||1419|1426|3|1|C0017152|Gastritis|dsyn|dsyn|||gastritis|||0|1000|1472|1481
SE|123||ab|10|relation|5|4|C0543467|Operative Surgical Procedures|topp|topp|||operation|||0|1000|1344|1353|VERB|PREVENTS||1419|1426|3|1|C1457887|Symptoms|sosy|sosy|||symptoms|||0|1000|1486|1494


SE|124||ti|1|text|16|169|Haemoglobin Rahere (beta Lys-Thr): A new high affinity haemoglobin associated with decreased 2, 3-diphosphoglycerate binding and relative polycythaemia.
SE|124||ti|1|entity|C0313380|hemoglobin Rahere|aapp,bacs|||Haemoglobin Rahere|||0|1000|16|34
SE|124||ti|1|entity|C0024337|Lysine|aapp,bacs,phsu|||Lys|||0|790|41|44
SE|124||ti|1|entity|C0040005|Threonine|aapp,bacs,phsu|||Thr|||0|790|45|48
SE|124||ti|1|entity|C0205314|New|tmco|||new|||0|916|53|56
SE|124||ti|1|entity|C0472780|High affinity hemoglobin|patf|||high affinity haemoglobin|||0|916|57|82
SE|124||ti|1|entity|C0205216|Decreased|qnco|||decreased|||0|861|99|108
SE|124||ti|1|entity|C0178597|diphosphoglycerate|carb|||diphosphoglycerate|||0|623|114|132
SE|124||ti|1|entity|C0221276|Relative erythrocytosis|dsyn|||relative polycythaemia|||0|1000|145|167
SE|124||ti|1|relation|3|3|C0313380|hemoglobin Rahere|aapp,gngm,bacs|aapp|||Haemoglobin Rahere|||0|1000|16|34|NOM|INTERACTS_WITH||133|140|3|0|C0178597|diphosphoglycerate|carb|carb|||diphosphoglycerate|||0|623|114|132

SE|124||ab|1|text|175|411|A new haemoglobin with increased oxygen affinity, beta82 (EF6) lysine leads to threonine (Hb Rahere), was found during the investigation of a patient who was found to have a raised haemoglobin concentration after a routine blood count.
SE|124||ab|1|entity|C0205314|New|tmco|||new|||0|888|177|180
SE|124||ab|1|entity|C0019046|Hemoglobin|aapp,bacs|||haemoglobin|||0|888|181|192
SE|124||ab|1|entity|C0311408|Increased oxygen affinity|fndg|||increased oxygen affinity|||0|1000|198|223
SE|124||ab|1|entity|C0024337|Lysine|aapp,bacs,phsu|||lysine|||0|1000|238|244
SE|124||ab|1|entity|C0040005|Threonine|aapp,bacs,phsu|||threonine|||0|1000|254|263
SE|124||ab|1|entity|C0313380|hemoglobin Rahere|aapp,bacs|||Hb Rahere|||0|1000|265|274
SE|124||ab|1|entity|C0030705|Patients|podg|||patient|||0|1000|317|324
SE|124||ab|1|entity|C0442818|Raised|qnco|||raised|||0|790|349|355
SE|124||ab|1|entity|C0019046|Hemoglobin|aapp,bacs|||haemoglobin|||0|790|356|367
SE|124||ab|1|entity|C0205547|Routine|qlco|||routine|||0|901|390|397
SE|124||ab|1|entity|C1535968|Blood count|lbpr|||blood count|||0|901|398|409
SE|124||ab|1|relation|4|2|C0030705|Patients|podg,humn|humn|||patient|||0|1000|317|324|VERB|LOCATION_OF||281|286|7|2|C0040005|Threonine|aapp,gngm,bacs,phsu|aapp|||threonine|||0|1000|254|263

SE|124||ab|2|text|411|628|The substitution affects one of the 2, 3-diphosphoglycerate binding sites, resulting in an increased affinity for oxygen, but both the haem-haem interaction and the alkaline Bohr effect are normal in the haemolysate.
SE|124||ab|2|entity|C1555721|Substitution|idcn|||substitution|||0|1000|415|427
SE|124||ab|2|entity|C0205447|One|qnco|||one|||0|1000|436|439
SE|124||ab|2|entity|C0178597|diphosphoglycerate|carb|||diphosphoglycerate|||0|861|452|470
SE|124||ab|2|entity|C0005456|Binding Sites|rcpt|||binding sites|||0|861|471|484
SE|124||ab|2|entity|C0205217|Increased|qnco|||increased|||0|888|502|511
SE|124||ab|2|entity|C0030054|Oxygen|elii,phsu|||oxygen|||0|1000|525|531
SE|124||ab|2|entity|C0313268|Heme-heme interaction|moft|||haem-haem interaction|||0|1000|546|567
SE|124||ab|2|entity|C0002055|Alkalies|inch|||alkaline|||0|865|576|584
SE|124||ab|2|entity|C0231825|Bohr effect|npop|||Bohr effect|||0|865|585|596
SE|124||ab|2|entity|C0205307|Normal|qlco|||normal|||0|1000|601|607
SE|124||ab|2|relation|3|1|C0005456|Binding Sites|rcpt|rcpt|||binding sites|||0|861|471|484|NOM|INTERACTS_WITH||512|520|5|1|C0030054|Oxygen|elii,phsu|elii|||oxygen|||0|1000|525|531

SE|124||ab|3|text|628|867|This variant had the same mobility as haemoglobin A on electrophoresis at alkaline pH but was detected by measuring the whole blood oxygen affinity; it could be separated from haemoglobin A, however, by electrophoresis in agar at acid pH.
SE|124||ab|3|entity|C0205419|Variant|qlco|||variant|||0|1000|633|640
SE|124||ab|3|entity|C0445247|Same|qlco|||same|||0|694|649|653
SE|124||ab|3|entity|C0019016|Hemoglobin A|aapp,bacs|||haemoglobin A|||0|1000|666|679
SE|124||ab|3|entity|C0013855|Electrophoresis|lbpr|||electrophoresis|||0|1000|683|698
SE|124||ab|3|entity|C0002055|Alkalies|inch|||alkaline|||0|853|702|710
SE|124||ab|3|entity|C0079809|Measures|qnco|||measuring|||0|966|734|743
SE|124||ab|3|entity|C0370231|whole blood|bdsu|||whole blood|||0|888|748|759
SE|124||ab|3|entity|C0369765|Oxygen affinity|moft|||oxygen affinity|||0|888|760|775
SE|124||ab|3|entity|C0019016|Hemoglobin A|aapp,bacs|||haemoglobin A|||0|1000|804|817
SE|124||ab|3|entity|C0013855|Electrophoresis|lbpr|||electrophoresis|||0|1000|831|846
SE|124||ab|3|entity|C0001771|Agar|carb,irda,phsu|||agar|||0|1000|850|854
SE|124||ab|3|entity|C0001128|Acids|chem|||acid|||0|888|858|862
SE|124||ab|3|relation|9|2|C0019016|Hemoglobin A|aapp,gngm,bacs|aapp|||haemoglobin A|||0|1000|804|817|PREP|COEXISTS_WITH||847|849|2|1|C0001771|Agar|carb,irda,phsu|carb|||agar|||0|1000|850|854

SE|124||ab|4|text|867|1043|The raised haemoglobin concentration was mainly due to a reduction in plasma volume (a relative polycythaemia) and was associated with a persistently raised white blood count.
SE|124||ab|4|entity|C0442818|Raised|qnco|||raised|||0|790|871|877
SE|124||ab|4|entity|C0019046|Hemoglobin|aapp,bacs|||haemoglobin|||0|790|878|889
SE|124||ab|4|entity|C0032105|Plasma|bdsu|||plasma|||0|888|937|943
SE|124||ab|4|entity|C0449468|Volume|qnco|||volume|||0|888|944|950
SE|124||ab|4|entity|C0221276|Relative erythrocytosis|dsyn|||relative polycythaemia|||0|1000|954|976
SE|124||ab|4|entity|C0750508|PERSISTENTLY|idcn|||persistently|||0|1000|1004|1016
SE|124||ab|4|entity|C0007457|Caucasoid Race|popg|||white|||0|901|1024|1029
SE|124||ab|4|entity|C1535968|Blood count|lbpr|||blood count|||0|901|1030|1041

SE|124||ab|5|text|1043|1214|This case emphasises the need to measure the oxygen affinity of haemoglobin in all patients with absolute or relative polycythaemia when some obvious cause is not evident.
SE|124||ab|5|entity|C0027552|Needs|qlco|||need|||0|1000|1068|1072
SE|124||ab|5|entity|C0369765|Oxygen affinity|moft|||oxygen affinity|||0|1000|1088|1103
SE|124||ab|5|entity|C0019046|Hemoglobin|aapp,bacs|||haemoglobin|||0|1000|1107|1118
SE|124||ab|5|entity|C0030705|Patients|podg|||patients|||0|1000|1126|1134
SE|124||ab|5|entity|C0205344|Absolute|qlco|||absolute|||0|1000|1140|1148
SE|124||ab|5|entity|C0221276|Relative erythrocytosis|dsyn|||relative polycythaemia|||0|1000|1152|1174
SE|124||ab|5|entity|C0015127|Etiology aspects|ftcn|||cause|||0|827|1193|1198
SE|124||ab|5|entity|C1518422|Not|ftcn|||not|||0|694|1202|1205
SE|124||ab|5|relation|4|2|C0369765|Oxygen affinity|moft|moft|||oxygen affinity|||0|1000|1088|1103|PREP|PROCESS_OF||1119|1121|5|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|1126|1134


SE|125||ti|1|text|16|67|Endoscopic papillotomy and removal of gall stones.
SE|125||ti|1|entity|C0085263|Sphincterotomy, Endoscopic|topp|||Endoscopic papillotomy|||0|1000|16|38
SE|125||ti|1|entity|C0728940|Excision|topp|||removal|||0|1000|43|50
SE|125||ti|1|entity|C0008350|Cholelithiasis|dsyn|||gall stones|||0|1000|54|65

SE|125||ab|1|text|73|225|Endoscopic papillotomy was attempted in 59 patients with extrahepatic obstruction of the biliary duct system and was actually performed in 50 patients.
SE|125||ab|1|entity|C0085263|Sphincterotomy, Endoscopic|topp|||Endoscopic papillotomy|||0|1000|73|95
SE|125||ab|1|entity|C0030705|Patients|podg|||patients|||0|861|116|124
SE|125||ab|1|entity|C1517058|Extrahepatic|spco|||extrahepatic|||0|888|130|142
SE|125||ab|1|entity|C0028778|Obstruction|patf|||obstruction|||0|888|143|154
SE|125||ab|1|entity|C1267211|Entire duct|bpoc|||duct|||0|901|170|174
SE|125||ab|1|entity|C0005423|Biliary tract structure|bpoc|||biliary duct system|||0|901|162|181
SE|125||ab|1|entity|C0030705|Patients|podg|||patients|||0|861|215|223
SE|125||ab|1|relation|0|0|C0005423|Biliary tract structure|bpoc|bpoc|||biliary duct system|||0|901|162|181|MOD/HEAD|PART_OF||170|181|0|0|C1267211|Entire duct|bpoc|bpoc|||duct|||0|901|170|174
SE|125||ab|1|relation|0|0|C0085263|Sphincterotomy, Endoscopic|topp|topp|||Endoscopic papillotomy|||0|1000|73|95|INFER|TREATS(INFER)||110|112|0|0|C0028778|Obstruction|patf|patf|||obstruction|||0|888|143|154
SE|125||ab|1|relation|1|1|C0085263|Sphincterotomy, Endoscopic|topp|topp|||Endoscopic papillotomy|||0|1000|73|95|PREP|TREATS||110|112|4|1|C0030705|Patients|podg,humn|podg|||patients|||0|861|116|124
SE|125||ab|1|relation|2|1|C0005423|Biliary tract structure|bpoc|bpoc|||biliary duct system|||0|901|162|181|PREP|LOCATION_OF||155|157|3|1|C0028778|Obstruction|patf|patf|||obstruction|||0|888|143|154
SE|125||ab|1|relation|3|1|C0028778|Obstruction|patf|patf|||obstruction|||0|888|143|154|PREP|PROCESS_OF||125|129|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|861|116|124

SE|125||ab|2|text|225|376|A special high-frequency diathermy knife was introduced via a duodenoscope into the terminal common bile duct and the roof of the papilla was incised.
SE|125||ab|2|entity|C0205212|High frequency|tmco|||high-frequency|||0|798|235|249
SE|125||ab|2|entity|C0012002|Diathermy|topp|||diathermy|||0|798|250|259
SE|125||ab|2|entity|C0181467|knife|mnob|||knife|||0|798|260|265
SE|125||ab|2|entity|C1550513|via|idcn|||via|||0|1000|281|284
SE|125||ab|2|entity|C0180565|Duodenoscopes|medd|||duodenoscope|||0|1000|287|299
SE|125||ab|2|entity|C1305392|Entire common bile duct|bpoc|||common bile duct|||0|916|318|334

SE|125||ab|3|text|376|508|In 33 out of 39 patients with choledocholithiasis the stones passed into the duodenum spontaneously or were removed endoscopically.
SE|125||ab|3|entity|C0030705|Patients|podg|||patients|||0|861|392|400
SE|125||ab|3|entity|C0701818|Choledocholithiasis|dsyn|||choledocholithiasis|||0|1000|406|425
SE|125||ab|3|entity|C0013303|Duodenum|bpoc|||duodenum|||0|861|453|461
SE|125||ab|3|relation|3|1|C0701818|Choledocholithiasis|dsyn|dsyn|||choledocholithiasis|||0|1000|406|425|PREP|PROCESS_OF||401|405|1|1|C0030705|Patients|podg,humn|humn|||patients|||0|861|392|400

SE|125||ab|4|text|508|620|Papillary stenosis without ductal stones was successfully treated with this method in eight out of 11 patients.
SE|125||ab|4|entity|C0238340|PAPILLARY STENOSIS|dsyn|||Papillary stenosis|||0|1000|508|526
SE|125||ab|4|entity|C1512083|Ductal|qlco|||ductal|||0|694|535|541
SE|125||ab|4|entity|C0025663|Methods|inpr|||method|||0|1000|584|590
SE|125||ab|4|entity|C0205454|Eight|qnco|||eight|||0|1000|594|599
SE|125||ab|4|entity|C0030705|Patients|podg|||patients|||0|861|610|618

SE|125||ab|5|text|620|709|One perforation of the duodenocholedochal junction occurred and was repaired surgically.
SE|125||ab|5|entity|C0205447|One|qnco|||One|||0|694|620|623
SE|125||ab|5|entity|C0545836|Duodenum and common bile duct|bpoc|||duodenocholedochal|||0|901|643|661
SE|125||ab|5|entity|C0205144|Junctional|spco|||junction|||0|901|662|670

SE|125||ab|6|text|709|829|Endoscopic papillotomy and stone extraction is a relatively safe and effective method of treating extrahepatic jaundice.
SE|125||ab|6|entity|C0085263|Sphincterotomy, Endoscopic|topp|||Endoscopic papillotomy|||0|1000|709|731
SE|125||ab|6|entity|C0883371|STONE REMOVAL|topp|||stone extraction|||0|1000|736|752
SE|125||ab|6|entity|C0025663|Methods|inpr|||method|||0|888|788|794
SE|125||ab|6|entity|C1522326|Treating|qlco|||treating|||0|851|798|806
SE|125||ab|6|entity|C1517058|Extrahepatic|spco|||extrahepatic|||0|851|807|819
SE|125||ab|6|entity|C0022346|Icterus|patf|||jaundice|||0|851|820|828
SE|125||ab|6|relation|4|3|C0085263|Sphincterotomy, Endoscopic|topp|topp|||Endoscopic papillotomy|||0|1000|709|731|NOM|TREATS||798|806|4|0|C0022346|Icterus|patf|patf|||jaundice|||0|851|820|828
SE|125||ab|6|relation|4|3|C0883371|STONE REMOVAL|topp|topp|||stone extraction|||0|1000|736|752|NOM|TREATS||798|806|4|0|C0022346|Icterus|patf|patf|||jaundice|||0|851|820|828


[125]: *** ERROR *** ERROR *** ERROR ***
[126]: *** ERROR *** ERROR *** ERROR ***
SE|128||ti|1|text|16|136|Inhibitory postsynaptic actions of taurine, GABA and other amino acids on motoneurons of the isolated frog spinal cord.
SE|128||ti|1|entity|C0243077|inhibitors|chvf|||Inhibitory|||0|589|16|26
SE|128||ti|1|entity|C0039350|Taurine|aapp,bacs,phsu|||taurine|||0|1000|51|58
SE|128||ti|1|entity|C0016904|gamma-Aminobutyric Acid|aapp,nsba|||GABA|||0|1000|60|64
SE|128||ti|1|entity|C0002520|Amino Acids|aapp,bacs,phsu|||amino acids|||0|1000|75|86
SE|128||ti|1|entity|C0026609|Motor Neurons|cell|||motoneurons|||0|966|90|101
SE|128||ti|1|entity|C0205409|Isolated|ftcn|||isolated|||0|861|109|117
SE|128||ti|1|entity|C0003459|Anura|amph|||frog|||0|861|118|122
SE|128||ti|1|entity|C0037925|Spinal Cord|bpoc|||spinal cord|||0|861|123|134
SE|128||ti|1|relation|0|0|C0016904|gamma-Aminobutyric Acid|aapp,gngm,nsba|aapp|||GABA|||0|1000|60|64|INFER|INTERACTS_WITH(SPEC)||60|86|0|0|C0026609|Motor Neurons|cell|cell|||motoneurons|||0|966|90|101
SE|128||ti|1|relation|0|0|C0016904|gamma-Aminobutyric Acid|aapp,gngm,nsba|aapp|||GABA|||0|1000|60|64|SPEC|ISA||60|86|0|0|C0002520|Amino Acids|aapp,gngm,bacs,phsu|aapp|||amino acids|||0|1000|75|86
SE|128||ti|1|relation|0|0|C0037925|Spinal Cord|bpoc|bpoc|||spinal cord|||0|861|123|134|MOD/HEAD|PART_OF||118|134|0|0|C0003459|Anura|amph|amph|||frog|||0|861|118|122
SE|128||ti|1|relation|0|0|C0039350|Taurine|aapp,gngm,bacs,phsu|aapp|||taurine|||0|1000|51|58|INFER|INTERACTS_WITH(SPEC)||60|86|0|0|C0026609|Motor Neurons|cell|cell|||motoneurons|||0|966|90|101
SE|128||ti|1|relation|0|0|C0039350|Taurine|aapp,gngm,bacs,phsu|aapp|||taurine|||0|1000|51|58|SPEC|ISA||60|86|0|0|C0002520|Amino Acids|aapp,gngm,bacs,phsu|aapp|||amino acids|||0|1000|75|86
SE|128||ti|1|relation|5|1|C0026609|Motor Neurons|cell|cell|||motoneurons|||0|966|90|101|PREP|PART_OF||102|104|1|1|C0037925|Spinal Cord|bpoc|bpoc|||spinal cord|||0|861|123|134
SE|128||ti|1|relation|5|3|C0002520|Amino Acids|aapp,gngm,bacs,phsu|gngm|||amino acids|||0|1000|75|86|NOM|INTERACTS_WITH||40|47|5|4|C0026609|Motor Neurons|cell|cell|||motoneurons|||0|966|90|101
SE|128||ti|1|relation|5|3|C0016904|gamma-Aminobutyric Acid|aapp,gngm,nsba|aapp|||GABA|||0|1000|60|64|NOM|INTERACTS_WITH||40|47|5|4|C0026609|Motor Neurons|cell|cell|||motoneurons|||0|966|90|101
SE|128||ti|1|relation|5|3|C0039350|Taurine|aapp,gngm,bacs,phsu|aapp|||taurine|||0|1000|51|58|NOM|INTERACTS_WITH||40|47|5|4|C0026609|Motor Neurons|cell|cell|||motoneurons|||0|966|90|101

SE|128||ab|1|text|142|318|The actions of glycine, GABA, alpha-alanine, beta-alanine and taurine were studied by intracellular recordings from lumbar motoneurons of the isolated spinal cord of the frog.
SE|128||ab|1|entity|C0017890|Glycine|aapp,bacs,phsu|||glycine|||0|1000|157|164
SE|128||ab|1|entity|C0016904|gamma-Aminobutyric Acid|aapp,nsba|||GABA|||0|1000|166|170
SE|128||ab|1|entity|C0439095|Alpha|inpr|||alpha|||0|888|172|177
SE|128||ab|1|entity|C0001898|Alanine|aapp,bacs|||alanine|||0|888|178|185
SE|128||ab|1|entity|C0000392|beta-Alanine|aapp,bacs,phsu|||beta-alanine|||0|1000|187|199
SE|128||ab|1|entity|C0039350|Taurine|aapp,bacs,phsu|||taurine|||0|1000|204|211
SE|128||ab|1|entity|C0175996|Protoplasm|celc|||intracellular|||0|694|228|241
SE|128||ab|1|entity|C0026609|Motor Neurons|cell|||motoneurons|||0|827|265|276
SE|128||ab|1|entity|C0205409|Isolated|ftcn|||isolated|||0|901|284|292
SE|128||ab|1|entity|C0037925|Spinal Cord|bpoc|||spinal cord|||0|901|293|304
SE|128||ab|1|entity|C0003459|Anura|amph|||frog|||0|1000|312|316
SE|128||ab|1|relation|8|1|C0026609|Motor Neurons|cell|cell|||motoneurons|||0|827|265|276|PREP|PART_OF||277|279|2|1|C0037925|Spinal Cord|bpoc|bpoc|||spinal cord|||0|901|293|304
SE|128||ab|1|relation|9|1|C0037925|Spinal Cord|bpoc|bpoc|||spinal cord|||0|901|293|304|PREP|PART_OF||305|307|1|1|C0003459|Anura|amph|amph|||frog|||0|1000|312|316

SE|128||ab|2|text|318|494|All amino acids tested produced a reduction in the amplitude of postsynaptic potentials, a blockade of the antidromic action potential and an increase of membrane conductance.
SE|128||ab|2|entity|C0002520|Amino Acids|aapp,bacs,phsu|||amino acids|||0|1000|322|333
SE|128||ab|2|entity|C0237399|Potential|qlco|||potentials|||0|827|395|405
SE|128||ab|2|entity|C0003296|Antidromic Potentials|diap,ortf|||antidromic action potential|||0|913|425|452
SE|128||ab|2|entity|C0442805|Increase|ftcn|||increase|||0|1000|460|468
SE|128||ab|2|entity|C0596901|Membrane|celc|||membrane|||0|694|472|480
SE|128||ab|2|relation|4|4|C0002520|Amino Acids|aapp,gngm,bacs,phsu|phsu|||amino acids|||0|1000|322|333|NOM|INHIBITS||409|417|3|1|C0003296|Antidromic Potentials|diap,ortf|ortf|||antidromic action potential|||0|913|425|452

SE|128||ab|3|text|494|593|Furthermore, membrane polarizations occurred, which were always in the same direction as the IPSP.
SE|128||ab|3|entity|C0596901|Membrane|celc|||membrane|||0|872|507|515
SE|128||ab|3|entity|C0946292|POLARIZATION|orga|||polarizations|||0|872|516|529
SE|128||ab|3|entity|C1549493|Always|idcn|||always|||0|1000|551|557
SE|128||ab|3|entity|C0445247|Same|qlco|||same|||0|888|565|569
SE|128||ab|3|entity|C0449738|Direction|spco|||direction|||0|888|570|579

SE|128||ab|4|text|593|675|All these effects indicate a postsynaptic inhibitory action of these amino acids.
SE|128||ab|4|entity|C1280500|Effect|qlco|||effects|||0|966|603|610
SE|128||ab|4|entity|C0243077|inhibitors|chvf|||inhibitory|||0|589|635|645
SE|128||ab|4|entity|C0002520|Amino Acids|aapp,bacs,phsu|||amino acids|||0|1000|662|673

SE|128||ab|5|text|675|846|When the relative strength of different amino acids was compared, taurine had the strongest inhibitory potency, followed by beta-alanine, alpha-alanine, GABA and glycine.
SE|128||ab|5|entity|C0205345|Relative|qlco|||relative|||0|888|684|692
SE|128||ab|5|entity|C0808080|STRENGTH|idcn|||strength|||0|888|693|701
SE|128||ab|5|entity|C1547020|*Difference|qnco|||different|||0|865|705|714
SE|128||ab|5|entity|C0002520|Amino Acids|aapp,bacs,phsu|||amino acids|||0|865|715|726
SE|128||ab|5|entity|C0039350|Taurine|aapp,bacs,phsu|||taurine|||0|1000|741|748
SE|128||ab|5|entity|C0442821|Strong|qlco|||strongest|||0|851|757|766
SE|128||ab|5|entity|C0234122|Inhibitory potential|ortf|||inhibitory potency|||0|851|767|785
SE|128||ab|5|entity|C0000392|beta-Alanine|aapp,bacs,phsu|||beta-alanine|||0|1000|799|811
SE|128||ab|5|entity|C0439095|Alpha|inpr|||alpha|||0|888|813|818
SE|128||ab|5|entity|C0001898|Alanine|aapp,bacs|||alanine|||0|888|819|826
SE|128||ab|5|entity|C0016904|gamma-Aminobutyric Acid|aapp,nsba|||GABA|||0|1000|828|832
SE|128||ab|5|entity|C0017890|Glycine|aapp,bacs,phsu|||glycine|||0|1000|837|844
SE|128||ab|5|relation|6|5|C0016904|gamma-Aminobutyric Acid|aapp,gngm,nsba|aapp|||GABA|||0|1000|828|832|VERB|compared_with||731|739|6|6|C0017890|Glycine|aapp,gngm,bacs,phsu|aapp|||glycine|||0|1000|837|844

SE|128||ab|6|text|846|1035|Topically applied strychnine and picrotoxin induced different changes of post-synaptic potentials, indicating that distinct inhibitory systems might be influenced by these two convulsants.
SE|128||ab|6|entity|C0202474|Strychnine|hops,orch,phsu|||strychnine|||0|827|864|874
SE|128||ab|6|entity|C0031890|Picrotoxin|hops,orch,phsu|||picrotoxin|||0|1000|879|889
SE|128||ab|6|entity|C1547020|*Difference|qnco|||different|||0|836|898|907
SE|128||ab|6|entity|C0205855|Synaptic Potentials|ortf|||synaptic potentials|||0|901|924|943
SE|128||ab|6|entity|C0243077|inhibitors|chvf|||inhibitory|||0|754|970|980
SE|128||ab|6|entity|C0449913|System|ftcn|||systems|||0|754|981|988
SE|128||ab|6|entity|C0205448|Two|qnco|||two|||0|888|1018|1021
SE|128||ab|6|entity|C0009950|Convulsants|hops,phsu|||convulsants|||0|888|1022|1033
SE|128||ab|6|relation|2|1|C0031890|Picrotoxin|hops,orch,phsu|hops|||picrotoxin|||0|1000|879|889|VERB|AUGMENTS||890|897|4|2|C0205855|Synaptic Potentials|ortf|ortf|||synaptic potentials|||0|901|924|943
SE|128||ab|6|relation|2|1|C0202474|Strychnine|hops,orch,phsu|hops|||strychnine|||0|827|864|874|VERB|AUGMENTS||890|897|4|2|C0205855|Synaptic Potentials|ortf|ortf|||synaptic potentials|||0|901|924|943

SE|128||ab|7|text|1035|1227|Interactions with amino acids showed that picrotoxin seletively diminished the postsymaptic actions of GABA, while strychnine reduced the effects of taurine, glycine, alpha- and beta-alanine.
SE|128||ab|7|entity|C0002520|Amino Acids|aapp,bacs,phsu|||amino acids|||0|1000|1053|1064
SE|128||ab|7|entity|C0031890|Picrotoxin|hops,orch,phsu|||picrotoxin|||0|694|1077|1087
SE|128||ab|7|entity|C0016904|gamma-Aminobutyric Acid|aapp,nsba|||GABA|||0|1000|1138|1142
SE|128||ab|7|entity|C0202474|Strychnine|hops,orch,phsu|||strychnine|||0|1000|1150|1160
SE|128||ab|7|entity|C1280500|Effect|qlco|||effects|||0|966|1173|1180
SE|128||ab|7|entity|C0039350|Taurine|aapp,bacs,phsu|||taurine|||0|1000|1184|1191
SE|128||ab|7|entity|C0017890|Glycine|aapp,bacs,phsu|||glycine|||0|1000|1193|1200
SE|128||ab|7|entity|C0439095|Alpha|inpr|||alpha|||0|1000|1202|1207
SE|128||ab|7|entity|C0000392|beta-Alanine|aapp,bacs,phsu|||beta-alanine|||0|1000|1213|1225
SE|128||ab|7|relation|6|1|C0202474|Strychnine|hops,orch,phsu|hops|||strychnine|||0|1000|1150|1160|NOM|INTERACTS_WITH||1173|1180|4|1|C0039350|Taurine|aapp,gngm,bacs,phsu|aapp|||taurine|||0|1000|1184|1191
SE|128||ab|7|relation|7|5|C0017890|Glycine|aapp,gngm,bacs,phsu|aapp|||glycine|||0|1000|1193|1200|NOM|INTERACTS_WITH||1127|1134|7|1|C0016904|gamma-Aminobutyric Acid|aapp,gngm,nsba|aapp|||GABA|||0|1000|1138|1142

SE|128||ab|8|text|1227|1439|But differences in the susceptibility of these amino acid actions to strychnine could be detected: the action of taurine was more sensitively blocked by strychnine compared with glycine, alpha- and beta-alanine.
SE|128||ab|8|entity|C1547020|*Difference|qnco|||differences|||0|966|1231|1242
SE|128||ab|8|entity|C0220898|Predisposition|orga|||susceptibility|||0|1000|1250|1264
SE|128||ab|8|entity|C0002520|Amino Acids|aapp,bacs,phsu|||amino acid|||0|734|1274|1284
SE|128||ab|8|entity|C0202474|Strychnine|hops,orch,phsu|||strychnine|||0|1000|1296|1306
SE|128||ab|8|entity|C0039350|Taurine|aapp,bacs,phsu|||taurine|||0|1000|1340|1347
SE|128||ab|8|entity|C0205172|More|ftcn|||more|||0|1000|1352|1356
SE|128||ab|8|entity|C0202474|Strychnine|hops,orch,phsu|||strychnine|||0|1000|1380|1390
SE|128||ab|8|entity|C0017890|Glycine|aapp,bacs,phsu|||glycine|||0|1000|1405|1412
SE|128||ab|8|entity|C0439095|Alpha|inpr|||alpha|||0|1000|1414|1419
SE|128||ab|8|entity|C0000392|beta-Alanine|aapp,bacs,phsu|||beta-alanine|||0|1000|1425|1437
SE|128||ab|8|relation|4|1|C0202474|Strychnine|hops,orch,phsu|hops|||strychnine|||0|1000|1296|1306|NOM|INTERACTS_WITH||1330|1336|5|1|C0039350|Taurine|aapp,gngm,bacs,phsu|aapp|||taurine|||0|1000|1340|1347
SE|128||ab|8|relation|7|1|C0202474|Strychnine|hops,orch,phsu|hops|||strychnine|||0|1000|1380|1390|VERB|compared_with||1391|1399|3|1|C0017890|Glycine|aapp,gngm,bacs,phsu|aapp|||glycine|||0|1000|1405|1412
SE|128||ab|8|relation|7|7|C0000392|beta-Alanine|aapp,gngm,bacs,phsu|aapp|||beta-alanine|||0|1000|1425|1437|NOM|INTERACTS_WITH||1285|1292|2|0|C0002520|Amino Acids|aapp,gngm,bacs,phsu|aapp|||amino acid|||0|734|1274|1284

SE|128||ab|9|text|1439|1605|With regard to these results the importance of taurine and GABA as transmitters of postsynaptic inhibition on motoneurons in the spinal cord of the frog is discussed.
SE|128||ab|9|entity|C0039350|Taurine|aapp,bacs,phsu|||taurine|||0|1000|1486|1493
SE|128||ab|9|entity|C0016904|gamma-Aminobutyric Acid|aapp,nsba|||GABA|||0|1000|1498|1502
SE|128||ab|9|entity|C0026609|Motor Neurons|cell|||motoneurons|||0|966|1549|1560
SE|128||ab|9|entity|C0037925|Spinal Cord|bpoc|||spinal cord|||0|1000|1568|1579
SE|128||ab|9|entity|C0003459|Anura|amph|||frog|||0|1000|1587|1591
SE|128||ab|9|relation|2|1|C0037925|Spinal Cord|bpoc|bpoc|||spinal cord|||0|1000|1568|1579|PREP|LOCATION_OF||1561|1563|7|4|C0016904|gamma-Aminobutyric Acid|aapp,gngm,nsba|aapp|||GABA|||0|1000|1498|1502
SE|128||ab|9|relation|2|1|C0037925|Spinal Cord|bpoc|bpoc|||spinal cord|||0|1000|1568|1579|PREP|LOCATION_OF||1561|1563|7|4|C0039350|Taurine|aapp,gngm,bacs,phsu|aapp|||taurine|||0|1000|1486|1493
SE|128||ab|9|relation|3|1|C0026609|Motor Neurons|cell|cell|||motoneurons|||0|966|1549|1560|PREP|LOCATION_OF||1546|1548|6|3|C0016904|gamma-Aminobutyric Acid|aapp,gngm,nsba|aapp|||GABA|||0|1000|1498|1502
SE|128||ab|9|relation|3|1|C0026609|Motor Neurons|cell|cell|||motoneurons|||0|966|1549|1560|PREP|LOCATION_OF||1546|1548|6|3|C0039350|Taurine|aapp,gngm,bacs,phsu|aapp|||taurine|||0|1000|1486|1493
SE|128||ab|9|relation|8|1|C0037925|Spinal Cord|bpoc|bpoc|||spinal cord|||0|1000|1568|1579|PREP|PART_OF||1580|1582|1|1|C0003459|Anura|amph|amph|||frog|||0|1000|1587|1591


[128]: *** ERROR *** ERROR *** ERROR ***
SE|129||ti|1|text|16|241|The involvement of lysophosphoglycerides in neurotransmitter release; the composition and turnover of phospholipids of synaptic vesicles of guinea-pig cerebral cortex and Torpedo electric organ and the effect of stimulation.
SE|129||ti|1|entity|C0065395|lysophosphoglycerides|carb|||lysophosphoglycerides|||0|1000|35|56
SE|129||ti|1|entity|C0598964|neurotransmitter secretion|celf|||neurotransmitter release|||0|1000|60|84
SE|129||ti|1|entity|C0486616|Composition|clna|||composition|||0|1000|90|101
SE|129||ti|1|entity|C0031676|Phospholipids|bacs,lipd|||phospholipids|||0|1000|118|131
SE|129||ti|1|entity|C0039065|Synaptic Vesicles|celc|||synaptic vesicles|||0|1000|135|152
SE|129||ti|1|entity|C0085979|Cavia|mamm|||guinea-pig|||0|888|156|166
SE|129||ti|1|entity|C0007776|Cerebral cortex|bpoc|||cerebral cortex|||0|888|167|182
SE|129||ti|1|entity|C0040478|Torpedo|fish|||Torpedo|||0|901|187|194
SE|129||ti|1|entity|C0013782|Electric Organ|orga|||electric organ|||0|901|195|209
SE|129||ti|1|entity|C1280500|Effect|qlco|||effect|||0|1000|218|224
SE|129||ti|1|relation|0|0|C0007776|Cerebral cortex|bpoc|bpoc|||cerebral cortex|||0|888|167|182|MOD/HEAD|PART_OF||156|182|0|0|C0085979|Cavia|mamm|mamm|||guinea-pig|||0|888|156|166
SE|129||ti|1|relation|6|1|C0031676|Phospholipids|bacs,lipd|bacs|||phospholipids|||0|1000|118|131|PREP|PART_OF||132|134|5|1|C0039065|Synaptic Vesicles|celc|celc|||synaptic vesicles|||0|1000|135|152
SE|129||ti|1|relation|7|1|C0039065|Synaptic Vesicles|celc|celc|||synaptic vesicles|||0|1000|135|152|PREP|PART_OF||153|155|4|1|C0007776|Cerebral cortex|bpoc|bpoc|||cerebral cortex|||0|888|167|182
SE|129||ti|1|relation|10|1|C0065395|lysophosphoglycerides|carb|carb|||lysophosphoglycerides|||0|1000|35|56|NOM|AFFECTS||20|31|10|2|C0598964|neurotransmitter secretion|celf|celf|||neurotransmitter release|||0|1000|60|84

SE|129||ab|1|text|247|396|(1) Crude synaptosomal fractions (P2) derived from guinea-pig cerebral cortex were incubated in the presence of 50 mM KCl in a Krebs-glucose medium.
SE|129||ab|1|entity|C0039067|Synaptosomes|celc|||synaptosomal|||0|754|257|269
SE|129||ab|1|entity|C1264633|Fraction of|qnco|||fractions|||0|754|270|279
SE|129||ab|1|entity|C0085979|Cavia|mamm|||guinea-pig|||0|888|298|308
SE|129||ab|1|entity|C0007776|Cerebral cortex|bpoc|||cerebral cortex|||0|888|309|324
SE|129||ab|1|entity|C0017725|Glucose|bacs,carb,phsu|||glucose|||0|790|380|387
SE|129||ab|1|entity|C0439536|Medium|qlco|||medium|||0|790|388|394
SE|129||ab|1|relation|0|0|C0007776|Cerebral cortex|bpoc|bpoc|||cerebral cortex|||0|888|309|324|MOD/HEAD|PART_OF||298|324|0|0|C0085979|Cavia|mamm|mamm|||guinea-pig|||0|888|298|308

SE|129||ab|2|text|396|537|Torpedo marmorata electric organs were stimulated electrically in vivo at 5 pulses/sec for 30 min by electrodes placed on the electric lobe.
SE|129||ab|2|entity|C0998768|Torpedo marmorata|fish|||Torpedo marmorata|||0|888|396|413
SE|129||ab|2|entity|C0013782|Electric Organ|orga|||electric organs|||0|888|414|429
SE|129||ab|2|entity|C1515655|in vivo|spco|||in vivo|||0|901|459|466
SE|129||ab|2|entity|C0034107|Pulse taking|diap|||pulses|||0|840|472|478
SE|129||ab|2|entity|C0457385|seconds|tmco|||sec|||0|840|479|482
SE|129||ab|2|entity|C0456693|/30 min|tmco|||30 min|||0|1000|487|493
SE|129||ab|2|entity|C0013812|electrode|mnob|||electrodes|||0|1000|497|507
SE|129||ab|2|entity|C0013790|Electricity|npop|||electric|||0|853|522|530
SE|129||ab|2|entity|C0796494|Lobe|bpoc|||lobe|||0|853|531|535

SE|129||ab|3|text|537|685|Synaptic vesicles were isolated from each source and the phospholipid compositions analysed and compared with vesicles  from unstimulated controls.
SE|129||ab|3|entity|C0039065|Synaptic Vesicles|celc|||Synaptic vesicles|||0|1000|537|554
SE|129||ab|3|entity|C0031676|Phospholipids|bacs,lipd|||phospholipid|||0|872|594|606
SE|129||ab|3|entity|C0486616|Composition|clna|||compositions|||0|872|607|619
SE|129||ab|3|entity|C0333262|Vesicle|acab|||vesicles|||0|1000|647|655
SE|129||ab|3|entity|C0439819|Unstimulated|qlco|||unstimulated|||0|872|662|674
SE|129||ab|3|entity|C0243148|control|ftcn|||controls|||0|872|675|683

SE|129||ab|4|text|685|891|(2) Lysophosphatidylcholine was the only lysophosphoglyceride demonstrable in the synaptic vesicles from either source and its low levels did not increase as a result of chemical or electircal stimulation.
SE|129||ab|4|entity|C0024360|Lysophosphatidylcholines|lipd|||Lysophosphatidylcholine|||0|1000|689|712
SE|129||ab|4|entity|C0065395|lysophosphoglycerides|carb|||lysophosphoglyceride|||0|827|726|746
SE|129||ab|4|entity|C0332265|Demonstrable|ftcn|||demonstrable|||0|1000|747|759
SE|129||ab|4|entity|C0039065|Synaptic Vesicles|celc|||synaptic vesicles|||0|1000|767|784
SE|129||ab|4|entity|C0205251|low|qlco|||low|||0|888|812|815
SE|129||ab|4|entity|C0441889|Levels|inpr|||levels|||0|888|816|822
SE|129||ab|4|entity|C1518422|Not|ftcn|||not|||0|1000|827|830
SE|129||ab|4|entity|C0220806|Chemicals|chem|||chemical|||0|1000|855|863
SE|129||ab|4|relation|6|1|C0039065|Synaptic Vesicles|celc|celc|||synaptic vesicles|||0|1000|767|784|PREP|LOCATION_OF||760|762|3|2|C0065395|lysophosphoglycerides|carb|carb|||lysophosphoglyceride|||0|827|726|746

SE|129||ab|5|text|891|1026|In each case there was a close similarity of the phospholipid distributions in the vesicles taken from control and stimulated samples.
SE|129||ab|5|entity|C0871364|Simile|inpr|||similarity|||0|761|922|932
SE|129||ab|5|entity|C0031676|Phospholipids|bacs,lipd|||phospholipid|||0|888|940|952
SE|129||ab|5|entity|C0037775|Spatial Distribution|spco|||distributions|||0|888|953|966
SE|129||ab|5|entity|C0333262|Vesicle|acab|||vesicles|||0|1000|974|982
SE|129||ab|5|entity|C0243148|control|ftcn|||control|||0|1000|994|1001

SE|129||ab|6|text|1026|1282|(3) Control experiments indicated extensive decreases in the acetylcholine content of the vesicles from the stimulated electric organ and smaller decreases in the acetylcholine content of the synaptic vesicles from stimulated crude synaptosomal fractions.
SE|129||ab|6|entity|C0681814|research study|resa|||experiments|||0|1000|1038|1049
SE|129||ab|6|entity|C0205231|Extensive|qlco|||extensive|||0|872|1060|1069
SE|129||ab|6|entity|C0547047|Decrease|qnco|||decreases|||0|872|1070|1079
SE|129||ab|6|entity|C0001041|Acetylcholine|nsba,orch,phsu|||acetylcholine|||0|694|1087|1100
SE|129||ab|6|entity|C0333262|Vesicle|acab|||vesicles|||0|1000|1116|1124
SE|129||ab|6|entity|C0013782|Electric Organ|orga|||electric organ|||0|901|1145|1159
SE|129||ab|6|entity|C0547044|Smaller|qlco|||smaller|||0|872|1164|1171
SE|129||ab|6|entity|C0547047|Decrease|qnco|||decreases|||0|872|1172|1181
SE|129||ab|6|entity|C0001041|Acetylcholine|nsba,orch,phsu|||acetylcholine|||0|694|1189|1202
SE|129||ab|6|entity|C0039065|Synaptic Vesicles|celc|||synaptic vesicles|||0|1000|1218|1235
SE|129||ab|6|entity|C0039067|Synaptosomes|celc|||synaptosomal|||0|714|1258|1270
SE|129||ab|6|entity|C1264633|Fraction of|qnco|||fractions|||0|714|1271|1280
SE|129||ab|6|relation|7|1|C0001041|Acetylcholine|nsba,orch,phsu|nsba|||acetylcholine|||0|694|1189|1202|PREP|PART_OF||1211|1213|2|1|C0039065|Synaptic Vesicles|celc|celc|||synaptic vesicles|||0|1000|1218|1235
SE|129||ab|6|relation|8|2|C0001041|Acetylcholine|nsba,orch,phsu|orch|||acetylcholine|||0|694|1189|1202|ADJ|AUGMENTS||1241|1251|8|0|C0039067|Synaptosomes|celc|celc|||synaptosomal|||0|714|1258|1270

SE|129||ab|7|text|1282|1483|These fractions were found to respire linearly in the presence of 10 mM glucose and the vesicle fractions were shown to have low levels of contaiminating membranes as judged by marker enzyme analyses.
SE|129||ab|7|entity|C1264633|Fraction of|qnco|||fractions|||0|1000|1288|1297
SE|129||ab|7|entity|C0017725|Glucose|bacs,carb,phsu|||glucose|||0|790|1354|1361
SE|129||ab|7|entity|C1325522|vesicular fraction|celc|||vesicle fractions|||0|947|1370|1387
SE|129||ab|7|entity|C0205251|low|qlco|||low|||0|888|1407|1410
SE|129||ab|7|entity|C0441889|Levels|inpr|||levels|||0|888|1411|1417
SE|129||ab|7|entity|C0025255|Tissue membrane|tisu|||membranes|||0|861|1436|1445
SE|129||ab|7|entity|C0005516|Biological Markers|qlco|||marker|||0|840|1459|1465
SE|129||ab|7|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|840|1466|1472
SE|129||ab|7|entity|C0936012|Analysis|resa|||analyses|||0|840|1473|1481

SE|129||ab|8|text|1483|1672|(4) Crude synaptosomal fractions from guinea-pig cerebral cortex were incubated in a Krebs-glucose medium with labelled fatty acids and [3H]glucose in the presence or absence of 50 mM KCl.
SE|129||ab|8|entity|C0039067|Synaptosomes|celc|||synaptosomal|||0|754|1493|1505
SE|129||ab|8|entity|C1264633|Fraction of|qnco|||fractions|||0|754|1506|1515
SE|129||ab|8|entity|C0085979|Cavia|mamm|||guinea-pig|||0|888|1521|1531
SE|129||ab|8|entity|C0007776|Cerebral cortex|bpoc|||cerebral cortex|||0|888|1532|1547
SE|129||ab|8|entity|C0017725|Glucose|bacs,carb,phsu|||glucose|||0|790|1574|1581
SE|129||ab|8|entity|C0439536|Medium|qlco|||medium|||0|790|1582|1588
SE|129||ab|8|entity|C0181496|Labels|mnob|||labelled|||0|884|1594|1602
SE|129||ab|8|entity|C0015684|Fatty Acids|bacs,lipd|||fatty acids|||0|884|1603|1614
SE|129||ab|8|entity|C0017725|Glucose|bacs,carb,phsu|||glucose|||0|1000|1623|1630
SE|129||ab|8|relation|0|0|C0007776|Cerebral cortex|bpoc|bpoc|||cerebral cortex|||0|888|1532|1547|MOD/HEAD|PART_OF||1521|1547|0|0|C0085979|Cavia|mamm|mamm|||guinea-pig|||0|888|1521|1531

SE|129||ab|9|text|1672|1940|Subsynaptosomal fractionation was carried out and specific radioactivities of phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine and phosphatidylinositol were determined in fractions D (synaptic vesicles), E (microsomes) and H (disrupted synaptosomes).
SE|129||ab|9|entity|C0016640|Fractionation|lbpr|||fractionation|||0|861|1688|1701
SE|129||ab|9|entity|C0439787|Out|spco|||out|||0|1000|1714|1717
SE|129||ab|9|entity|C0034553|Radioactivity|npop|||radioactivities|||0|861|1731|1746
SE|129||ab|9|entity|C0031617|Lecithin|bacs,lipd,phsu|||phosphatidylcholine|||0|1000|1750|1769
SE|129||ab|9|entity|C0031618|Phosphatidylethanolamines|bacs,lipd,phsu|||phosphatidylethanolamine|||0|1000|1771|1795
SE|129||ab|9|entity|C0031623|Phosphatidylserines|lipd|||phosphatidylserine|||0|1000|1797|1815
SE|129||ab|9|entity|C0031621|Phosphatidylinositols|bacs,lipd|||phosphatidylinositol|||0|1000|1820|1840
SE|129||ab|9|entity|C1264633|Fraction of|qnco|||fractions|||0|1000|1860|1869
SE|129||ab|9|entity|C0039065|Synaptic Vesicles|celc|||synaptic vesicles|||0|1000|1873|1890
SE|129||ab|9|entity|C0026029|Microsomes|celc|||microsomes|||0|1000|1896|1906
SE|129||ab|9|entity|C0332454|Disrupted|qlco|||disrupted|||0|888|1915|1924
SE|129||ab|9|entity|C0039067|Synaptosomes|celc|||synaptosomes|||0|888|1925|1937
SE|129||ab|9|relation|6|6|C0016640|Fractionation|lbpr|lbpr|||fractionation|||0|861|1688|1701|VERB|MEASURES||1846|1856|6|1|C1264633|Fraction of|qnco|qnco|||fractions|||0|1000|1860|1869

SE|129||ab|10|text|1940|2125|The release of neurotransmitter did not significantly enhance the labelling of phospholipids in any of the fractions studied as compared with phospholipids from unstimulated fractions.
SE|129||ab|10|entity|C0027908|Neurotransmitters|nsba|||neurotransmitter|||0|1000|1955|1971
SE|129||ab|10|entity|C1518422|Not|ftcn|||not|||0|1000|1976|1979
SE|129||ab|10|entity|C0031676|Phospholipids|bacs,lipd|||phospholipids|||0|1000|2019|2032
SE|129||ab|10|entity|C1264633|Fraction of|qnco|||fractions|||0|1000|2047|2056
SE|129||ab|10|entity|C0031676|Phospholipids|bacs,lipd|||phospholipids|||0|1000|2082|2095
SE|129||ab|10|entity|C0439819|Unstimulated|qlco|||unstimulated|||0|888|2101|2113
SE|129||ab|10|entity|C1264633|Fraction of|qnco|||fractions|||0|888|2114|2123
SE|129||ab|10|relation|5|2|C0031676|Phospholipids|bacs,lipd|bacs|||phospholipids|||0|1000|2019|2032|VERB|compared_with||2068|2076|2|1|C0031676|Phospholipids|bacs,lipd|bacs|||phospholipids|||0|1000|2082|2095

SE|129||ab|11|text|2125|2239|This was found after two incubation times and using [14C]oleate, [14C]arachidonate, [3H]palmitate and [3H]glucose.
SE|129||ab|11|entity|C0205448|Two|qnco|||two|||0|785|2146|2149
SE|129||ab|11|entity|C0040223|Time|tmco|||times|||0|785|2161|2166
SE|129||ab|11|entity|C0133788|Oleates|lipd|||oleate|||0|1000|2182|2188
SE|129||ab|11|entity|C0178485|Arachidonate|bacs,eico|||arachidonate|||0|1000|2195|2207
SE|129||ab|11|entity|C0030233|Palmitates|lipd|||palmitate|||0|1000|2213|2222
SE|129||ab|11|entity|C0017725|Glucose|bacs,carb,phsu|||glucose|||0|1000|2231|2238


[130]: *** ERROR *** ERROR *** ERROR ***
SE|132||ti|1|text|16|102|Cardiac output response to altered acid-base status during diethyl ether anaesthesia.
SE|132||ti|1|entity|C0007165|Cardiac Output|fndg|||Cardiac output|||0|901|16|30
SE|132||ti|1|entity|C0871261|response|clna|||response|||0|901|31|39
SE|132||ti|1|entity|C0205349|Altered|ftcn|||altered|||0|916|43|50
SE|132||ti|1|entity|C0740747|ACID BASE STATUS|dsyn|||acid-base status|||0|916|51|67
SE|132||ti|1|entity|C0014994|Ether, Ethyl|orch,phsu|||diethyl ether|||0|901|75|88
SE|132||ti|1|entity|C0002903|Anesthesia procedures|topp|||anaesthesia|||0|901|89|100
SE|132||ti|1|relation|0|0|C0002903|Anesthesia procedures|topp|topp|||anaesthesia|||0|901|89|100|MOD/HEAD|USES||75|100|0|0|C0014994|Ether, Ethyl|orch,phsu|phsu|||diethyl ether|||0|901|75|88

SE|132||ab|1|text|108|339|The effects of acid-base changes on cardiac output during diethyl ether anaesthesia were studied in 25 mongrel dogs prepared by surgically implanting a plastic encased non-ferrous core electromagnetic probe on the ascending aorta.
SE|132||ab|1|entity|C1280500|Effect|qlco|||effects|||0|966|112|119
SE|132||ab|1|entity|C0001128|Acids|chem|||acid|||0|888|123|127
SE|132||ab|1|entity|C0007165|Cardiac Output|fndg|||cardiac output|||0|1000|144|158
SE|132||ab|1|entity|C0014994|Ether, Ethyl|orch,phsu|||diethyl ether|||0|901|166|179
SE|132||ab|1|entity|C0002903|Anesthesia procedures|topp|||anaesthesia|||0|901|180|191
SE|132||ab|1|entity|C0012984|Canis familiaris|mamm|||dogs|||0|827|219|223
SE|132||ab|1|entity|C0032167|Plastics|sbst|||plastic|||0|744|260|267
SE|132||ab|1|entity|C0444669|Core|spco|||core|||0|744|288|292
SE|132||ab|1|entity|C0013838|Electromagnetics|npop|||electromagnetic|||0|744|293|308
SE|132||ab|1|entity|C0182400|Probes|medd|||probe|||0|744|309|314
SE|132||ab|1|entity|C1269009|Entire ascending aorta|bpoc|||ascending aorta|||0|1000|322|337
SE|132||ab|1|relation|0|0|C0002903|Anesthesia procedures|topp|topp|||anaesthesia|||0|901|180|191|MOD/HEAD|USES||166|191|0|0|C0014994|Ether, Ethyl|orch,phsu|phsu|||diethyl ether|||0|901|166|179
SE|132||ab|1|relation|1|1|C1269009|Entire ascending aorta|bpoc|bpoc|||ascending aorta|||0|1000|322|337|PREP|LOCATION_OF||315|317|6|1|C0182400|Probes|medd|medd|||probe|||0|744|309|314
SE|132||ab|1|relation|4|1|C0002903|Anesthesia procedures|topp|topp|||anaesthesia|||0|901|180|191|PREP|TREATS||205|207|3|1|C0012984|Canis familiaris|mamm|mamm|||dogs|||0|827|219|223

SE|132||ab|2|text|339|551|The findings are: (1) Metabolic acidaemia produced only slight decrease in cardiac output but a more marked fall became evident with decreasing pH(2) Respiratory acidaemia led to a slight rise in cardiac output.
SE|132||ab|2|entity|C0243095|Finding|ftcn|||findings|||0|1000|343|351
SE|132||ab|2|entity|C0311400|Metabolic|ftcn|||Metabolic|||0|888|361|370
SE|132||ab|2|entity|C0268030|Acidemia|patf|||acidaemia|||0|888|371|380
SE|132||ab|2|entity|C0547040|Minimal|qlco|||slight|||0|790|395|401
SE|132||ab|2|entity|C0547047|Decrease|qnco|||decrease|||0|790|402|410
SE|132||ab|2|entity|C0007165|Cardiac Output|fndg|||cardiac output|||0|1000|414|428
SE|132||ab|2|entity|C0205172|More|ftcn|||more|||0|851|435|439
SE|132||ab|2|entity|C0522501|Massive|qlco|||marked|||0|851|440|446
SE|132||ab|2|entity|C0085639|Falls|fndg|||fall|||0|851|447|451
SE|132||ab|2|entity|C0442797|Decreasing|qlco|||decreasing|||0|890|472|482
SE|132||ab|2|entity|C1367485|PTGS2 gene|gngm|5743|PTGS2|pH(2|||0|890|483|487
SE|132||ab|2|entity|C0347961|Respiratory acidemia|patf|||Respiratory acidaemia|||0|1000|489|510
SE|132||ab|2|entity|C0547040|Minimal|qlco|||slight|||0|694|520|526
SE|132||ab|2|entity|C0007165|Cardiac Output|fndg|||cardiac output|||0|1000|535|549
SE|132||ab|2|relation|8|2|C0347961|Respiratory acidemia|patf|patf|||Respiratory acidaemia|||0|1000|489|510|PREP|COEXISTS_WITH||532|534|1|1|C0007165|Cardiac Output|fndg|fndg|||cardiac output|||0|1000|535|549

SE|132||ab|3|text|551|604|(3) Respiratory alkalaemia decreased cardiac output.
SE|132||ab|3|entity|C0347963|Respiratory alkalemia|patf|||Respiratory alkalaemia|||0|1000|555|577
SE|132||ab|3|entity|C0007165|Cardiac Output|fndg|||cardiac output|||0|1000|588|602

SE|132||ab|4|text|604|671|(4) Metabolic alkalaemia also produced a decline in cardiac output.
SE|132||ab|4|entity|C0347962|Metabolic alkalemia|patf|||Metabolic alkalaemia|||0|1000|608|628
SE|132||ab|4|entity|C0007165|Cardiac Output|fndg|||cardiac output|||0|1000|656|670
SE|132||ab|4|relation|2|2|C0347962|Metabolic alkalemia|patf|patf|||Metabolic alkalaemia|||0|1000|608|628|PREP|COEXISTS_WITH||653|655|1|1|C0007165|Cardiac Output|fndg|fndg|||cardiac output|||0|1000|656|670


SE|133||ti|1|text|16|110|The prevention of autolysis of stored cornea using steroid as a lysosome membrane stabilizer.
SE|133||ti|1|entity|C0199176|Prophylactic treatment|topp|||prevention|||0|1000|20|30
SE|133||ti|1|entity|C0004372|Autolysis|patf|||autolysis|||0|1000|34|43
SE|133||ti|1|entity|C0010031|Cornea|bpoc|||cornea|||0|861|54|60
SE|133||ti|1|entity|C0038317|Steroids|strd|||steroid|||0|1000|67|74
SE|133||ti|1|entity|C1167025|lysosomal membrane|celc|||lysosome membrane|||0|698|80|97
SE|133||ti|1|relation|3|1|C0010031|Cornea|bpoc|bpoc|||cornea|||0|861|54|60|PREP|LOCATION_OF||44|46|2|1|C0004372|Autolysis|patf|patf|||autolysis|||0|1000|34|43

SE|133||ab|1|text|116|228|Many eyes donated for use in corneal grafting are rejected because of signs of autolysis in the donor material.
SE|133||ab|1|entity|C0015392|Eye|bpoc|||eyes|||0|1000|121|125
SE|133||ab|1|entity|C0010042|Keratoplasty|topp|||corneal grafting|||0|1000|145|161
SE|133||ab|1|entity|C0220913|Manufactured sign|mnob|||signs|||0|1000|186|191
SE|133||ab|1|entity|C0004372|Autolysis|patf|||autolysis|||0|1000|195|204
SE|133||ab|1|entity|C0520510|Materials|sbst|||material|||0|861|218|226

SE|133||ab|2|text|228|468|The purpose of this experimental study was to determine whether hydrocortisone acting as a lysosome membrane stabilizer could prevent or retard autolysis of the corneas under storage, and if so, what was the most efficacious concentration.
SE|133||ab|2|entity|C1285529|Purpose|ftcn|||purpose|||0|1000|232|239
SE|133||ab|2|entity|C0681814|research study|resa|||experimental study|||0|1000|248|266
SE|133||ab|2|entity|C0020268|Hydrocortisone|horm,phsu,strd|||hydrocortisone|||0|1000|292|306
SE|133||ab|2|entity|C1167025|lysosomal membrane|celc|||lysosome membrane|||0|698|319|336
SE|133||ab|2|entity|C0004372|Autolysis|patf|||autolysis|||0|1000|372|381
SE|133||ab|2|entity|C0010031|Cornea|bpoc|||corneas|||0|1000|389|396
SE|133||ab|2|entity|C0205393|Most|qnco|||most|||0|660|436|440
SE|133||ab|2|relation|3|1|C0010031|Cornea|bpoc|bpoc|||corneas|||0|1000|389|396|PREP|LOCATION_OF||382|384|5|1|C0004372|Autolysis|patf|patf|||autolysis|||0|1000|372|381

SE|133||ab|3|text|468|651|Different groups of rabbit corneas were placed in saline as controls or in varying concentrations of hydrocortisone (10(-10) M to 10(-4) M at pH 7.4) at 37 degrees C and 4 degrees C.
SE|133||ab|3|entity|C1547020|*Difference|qnco|||Different|||0|853|468|477
SE|133||ab|3|entity|C0441833|Groups|inpr|||groups|||0|853|478|484
SE|133||ab|3|entity|C0034493|Oryctolagus cuniculus|mamm|||rabbit|||0|888|488|494
SE|133||ab|3|entity|C0010031|Cornea|bpoc|||corneas|||0|888|495|502
SE|133||ab|3|entity|C0036082|Saline|clnd|||saline|||0|1000|518|524
SE|133||ab|3|entity|C0243148|control|ftcn|||controls|||0|966|528|536
SE|133||ab|3|entity|C1548673|Varies|inpr|||varying|||0|872|543|550
SE|133||ab|3|entity|C0020268|Hydrocortisone|horm,phsu,strd|||hydrocortisone|||0|1000|569|583
SE|133||ab|3|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|624|633
SE|133||ab|3|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|640|649
SE|133||ab|3|relation|0|0|C0010031|Cornea|bpoc|bpoc|||corneas|||0|888|495|502|MOD/HEAD|PART_OF||488|502|0|0|C0034493|Oryctolagus cuniculus|mamm|mamm|||rabbit|||0|888|488|494

SE|133||ab|4|text|651|721|Acid phosphatase released after six hours was measured biochemically.
SE|133||ab|4|entity|C0001109|Acid Phosphatase|aapp,enzy|||Acid phosphatase|||0|1000|651|667
SE|133||ab|4|entity|C0205452|Six|qnco|||six|||0|888|683|686
SE|133||ab|4|entity|C0439227|Hour|tmco|||hours|||0|888|687|692

SE|133||ab|5|text|721|796|This enzyme was used as a marker enzyme reflecting lysosomal labilization.
SE|133||ab|5|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|726|732
SE|133||ab|5|entity|C0005516|Biological Markers|qlco|||marker|||0|888|747|753
SE|133||ab|5|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|888|754|760
SE|133||ab|5|entity|C0521450|Lysosomal|blor|||lysosomal|||0|694|772|781

SE|133||ab|6|text|796|909|Results showed a significant stabilization of the lysosomal membrane at 4 degrees C as compared to 37 degrees C.
SE|133||ab|6|entity|C1274040|result|ftcn|||Results|||0|966|796|803
SE|133||ab|6|entity|C0750502|Significant|idcn|||significant|||0|888|813|824
SE|133||ab|6|entity|C1293130|Stabilization|topp|||stabilization|||0|888|825|838
SE|133||ab|6|entity|C1167025|lysosomal membrane|celc|||lysosomal membrane|||0|1000|846|864
SE|133||ab|6|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|870|879
SE|133||ab|6|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|898|907

SE|133||ab|7|text|909|1103|A trend towards stabilization of the lysosomal membrane was seen when 10(-8) M concentration of hydrocortisone at 37 degrees C was used, there being no demonstrable stabilization at 4 degrees C.
SE|133||ab|7|entity|C1521798|trend|tmco|||trend|||0|1000|911|916
SE|133||ab|7|entity|C1293130|Stabilization|topp|||stabilization|||0|1000|925|938
SE|133||ab|7|entity|C1167025|lysosomal membrane|celc|||lysosomal membrane|||0|1000|946|964
SE|133||ab|7|entity|C0020268|Hydrocortisone|horm,phsu,strd|||hydrocortisone|||0|1000|1005|1019
SE|133||ab|7|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|1026|1035
SE|133||ab|7|entity|C0332265|Demonstrable|ftcn|||demonstrable|||0|888|1061|1073
SE|133||ab|7|entity|C1293130|Stabilization|topp|||stabilization|||0|888|1074|1087
SE|133||ab|7|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|1093|1102


SE|134||ti|1|text|16|126|Respiratory effects of H+ and dinitrophenol injections into the brain stem subarachnoid space of fetal lambs.
SE|134||ti|1|entity|C0521346|respiratory|ftcn|||Respiratory|||0|872|16|27
SE|134||ti|1|entity|C1280500|Effect|qlco|||effects|||0|872|28|35
SE|134||ti|1|entity|C0012466|Dinitrophenols|orch|||dinitrophenol|||0|888|46|59
SE|134||ti|1|entity|C1533685|Injection procedure|topp|||injections|||0|888|60|70
SE|134||ti|1|entity|C0006121|Brain Stem|bpoc|||brain stem|||0|901|80|90
SE|134||ti|1|entity|C0038527|Subarachnoid Space|bsoj|||subarachnoid space|||0|901|91|109
SE|134||ti|1|entity|C0521457|Foeto-|ftcn|||fetal|||0|888|113|118
SE|134||ti|1|entity|C1123019|Domestic Sheep|mamm|||lambs|||0|888|119|124
SE|134||ti|1|relation|0|0|C0038527|Subarachnoid Space|bsoj|bsoj|||subarachnoid space|||0|901|91|109|MOD/HEAD|PART_OF||80|109|0|0|C0006121|Brain Stem|bpoc|bpoc|||brain stem|||0|901|80|90

SE|134||ab|1|text|132|309|Mock cerebrospinal fluid (pH 5.37-8.38) or 2,4-dinitrophenol (DNP) (0.15-1.5 mg) was injected into the subarachnoid space of the ventral brain stem of exteriorized fetal sheep.
SE|134||ab|1|entity|C0007806|Cerebrospinal Fluid|bdsu|||cerebrospinal fluid|||0|1000|137|156
SE|134||ab|1|entity|C0012466|Dinitrophenols|orch|||dinitrophenol|||0|861|179|192
SE|134||ab|1|entity|C0444499|0/5|qnco|||0.15-1.5|||0|812|200|208
SE|134||ab|1|entity|C0038527|Subarachnoid Space|bsoj|||subarachnoid space|||0|1000|235|253
SE|134||ab|1|entity|C0205094|Anterior|spco|||ventral|||0|888|261|268
SE|134||ab|1|entity|C0006121|Brain Stem|bpoc|||brain stem|||0|888|269|279
SE|134||ab|1|entity|C0475403|Exteriorized|spco|||exteriorized|||0|851|283|295
SE|134||ab|1|entity|C0521457|Foeto-|ftcn|||fetal|||0|851|296|301
SE|134||ab|1|entity|C0036945|Sheep|mamm|||sheep|||0|851|302|307
SE|134||ab|1|relation|4|1|C0038527|Subarachnoid Space|bsoj|bsoj|||subarachnoid space|||0|1000|235|253|PREP|PART_OF||254|256|2|1|C0006121|Brain Stem|bpoc|bpoc|||brain stem|||0|888|269|279
SE|134||ab|1|relation|5|1|C0006121|Brain Stem|bpoc|bpoc|||brain stem|||0|888|269|279|PREP|PART_OF||280|282|1|1|C0036945|Sheep|mamm|mamm|||sheep|||0|851|302|307

SE|134||ab|2|text|309|445|Changes in pH on the ventral surface of the medulla did not stimulate respiratory efforts or induce significant cardiovascular changes.
SE|134||ab|2|entity|C0205094|Anterior|spco|||ventral|||0|888|330|337
SE|134||ab|2|entity|C0205148|Surface|spco|||surface|||0|888|338|345
SE|134||ab|2|entity|C1305694|Medulla|bpoc|||medulla|||0|1000|353|360
SE|134||ab|2|entity|C1518422|Not|ftcn|||not|||0|1000|365|368
SE|134||ab|2|entity|C0425466|Respiratory effort|fndg|||respiratory efforts|||0|983|379|398
SE|134||ab|2|entity|C0750502|Significant|idcn|||significant|||0|785|409|420

SE|134||ab|3|text|445|651|The respiratory response to DNP injections ranged from no response to prolonged rhythmic ventilation that was independent of the peripheral chemoreceptors or the control arterial pH and blood gas tensions.
SE|134||ab|3|entity|C0521346|respiratory|ftcn|||respiratory|||0|888|449|460
SE|134||ab|3|entity|C0871261|response|clna|||response|||0|888|461|469
SE|134||ab|3|entity|C0012466|Dinitrophenols|orch|||DNP|||0|888|473|476
SE|134||ab|3|entity|C1533685|Injection procedure|topp|||injections|||0|888|477|487
SE|134||ab|3|entity|C0871261|response|clna|||response|||0|1000|503|511
SE|134||ab|3|entity|C0439590|Prolonged|tmco|||prolonged|||0|828|515|524
SE|134||ab|3|entity|C0031084|Periodicity|tmco|||rhythmic|||0|828|525|533
SE|134||ab|3|entity|C0035203|Respiration|phsf|||ventilation|||0|828|534|545
SE|134||ab|3|entity|C0205100|Peripheral|spco|||peripheral|||0|888|574|584
SE|134||ab|3|entity|C0008010|Chemoreceptors|cell|||chemoreceptors|||0|888|585|599
SE|134||ab|3|entity|C0243148|control|ftcn|||control|||0|901|607|614
SE|134||ab|3|entity|C0003840|arterial pH|lbpr|||arterial pH|||0|901|615|626
SE|134||ab|3|entity|C0005800|Blood Gas Analysis|lbpr|||blood gas|||0|890|631|640
SE|134||ab|3|entity|C0233494|Tension|mobd|||tensions|||0|890|641|649
SE|134||ab|3|relation|0|0|C0205100|Peripheral|spco|spco|||peripheral|||0|888|574|584|MOD/HEAD|LOCATION_OF||574|599|0|0|C0008010|Chemoreceptors|cell|cell|||chemoreceptors|||0|888|585|599

SE|134||ab|4|text|651|756|This inconsistency suggests an effector site somewhat removed from the immediate surface of the medulla.
SE|134||ab|4|entity|C0442809|Inconsistent|qlco|||inconsistency|||0|928|656|669
SE|134||ab|4|entity|C0205145|Site|spco|||site|||0|861|691|695
SE|134||ab|4|entity|C0205253|Immediate|tmco|||immediate|||0|888|722|731
SE|134||ab|4|entity|C0205148|Surface|spco|||surface|||0|888|732|739
SE|134||ab|4|entity|C1305694|Medulla|bpoc|||medulla|||0|1000|747|754

SE|134||ab|5|text|756|809|The heart rate and blood pressure were not affected.
SE|134||ab|5|entity|C0018810|heart rate|orga|||heart rate|||0|1000|760|770
SE|134||ab|5|entity|C0005823|Blood Pressure|orgf|||blood pressure|||0|1000|775|789
SE|134||ab|5|entity|C1518422|Not|ftcn|||not|||0|1000|795|798

SE|134||ab|6|text|809|1084|It is concluded that increased H+ concentration in the extracellular fluid of the fetal ventral medulla does not initiate respiration, and any respiratory response to metabolic inhibitors applied to this area therefore is not attributable to a secondary change in surface pH.
SE|134||ab|6|entity|C0205217|Increased|qnco|||increased|||0|901|830|839
SE|134||ab|6|entity|C0020283|Hydrogen-Ion Concentration|qnco|||H+ concentration|||0|901|840|856
SE|134||ab|6|entity|C0015349|Extracellular Fluid|bdsu|||extracellular fluid|||0|1000|864|883
SE|134||ab|6|entity|C0521457|Foeto-|ftcn|||fetal|||0|851|891|896
SE|134||ab|6|entity|C0205094|Anterior|spco|||ventral|||0|851|897|904
SE|134||ab|6|entity|C1305694|Medulla|bpoc|||medulla|||0|851|905|912
SE|134||ab|6|entity|C1518422|Not|ftcn|||not|||0|1000|918|921
SE|134||ab|6|entity|C0035203|Respiration|phsf|||respiration|||0|1000|931|942
SE|134||ab|6|entity|C0521346|respiratory|ftcn|||respiratory|||0|888|952|963
SE|134||ab|6|entity|C0871261|response|clna|||response|||0|888|964|972
SE|134||ab|6|entity|C0311400|Metabolic|ftcn|||metabolic|||0|888|976|985
SE|134||ab|6|entity|C0243077|inhibitors|chvf|||inhibitors|||0|888|986|996
SE|134||ab|6|entity|C0205146|Area|spco|||area|||0|1000|1013|1017
SE|134||ab|6|entity|C1518422|Not|ftcn|||not|||0|694|1031|1034
SE|134||ab|6|entity|C1522484|metastatic qualifier|qnco|||secondary|||0|888|1053|1062
SE|134||ab|6|entity|C0205148|Surface|spco|||surface|||0|888|1073|1080
SE|134||ab|6|relation|2|1|C0015349|Extracellular Fluid|bdsu|bdsu|||extracellular fluid|||0|1000|864|883|PREP|PART_OF||884|886|8|1|C1305694|Medulla|bpoc|bpoc|||medulla|||0|851|905|912


SE|135||ti|1|text|16|151|Soil fungistasis: elevation of the exogenous carbon and nitrogen requirements for spore germination by fungistatic volatiles in soils.
SE|135||ti|1|entity|C0037592|Soil|sbst|||Soil|||0|694|16|20
SE|135||ti|1|entity|C0439775|Elevation procedure|topp|||elevation|||0|1000|34|43
SE|135||ti|1|entity|C0205228|Exogenous|ftcn|||exogenous|||0|888|51|60
SE|135||ti|1|entity|C0007009|Carbon|elii|||carbon|||0|888|61|67
SE|135||ti|1|entity|C0556048|Nitrogen requirement|fndg|||nitrogen requirements|||0|983|72|93
SE|135||ti|1|entity|C1160190|spore germination|moft|||spore germination|||0|1000|98|115
SE|135||ti|1|entity|C0443769|volatile substances|chvf|||volatiles|||0|861|131|140
SE|135||ti|1|entity|C0037592|Soil|sbst|||soils|||0|1000|144|149

SE|135||ab|1|text|157|411|Axenic, washed conidia of Fusarium solani f. sp. phaseoli, Aspergillus flavus, and Verticillium albo-atrum were placed on washed Difco purified agar discs along with an inorganic salt solution containing various levels of carbon and nitrogen substrates.
SE|135||ab|1|entity|C1548982|Washed|idcn|||washed|||0|790|165|171
SE|135||ab|1|entity|C0521049|Conidium|fngs|||conidia|||0|790|172|179
SE|135||ab|1|entity|C0320166|Nectria ipomoeae|fngs|||Fusarium solani|||0|621|183|198
SE|135||ab|1|entity|C0004036|Aspergillus flavus|fngs|||Aspergillus flavus|||0|1000|216|234
SE|135||ab|1|entity|C1001431|Verticillium albo-atrum|fngs|||Verticillium albo-atrum|||0|1000|240|263
SE|135||ab|1|entity|C1548982|Washed|idcn|||washed|||0|694|279|285
SE|135||ab|1|entity|C0001771|Agar|carb,irda,phsu|||agar|||0|888|301|305
SE|135||ab|1|entity|C0180459|Disks|medd|||discs|||0|888|306|311
SE|135||ab|1|entity|C0036140|Salts|chvs|||salt|||0|790|336|340
SE|135||ab|1|entity|C0037633|Solutions|sbst|||solution|||0|790|341|349
SE|135||ab|1|entity|C0441889|Levels|inpr|||levels|||0|861|369|375
SE|135||ab|1|entity|C0007009|Carbon|elii|||carbon|||0|1000|379|385
SE|135||ab|1|entity|C0028158|Nitrogen|elii|||nitrogen|||0|694|390|398
SE|135||ab|1|relation|0|0|C0180459|Disks|medd|medd|||discs|||0|888|306|311|MOD/HEAD|USES||301|311|0|0|C0001771|Agar|carb,irda,phsu|phsu|||agar|||0|888|301|305
SE|135||ab|1|relation|3|2|C0007009|Carbon|elii|elii|||carbon|||0|1000|379|385|VERB|PART_OF||350|360|7|4|C0004036|Aspergillus flavus|fngs|fngs|||Aspergillus flavus|||0|1000|216|234
SE|135||ab|1|relation|3|2|C0007009|Carbon|elii|elii|||carbon|||0|1000|379|385|VERB|PART_OF||350|360|7|4|C1001431|Verticillium albo-atrum|fngs|fngs|||Verticillium albo-atrum|||0|1000|240|263
SE|135||ab|1|relation|3|2|C0028158|Nitrogen|elii|elii|||nitrogen|||0|694|390|398|VERB|PART_OF||350|360|7|4|C1001431|Verticillium albo-atrum|fngs|fngs|||Verticillium albo-atrum|||0|1000|240|263
SE|135||ab|1|relation|3|3|C0028158|Nitrogen|elii|elii|||nitrogen|||0|694|390|398|VERB|PART_OF||350|360|7|5|C0004036|Aspergillus flavus|fngs|fngs|||Aspergillus flavus|||0|1000|216|234

SE|135||ab|2|text|411|478|These discs were exposed to volatiles from six soils (pH 5.1-8.6).
SE|135||ab|2|entity|C0180459|Disks|medd|||discs|||0|1000|417|422
SE|135||ab|2|entity|C0443769|volatile substances|chvf|||volatiles|||0|1000|439|448
SE|135||ab|2|entity|C0205452|Six|qnco|||six|||0|888|454|457
SE|135||ab|2|entity|C0037592|Soil|sbst|||soils|||0|888|458|463

SE|135||ab|3|text|478|730|Fusarium solani macroconidial germination was inhibited mostly by volatiles from soils of pH 5.1, 6.1, 7.0, and 7.5, but high levels of glucose and NH4Cl reversed this inhibition, raising germination to that of no-soil, no-carbon or nitrogen controls.
SE|135||ab|3|entity|C0320166|Nectria ipomoeae|fngs|||Fusarium solani|||0|824|478|493
SE|135||ab|3|entity|C0242735|Germination|biof|||germination|||0|824|508|519
SE|135||ab|3|entity|C0750554|MOSTLY|idcn|||mostly|||0|1000|534|540
SE|135||ab|3|entity|C0443769|volatile substances|chvf|||volatiles|||0|1000|544|553
SE|135||ab|3|entity|C0037592|Soil|sbst|||soils|||0|1000|559|564
SE|135||ab|3|entity|C0205250|High|qlco|||high|||0|888|599|603
SE|135||ab|3|entity|C0441889|Levels|inpr|||levels|||0|888|604|610
SE|135||ab|3|entity|C0017725|Glucose|bacs,carb,phsu|||glucose|||0|1000|614|621
SE|135||ab|3|entity|C0242735|Germination|biof|||germination|||0|1000|666|677
SE|135||ab|3|entity|C0037592|Soil|sbst|||soil|||0|1000|692|696
SE|135||ab|3|entity|C0007009|Carbon|elii|||carbon|||0|1000|701|707
SE|135||ab|3|entity|C0028158|Nitrogen|elii|||nitrogen|||0|872|711|719
SE|135||ab|3|entity|C0243148|control|ftcn|||controls|||0|872|720|728
SE|135||ab|3|relation|7|3|C0017725|Glucose|bacs,carb,phsu|carb|||glucose|||0|1000|614|621|VERB|AUGMENTS||658|665|4|1|C0242735|Germination|biof|biof|||germination|||0|1000|666|677

SE|135||ab|4|text|730|924|Conidial germination of A. flavus was inhibited mainly by volatiles from high pH (7.0, 7.8, and 8.6) soils, and increased levels of glucose plus an amino acid mixture nullified this inhibition.
SE|135||ab|4|entity|C0521049|Conidium|fngs|||Conidial|||0|853|730|738
SE|135||ab|4|entity|C0242735|Germination|biof|||germination|||0|853|739|750
SE|135||ab|4|entity|C0443769|volatile substances|chvf|||volatiles|||0|1000|788|797
SE|135||ab|4|entity|C0205250|High|qlco|||high|||0|750|803|807
SE|135||ab|4|entity|C0020283|Hydrogen-Ion Concentration|qnco|||pH|||0|750|808|810
SE|135||ab|4|entity|C0037592|Soil|sbst|||soils|||0|1000|831|836
SE|135||ab|4|entity|C0205217|Increased|qnco|||increased|||0|888|842|851
SE|135||ab|4|entity|C0441889|Levels|inpr|||levels|||0|888|852|858
SE|135||ab|4|entity|C0017725|Glucose|bacs,carb,phsu|||glucose|||0|1000|862|869
SE|135||ab|4|entity|C0002520|Amino Acids|aapp,bacs,phsu|||amino acid|||0|888|878|888
SE|135||ab|4|entity|C0439962|Mixture|sbst|||mixture|||0|888|889|896

SE|135||ab|5|text|924|1012|Volatiles from soils of pH 5.1, 6.1, and 7.5 stimulated A. flavus conidial germination.
SE|135||ab|5|entity|C0443769|volatile substances|chvf|||Volatiles|||0|1000|924|933
SE|135||ab|5|entity|C0037592|Soil|sbst|||soils|||0|1000|939|944
SE|135||ab|5|entity|C0521049|Conidium|fngs|||conidial|||0|754|990|998
SE|135||ab|5|entity|C0242735|Germination|biof|||germination|||0|754|999|1010

SE|135||ab|6|text|1012|1158|Assays after the removal of CO2 from the air above soil of pH 5.1 demonstrated that volatiles inhibitory to A. flavus were produced by this soil.
SE|135||ab|6|entity|C1510438|Assay|lbpr|||Assays|||0|966|1012|1018
SE|135||ab|6|entity|C0728940|Excision|topp|||removal|||0|1000|1029|1036
SE|135||ab|6|entity|C0007012|Carbon Dioxide|bacs,inch|||CO2|||0|1000|1040|1043
SE|135||ab|6|entity|C0001861|Air|sbst|||air|||0|1000|1053|1056
SE|135||ab|6|entity|C0037592|Soil|sbst|||soil|||0|1000|1063|1067
SE|135||ab|6|entity|C0443769|volatile substances|chvf|||volatiles|||0|1000|1096|1105
SE|135||ab|6|entity|C0243077|inhibitors|chvf|||inhibitory|||0|928|1106|1116
SE|135||ab|6|entity|C0037592|Soil|sbst|||soil|||0|1000|1152|1156

SE|135||ab|7|text|1158|1275|Assays indicated that a KOH-soluble compound was a fungistatic soil volatile to F. solani macroconidial germination.
SE|135||ab|7|entity|C1510438|Assay|lbpr|||Assays|||0|966|1158|1164
SE|135||ab|7|entity|C0205198|Compound|qlco|||compound|||0|827|1194|1202
SE|135||ab|7|entity|C0037592|Soil|sbst|||soil|||0|861|1221|1225
SE|135||ab|7|entity|C0373746|Assay of volatiles|lbpr|||volatile|||0|1000|1226|1234
SE|135||ab|7|entity|C0242735|Germination|biof|||germination|||0|812|1262|1273

SE|135||ab|8|text|1275|1427|The nullification by carbon and nitrogen substrates of F. solani and A. flavus inhibition caused by soil volatiles parallels that for soil fungistasis.
SE|135||ab|8|entity|C0007009|Carbon|elii|||carbon|||0|1000|1296|1302
SE|135||ab|8|entity|C0028158|Nitrogen|elii|||nitrogen|||0|694|1307|1315
SE|135||ab|8|entity|C0037592|Soil|sbst|||soil|||0|888|1375|1379
SE|135||ab|8|entity|C0443769|volatile substances|chvf|||volatiles|||0|888|1380|1389
SE|135||ab|8|entity|C0037592|Soil|sbst|||soil|||0|694|1409|1413

SE|135||ab|9|text|1427|1563|Conidial germination of V. albo-atrum was markedly stimulated by volatiles in all soils tested, and was not affected by removal of CO2.
SE|135||ab|9|entity|C0521049|Conidium|fngs|||Conidial|||0|853|1427|1435
SE|135||ab|9|entity|C0242735|Germination|biof|||germination|||0|853|1436|1447
SE|135||ab|9|entity|C0102082|Albo|bodm|||albo|||0|660|1454|1458
SE|135||ab|9|entity|C0522501|Massive|qlco|||markedly|||0|1000|1469|1477
SE|135||ab|9|entity|C0443769|volatile substances|chvf|||volatiles|||0|1000|1492|1501
SE|135||ab|9|entity|C0037592|Soil|sbst|||soils|||0|1000|1509|1514
SE|135||ab|9|entity|C1518422|Not|ftcn|||not|||0|1000|1531|1534
SE|135||ab|9|entity|C0728940|Excision|topp|||removal|||0|1000|1547|1554
SE|135||ab|9|entity|C0007012|Carbon Dioxide|bacs,inch|||CO2|||0|1000|1558|1561
SE|135||ab|9|relation|2|1|C0728940|Excision|topp|topp|||removal|||0|1000|1547|1554|VERB|AFFECTS|negation|1535|1543|4|4|C0242735|Germination|biof|biof|||germination|||0|853|1436|1447

SE|135||ab|10|text|1563|1670|Inhibitory soil volatiles may increase the nutritional requirements for spore germination of certain fungi.
SE|135||ab|10|entity|C0243077|inhibitors|chvf|||Inhibitory|||0|828|1563|1573
SE|135||ab|10|entity|C0037592|Soil|sbst|||soil|||0|828|1574|1578
SE|135||ab|10|entity|C0443769|volatile substances|chvf|||volatiles|||0|828|1579|1588
SE|135||ab|10|entity|C0028719|Nutritional Requirements|orga|||nutritional requirements|||0|1000|1606|1630
SE|135||ab|10|entity|C1160190|spore germination|moft|||spore germination|||0|1000|1635|1652
SE|135||ab|10|entity|C0016832|fungus|fngs|||fungi|||0|888|1664|1669


SE|136||ti|1|text|16|101|Nitrofurazone-reducing enzymes in E. coli and their role in drug activation in vivo.
SE|136||ti|1|entity|C0028157|Nitrofurazone|orch,phsu|||Nitrofurazone|||0|840|16|29
SE|136||ti|1|entity|C0392756|Reduced|qlco|||reducing|||0|840|30|38
SE|136||ti|1|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|840|39|46
SE|136||ti|1|entity|C0014834|Escherichia coli|bact|||E. coli|||0|1000|50|57
SE|136||ti|1|entity|C0035820|Role|socb|||role|||0|1000|68|72
SE|136||ti|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug|||0|694|76|80
SE|136||ti|1|entity|C1515655|in vivo|spco|||in vivo|||0|1000|92|99

SE|136||ab|1|text|107|240|Earlier work showed that Escherichia coli contains at least two enzymes which reduce nitrofurazone and other nitrofuran derivatives.
SE|136||ab|1|entity|C1279919|Early|tmco|||Earlier|||0|966|107|114
SE|136||ab|1|entity|C0014834|Escherichia coli|bact|||Escherichia coli|||0|1000|132|148
SE|136||ab|1|entity|C0205448|Two|qnco|||two|||0|790|167|170
SE|136||ab|1|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|790|171|178
SE|136||ab|1|entity|C0028157|Nitrofurazone|orch,phsu|||nitrofurazone|||0|1000|192|205
SE|136||ab|1|entity|C0770668|Nitrofuran derivative|orch,phsu|||nitrofuran derivatives|||0|983|216|238
SE|136||ab|1|relation|0|0|C0028157|Nitrofurazone|orch,phsu|orch|||nitrofurazone|||0|1000|192|205|SPEC|ISA||192|238|0|0|C0770668|Nitrofuran derivative|orch,phsu|orch|||nitrofuran derivatives|||0|983|216|238

SE|136||ab|2|text|240|320|One of these enzymes is lacking in some nitrofurazone-resistant mutant strains.
SE|136||ab|2|entity|C0205447|One|qnco|||One|||0|1000|240|243
SE|136||ab|2|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|1000|253|260
SE|136||ab|2|entity|C0028157|Nitrofurazone|orch,phsu|||nitrofurazone|||0|833|280|293
SE|136||ab|2|entity|C0332325|Resistant|ftcn|||resistant|||0|833|294|303
SE|136||ab|2|entity|C0596988|Mutant|comd|||mutant|||0|833|304|310

SE|136||ab|3|text|320|603|We now report that there are three separable nitrofuran reductases in this organism: reductase I (mol. wt. approximately 50 000, insensitive to O2), reductase IIa (mol. wt. approximately 120 000, inhibited by oxygen), reductase IIb (mol. wt. approximately 700 000, inhibited by O2).
SE|136||ab|3|entity|C0205449|Three|qnco|||three|||0|813|349|354
SE|136||ab|3|entity|C0132570|nitrofuran reductase|aapp,enzy|||nitrofuran reductases|||0|813|365|386
SE|136||ab|3|entity|C0029235|Organism|orgm|||organism|||0|1000|395|403
SE|136||ab|3|entity|C0030016|Oxidoreductase|aapp,enzy|||reductase|||0|1000|405|414
SE|136||ab|3|entity|C0027960|Nevus|neop|||mol|||0|736|418|421
SE|136||ab|3|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|736|427|440
SE|136||ab|3|entity|C0237677|Insensitivity|menp|||insensitive|||0|928|449|460
SE|136||ab|3|entity|C0030016|Oxidoreductase|aapp,enzy|||reductase|||0|694|469|478
SE|136||ab|3|entity|C0027960|Nevus|neop|||mol|||0|736|484|487
SE|136||ab|3|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|736|493|506
SE|136||ab|3|entity|C0030054|Oxygen|elii,phsu|||oxygen|||0|1000|529|535
SE|136||ab|3|entity|C0030016|Oxidoreductase|aapp,enzy|||reductase|||0|694|538|547
SE|136||ab|3|entity|C0027960|Nevus|neop|||mol|||0|736|553|556
SE|136||ab|3|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|736|562|575
SE|136||ab|3|relation|8|1|C0029235|Organism|orgm|orgm|||organism|||0|1000|395|403|PREP|LOCATION_OF||387|389|1|1|C0132570|nitrofuran reductase|aapp,gngm,enzy|aapp|||nitrofuran reductases|||0|813|365|386

SE|136||ab|4|text|603|751|Unstable metabolites formed during the reduction of nitrofurazone by preparations containing reductases IIa and IIb produce breaks in DNA in vitro.
SE|136||ab|4|entity|C0870883|Metabolites|bacs|||metabolites|||0|861|612|623
SE|136||ab|4|entity|C0028157|Nitrofurazone|orch,phsu|||nitrofurazone|||0|1000|655|668
SE|136||ab|4|entity|C1521827|Preparation|ftcn|||preparations|||0|966|672|684
SE|136||ab|4|entity|C0030016|Oxidoreductase|aapp,enzy|||reductases|||0|694|696|706
SE|136||ab|4|entity|C0012854|DNA|bacs,nnon|||DNA|||0|1000|737|740
SE|136||ab|4|entity|C1533691|in vitro|qlco|||in vitro|||0|1000|741|749
SE|136||ab|4|relation|7|5|C0028157|Nitrofurazone|orch,phsu|orch|||nitrofurazone|||0|1000|655|668|PREP|COEXISTS_WITH||734|736|2|1|C0012854|DNA|bacs,nnon|bacs|||DNA|||0|1000|737|740

SE|136||ab|5|text|751|1058|In vivo experiments with nitrofurazone-resistant strains, which lack reductase II but contain reductases IIa and IIb, demonstrated that lethality, mutation, and DNA breakage are all greatly increased when cultures are incubated under anaerobic conditions, i.e., conditions such that reductase II is active.
SE|136||ab|5|entity|C1515655|in vivo|spco|||In vivo|||0|901|751|758
SE|136||ab|5|entity|C0681814|research study|resa|||experiments|||0|901|759|770
SE|136||ab|5|entity|C0028157|Nitrofurazone|orch,phsu|||nitrofurazone|||0|851|776|789
SE|136||ab|5|entity|C0332325|Resistant|ftcn|||resistant|||0|851|790|799
SE|136||ab|5|entity|C0030016|Oxidoreductase|aapp,enzy|||reductase|||0|694|820|829
SE|136||ab|5|entity|C0030016|Oxidoreductase|aapp,enzy|||reductases|||0|694|845|855
SE|136||ab|5|entity|C1031740|Lethe|invt|||lethality|||0|900|887|896
SE|136||ab|5|entity|C0026882|Mutation|genf|||mutation|||0|1000|898|906
SE|136||ab|5|entity|C0012854|DNA|bacs,nnon|||DNA|||0|694|912|915
SE|136||ab|5|entity|C0010453|Anthropological Culture|idcn|||cultures|||0|1000|956|964
SE|136||ab|5|entity|C0348080|Condition|qlco|||conditions|||0|827|995|1005
SE|136||ab|5|entity|C0348080|Condition|qlco|||conditions|||0|966|1013|1023
SE|136||ab|5|entity|C0030016|Oxidoreductase|aapp,enzy|||reductase|||0|694|1034|1043
SE|136||ab|5|entity|C0205177|Active|ftcn|||active|||0|1000|1050|1056

SE|136||ab|6|text|1058|1157|These results provide further evidence for the importance of reductive activation of nitrofurazone.
SE|136||ab|6|entity|C1274040|result|ftcn|||results|||0|966|1064|1071
SE|136||ab|6|entity|C1517331|Further|spco|||further|||0|694|1080|1087
SE|136||ab|6|entity|C0028157|Nitrofurazone|orch,phsu|||nitrofurazone|||0|1000|1143|1156


SE|138||ti|1|text|16|99|Temperature and pH optima for 21 species of thermophilic and thermotolerant fungi.
SE|138||ti|1|entity|C0039476|Temperature|qnco|||Temperature|||0|1000|16|27
SE|138||ti|1|entity|C1548151|Species|idcn|||species|||0|861|49|56
SE|138||ti|1|entity|C0016832|fungus|fngs|||fungi|||0|861|92|97

SE|138||ab|1|text|105|278|A glucose-containing mineral medium supplemented with 0.01% yeast extract is described upon which all the species of thermophilic and thermotolerant fungi tested will grow.
SE|138||ab|1|entity|C0017725|Glucose|bacs,carb,phsu|||glucose|||0|833|107|114
SE|138||ab|1|entity|C0332256|Containing|ftcn|||containing|||0|833|115|125
SE|138||ab|1|entity|C0026162|Minerals|inch|||mineral|||0|833|126|133
SE|138||ab|1|entity|C0439536|Medium|qlco|||medium|||0|833|134|140
SE|138||ab|1|entity|C0873195|YEAST EXTRACT|orch,phsu|||yeast extract|||0|861|165|178
SE|138||ab|1|entity|C1548151|Species|idcn|||species|||0|1000|211|218
SE|138||ab|1|entity|C0016832|fungus|fngs|||fungi|||0|861|254|259

SE|138||ab|2|text|278|361|Thirteen of the 21 species do not require the yeast extract supplement for growth.
SE|138||ab|2|entity|C1548151|Species|idcn|||species|||0|861|297|304
SE|138||ab|2|entity|C1518422|Not|ftcn|||not|||0|1000|308|311
SE|138||ab|2|entity|C0873195|YEAST EXTRACT|orch,phsu|||yeast extract|||0|901|324|337
SE|138||ab|2|entity|C1549514|Supplement|idcn|||supplement|||0|901|338|348
SE|138||ab|2|entity|C0018270|Growth|orgf|||growth|||0|1000|353|359

SE|138||ab|3|text|361|479|Using this solid, supplemented mineral medium, the pH and temperature optima for growth of all strains were measured.
SE|138||ab|3|entity|C0205208|Solid|qlco|||solid|||0|1000|372|377
SE|138||ab|3|entity|C1549514|Supplement|idcn|||supplemented|||0|840|379|391
SE|138||ab|3|entity|C0026162|Minerals|inch|||mineral|||0|840|392|399
SE|138||ab|3|entity|C0439536|Medium|qlco|||medium|||0|840|400|406
SE|138||ab|3|entity|C0039476|Temperature|qnco|||temperature|||0|694|419|430
SE|138||ab|3|entity|C0018270|Growth|orgf|||growth|||0|1000|442|448

SE|138||ab|4|text|479|581|No correlation was found between temperature optimum and pH optimum among members of the group tested.
SE|138||ab|4|entity|C0039476|Temperature|qnco|||temperature|||0|694|512|523
SE|138||ab|4|entity|C0680022|member|popg|||members|||0|966|553|560
SE|138||ab|4|entity|C0441833|Groups|inpr|||group|||0|1000|568|573


SE|137||ti|1|text|16|154|Enzymatic hydrolysis of agar: purification and characterization of neoagarobiose hydrolase and p-nitrophenyl alpha-galactoside hydrolase.
SE|137||ti|1|entity|C0014442|Enzymes|enzy,orch|||Enzymatic|||0|853|16|25
SE|137||ti|1|entity|C0020291|Hydrolysis|npop|||hydrolysis|||0|853|26|36
SE|137||ti|1|entity|C0001771|Agar|carb,irda,phsu|||agar|||0|1000|40|44
SE|137||ti|1|entity|C0243114|purification|lbpr,resa|||purification|||0|1000|46|58
SE|137||ti|1|entity|C0619573|neoagarobiose hydrolase|aapp,enzy|||neoagarobiose hydrolase|||0|1000|83|106
SE|137||ti|1|entity|C0134799|4-nitrophenyl-alpha-galactoside|carb,irda|||p-nitrophenyl alpha-galactoside|||0|928|111|142
SE|137||ti|1|entity|C0020289|Hydrolase|aapp,enzy|||hydrolase|||0|928|143|152

SE|137||ab|1|text|160|362|The mixture of polysaccharides in the gelling component of agar (agarose) is hydrolyzed to D-galactose and 3,6-anhydro-L-galactose by a series of hydrolytic enzymes obtained from Pseudomonas atlantica.
SE|137||ab|1|entity|C0439962|Mixture|sbst|||mixture|||0|1000|164|171
SE|137||ab|1|entity|C0032594|Polysaccharides|carb,phsu|||polysaccharides|||0|1000|175|190
SE|137||ab|1|entity|C1524073|Component, LOINC Axis 1|clas|||component|||0|861|206|215
SE|137||ab|1|entity|C0001771|Agar|carb,irda,phsu|||agar|||0|1000|219|223
SE|137||ab|1|entity|C0036681|Sepharose|bodm,carb|||agarose|||0|1000|225|232
SE|137||ab|1|entity|C0016945|Galactose|carb,irda|||galactose|||0|1000|253|262
SE|137||ab|1|entity|C0016945|Galactose|carb,irda|||galactose|||0|812|281|290
SE|137||ab|1|entity|C0020291|Hydrolysis|npop|||hydrolytic|||0|853|306|316
SE|137||ab|1|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|853|317|324
SE|137||ab|1|entity|C0995308|Pseudoalteromonas atlantica|bact|||Pseudomonas atlantica|||0|1000|339|360

SE|137||ab|2|text|362|553|The final degradative step in the pathway of agarose decomposition is the hydrolysis of the alpha-linkage in the dissaccharide neoagarobiose yielding D-galactose and 3,6-anhydro-L-galactose.
SE|137||ab|2|entity|C0205088|End-stage|tmco|||final|||0|802|366|371
SE|137||ab|2|entity|C1261552|Step|ftcn|||step|||0|802|384|388
SE|137||ab|2|entity|C0243123|biochemical pathways|ftcn|||pathway|||0|1000|396|403
SE|137||ab|2|entity|C0036681|Sepharose|bodm,carb|||agarose|||0|694|407|414
SE|137||ab|2|entity|C0020291|Hydrolysis|npop|||hydrolysis|||0|1000|436|446
SE|137||ab|2|entity|C0439095|Alpha|inpr|||alpha|||0|694|454|459
SE|137||ab|2|entity|C0132114|neoagarobiose|carb|||neoagarobiose|||0|861|489|502
SE|137||ab|2|entity|C0016945|Galactose|carb,irda|||galactose|||0|1000|514|523
SE|137||ab|2|entity|C0016945|Galactose|carb,irda|||galactose|||0|812|542|551

SE|137||ab|3|text|553|694|Pseudomonas atlantica when grown on agar produces two specific enzymes, p-nitrophenyl alpha-galactose hydrolase and neoagarobiose hydrolase.
SE|137||ab|3|entity|C0995308|Pseudoalteromonas atlantica|bact|||Pseudomonas atlantica|||0|1000|553|574
SE|137||ab|3|entity|C0001771|Agar|carb,irda,phsu|||agar|||0|1000|589|593
SE|137||ab|3|entity|C0205448|Two|qnco|||two|||0|802|603|606
SE|137||ab|3|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|802|616|623
SE|137||ab|3|entity|C0439095|Alpha|inpr|||alpha|||0|766|639|644
SE|137||ab|3|entity|C0016945|Galactose|carb,irda|||galactose|||0|766|645|654
SE|137||ab|3|entity|C0020289|Hydrolase|aapp,enzy|||hydrolase|||0|766|655|664
SE|137||ab|3|entity|C0619573|neoagarobiose hydrolase|aapp,enzy|||neoagarobiose hydrolase|||0|1000|669|692

SE|137||ab|4|text|694|770|The purification and partial characterization of both enzymes are presented.
SE|137||ab|4|entity|C0243114|purification|lbpr,resa|||purification|||0|1000|698|710
SE|137||ab|4|entity|C0728938|Partial|qnco|||partial|||0|694|715|722
SE|137||ab|4|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|1000|748|755


SE|139||ti|1|text|16|84|Physiological differences among isolates of Phytophthora cinnamomi.
SE|139||ti|1|entity|C0205463|Physiological|ftcn|||Physiological|||0|872|16|29
SE|139||ti|1|entity|C1547020|*Difference|qnco|||differences|||0|872|30|41
SE|139||ti|1|entity|C1080930|Phytophthora cinnamomi|plnt|||Phytophthora cinnamomi|||0|1000|60|82

SE|139||ab|1|text|90|283|Significant differences in amylase, beta-glucosidase, and phosphatase activities were observed among four Phytophthora cinnamomi isolates grown in nutrient-amended sterilized soil for 20 days.
SE|139||ab|1|entity|C0750502|Significant|idcn|||Significant|||0|872|90|101
SE|139||ab|1|entity|C1547020|*Difference|qnco|||differences|||0|872|102|113
SE|139||ab|1|entity|C0002712|Amylases|aapp,enzy,phsu|||amylase|||0|1000|117|124
SE|139||ab|1|entity|C0005223|beta-Glucosidase|aapp,enzy|||beta-glucosidase|||0|1000|126|142
SE|139||ab|1|entity|C1151861|phosphatase activity|moft|||phosphatase activities|||0|983|148|170
SE|139||ab|1|entity|C0205450|Four|qnco|||four|||0|658|191|195
SE|139||ab|1|entity|C1080930|Phytophthora cinnamomi|plnt|||Phytophthora cinnamomi|||0|658|196|218
SE|139||ab|1|entity|C0678695|Nutrients|food|||nutrient|||0|775|237|245
SE|139||ab|1|entity|C0242383|Age related macular degeneration|dsyn|||amended|||0|775|246|253
SE|139||ab|1|entity|C0037592|Soil|sbst|||soil|||0|775|265|269
SE|139||ab|1|entity|C0439228|day|tmco|||days|||0|861|277|281

SE|139||ab|2|text|283|422|Amylase pH optima for the four isolates were within a relatively narrow range; at pH 5.5 each isolate was within 90% of its peak activity.
SE|139||ab|2|entity|C0002712|Amylases|aapp,enzy,phsu|||Amylase|||0|623|283|290
SE|139||ab|2|entity|C0205450|Four|qnco|||four|||0|694|309|313
SE|139||ab|2|entity|C1514721|Range|qnco|||range|||0|1000|355|360
SE|139||ab|2|entity|C0439083|>90|qnco|||90|||0|1000|396|398

SE|139||ab|3|text|422|564|Isolates SB-216-1, 1-281, and C-39 each exhibited maximal beta-glucosidase activity at pH 5.0 and maximal phosphatase activity at pH 5.0-5.5.
SE|139||ab|3|entity|C0141611|Sb 1|orch|||216-1|||0|913|434|439
SE|139||ab|3|entity|C0610536|C 39|lipd,phsu|||C-39|||0|1000|452|456
SE|139||ab|3|entity|C0205289|Maximal|qlco|||maximal|||0|916|472|479
SE|139||ab|3|entity|C1150056|beta-glucosidase activity|moft|||beta-glucosidase activity|||0|916|480|505
SE|139||ab|3|entity|C0205289|Maximal|qlco|||maximal|||0|901|520|527
SE|139||ab|3|entity|C1151861|phosphatase activity|moft|||phosphatase activity|||0|901|528|548

SE|139||ab|4|text|564|641|Maximal activity for these two enzymes of isolate A-7725 occurred at pH 3.5.
SE|139||ab|4|entity|C0205289|Maximal|qlco|||Maximal|||0|888|564|571
SE|139||ab|4|entity|C0205448|Two|qnco|||two|||0|888|591|594
SE|139||ab|4|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|888|595|602
SE|139||ab|4|entity|C0601906|PH.3|phsu|||pH 3|||0|901|633|637

SE|139||ab|5|text|641|759|In timed experiments, isolates 1-281 and A-7725 exhibited greater amylase activities than did the other two isolates.
SE|139||ab|5|entity|C0392761|Timed|tmco|||timed|||0|888|644|649
SE|139||ab|5|entity|C0681814|research study|resa|||experiments|||0|888|650|661
SE|139||ab|5|entity|C0443228|Largest|qnco|||greater|||0|890|699|706
SE|139||ab|5|entity|C1150038|amylase activity|moft|||amylase activities|||0|890|707|725
SE|139||ab|5|entity|C0205448|Two|qnco|||two|||0|694|745|748

SE|139||ab|6|text|759|923|For beta-glucosidase, greatest activity was observed for SB-216-1; ACTivity of 1-281 was intermediate and least activity was observed for isolates A-7725 and C-39.
SE|139||ab|6|entity|C0005223|beta-Glucosidase|aapp,enzy|||beta-glucosidase|||0|1000|763|779
SE|139||ab|6|entity|C0443228|Largest|qnco|||greatest|||0|872|781|789
SE|139||ab|6|entity|C0141611|Sb 1|orch|||216-1|||0|913|819|824
SE|139||ab|6|entity|C0205103|Intermediate|spco|||intermediate|||0|1000|848|860
SE|139||ab|6|entity|C0610536|C 39|lipd,phsu|||C-39|||0|1000|917|921

SE|139||ab|7|text|923|1066|Isolates SB-216-1 and 1-281 exhibited greatest phosphatase activities; isolate C-39 was intermediate in activity, and A-7725 was least active.
SE|139||ab|7|entity|C0141611|Sb 1|orch|||216-1|||0|913|935|940
SE|139||ab|7|entity|C0443228|Largest|qnco|||greatest|||0|879|961|969
SE|139||ab|7|entity|C1151861|phosphatase activity|moft|||phosphatase activities|||0|879|970|992
SE|139||ab|7|entity|C0205103|Intermediate|spco|||intermediate|||0|1000|1011|1023
SE|139||ab|7|entity|C0205177|Active|ftcn|||active|||0|861|1058|1064

SE|139||ab|8|text|1066|1227|Results indicate that significant differences exist among the isolates tested and that these differences can be quantitatively measured by the methods described.
SE|139||ab|8|entity|C1274040|result|ftcn|||Results|||0|966|1066|1073
SE|139||ab|8|entity|C0750502|Significant|idcn|||significant|||0|872|1088|1099
SE|139||ab|8|entity|C1547020|*Difference|qnco|||differences|||0|872|1100|1111
SE|139||ab|8|entity|C1547020|*Difference|qnco|||differences|||0|966|1159|1170
SE|139||ab|8|entity|C0025663|Methods|inpr|||methods|||0|1000|1209|1216


SE|140||ti|1|text|16|89|Regulation and properties of an invertase from Clostridium pasteurianum.
SE|140||ti|1|entity|C0851285|Regulation|gora|||Regulation|||0|1000|16|26
SE|140||ti|1|entity|C0871161|Property|qlco|||properties|||0|966|31|41
SE|140||ti|1|entity|C0053409|Invertase|aapp,enzy|||invertase|||0|1000|48|57
SE|140||ti|1|entity|C0315068|Clostridium pasteurianum|bact|||Clostridium pasteurianum|||0|1000|63|87
SE|140||ti|1|relation|1|1|C0315068|Clostridium pasteurianum|bact|bact|||Clostridium pasteurianum|||0|1000|63|87|PREP|LOCATION_OF||58|62|3|1|C0053409|Invertase|aapp,gngm,enzy|aapp|||invertase|||0|1000|48|57

SE|140||ab|1|text|95|225|An intracellular invertase was induced in cultures of Clostridium pasteurianum utilizing sucrose as its carbon source for growth.
SE|140||ab|1|entity|C0175996|Protoplasm|celc|||intracellular|||0|888|98|111
SE|140||ab|1|entity|C0053409|Invertase|aapp,enzy|||invertase|||0|888|112|121
SE|140||ab|1|entity|C0010453|Anthropological Culture|idcn|||cultures|||0|1000|137|145
SE|140||ab|1|entity|C0315068|Clostridium pasteurianum|bact|||Clostridium pasteurianum|||0|824|149|173
SE|140||ab|1|entity|C0038636|Sucrose|bacs,carb|||sucrose|||0|824|184|191
SE|140||ab|1|entity|C0007009|Carbon|elii|||carbon|||0|888|199|205
SE|140||ab|1|entity|C0018270|Growth|orgf|||growth|||0|1000|217|223
SE|140||ab|1|relation|0|0|C0053409|Invertase|aapp,gngm,enzy|aapp|||invertase|||0|888|112|121|MOD/HEAD|PART_OF||98|121|0|0|C0175996|Protoplasm|celc|celc|||intracellular|||0|888|98|111

SE|140||ab|2|text|225|324|This enzyme synthesis could be repressed by the addition of fructose of a sucrose-growing culture.
SE|140||ab|2|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|888|230|236
SE|140||ab|2|entity|C0869032|Synthesis|phpr|||synthesis|||0|888|237|246
SE|140||ab|2|entity|C0442796|Additive|qlco|||addition|||0|928|273|281
SE|140||ab|2|entity|C0016745|Fructose|carb,phsu|||fructose|||0|1000|285|293
SE|140||ab|2|entity|C0038636|Sucrose|bacs,carb|||sucrose|||0|802|299|306
SE|140||ab|2|entity|C0220814|Cultural|ftcn|||culture|||0|802|315|322

SE|140||ab|3|text|324|520|In contrast, invertase activity was not affected by the addition of glucose to sucrose-growing cells and this enzyme could be induced in a glucose-metabolizing culture by the addition of sucrose.
SE|140||ab|3|entity|C0053409|Invertase|aapp,enzy|||invertase|||0|888|337|346
SE|140||ab|3|entity|C1518422|Not|ftcn|||not|||0|1000|360|363
SE|140||ab|3|entity|C0442796|Additive|qlco|||addition|||0|928|380|388
SE|140||ab|3|entity|C0017725|Glucose|bacs,carb,phsu|||glucose|||0|1000|392|399
SE|140||ab|3|entity|C0038636|Sucrose|bacs,carb|||sucrose|||0|802|403|410
SE|140||ab|3|entity|C0007634|Cells|cell|||cells|||0|802|419|424
SE|140||ab|3|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|434|440
SE|140||ab|3|entity|C0017725|Glucose|bacs,carb,phsu|||glucose|||0|802|463|470
SE|140||ab|3|entity|C0220814|Cultural|ftcn|||culture|||0|802|484|491
SE|140||ab|3|entity|C0442796|Additive|qlco|||addition|||0|928|499|507
SE|140||ab|3|entity|C0038636|Sucrose|bacs,carb|||sucrose|||0|1000|511|518
SE|140||ab|3|relation|2|1|C0053409|Invertase|aapp,gngm,enzy|aapp|||invertase|||0|888|337|346|VERB|INTERACTS_WITH|negation|364|372|7|2|C0017725|Glucose|bacs,carb,phsu|bacs|||glucose|||0|1000|392|399

SE|140||ab|4|text|520|625|This enzyme was purified 10.5-fold over the induced lese, EC 3.2.1.26) by substrate-specificity studies.
SE|140||ab|4|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|525|531
SE|140||ab|4|entity|C0332462|Fold|spco|||fold|||0|827|550|554
SE|140||ab|4|entity|C0205136|Over|spco|||over|||0|1000|555|559
SE|140||ab|4|entity|C0205263|Induced|ftcn|||induced|||0|694|564|571
SE|140||ab|4|entity|C0040676|Transferase|aapp,enzy|||EC 3.2|||0|853|578|584
SE|140||ab|4|entity|C0038592|Substrate Specificity|qnco|||substrate-specificity|||0|884|594|615
SE|140||ab|4|entity|C0008972|Clinical Research|resa|||studies|||0|884|616|623

SE|140||ab|5|text|625|779|Invertase had a pH optimum of 6.5 and an apparent Km of 79.5 mM for sucrose, and required high concentration of potassium phosphate for maximum activity.
SE|140||ab|5|entity|C0053409|Invertase|aapp,enzy|||Invertase|||0|1000|625|634
SE|140||ab|5|entity|C0442749|6/5|fndg|||6.5|||0|1000|655|658
SE|140||ab|5|entity|C0750489|APPARENT|idcn|||apparent|||0|888|666|674
SE|140||ab|5|entity|C0038636|Sucrose|bacs,carb|||sucrose|||0|1000|693|700
SE|140||ab|5|entity|C1514872|Required|ftcn|||required|||0|623|706|714
SE|140||ab|5|entity|C0205250|High|qlco|||high|||0|623|715|719
SE|140||ab|5|entity|C0071778|potassium phosphate|inch,phsu|||potassium phosphate|||0|1000|737|756
SE|140||ab|5|entity|C0806909|Maximum|fndg|||maximum|||0|888|761|768
SE|140||ab|5|relation|7|1|C0071778|potassium phosphate|inch,phsu|phsu|||potassium phosphate|||0|1000|737|756|PREP|TREATS||757|760|1|1|C0806909|Maximum|fndg|fndg|||maximum|||0|888|761|768

SE|140||ab|6|text|779|859|Invertase was completely inactivated by a 2-min heat treatment at 60 degrees C.
SE|140||ab|6|entity|C0053409|Invertase|aapp,enzy|||Invertase|||0|1000|779|788
SE|140||ab|6|entity|C0439232|Minute of time|tmco|||min|||0|861|823|826
SE|140||ab|6|entity|C0093056|2-(beta-(4-hydroxyphenyl)ethylaminomethyl)tetralone|orch,phsu|||2-min heat|||0|861|821|831
SE|140||ab|6|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|848|857

SE|140||ab|7|text|859|1125|This enzyme was strongly inhibited by p-hydroxymercuribenzoate (pCMB) and weakly inhibited by 5,5'-dithiobis(2-nitrobenzoic acid), while cysteine could substantially reverse pCMB) inhibition, suggesting that sulfhydryl group(s) were necessary for invertase activity.
SE|140||ab|7|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|864|870
SE|140||ab|7|entity|C0048363|4-hydroxymercuribenzoate|orch,phsu|||p-hydroxymercuribenzoate|||0|1000|897|921
SE|140||ab|7|entity|C0134649|p-Chloromercuribenzoic Acid|irda,orch|||pCMB|||0|1000|923|927
SE|140||ab|7|entity|C0260053|Nitrobenzoic acid|orch|||nitrobenzoic acid|||0|901|970|987
SE|140||ab|7|entity|C0010654|Cysteine|aapp,bacs|||cysteine|||0|1000|996|1004
SE|140||ab|7|entity|C0134649|p-Chloromercuribenzoic Acid|irda,orch|||pCMB|||0|1000|1033|1037
SE|140||ab|7|entity|C0038734|Sulfhydryl Compounds|orch|||sulfhydryl group|||0|1000|1067|1083
SE|140||ab|7|entity|C0053409|Invertase|aapp,enzy|||invertase|||0|888|1106|1115
SE|140||ab|7|relation|11|1|C0048363|4-hydroxymercuribenzoate|orch,phsu|orch|||p-hydroxymercuribenzoate|||0|1000|897|921|VERB|INHIBITS||884|893|1|1|C0014442|Enzymes|enzy,orch|enzy|||enzyme|||0|1000|864|870


SE|141||ti|1|text|16|124|Characterization studies on the membrane-bound adenosine triphosphatase (ATPase) of Azotobacter vinelandii.
SE|141||ti|1|entity|C0596901|Membrane|celc|||membrane|||0|812|48|56
SE|141||ti|1|entity|C0001473|ATP phosphohydrolase|aapp,enzy|||adenosine triphosphatase|||0|812|63|87
SE|141||ti|1|entity|C0001473|ATP phosphohydrolase|aapp,enzy|1769|DNAH8|ATPase|||0|1000|89|95
SE|141||ti|1|entity|C0085462|Azotobacter vinelandii|bact|||Azotobacter vinelandii|||0|1000|100|122

SE|141||ab|1|text|130|332|The adenosinetriphosphatase (ATPase) (EC 3.6.1.3) activity in Azotobacter vinelandii concentrates in the membranous R3 fraction that is directly associated with Azotobacter electron transport function.
SE|141||ab|1|entity|C0001473|ATP phosphohydrolase|aapp,enzy|||adenosinetriphosphatase|||0|1000|134|157
SE|141||ab|1|entity|C0001473|ATP phosphohydrolase|aapp,enzy|1769|DNAH8|ATPase|||0|1000|159|165
SE|141||ab|1|entity|C0085462|Azotobacter vinelandii|bact|||Azotobacter vinelandii|||0|1000|192|214
SE|141||ab|1|entity|C1166621|membrane fraction|celc|||membranous R3 fraction|||0|877|235|257
SE|141||ab|1|entity|C0004515|Azotobacter|bact|||Azotobacter|||0|861|291|302
SE|141||ab|1|entity|C0013846|Electron Transport|moft|||electron transport|||0|861|303|321
SE|141||ab|1|entity|C0031843|physiological aspects|phsf|||function|||0|861|322|330
SE|141||ab|1|relation|1|1|C0013846|Electron Transport|moft|moft|||electron transport|||0|861|303|321|VERB|AFFECTS||275|285|5|5|C0001473|ATP phosphohydrolase|aapp,gngm,enzy|gngm|||adenosinetriphosphatase|||0|1000|134|157
SE|141||ab|1|relation|3|1|C0085462|Azotobacter vinelandii|bact|bact|||Azotobacter vinelandii|||0|1000|192|214|PREP|LOCATION_OF||189|191|3|3|C0001473|ATP phosphohydrolase|aapp,gngm,enzy|aapp|||adenosinetriphosphatase|||0|1000|134|157

SE|141||ab|2|text|332|603|Sonically disrupted Azotobacter cells were examined for distribution of ATPase activity and the highest specific activity (and activity units) was consistently found in the particulate R3 membranous fraction which sediments on ultracentrifugation at 144 000 X g for 2 h.
SE|141||ab|2|entity|C0332454|Disrupted|qlco|||disrupted|||0|775|342|351
SE|141||ab|2|entity|C0004515|Azotobacter|bact|||Azotobacter|||0|775|352|363
SE|141||ab|2|entity|C0007634|Cells|cell|||cells|||0|775|364|369
SE|141||ab|2|entity|C0520511|Distributing|idcn|||distribution|||0|1000|388|400
SE|141||ab|2|entity|C1148926|adenosinetriphosphatase activity|moft|||ATPase activity|||0|1000|404|419
SE|141||ab|2|entity|C1522410|Highest|qlco|||highest|||0|802|428|435
SE|141||ab|2|entity|C0439148|Unit|qnco|||units|||0|888|468|473
SE|141||ab|2|entity|C0457784|Particulate|qlco|||particulate|||0|801|505|516
SE|141||ab|2|entity|C1166621|membrane fraction|celc|||membranous fraction|||0|801|520|539
SE|141||ab|2|entity|C0041609|Ultracentrifugation|lbpr|||ultracentrifugation|||0|1000|559|578
SE|141||ab|2|relation|0|0|C0007634|Cells|cell|cell|||cells|||0|775|364|369|MOD/HEAD|PART_OF||352|369|0|0|C0004515|Azotobacter|bact|bact|||Azotobacter|||0|775|352|363
SE|141||ab|2|relation|4|1|C1166621|membrane fraction|celc|celc|||membranous fraction|||0|801|520|539|VERB|LOCATION_OF||492|497|5|3|C1148926|adenosinetriphosphatase activity|moft|moft|||ATPase activity|||0|1000|404|419

SE|141||ab|3|text|603|760|When the sonication time interval was increased, the membrane-bound ATPase activity could neither be solubilized nor released into the supernatant fraction.
SE|141||ab|3|entity|C0037680|Sonication|resa,topp|||sonication|||0|901|612|622
SE|141||ab|3|entity|C0872291|time interval|tmco|||time interval|||0|901|623|636
SE|141||ab|3|entity|C0001473|ATP phosphohydrolase|aapp,enzy|1769|DNAH8|ATPase|||0|824|671|677
SE|141||ab|3|entity|C0596897|membrane activity|celf|||membrane-bound ATPase activity|||0|824|656|686
SE|141||ab|3|entity|C1550101|Supernatant|bdsu|||supernatant|||0|694|738|749

SE|141||ab|4|text|760|853|Optimal ATPase activty occurred at pH 8.0; Mg2+ ion when added to the assay was stimulatory.
SE|141||ab|4|entity|C0001473|ATP phosphohydrolase|aapp,enzy|1769|DNAH8|ATPase|||0|660|768|774
SE|141||ab|4|entity|||gngm|4589,57192|MUC7,MCOLN1|Mg2|||0|861|803|806
SE|141||ab|4|entity|C0022023|Ions|elii|||ion|||0|861|808|811
SE|141||ab|4|entity|C1510438|Assay|lbpr|||assay|||0|1000|830|835
SE|141||ab|4|entity|C0175727|Stimulator|medd|||stimulatory|||0|928|840|851

SE|141||ab|5|text|853|976|Maximal activity always occurred when the Mg2+:ATP stoichiometry was 1:1 on a molar ratio at the 5 mM concentration level.
SE|141||ab|5|entity|C0205289|Maximal|qlco|||Maximal|||0|888|853|860
SE|141||ab|5|entity|C1549493|Always|idcn|||always|||0|1000|870|876
SE|141||ab|5|entity|||gngm|4589,57192|MUC7,MCOLN1|Mg2|||0|1000|895|898
SE|141||ab|5|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|ATP|||0|888|900|903
SE|141||ab|5|entity|C0597526|Stoichiometry|qnco|||stoichiometry|||0|888|904|917
SE|141||ab|5|entity|C0456603|Ratio|inpr|||ratio|||0|861|937|942

SE|141||ab|6|text|976|1029|Sodium and potassium ions had no stimulatory effect.
SE|141||ab|6|entity|C0037473|Sodium|bacs,elii|||Sodium|||0|1000|976|982
SE|141||ab|6|entity|C0597277|Potassium Ions|bacs,elii|||potassium ions|||0|1000|987|1001
SE|141||ab|6|entity|C0175727|Stimulator|medd|||stimulatory|||0|853|1009|1020
SE|141||ab|6|entity|C1280500|Effect|qlco|||effect|||0|853|1021|1027

SE|141||ab|7|text|1029|1106|The reaction kinetics were linear for the time intervals studied (0-60 min).
SE|141||ab|7|entity|C0443286|Reaction|ftcn|||reaction|||0|888|1033|1041
SE|141||ab|7|entity|C0022702|Kinetics|idcn|||kinetics|||0|888|1042|1050
SE|141||ab|7|entity|C0205132|Linear|spco|||linear|||0|1000|1056|1062
SE|141||ab|7|entity|C0872291|time interval|tmco|||time intervals|||0|983|1071|1085
SE|141||ab|7|entity|C0439232|Minute of time|tmco|||min|||0|827|1100|1103

SE|141||ab|8|text|1106|1343|The membrane-bound ATPase in the R3 fraction was stimulated 12-fold by treatment wiTH TRypsin, and fractionation studies showed that trypsin treatment did not solubilize ATPase activity off the membranous R3 electron transport fraction.
SE|141||ab|8|entity|C0596901|Membrane|celc|||membrane|||0|802|1110|1118
SE|141||ab|8|entity|C0001473|ATP phosphohydrolase|aapp,enzy|1769|DNAH8|ATPase|||0|802|1125|1131
SE|141||ab|8|entity|C0332462|Fold|spco|||fold|||0|861|1169|1173
SE|141||ab|8|entity|C0041236|TRYPSIN|aapp,enzy,phsu|||TRypsin|||0|1000|1192|1199
SE|141||ab|8|entity|C0016640|Fractionation|lbpr|||fractionation|||0|872|1205|1218
SE|141||ab|8|entity|C0008972|Clinical Research|resa|||studies|||0|872|1219|1226
SE|141||ab|8|entity|C0041236|TRYPSIN|aapp,enzy,phsu|||trypsin|||0|888|1239|1246
SE|141||ab|8|entity|C1518422|Not|ftcn|||not|||0|1000|1261|1264
SE|141||ab|8|entity|C1148926|adenosinetriphosphatase activity|moft|||ATPase activity|||0|1000|1276|1291
SE|141||ab|8|entity|C0013846|Electron Transport|moft|||electron transport|||0|804|1314|1332
SE|141||ab|8|entity|C1166621|membrane fraction|celc|||membranous R3 electron transport fraction|||0|804|1300|1341

SE|141||ab|9|text|1343|1634|The ATPase was not cold labile and the temperature during the preparation of the R3 fraction had no effect on activity; overnight refrigeration at 4 degrees C, however, resulted in a 25% loss of activity as compared with a 14% loss when the R3 fraction was stored overnight at 25 degrees C.
SE|141||ab|9|entity|C0001473|ATP phosphohydrolase|aapp,enzy|1769|DNAH8|ATPase|||0|1000|1347|1353
SE|141||ab|9|entity|C1518422|Not|ftcn|||not|||0|660|1358|1361
SE|141||ab|9|entity|C0039476|Temperature|qnco|||temperature|||0|1000|1382|1393
SE|141||ab|9|entity|C1521827|Preparation|ftcn|||preparation|||0|1000|1405|1416
SE|141||ab|9|entity|C1280500|Effect|qlco|||effect|||0|1000|1443|1449
SE|141||ab|9|entity|C0439583|Overnight|tmco|||overnight|||0|888|1463|1472
SE|141||ab|9|entity|C0034957|Refrigeration|mcha|||refrigeration|||0|888|1473|1486
SE|141||ab|9|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|1492|1501
SE|141||ab|9|entity|C1517945|Loss|qnco|||loss|||0|861|1530|1534
SE|141||ab|9|entity|C1517945|Loss|qnco|||loss|||0|861|1570|1574
SE|141||ab|9|entity|C0439583|Overnight|tmco|||overnight|||0|1000|1607|1616
SE|141||ab|9|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|1623|1632

SE|141||ab|10|text|1634|1805|A marked inactivation (although variable, usually about 60%) did occur by overnight freezing (-20 degrees C), and subsequent sonication failed to restore ATPase activity.
SE|141||ab|10|entity|C0522501|Massive|qlco|||marked|||0|888|1636|1642
SE|141||ab|10|entity|C0544461|Inactivation|comd|||inactivation|||0|888|1643|1655
SE|141||ab|10|entity|C0439828|Variable|qlco|||variable|||0|1000|1666|1674
SE|141||ab|10|entity|C0439583|Overnight|tmco|||overnight|||0|888|1708|1717
SE|141||ab|10|entity|C0016701|Freezing|npop|||freezing|||0|888|1718|1726
SE|141||ab|10|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|1732|1741
SE|141||ab|10|entity|C0750530|SUBSEQUENT|idcn|||subsequent|||0|888|1748|1758
SE|141||ab|10|entity|C0037680|Sonication|resa,topp|||sonication|||0|888|1759|1769
SE|141||ab|10|entity|C1148926|adenosinetriphosphatase activity|moft|||ATPase activity|||0|1000|1788|1803

SE|141||ab|11|text|1805|1907|This indicates that membrane reaggregation (by freezing) was not responsible for ATPase inactivation.
SE|141||ab|11|entity|C0596901|Membrane|celc|||membrane|||0|694|1825|1833
SE|141||ab|11|entity|C0016701|Freezing|npop|||freezing|||0|1000|1852|1860
SE|141||ab|11|entity|C1518422|Not|ftcn|||not|||0|694|1866|1869
SE|141||ab|11|entity|C0001473|ATP phosphohydrolase|aapp,enzy|1769|DNAH8|ATPase|||0|888|1886|1892
SE|141||ab|11|entity|C0544461|Inactivation|comd|||inactivation|||0|888|1893|1905

SE|141||ab|12|text|1907|2063|The addition of azide, ouabain, 2,4-dinitrophenol, or oligomycin to the assay system resulted in neither inhibition nor stimulation of the ATPase activity.
SE|141||ab|12|entity|C0442796|Additive|qlco|||addition|||0|928|1911|1919
SE|141||ab|12|entity|C0004492|Azides|chvs|||azide|||0|1000|1923|1928
SE|141||ab|12|entity|C0029904|Ouabain|carb,phsu,strd|||ouabain|||0|1000|1930|1937
SE|141||ab|12|entity|C0012466|Dinitrophenols|orch|||dinitrophenol|||0|861|1943|1956
SE|141||ab|12|entity|C0028951|Oligomycins|antb,orch|||oligomycin|||0|1000|1961|1971
SE|141||ab|12|entity|C1510438|Assay|lbpr|||assay|||0|888|1979|1984
SE|141||ab|12|entity|C0449913|System|ftcn|||system|||0|888|1985|1991
SE|141||ab|12|entity|C1148926|adenosinetriphosphatase activity|moft|||ATPase activity|||0|1000|2046|2061
SE|141||ab|12|relation|7|5|C0029904|Ouabain|carb,phsu,strd|carb|||ouabain|||0|1000|1930|1937|NOM|AUGMENTS|negation|2027|2038|1|1|C1148926|adenosinetriphosphatase activity|moft|moft|||ATPase activity|||0|1000|2046|2061

SE|141||ab|13|text|2063|2281|The property of trypsin activation and that ATPase activity is highest in the R3 electron transport fraction suggests that its probable functional role is in coupling of electron transport to oxidative phosphorylation.
SE|141||ab|13|entity|C0871161|Property|qlco|||property|||0|1000|2067|2075
SE|141||ab|13|entity|C0041236|TRYPSIN|aapp,enzy,phsu|||trypsin|||0|694|2079|2086
SE|141||ab|13|entity|C1148926|adenosinetriphosphatase activity|moft|||ATPase activity|||0|1000|2107|2122
SE|141||ab|13|entity|C1522410|Highest|qlco|||highest|||0|1000|2126|2133
SE|141||ab|13|entity|C0013846|Electron Transport|moft|||electron transport|||0|694|2144|2162
SE|141||ab|13|entity|C0205245|Functional|ftcn|||functional|||0|790|2199|2209
SE|141||ab|13|entity|C0035820|Role|socb|||role|||0|790|2210|2214
SE|141||ab|13|entity|C0013846|Electron Transport|moft|||electron transport|||0|1000|2233|2251
SE|141||ab|13|entity|C0030013|Oxidative Phosphorylation|moft|||oxidative phosphorylation|||0|1000|2255|2280


SE|142||ti|1|text|16|77|Effects of zinc-smelter emissions on forest soil microflora.
SE|142||ti|1|entity|C1280500|Effect|qlco|||Effects|||0|966|16|23
SE|142||ti|1|entity|C0043481|Zinc|bacs,elii,phsu|||zinc|||0|785|27|31
SE|142||ti|1|entity|C0233929|Emission|orgf|||emissions|||0|785|40|49
SE|142||ti|1|entity|C0086312|Forests|geoa|||forest|||0|623|53|59
SE|142||ti|1|entity|C0037592|Soil|sbst|||soil|||0|623|60|64

SE|142||ab|1|text|83|282|Within 2 km of a zinc (Zn) smelter in Palmerton, Pennsylvania, near the Lehigh Water Gap, up to 13.5% Zn by weight has been measured in the O2 horizon of the soil, and up to 8% Zn in the A1 horizon.
SE|142||ab|1|entity|C0043481|Zinc|bacs,elii,phsu|||zinc|||0|694|100|104
SE|142||ab|1|entity|C0030853|Pennsylvania|geoa|||Pennsylvania|||0|1000|132|144
SE|142||ab|1|entity|C0020311|Hydrotherapy|topp|||Water|||0|790|162|167
SE|142||ab|1|entity|C0061928|GTPase-Activating Proteins|aapp,bacs|||Gap|||0|790|168|171
SE|142||ab|1|entity|C0043481|Zinc|bacs,elii,phsu|||Zn|||0|827|185|187
SE|142||ab|1|entity|C0043100|Weight|qnco|||weight|||0|1000|191|197
SE|142||ab|1|entity|C0037592|Soil|sbst|||soil|||0|1000|241|245
SE|142||ab|1|entity|C0043481|Zinc|bacs,elii,phsu|||Zn|||0|861|260|262

SE|142||ab|2|text|282|467|The total numbers of bacteria, actinomycetes, and fungi (measured by dilution plate counts) were greatly reduced in the most severely Zn-contaminated soils compared with control soils.
SE|142||ab|2|entity|C0439175|% of total|qnco|||total|||0|888|286|291
SE|142||ab|2|entity|C0237753|Numbers|qnco|||numbers|||0|888|292|299
SE|142||ab|2|entity|C0004611|Bacteria|bact|||bacteria|||0|1000|303|311
SE|142||ab|2|entity|C0600148|Actinobacteria class|bact|||actinomycetes|||0|1000|313|326
SE|142||ab|2|entity|C0016832|fungus|fngs|||fungi|||0|1000|332|337
SE|142||ab|2|entity|C0441666|Dilution|lbpr|||dilution|||0|851|351|359
SE|142||ab|2|entity|C0005971|Bone plates|medd|||plate|||0|851|360|365
SE|142||ab|2|entity|C0439157|counts|qnco|||counts|||0|851|366|372
SE|142||ab|2|entity|C0205393|Most|qnco|||most|||0|833|402|406
SE|142||ab|2|entity|C0205082|Severe|qlco|||severely|||0|833|407|415
SE|142||ab|2|entity|C0043481|Zinc|bacs,elii,phsu|||Zn|||0|833|416|418
SE|142||ab|2|entity|C0522737|Soil pollution|eehu|||contaminated soils|||0|833|419|437
SE|142||ab|2|entity|C0243148|control|ftcn|||control|||0|888|452|459
SE|142||ab|2|entity|C0037592|Soil|sbst|||soils|||0|888|460|465

SE|142||ab|3|text|467|590|The reduction of microbial populations may be a partial cause of the decreased rate of litter decomposition at Lehigh Gap.
SE|142||ab|3|entity|C0599840|microbial|orgm|||microbial|||0|888|484|493
SE|142||ab|3|entity|C0032659|geographic population|qnco|||populations|||0|888|494|505
SE|142||ab|3|entity|C0728938|Partial|qnco|||partial|||0|872|515|522
SE|142||ab|3|entity|C0015127|Etiology aspects|ftcn|||cause|||0|872|523|528
SE|142||ab|3|entity|C0205216|Decreased|qnco|||decreased|||0|888|536|545
SE|142||ab|3|entity|C1521828|Rate|qnco|||rate|||0|888|546|550
SE|142||ab|3|entity|C1299950|Litter|mnob|||litter|||0|694|554|560
SE|142||ab|3|entity|C0061928|GTPase-Activating Proteins|aapp,bacs|||Gap|||0|861|585|588

SE|142||ab|4|text|590|774|Growth of most bacteria from control sites was reduced by 100 to 200 muM Zn, most actinomycetes by 100 muM Zn, and most fungi by 100 to 1000 muM Zn in thin-Pablum extract agar (TPab).
SE|142||ab|4|entity|C0018270|Growth|orgf|||Growth|||0|1000|590|596
SE|142||ab|4|entity|C0004611|Bacteria|bact|||bacteria|||0|1000|605|613
SE|142||ab|4|entity|C0243148|control|ftcn|||control|||0|888|619|626
SE|142||ab|4|entity|C0205145|Site|spco|||sites|||0|888|627|632
SE|142||ab|4|entity|C1009574|Chrysanthemum x morifolium|plnt|||muM|||0|790|659|662
SE|142||ab|4|entity|C0043481|Zinc|bacs,elii,phsu|||Zn|||0|790|663|665
SE|142||ab|4|entity|C0205393|Most|qnco|||most|||0|888|667|671
SE|142||ab|4|entity|C0600148|Actinobacteria class|bact|||actinomycetes|||0|888|672|685
SE|142||ab|4|entity|C1009574|Chrysanthemum x morifolium|plnt|||muM|||0|790|693|696
SE|142||ab|4|entity|C0043481|Zinc|bacs,elii,phsu|||Zn|||0|790|697|699
SE|142||ab|4|entity|C0016832|fungus|fngs|||fungi|||0|1000|710|715
SE|142||ab|4|entity|C1009574|Chrysanthemum x morifolium|plnt|||muM|||0|790|731|734
SE|142||ab|4|entity|C0043481|Zinc|bacs,elii,phsu|||Zn|||0|790|735|737
SE|142||ab|4|entity|C0205168|Thin|qlco|||thin|||0|775|741|745
SE|142||ab|4|entity|C1555707|extract|idcn|||extract|||0|775|753|760
SE|142||ab|4|entity|C0001771|Agar|carb,irda,phsu|||agar|||0|775|761|765
SE|142||ab|4|relation|0|0|C1009574|Chrysanthemum x morifolium|plnt|plnt|||muM|||0|790|659|662|MOD/HEAD|LOCATION_OF||659|665|0|0|C0043481|Zinc|bacs,elii,phsu|elii|||Zn|||0|790|663|665
SE|142||ab|4|relation|0|0|C1009574|Chrysanthemum x morifolium|plnt|plnt|||muM|||0|790|693|696|MOD/HEAD|LOCATION_OF||693|699|0|0|C0043481|Zinc|bacs,elii,phsu|elii|||Zn|||0|790|697|699
SE|142||ab|4|relation|0|0|C1009574|Chrysanthemum x morifolium|plnt|plnt|||muM|||0|790|731|734|MOD/HEAD|LOCATION_OF||731|737|0|0|C0043481|Zinc|bacs,elii,phsu|elii|||Zn|||0|790|735|737
SE|142||ab|4|relation|8|1|C0043481|Zinc|bacs,elii,phsu|bacs|||Zn|||0|790|735|737|PREP|COEXISTS_WITH||738|740|2|1|C0001771|Agar|carb,irda,phsu|carb|||agar|||0|775|761|765

SE|142||ab|5|text|774|953|All the tested actinomycetes and non-spore-forming bacteria isolated from Zn-contaminated Lehigh Gap soils were Zn-tolerant, growing normally in media containing 600-2000 muM Zn.
SE|142||ab|5|entity|C0039593|Testing|resa|||tested|||0|872|782|788
SE|142||ab|5|entity|C0600148|Actinobacteria class|bact|||actinomycetes|||0|872|789|802
SE|142||ab|5|entity|C0205431|Formed|ftcn|||forming|||0|775|817|824
SE|142||ab|5|entity|C0004611|Bacteria|bact|||bacteria|||0|775|825|833
SE|142||ab|5|entity|C0043481|Zinc|bacs,elii,phsu|||Zn|||0|777|848|850
SE|142||ab|5|entity|C0061928|GTPase-Activating Proteins|aapp,bacs|||Gap|||0|777|871|874
SE|142||ab|5|entity|C0522737|Soil pollution|eehu|||contaminated Lehigh Gap soils|||0|777|851|880
SE|142||ab|5|entity|C0043481|Zinc|bacs,elii,phsu|||Zn|||0|888|886|888
SE|142||ab|5|entity|C0231198|Tolerant|ftcn|||tolerant|||0|888|889|897
SE|142||ab|5|entity|C1009574|Chrysanthemum x morifolium|plnt|||muM|||0|750|945|948
SE|142||ab|5|entity|C0043481|Zinc|bacs,elii,phsu|||Zn|||0|750|949|951
SE|142||ab|5|relation|0|0|C1009574|Chrysanthemum x morifolium|plnt|plnt|||muM|||0|750|945|948|MOD/HEAD|LOCATION_OF||945|951|0|0|C0043481|Zinc|bacs,elii,phsu|elii|||Zn|||0|750|949|951
SE|142||ab|5|relation|1|1|C0043481|Zinc|bacs,elii,phsu|bacs|||Zn|||0|750|949|951|VERB|PART_OF||925|935|5|4|C0004611|Bacteria|bact|bact|||bacteria|||0|775|825|833
SE|142||ab|5|relation|1|1|C0043481|Zinc|bacs,elii,phsu|bacs|||Zn|||0|750|949|951|VERB|PART_OF||925|935|5|4|C0600148|Actinobacteria class|bact|bact|||actinomycetes|||0|872|789|802

SE|142||ab|6|text|953|1048|Most fungi, regardless of source, were capable of at least 50% of normal growth at 700 muM Zn.
SE|142||ab|6|entity|C0016832|fungus|fngs|||fungi|||0|1000|958|963
SE|142||ab|6|entity|C0578019|Normal growth|orgf|||normal growth|||0|1000|1019|1032
SE|142||ab|6|entity|C1009574|Chrysanthemum x morifolium|plnt|||muM|||0|790|1040|1043
SE|142||ab|6|entity|C0043481|Zinc|bacs,elii,phsu|||Zn|||0|790|1044|1046
SE|142||ab|6|relation|0|0|C1009574|Chrysanthemum x morifolium|plnt|plnt|||muM|||0|790|1040|1043|MOD/HEAD|LOCATION_OF||1040|1046|0|0|C0043481|Zinc|bacs,elii,phsu|elii|||Zn|||0|790|1044|1046

SE|142||ab|7|text|1048|1202|Zinc-tolerant bacteria, actinomycetes, and fungi were readily isolated from low-Zn soils, suggesting that selection for Zn tolerance may proceed rapidly.
SE|142||ab|7|entity|C0043481|Zinc|bacs,elii,phsu|||Zinc|||0|851|1048|1052
SE|142||ab|7|entity|C0231198|Tolerant|ftcn|||tolerant|||0|851|1053|1061
SE|142||ab|7|entity|C0004611|Bacteria|bact|||bacteria|||0|851|1062|1070
SE|142||ab|7|entity|C0600148|Actinobacteria class|bact|||actinomycetes|||0|1000|1072|1085
SE|142||ab|7|entity|C0016832|fungus|fngs|||fungi|||0|1000|1091|1096
SE|142||ab|7|entity|C0205251|low|qlco|||low|||0|851|1124|1127
SE|142||ab|7|entity|C0043481|Zinc|bacs,elii,phsu|||Zn|||0|851|1128|1130
SE|142||ab|7|entity|C0037592|Soil|sbst|||soils|||0|851|1131|1136
SE|142||ab|7|entity|C0043481|Zinc|bacs,elii,phsu|||Zn|||0|694|1168|1170

SE|142||ab|8|text|1202|1325|Acidophilic Mortierella species have been selectively eliminated near the smelter, apparently because of elevated soil pH.
SE|142||ab|8|entity|C0333931|Acidophilic|ftcn|||Acidophilic|||0|851|1202|1213
SE|142||ab|8|entity|C0319524|Mortierella|fngs|||Mortierella|||0|851|1214|1225
SE|142||ab|8|entity|C1548151|Species|idcn|||species|||0|851|1226|1233
SE|142||ab|8|entity|C0750541|APPARENTLY|idcn|||apparently|||0|1000|1285|1295
SE|142||ab|8|entity|C0037592|Soil|sbst|||soil|||0|901|1316|1320
SE|142||ab|8|entity|C0221106|Alkalemia|dsyn|||elevated soil pH|||0|901|1307|1323

SE|142||ab|9|text|1325|1426|Peryronellaea glomerata (Corda) Goidanich and Coniothyrium spp. were found only in the high-Zn soils.
SE|142||ab|9|entity|C1033082|Coniothyrium|fngs|||Coniothyrium|||0|888|1371|1383
SE|142||ab|9|entity|C1150110|signal peptide peptidase activity|moft|||spp|||0|888|1384|1387
SE|142||ab|9|entity|C0205250|High|qlco|||high|||0|851|1412|1416
SE|142||ab|9|entity|C0043481|Zinc|bacs,elii,phsu|||Zn|||0|851|1417|1419
SE|142||ab|9|entity|C0037592|Soil|sbst|||soils|||0|851|1420|1425


SE|143||ti|1|text|16|97|alpha-Naphthoflavone activation of 6-hydroxymethylbenzo(alpha)pyrene synthetase.
SE|143||ti|1|entity|C0051441|alpha-naphthoflavone|orch|||alpha-Naphthoflavone|||0|734|16|36
SE|143||ti|1|entity|C0439095|Alpha|inpr|||alpha|||0|1000|72|77
SE|143||ti|1|entity|C0034243|Pyrenes|hops,orch|||pyrene|||0|888|78|84
SE|143||ti|1|entity|C0023689|Ligase|aapp,enzy|||synthetase|||0|888|85|95

SE|143||ab|1|text|103|253|alpha-Naphthoflavone activates the aryl hydroxymethyl synthetase of both the microsomal membrane-bound and soluble enzymes of rat liver and rat lung.
SE|143||ab|1|entity|C0051441|alpha-naphthoflavone|orch|||alpha-Naphthoflavone|||0|1000|103|123
SE|143||ab|1|entity|C0023689|Ligase|aapp,enzy|||synthetase|||0|827|157|167
SE|143||ab|1|entity|C0026029|Microsomes|celc|||microsomal|||0|754|180|190
SE|143||ab|1|entity|C0596901|Membrane|celc|||membrane|||0|754|191|199
SE|143||ab|1|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|861|218|225
SE|143||ab|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|888|229|232
SE|143||ab|1|entity|C0023884|Liver|bpoc|||liver|||0|888|233|238
SE|143||ab|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|888|243|246
SE|143||ab|1|entity|C0024109|Lung|bpoc|||lung|||0|888|247|251
SE|143||ab|1|relation|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|888|233|238|MOD/HEAD|PART_OF||229|238|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|888|229|232
SE|143||ab|1|relation|0|0|C0024109|Lung|bpoc|bpoc|||lung|||0|888|247|251|MOD/HEAD|PART_OF||243|251|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|888|243|246
SE|143||ab|1|relation|1|1|C0051441|alpha-naphthoflavone|orch|orch|||alpha-Naphthoflavone|||0|1000|103|123|VERB|STIMULATES||124|133|5|1|C0023689|Ligase|aapp,gngm,enzy|gngm|||synthetase|||0|827|157|167

SE|143||ab|2|text|253|353|The enzyme catalyzes the hydroxymethylation of benzo(alpha)pyrene to the 6-hydroxymethyl derivative.
SE|143||ab|2|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|257|263
SE|143||ab|2|entity|C0439095|Alpha|inpr|||alpha|||0|1000|306|311
SE|143||ab|2|entity|C0034243|Pyrenes|hops,orch|||pyrene|||0|1000|312|318
SE|143||ab|2|entity|C1527240|Derivative|ftcn|||derivative|||0|827|342|352


[143]: *** ERROR *** ERROR *** ERROR ***
[144]: *** ERROR *** ERROR *** ERROR ***
[145]: *** ERROR *** ERROR *** ERROR ***
[146]: *** ERROR *** ERROR *** ERROR ***
SE|148||ti|1|text|16|191|The effects of the continuous administration of N,N-dimethyl-4-phenylazoaniline (DAB) on the activities and the inducibilities of some drug-metabolizing enzymes in rat liver.
SE|148||ti|1|entity|C1280500|Effect|qlco|||effects|||0|966|20|27
SE|148||ti|1|entity|C0549178|Continuous|tmco|||continuous|||0|888|35|45
SE|148||ti|1|entity|C0441655|Activities|acty|||activities|||0|1000|109|119
SE|148||ti|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug|||0|802|151|155
SE|148||ti|1|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|802|169|176
SE|148||ti|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|888|180|183
SE|148||ti|1|entity|C0023884|Liver|bpoc|||liver|||0|888|184|189
SE|148||ti|1|relation|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|888|184|189|MOD/HEAD|PART_OF||180|189|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|888|180|183
SE|148||ti|1|relation|8|7|C0014442|Enzymes|enzy,orch|enzy|||enzymes|||0|802|169|176|NOM|AFFECTS||20|27|8|8|C0023884|Liver|bpoc|bpoc|||liver|||0|888|184|189

SE|148||ab|1|text|197|518|(1) The effect of feeding a relatively low-protein diet containing 0.06% DAB for 29 weeks on the activity of DAB-azoreductase, nitroreductase (p-nitrobenzoic acid), N-oxidase (N,N-dimethylaniline), N-demethylase (DAB), cytochrome P-450, NADPH-cytochrome c reductase, beta-glucuronidase and arylsulphatase A were studied.
SE|148||ab|1|entity|C1280500|Effect|qlco|||effect|||0|1000|205|211
SE|148||ab|1|entity|C0242972|Diet, Protein-Restricted|topp|||low-protein diet|||0|923|236|252
SE|148||ab|1|entity|C0439230|week|tmco|||weeks|||0|861|281|286
SE|148||ab|1|entity|C0052803|azobenzene reductase|aapp,enzy|||DAB-azoreductase|||0|1000|306|322
SE|148||ab|1|entity|C0028195|Nitroreductases|aapp,enzy|||nitroreductase|||0|966|324|338
SE|148||ab|1|entity|C0048561|4-nitrobenzoic acid|orch|||p-nitrobenzoic acid|||0|1000|340|359
SE|148||ab|1|entity|C0242417|Oxidase|aapp,enzy|||oxidase|||0|888|364|371
SE|148||ab|1|entity|C0175817|Dimethylaniline|orch|||dimethylaniline|||0|888|377|392
SE|148||ab|1|entity|C0030017|Oxidoreductases, N-Demethylating|aapp,enzy|||N-demethylase|||0|983|395|408
SE|148||ab|1|entity|C0010762|Cytochrome P450|aapp,enzy|||cytochrome P-450|||0|1000|416|432
SE|148||ab|1|entity|C0027310|NADPH-Ferrihemoprotein Reductase|aapp,enzy|||NADPH-cytochrome c reductase|||0|1000|434|462
SE|148||ab|1|entity|C0017776|Beta-glucuronidase|aapp,enzy,irda|||beta-glucuronidase|||0|1000|464|482
SE|148||ab|1|entity|C0003940|Arylsulfatases|aapp,enzy|||arylsulphatase|||0|1000|487|501

SE|148||ab|2|text|518|637|Rapid decreases occurred in the activities of the first six enzymes, reaching minimal values at between 4 and 8 weeks.
SE|148||ab|2|entity|C0439831|Rapid|qlco|||Rapid|||0|872|518|523
SE|148||ab|2|entity|C0547047|Decrease|qnco|||decreases|||0|872|524|533
SE|148||ab|2|entity|C0441655|Activities|acty|||activities|||0|1000|550|560
SE|148||ab|2|entity|C1279901|Firstly|qlco|||first|||0|851|568|573
SE|148||ab|2|entity|C0205452|Six|qnco|||six|||0|851|574|577
SE|148||ab|2|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|851|578|585
SE|148||ab|2|entity|C0547040|Minimal|qlco|||minimal|||0|888|596|603
SE|148||ab|2|entity|C0042295|Values|qlco|||values|||0|888|604|610
SE|148||ab|2|entity|C0439230|week|tmco|||weeks|||0|861|630|635

SE|148||ab|3|text|637|713|Activities then increased in all cases to control or nearly control levels.
SE|148||ab|3|entity|C0441655|Activities|acty|||Activities|||0|1000|637|647
SE|148||ab|3|entity|C0868928|Case (situation)|ftcn|||cases|||0|1000|670|675
SE|148||ab|3|entity|C0441889|Levels|inpr|||levels|||0|1000|705|711

SE|148||ab|4|text|713|767|This rate of increase was least for cytochrome P-450.
SE|148||ab|4|entity|C1521828|Rate|qnco|||rate|||0|1000|718|722
SE|148||ab|4|entity|C0442805|Increase|ftcn|||increase|||0|1000|726|734
SE|148||ab|4|entity|C0010762|Cytochrome P450|aapp,enzy|||cytochrome P-450|||0|1000|749|765

SE|148||ab|5|text|767|905|At 4 weeks azoreductase activity with the chemotherapeutic agent CB10-252 (I) as substrate was significantly higher than in control rats.
SE|148||ab|5|entity|C1442465|4 Weeks|tmco|||4 weeks|||0|861|770|777
SE|148||ab|5|entity|C0052819|azoreductase|aapp,enzy|||azoreductase|||0|861|778|790
SE|148||ab|5|entity|C0003392|Antineoplastic Agents|phsu|||chemotherapeutic agent|||0|861|809|831
SE|148||ab|5|entity|C0205250|High|qlco|||higher|||0|827|876|882
SE|148||ab|5|entity|C0243148|control|ftcn|||control|||0|888|891|898
SE|148||ab|5|entity|C0034693|Rattus norvegicus|mamm|||rats|||0|888|899|903
SE|148||ab|5|relation|1|1|C0034693|Rattus norvegicus|mamm|mamm|||rats|||0|888|899|903|PREP|LOCATION_OF||888|890|3|3|C0052819|azoreductase|aapp,gngm,enzy|aapp|||azoreductase|||0|861|778|790

SE|148||ab|6|text|905|1061|Early increases occurred in the activities of beta-glucuronidase and arylsulphatase A and the activity of the latter never dropped below the control level.
SE|148||ab|6|entity|C1279919|Early|tmco|||Early|||0|872|905|910
SE|148||ab|6|entity|C0442805|Increase|ftcn|||increases|||0|872|911|920
SE|148||ab|6|entity|C0441655|Activities|acty|||activities|||0|1000|937|947
SE|148||ab|6|entity|C0017776|Beta-glucuronidase|aapp,enzy,irda|||beta-glucuronidase|||0|1000|951|969
SE|148||ab|6|entity|C0003940|Arylsulfatases|aapp,enzy|||arylsulphatase|||0|1000|974|988
SE|148||ab|6|entity|C1549495|Never|idcn|||never|||0|1000|1022|1027
SE|148||ab|6|entity|C0542339|Inferior|spco|||below|||0|1000|1036|1041
SE|148||ab|6|entity|C0243148|control|ftcn|||control|||0|694|1046|1053

SE|148||ab|7|text|1061|1224|(2) An investigation was made of the differential effects of dye feeding on some of the enzyme activities in the two major liver lobes and differences were found.
SE|148||ab|7|entity|C1280500|Effect|qlco|||effects|||0|827|1111|1118
SE|148||ab|7|entity|C0013343|Dyes|irda|||dye|||0|694|1122|1125
SE|148||ab|7|entity|C0243102|enzyme activity|moft|||enzyme activities|||0|983|1149|1166
SE|148||ab|7|entity|C0205448|Two|qnco|||two|||0|825|1174|1177
SE|148||ab|7|entity|C0205164|Major|qlco|||major|||0|825|1178|1183
SE|148||ab|7|entity|C0023884|Liver|bpoc|||liver|||0|825|1184|1189
SE|148||ab|7|entity|C0796494|Lobe|bpoc|||lobes|||0|825|1190|1195
SE|148||ab|7|entity|C1547020|*Difference|qnco|||differences|||0|966|1200|1211
SE|148||ab|7|relation|0|0|C0796494|Lobe|bpoc|bpoc|||lobes|||0|825|1190|1195|MOD/HEAD|PART_OF||1184|1195|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|825|1184|1189

SE|148||ab|8|text|1224|1327|(3) The effect of phenobarbital (PB) pretreatment on the DAB-fed rats was studied at 4-week intervals.
SE|148||ab|8|entity|C1280500|Effect|qlco|||effect|||0|1000|1232|1238
SE|148||ab|8|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital|||0|888|1242|1255
SE|148||ab|8|entity|C0204695|Feeding patient|hlca|||fed|||0|773|1285|1288
SE|148||ab|8|entity|C0034693|Rattus norvegicus|mamm|||rats|||0|773|1289|1293
SE|148||ab|8|entity|C1442465|4 Weeks|tmco|||4-week|||0|879|1309|1315
SE|148||ab|8|entity|C1272706|Interval|tmco|||intervals|||0|879|1316|1325

SE|148||ab|9|text|1327|1485|The activities of DAB-azoreductase and of nitroreductase increased throughout the whole period, while the activities of the lysosomal enzymes were decreased.
SE|148||ab|9|entity|C0441655|Activities|acty|||activities|||0|1000|1331|1341
SE|148||ab|9|entity|C0052803|azobenzene reductase|aapp,enzy|||DAB-azoreductase|||0|1000|1345|1361
SE|148||ab|9|entity|C0028195|Nitroreductases|aapp,enzy|||nitroreductase|||0|966|1369|1383
SE|148||ab|9|entity|C0444667|Whole|qnco|||whole|||0|888|1409|1414
SE|148||ab|9|entity|C0439531|/period|tmco|||period|||0|888|1415|1421
SE|148||ab|9|entity|C0441655|Activities|acty|||activities|||0|1000|1433|1443
SE|148||ab|9|entity|C0391845|Lysosomal enzyme|aapp,enzy|||lysosomal enzymes|||0|1000|1451|1468

SE|148||ab|10|text|1485|1807|(4) After feeding DAB for 4 weeks the effect of PB and 3-methylcholanthrene (MC) on the activities of DAB-azoreductase, CB10-252-azoreductase and components of the azoreductases-cytochrome P-450, NADPH-cytochrome c reductase, the CO-CB10-252-azoreductase was not induced by PB or MC, and CO did not inhibit its reduction.
SE|148||ab|10|entity|C1442465|4 Weeks|tmco|||4 weeks|||0|1000|1511|1518
SE|148||ab|10|entity|C1280500|Effect|qlco|||effect|||0|1000|1523|1529
SE|148||ab|10|entity|C0031412|Phenobarbital|orch,phsu|||PB|||0|1000|1533|1535
SE|148||ab|10|entity|C0000431|3MC|hops,orch|||3-methylcholanthrene|||0|1000|1540|1560
SE|148||ab|10|entity|C0441655|Activities|acty|||activities|||0|1000|1573|1583
SE|148||ab|10|entity|C0052803|azobenzene reductase|aapp,enzy|||DAB-azoreductase|||0|1000|1587|1603
SE|148||ab|10|entity|C0052819|azoreductase|aapp,enzy|||azoreductase|||0|827|1614|1626
SE|148||ab|10|entity|C1524073|Component, LOINC Axis 1|clas|||components|||0|966|1631|1641
SE|148||ab|10|entity|C0010762|Cytochrome P450|aapp,enzy|||cytochrome P-450|||0|923|1663|1679
SE|148||ab|10|entity|C0027310|NADPH-Ferrihemoprotein Reductase|aapp,enzy|||NADPH-cytochrome c reductase|||0|1000|1681|1709
SE|148||ab|10|entity|C0052819|azoreductase|aapp,enzy|||azoreductase|||0|812|1727|1739
SE|148||ab|10|entity|C1518422|Not|ftcn|||not|||0|1000|1744|1747
SE|148||ab|10|entity|C0031412|Phenobarbital|orch,phsu|||PB|||0|1000|1759|1761
SE|148||ab|10|entity|C0025732|Methylcholanthrene|hops,orch|||MC|||0|1000|1765|1767
SE|148||ab|10|entity|C1518422|Not|ftcn|||not|||0|1000|1780|1783
SE|148||ab|10|relation|0|0|C0027310|NADPH-Ferrihemoprotein Reductase|aapp,gngm,enzy|aapp|||NADPH-cytochrome c reductase|||0|1000|1681|1709|SPEC|ISA||1663|1709|0|0|C0010762|Cytochrome P450|aapp,gngm,enzy|aapp|||cytochrome P-450|||0|923|1663|1679
SE|148||ab|10|relation|13|10|C0031412|Phenobarbital|orch,phsu|orch|||PB|||0|1000|1759|1761|NOM|INTERACTS_WITH||1523|1529|13|2|C0000431|3MC|hops,orch|orch|||3-methylcholanthrene|||0|1000|1540|1560
SE|148||ab|10|relation|13|11|C0025732|Methylcholanthrene|hops,orch|hops|||MC|||0|1000|1765|1767|NOM|INTERACTS_WITH||1523|1529|13|1|C0000431|3MC|hops,orch|orch|||3-methylcholanthrene|||0|1000|1540|1560
SE|148||ab|10|relation|13|11|C0025732|Methylcholanthrene|hops,orch|hops|||MC|||0|1000|1765|1767|NOM|INTERACTS_WITH||1523|1529|13|1|C0031412|Phenobarbital|orch,phsu|orch|||PB|||0|1000|1533|1535

SE|148||ab|11|text|1807|1853|Its reduction depended only slightly on NADH.
SE|148||ab|11|entity|C0750482|SLIGHTLY|idcn|||slightly|||0|861|1835|1843
SE|148||ab|11|entity|C0027289|NADH|bacs,nnon,phsu|||NADH|||0|1000|1847|1851

SE|148||ab|12|text|1853|2064|CO caused a greater relative decrease in the activity of DAB-azoreductase in dye-fed animals and also in animals following PB and MC pretreatment, implying a greater role of  cytochrome P-450 in dye-fed animals.
SE|148||ab|12|entity|C0443228|Largest|qnco|||greater|||0|851|1865|1872
SE|148||ab|12|entity|C0205345|Relative|qlco|||relative|||0|851|1873|1881
SE|148||ab|12|entity|C0547047|Decrease|qnco|||decrease|||0|851|1882|1890
SE|148||ab|12|entity|C0052803|azobenzene reductase|aapp,enzy|||DAB-azoreductase|||0|1000|1910|1926
SE|148||ab|12|entity|C0013343|Dyes|irda|||dye|||0|840|1930|1933
SE|148||ab|12|entity|C0204695|Feeding patient|hlca|||fed|||0|840|1934|1937
SE|148||ab|12|entity|C0003062|Animals|anim|||animals|||0|840|1938|1945
SE|148||ab|12|entity|C0003062|Animals|anim|||animals|||0|1000|1958|1965
SE|148||ab|12|entity|C0031412|Phenobarbital|orch,phsu|||PB|||0|1000|1976|1978
SE|148||ab|12|entity|C0025732|Methylcholanthrene|hops,orch|||MC|||0|888|1983|1985
SE|148||ab|12|entity|C0443228|Largest|qnco|||greater|||0|888|2011|2018
SE|148||ab|12|entity|C0035820|Role|socb|||role|||0|888|2019|2023
SE|148||ab|12|entity|C0010762|Cytochrome P450|aapp,enzy|||cytochrome P-450|||0|1000|2028|2044
SE|148||ab|12|entity|C0013343|Dyes|irda|||dye|||0|840|2048|2051
SE|148||ab|12|entity|C0204695|Feeding patient|hlca|||fed|||0|840|2052|2055
SE|148||ab|12|entity|C0003062|Animals|anim|||animals|||0|840|2056|2063
SE|148||ab|12|relation|1|1|C0003062|Animals|anim|anim|||animals|||0|840|2056|2063|PREP|LOCATION_OF||2045|2047|10|1|C0010762|Cytochrome P450|aapp,gngm,enzy|aapp|||cytochrome P-450|||0|1000|2028|2044
SE|148||ab|12|relation|6|1|C0003062|Animals|anim|anim|||animals|||0|1000|1958|1965|PREP|LOCATION_OF||1955|1957|5|2|C0052803|azobenzene reductase|aapp,gngm,enzy|aapp|||DAB-azoreductase|||0|1000|1910|1926
SE|148||ab|12|relation|7|1|C0003062|Animals|anim|anim|||animals|||0|840|1938|1945|PREP|LOCATION_OF||1927|1929|4|1|C0052803|azobenzene reductase|aapp,gngm,enzy|aapp|||DAB-azoreductase|||0|1000|1910|1926


SE|149||ti|1|text|16|79|Some characteristics of two azoreductase systems in rat liver.
SE|149||ti|1|entity|C1521970|Characteristics|grpa|||characteristics|||0|1000|21|36
SE|149||ti|1|entity|C0205448|Two|qnco|||two|||0|851|40|43
SE|149||ti|1|entity|C0052819|azoreductase|aapp,enzy|||azoreductase|||0|851|44|56
SE|149||ti|1|entity|C0449913|System|ftcn|||systems|||0|851|57|64
SE|149||ti|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|888|68|71
SE|149||ti|1|entity|C0023884|Liver|bpoc|||liver|||0|888|72|77
SE|149||ti|1|relation|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|888|72|77|MOD/HEAD|PART_OF||68|77|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|888|68|71
SE|149||ti|1|relation|1|1|C0023884|Liver|bpoc|bpoc|||liver|||0|888|72|77|PREP|LOCATION_OF||65|67|2|1|C0052819|azoreductase|aapp,gngm,enzy|aapp|||azoreductase|||0|851|44|56

SE|149||ti|2|text|79|222|Relevance to the activity of 2-[4'-di(2"-bromopropyl)-aminophenylazo]benzoic acid (CB10-252), a compound possessing latent cytotoxic activity.
SE|149||ti|2|entity|C0053225|Benzoic Acid|orch,phsu|||benzoic acid|||0|1000|148|160
SE|149||ti|2|entity|C0205198|Compound|qlco|||compound|||0|815|175|183
SE|149||ti|2|entity|C0205275|Latent|qlco|||latent|||0|815|195|201
SE|149||ti|2|entity|C1511636|cytotoxic|ftcn|||cytotoxic|||0|815|202|211

SE|149||ab|1|text|228|502|The system involved in the reduction of 2-[4'-di(2''-bromopropyl) aminophenylazolbenzoic acid (CB10-252), an agent designed for treating primary liver cell cancer, has been demonstrated to be localised mainly in the 108 000 X g supernatant fraction of rat liver homogenate.
SE|149||ab|1|entity|C0449913|System|ftcn|||system|||0|1000|232|238
SE|149||ab|1|entity|C0001128|Acids|chem|||acid|||0|861|317|321
SE|149||ab|1|entity|C0450442|Agent|chvf|||agent|||0|1000|337|342
SE|149||ab|1|entity|C1522326|Treating|qlco|||treating|||0|840|356|364
SE|149||ab|1|entity|C0007634|Cells|cell|||cell|||0|840|379|383
SE|149||ab|1|entity|C0279000|Liver and Intrahepatic Biliary Tract Carcinoma|neop|||liver cell cancer|||0|840|373|390
SE|149||ab|1|entity|C1550101|Supernatant|bdsu|||supernatant|||0|632|456|467
SE|149||ab|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|623|480|483
SE|149||ab|1|entity|C0023884|Liver|bpoc|||liver|||0|623|484|489
SE|149||ab|1|relation|0|0|C0007634|Cells|cell|cell|||cell|||0|840|379|383|MOD/HEAD|LOCATION_OF||379|390|0|0|C0279000|Liver and Intrahepatic Biliary Tract Carcinoma|neop|neop|||liver cell cancer|||0|840|373|390
SE|149||ab|1|relation|6|1|C0450442|Agent|chvf|chvf|||agent|||0|1000|337|342|NOM|TREATS||356|364|6|0|C0279000|Liver and Intrahepatic Biliary Tract Carcinoma|neop|neop|||liver cell cancer|||0|840|373|390

SE|149||ab|2|text|502|565|It is also present in other organs particularly in the spleen.
SE|149||ab|2|entity|C0178784|Organ|bpoc|||organs|||0|827|530|536
SE|149||ab|2|entity|C0037993|Spleen|bpoc|||spleen|||0|1000|557|563

SE|149||ab|3|text|565|706|DAB-azoreductase as shown previously is present almost entirely in the microsomal fraction and is found in high concentration only in liver.
SE|149||ab|3|entity|C0052803|azobenzene reductase|aapp,enzy|||DAB-azoreductase|||0|1000|565|581
SE|149||ab|3|entity|C0150312|Present|qnco|||present|||0|827|605|612
SE|149||ab|3|entity|C0026029|Microsomes|celc|||microsomal|||0|623|636|646
SE|149||ab|3|entity|C0205250|High|qlco|||high|||0|660|672|676
SE|149||ab|3|entity|C0023884|Liver|bpoc|||liver|||0|1000|699|704
SE|149||ab|3|relation|2|2|C0023884|Liver|bpoc|bpoc|||liver|||0|1000|699|704|VERB|LOCATION_OF||663|668|2|2|C0052803|azobenzene reductase|aapp,gngm,enzy|aapp|||DAB-azoreductase|||0|1000|565|581

SE|149||ab|4|text|706|834|The pH maximum for CB10-252-azoreductase implying the importance of the 2'-carboxyl group in determining substrate specificity.
SE|149||ab|4|entity|C0806909|Maximum|fndg|||maximum|||0|888|713|720
SE|149||ab|4|entity|C0052819|azoreductase|aapp,enzy|||azoreductase|||0|827|734|746
SE|149||ab|4|entity|C0596260|carboxyl group|inch|||carboxyl group|||0|901|781|795
SE|149||ab|4|entity|C0038592|Substrate Specificity|qnco|||substrate specificity|||0|901|811|832

SE|149||ab|5|text|834|958|The use of enzyme inhibitors and other additives showed that CB10-252 WAS NOT AXANTHINE OXIDASE OR DIHYDROFOLATE REDUCTASE.
SE|149||ab|5|entity|C0014432|Enzyme Inhibitors|phsu|||enzyme inhibitors|||0|1000|845|862
SE|149||ab|5|entity|C0442796|Additive|qlco|||additives|||0|1000|873|882
SE|149||ab|5|entity|C1518422|Not|ftcn|||NOT|||0|802|908|911
SE|149||ab|5|entity|C0242417|Oxidase|aapp,enzy|||OXIDASE|||0|802|922|929
SE|149||ab|5|entity|C0039667|Dihydrofolate Reductase|aapp,enzy|1719|DHFR|DIHYDROFOLATE REDUCTASE|||0|1000|933|956

SE|149||ab|6|text|958|1072|Its activity was not affected by carbon monoxide, phenobarbitone (PB), or 3-methylcholanthrene (MC) pretreatment.
SE|149||ab|6|entity|C1518422|Not|ftcn|||not|||0|1000|975|978
SE|149||ab|6|entity|C0007018|Carbon Monoxide|hops,inch|||carbon monoxide|||0|1000|991|1006
SE|149||ab|6|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbitone|||0|1000|1008|1022
SE|149||ab|6|entity|C0000431|3MC|hops,orch|||3-methylcholanthrene|||0|901|1032|1052

SE|149||ab|7|text|1072|1240|Enhancement of the activity by ferrous ions and FAD indicated that at least part of the reduction system could involve a flavoprotein with FAD as the prosthetic group.
SE|149||ab|7|entity|C0022023|Ions|elii|||ions|||0|861|1111|1115
SE|149||ab|7|entity|C0015540|Flavin-Adenine Dinucleotide|bacs,nnon|||FAD|||0|1000|1120|1123
SE|149||ab|7|entity|C0449719|Part|spco|||part|||0|861|1148|1152
SE|149||ab|7|entity|C0449913|System|ftcn|||system|||0|861|1170|1176
SE|149||ab|7|entity|C0016223|Flavoproteins|aapp,bacs|||flavoprotein|||0|1000|1193|1205
SE|149||ab|7|entity|C0015540|Flavin-Adenine Dinucleotide|bacs,nnon|||FAD|||0|1000|1211|1214
SE|149||ab|7|entity|C0441833|Groups|inpr|||group|||0|861|1233|1238
SE|149||ab|7|relation|2|1|C0015540|Flavin-Adenine Dinucleotide|bacs,nnon|bacs|||FAD|||0|1000|1211|1214|PREP|PART_OF||1206|1210|7|1|C0016223|Flavoproteins|aapp,gngm,bacs|aapp|||flavoprotein|||0|1000|1193|1205
SE|149||ab|7|relation|6|3|C0015540|Flavin-Adenine Dinucleotide|bacs,nnon|bacs|||FAD|||0|1000|1120|1123|VERB|INTERACTS_WITH||1183|1190|3|1|C0016223|Flavoproteins|aapp,gngm,bacs|aapp|||flavoprotein|||0|1000|1193|1205
SE|149||ab|7|relation|6|3|C0022023|Ions|elii|elii|||ions|||0|861|1111|1115|VERB|INTERACTS_WITH||1183|1190|3|1|C0016223|Flavoproteins|aapp,gngm,bacs|aapp|||flavoprotein|||0|1000|1193|1205

SE|149||ab|8|text|1240|1371|The activity of CB10-252-azoreductase and methylred-azoreductase was reduced by menadione (vitamin K3), cyanide and propylgallate.
SE|149||ab|8|entity|C0052819|azoreductase|aapp,enzy|||azoreductase|||0|827|1265|1277
SE|149||ab|8|entity|C0052819|azoreductase|aapp,enzy|||azoreductase|||0|861|1292|1304
SE|149||ab|8|entity|C0025270|Vitamin K 3|orch,phsu,vita|||menadione|||0|1000|1320|1329
SE|149||ab|8|entity|C0025270|Vitamin K 3|orch,phsu,vita|||vitamin K3|||0|1000|1331|1341
SE|149||ab|8|entity|C0010505|Cyanides|inch|||cyanide|||0|1000|1344|1351
SE|149||ab|8|relation|4|1|C0025270|Vitamin K 3|orch,phsu,vita|orch|||menadione|||0|1000|1320|1329|VERB|INHIBITS||1309|1316|3|1|C0052819|azoreductase|aapp,gngm,enzy|aapp|||azoreductase|||0|827|1265|1277
SE|149||ab|8|relation|4|1|C0025270|Vitamin K 3|orch,phsu,vita|orch|||menadione|||0|1000|1320|1329|VERB|INHIBITS||1309|1316|3|1|C0052819|azoreductase|aapp,gngm,enzy|gngm|||azoreductase|||0|861|1292|1304

SE|149||ab|9|text|1371|1492|A diaphorase preparation from pig heart reduced both CB10-252 and methylred with both NADPH- and NADH-generating systems.
SE|149||ab|9|entity|C0023783|DIHYDROLIPOAMIDE DEHYDROGENASE|aapp,enzy|||diaphorase|||0|888|1373|1383
SE|149||ab|9|entity|C1521827|Preparation|ftcn|||preparation|||0|888|1384|1395
SE|149||ab|9|entity|C0039005|Family suidae|mamm|||pig|||0|888|1401|1404
SE|149||ab|9|entity|C0018787|Heart|bpoc|||heart|||0|888|1405|1410
SE|149||ab|9|entity|C0027303|NADP|bacs,nnon|||NADPH|||0|1000|1457|1462
SE|149||ab|9|entity|C0027289|NADH|bacs,nnon,phsu|||NADH|||0|802|1468|1472
SE|149||ab|9|entity|C0449913|System|ftcn|||systems|||0|802|1484|1491
SE|149||ab|9|relation|0|0|C0018787|Heart|bpoc|bpoc|||heart|||0|888|1405|1410|MOD/HEAD|PART_OF||1401|1410|0|0|C0039005|Family suidae|mamm|mamm|||pig|||0|888|1401|1404
SE|149||ab|9|relation|4|1|C0018787|Heart|bpoc|bpoc|||heart|||0|888|1405|1410|PREP|LOCATION_OF||1396|1400|1|1|C0023783|DIHYDROLIPOAMIDE DEHYDROGENASE|aapp,gngm,enzy|aapp|||diaphorase|||0|888|1373|1383


SE|150||ti|1|text|16|75|Mercury inhibition of avian fatty acid synthetase complex.
SE|150||ti|1|entity|C0025424|Mercury|elii,hops|||Mercury|||0|888|16|23
SE|150||ti|1|entity|C0005595|Aves|bird|||avian|||0|928|38|43
SE|150||ti|1|entity|C0015683|Fatty-acid synthase|aapp,enzy|||fatty acid synthetase complex|||0|928|44|73
SE|150||ti|1|relation|0|0|C0025424|Mercury|elii,hops|elii|||Mercury|||0|888|16|23|NOM|INHIBITS||24|34|1|1|C0015683|Fatty-acid synthase|aapp,gngm,enzy|gngm|||fatty acid synthetase complex|||0|928|44|73

SE|150||ab|1|text|81|254|(1) Subcutaneous or intra-abdominal injections of 8 mg of HgCl2/100 g body weight markedly depressed hepatic fatty acid synthetase activity of chicks at 1 h post-injection.
SE|150||ab|1|entity|C0443315|subcutaneous|spco|||Subcutaneous|||0|1000|85|97
SE|150||ab|1|entity|C1555351|Injection, intra-abdominal|ftcn|||intra-abdominal injections|||0|983|101|127
SE|150||ab|1|entity|C0025417|Mercuric chloride|hops,inch,phsu|||HgCl2|||0|812|139|144
SE|150||ab|1|entity|C0005910|Body Weight|orga|||body weight|||0|812|151|162
SE|150||ab|1|entity|C0522501|Massive|qlco|||markedly|||0|1000|163|171
SE|150||ab|1|entity|C0205054|Hepatic|blor|||hepatic|||0|840|182|189
SE|150||ab|1|entity|C0015684|Fatty Acids|bacs,lipd|||fatty acid|||0|840|190|200
SE|150||ab|1|entity|C0023689|Ligase|aapp,enzy|||synthetase|||0|840|201|211
SE|150||ab|1|entity|C1533685|Injection procedure|topp|||injection|||0|888|243|252

SE|150||ab|2|text|254|364|The depression occurred despite the fact that the chicks continued to eat up until the time they were killed.
SE|150||ab|2|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|258|268
SE|150||ab|2|entity|C0040223|Time|tmco|||time|||0|1000|341|345

SE|150||ab|3|text|364|568|Under these same conditions, the hepatic activity of acetyl-CoA carboxylase (EC 6.4.1.2) was not affected by HgCl2, while the activity of the mitochondrial system of fatty acid elongation was stimulated.
SE|150||ab|3|entity|C0445247|Same|qlco|||same|||0|872|376|380
SE|150||ab|3|entity|C0348080|Condition|qlco|||conditions|||0|872|381|391
SE|150||ab|3|entity|C0205054|Hepatic|blor|||hepatic|||0|888|397|404
SE|150||ab|3|entity|C0001022|Acetyl-CoA Carboxylase|aapp,enzy|||acetyl-CoA carboxylase|||0|1000|417|439
SE|150||ab|3|entity|C0040676|Transferase|aapp,enzy|||EC 6.4.1.2|||0|897|441|451
SE|150||ab|3|entity|C1518422|Not|ftcn|||not|||0|1000|457|460
SE|150||ab|3|entity|C0025417|Mercuric chloride|hops,inch,phsu|||HgCl2|||0|1000|473|478
SE|150||ab|3|entity|C0521451|Mitochondrial|ftcn|||mitochondrial|||0|888|506|519
SE|150||ab|3|entity|C0449913|System|ftcn|||system|||0|888|520|526
SE|150||ab|3|entity|C1157326|fatty acid elongation|moft|||fatty acid elongation|||0|1000|530|551
SE|150||ab|3|relation|4|1|C0025417|Mercuric chloride|hops,inch,phsu|hops|||HgCl2|||0|1000|473|478|VERB|INTERACTS_WITH|negation|461|469|3|1|C0001022|Acetyl-CoA Carboxylase|aapp,gngm,enzy|aapp|||acetyl-CoA carboxylase|||0|1000|417|439

SE|150||ab|4|text|568|763|(2) When 2-mercaptoethanol was included in the incubation medium for a highly purified preparation of fatty acid synthetase, 500 muM HgCl2 was required to show definite inhibition of the enzyme.
SE|150||ab|4|entity|C0025402|2-Mercaptoethanol|orch|||2-mercaptoethanol|||0|1000|577|594
SE|150||ab|4|entity|C0439536|Medium|qlco|||medium|||0|861|626|632
SE|150||ab|4|entity|C0353043|Cleansing preparations|phsu|||purified preparation|||0|838|646|666
SE|150||ab|4|entity|C0015684|Fatty Acids|bacs,lipd|||fatty acid|||0|901|670|680
SE|150||ab|4|entity|C0023689|Ligase|aapp,enzy|||synthetase|||0|901|681|691
SE|150||ab|4|entity|C1009574|Chrysanthemum x morifolium|plnt|||muM|||0|790|697|700
SE|150||ab|4|entity|C0025417|Mercuric chloride|hops,inch,phsu|||HgCl2|||0|790|701|706
SE|150||ab|4|entity|C0439544|Definite|qlco|||definite|||0|888|728|736
SE|150||ab|4|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|755|761
SE|150||ab|4|relation|0|0|C1009574|Chrysanthemum x morifolium|plnt|plnt|||muM|||0|790|697|700|MOD/HEAD|LOCATION_OF||697|706|0|0|C0025417|Mercuric chloride|hops,inch,phsu|hops|||HgCl2|||0|790|701|706
SE|150||ab|4|relation|5|1|C0025417|Mercuric chloride|hops,inch,phsu|hops|||HgCl2|||0|790|701|706|NOM|INHIBITS||737|747|1|1|C0014442|Enzymes|enzy,orch|enzy|||enzyme|||0|1000|755|761

SE|150||ab|5|text|763|872|When 2-mercaptoethanol was omitted, 50 muM HgCl2 was inhibitory and 100 muM HgCl2 abolished enzyme activity.
SE|150||ab|5|entity|C0025402|2-Mercaptoethanol|orch|||2-mercaptoethanol|||0|1000|768|785
SE|150||ab|5|entity|C1009574|Chrysanthemum x morifolium|plnt|||muM|||0|790|802|805
SE|150||ab|5|entity|C0025417|Mercuric chloride|hops,inch,phsu|||HgCl2|||0|790|806|811
SE|150||ab|5|entity|C0243077|inhibitors|chvf|||inhibitory|||0|928|816|826
SE|150||ab|5|entity|C1009574|Chrysanthemum x morifolium|plnt|||muM|||0|790|835|838
SE|150||ab|5|entity|C0025417|Mercuric chloride|hops,inch,phsu|||HgCl2|||0|790|839|844
SE|150||ab|5|entity|C0243102|enzyme activity|moft|||enzyme activity|||0|1000|855|870
SE|150||ab|5|relation|0|0|C1009574|Chrysanthemum x morifolium|plnt|plnt|||muM|||0|790|802|805|MOD/HEAD|LOCATION_OF||802|811|0|0|C0025417|Mercuric chloride|hops,inch,phsu|hops|||HgCl2|||0|790|806|811
SE|150||ab|5|relation|0|0|C1009574|Chrysanthemum x morifolium|plnt|plnt|||muM|||0|790|835|838|MOD/HEAD|LOCATION_OF||835|844|0|0|C0025417|Mercuric chloride|hops,inch,phsu|hops|||HgCl2|||0|790|839|844
SE|150||ab|5|relation|4|1|C0025417|Mercuric chloride|hops,inch,phsu|hops|||HgCl2|||0|790|839|844|VERB|DISRUPTS||845|854|1|1|C0243102|enzyme activity|moft|moft|||enzyme activity|||0|1000|855|870

SE|150||ab|6|text|872|998|(3) 2 mM dithiothreitol completely protected the purified fatty acid synthetase preparation from inhibition by 100 muM HgCl2.
SE|150||ab|6|entity|C0012789|Dithiothreitol|carb,phsu|||dithiothreitol|||0|790|881|895
SE|150||ab|6|entity|C0023689|Ligase|aapp,enzy|||synthetase|||0|854|941|951
SE|150||ab|6|entity|C0015684|Fatty Acids|bacs,lipd|||fatty acid synthetase preparation|||0|854|930|963
SE|150||ab|6|entity|C1009574|Chrysanthemum x morifolium|plnt|||muM|||0|790|987|990
SE|150||ab|6|entity|C0025417|Mercuric chloride|hops,inch,phsu|||HgCl2|||0|790|991|996
SE|150||ab|6|relation|0|0|C0015684|Fatty Acids|bacs,lipd|bacs|||fatty acid synthetase preparation|||0|854|930|963|MOD/HEAD|PART_OF||941|963|0|0|C0023689|Ligase|aapp,gngm,enzy|aapp|||synthetase|||0|854|941|951
SE|150||ab|6|relation|0|0|C1009574|Chrysanthemum x morifolium|plnt|plnt|||muM|||0|790|987|990|MOD/HEAD|LOCATION_OF||987|996|0|0|C0025417|Mercuric chloride|hops,inch,phsu|hops|||HgCl2|||0|790|991|996

SE|150||ab|7|text|998|1134|When dithiothreitol was added after the addition of enzyme to the mercury-containing medium, protection of the enzyme was not complete.
SE|150||ab|7|entity|C0012789|Dithiothreitol|carb,phsu|||dithiothreitol|||0|1000|1003|1017
SE|150||ab|7|entity|C0442796|Additive|qlco|||addition|||0|928|1038|1046
SE|150||ab|7|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|1050|1056
SE|150||ab|7|entity|C0025424|Mercury|elii,hops|||mercury|||0|851|1064|1071
SE|150||ab|7|entity|C0332256|Containing|ftcn|||containing|||0|851|1072|1082
SE|150||ab|7|entity|C0439536|Medium|qlco|||medium|||0|851|1083|1089
SE|150||ab|7|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|1109|1115
SE|150||ab|7|entity|C1518422|Not|ftcn|||not|||0|1000|1120|1123
SE|150||ab|7|relation|4|4|C0012789|Dithiothreitol|carb,phsu|carb|||dithiothreitol|||0|1000|1003|1017|NOM|INTERACTS_WITH||1091|1101|1|1|C0014442|Enzymes|enzy,orch|enzy|||enzyme|||0|1000|1109|1115

SE|150||ab|8|text|1134|1393|(4) Dialysis of cytosol fractions from chicks injected with HgCl2 against 500 vol. of 0.2 M potassium phosphate buffer (pH 7.0) containing 1 mM EDTA and 10 mM dithiothreitol for 4 h at 4 degrees stimulated the fatty acid synthetase activity of the fractions.
SE|150||ab|8|entity|C0011946|Dialysis procedure|topp|||Dialysis|||0|1000|1138|1146
SE|150||ab|8|entity|C0010854|Cytosol|celc|||cytosol|||0|888|1150|1157
SE|150||ab|8|entity|C1264633|Fraction of|qnco|||fractions|||0|888|1158|1167
SE|150||ab|8|entity|C0025417|Mercuric chloride|hops,inch,phsu|||HgCl2|||0|1000|1194|1199
SE|150||ab|8|entity|C0449468|Volume|qnco|||vol|||0|861|1212|1215
SE|150||ab|8|entity|C0071778|potassium phosphate|inch,phsu|||potassium phosphate|||0|762|1226|1245
SE|150||ab|8|entity|C0006353|Buffers|bacs,irda|||buffer|||0|762|1246|1252
SE|150||ab|8|entity|C0013618|Edetic Acid|irda,orch,phsu|||EDTA|||0|790|1278|1282
SE|150||ab|8|entity|C0012789|Dithiothreitol|carb,phsu|||dithiothreitol|||0|790|1293|1307
SE|150||ab|8|entity|C0015684|Fatty Acids|bacs,lipd|||fatty acid|||0|861|1344|1354
SE|150||ab|8|entity|C0023689|Ligase|aapp,enzy|||synthetase|||0|861|1355|1365
SE|150||ab|8|entity|C1264633|Fraction of|qnco|||fractions|||0|1000|1382|1391
SE|150||ab|8|relation|10|3|C0012789|Dithiothreitol|carb,phsu|carb|||dithiothreitol|||0|790|1293|1307|VERB|STIMULATES||1329|1339|2|1|C0023689|Ligase|aapp,gngm,enzy|gngm|||synthetase|||0|861|1355|1365
SE|150||ab|8|relation|10|3|C0013618|Edetic Acid|irda,orch,phsu|phsu|||EDTA|||0|790|1278|1282|VERB|STIMULATES||1329|1339|2|1|C0023689|Ligase|aapp,gngm,enzy|gngm|||synthetase|||0|861|1355|1365

SE|150||ab|9|text|1393|1527|Dialysis of cytosol fractions from noninjected chicks under the same conditions was without effect on fatty acid synthetase activity.
SE|150||ab|9|entity|C0011946|Dialysis procedure|topp|||Dialysis|||0|1000|1393|1401
SE|150||ab|9|entity|C0010854|Cytosol|celc|||cytosol|||0|888|1405|1412
SE|150||ab|9|entity|C1264633|Fraction of|qnco|||fractions|||0|888|1413|1422
SE|150||ab|9|entity|C0445247|Same|qlco|||same|||0|872|1457|1461
SE|150||ab|9|entity|C0348080|Condition|qlco|||conditions|||0|872|1462|1472
SE|150||ab|9|entity|C1280500|Effect|qlco|||effect|||0|1000|1485|1491
SE|150||ab|9|entity|C0015684|Fatty Acids|bacs,lipd|||fatty acid|||0|861|1495|1505
SE|150||ab|9|entity|C0023689|Ligase|aapp,enzy|||synthetase|||0|861|1506|1516

SE|150||ab|10|text|1527|1762|(5) These data support the hypothesis that the inhibitory effect of HgCl2 administered in vivo on hepatic fatty acid synthetase activity in chicks is mediated through the interaction of mercury with the sulfhydryl groups of the enzyme.
SE|150||ab|10|entity|C1511726|Data|idcn|||data|||0|1000|1537|1541
SE|150||ab|10|entity|C1512571|Hypothesis|idcn|||hypothesis|||0|1000|1554|1564
SE|150||ab|10|entity|C0243077|inhibitors|chvf|||inhibitory|||0|853|1574|1584
SE|150||ab|10|entity|C1280500|Effect|qlco|||effect|||0|853|1585|1591
SE|150||ab|10|entity|C0025417|Mercuric chloride|hops,inch,phsu|||HgCl2|||0|1000|1595|1600
SE|150||ab|10|entity|C1515655|in vivo|spco|||in vivo|||0|1000|1614|1621
SE|150||ab|10|entity|C0205054|Hepatic|blor|||hepatic|||0|840|1625|1632
SE|150||ab|10|entity|C0015684|Fatty Acids|bacs,lipd|||fatty acid|||0|840|1633|1643
SE|150||ab|10|entity|C0023689|Ligase|aapp,enzy|||synthetase|||0|840|1644|1654
SE|150||ab|10|entity|C0025424|Mercury|elii,hops|||mercury|||0|1000|1713|1720
SE|150||ab|10|entity|C0038734|Sulfhydryl Compounds|orch|||sulfhydryl|||0|966|1730|1740
SE|150||ab|10|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|1755|1761
SE|150||ab|10|relation|3|2|C0038734|Sulfhydryl Compounds|orch|orch|||sulfhydryl|||0|966|1730|1740|NOM|INTERACTS_WITH||1698|1709|3|1|C0025424|Mercury|elii,hops|elii|||mercury|||0|1000|1713|1720


SE|151||ti|1|text|16|65|[Basic phospholipase of Naja nigricollis venom].
SE|151||ti|1|entity|C0031671|Phospholipase|aapp,enzy|||phospholipase|||0|853|23|36
SE|151||ti|1|entity|C0009165|Cobra Venoms|aapp,bacs,hops|||Naja nigricollis venom|||0|913|40|62

SE|151||ab|1|text|71|186|It is confirmed that N. nigricollis venom contains several phospholipases one of these is a basic phospholipase A.
SE|151||ab|1|entity|C0042479|Venoms|bacs,hops,orch|||venom|||0|802|107|112
SE|151||ab|1|entity|C0443302|Several|qnco|||several|||0|888|122|129
SE|151||ab|1|entity|C0031671|Phospholipase|aapp,enzy|||phospholipases|||0|888|130|144
SE|151||ab|1|entity|C0205447|One|qnco|||one|||0|1000|145|148
SE|151||ab|1|entity|C0031671|Phospholipase|aapp,enzy|||phospholipase|||0|853|169|182

SE|151||ab|2|text|186|245|This enzyme is toxic for mice when injected intravenously.
SE|151||ab|2|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|191|197
SE|151||ab|2|entity|C1407029|Toxic|qlco|||toxic|||0|1000|201|206
SE|151||ab|2|entity|C0026809|Mus|mamm|||mice|||0|1000|211|215

SE|151||ab|3|text|245|355|In vitro it reacts on egg yolk lecithin producing lysolecithin and prevents the phenomenon of blood clotting.
SE|151||ab|3|entity|C1533691|in vitro|qlco|||In vitro|||0|1000|245|253
SE|151||ab|3|entity|C0013707|Egg Yolk|food|||egg yolk|||0|794|267|275
SE|151||ab|3|entity|C0031617|Lecithin|bacs,lipd,phsu|||lecithin|||0|794|276|284
SE|151||ab|3|entity|C0024360|Lysophosphatidylcholines|lipd|||lysolecithin|||0|794|295|307
SE|151||ab|3|entity|C0005778|Blood coagulation|ortf|||blood clotting|||0|1000|339|353

SE|151||ab|4|text|355|491|An immunological identity has been established between this basic phospholipase and two acidic phospholipases present in the same venom.
SE|151||ab|4|entity|C0205470|immunologic|ftcn|||immunological|||0|694|358|371
SE|151||ab|4|entity|C0031671|Phospholipase|aapp,enzy|||phospholipase|||0|853|421|434
SE|151||ab|4|entity|C0205448|Two|qnco|||two|||0|828|439|442
SE|151||ab|4|entity|C0001128|Acids|chem|||acidic|||0|828|443|449
SE|151||ab|4|entity|C0031671|Phospholipase|aapp,enzy|||phospholipases|||0|828|450|464
SE|151||ab|4|entity|C0445247|Same|qlco|||same|||0|888|480|484
SE|151||ab|4|entity|C0042479|Venoms|bacs,hops,orch|||venom|||0|888|485|490
SE|151||ab|4|relation|3|1|C0031671|Phospholipase|aapp,gngm,enzy|aapp|||phospholipase|||0|853|421|434|PREP|COEXISTS_WITH||473|475|1|1|C0042479|Venoms|bacs,hops,orch|bacs|||venom|||0|888|485|490
SE|151||ab|4|relation|3|1|C0031671|Phospholipase|aapp,gngm,enzy|aapp|||phospholipases|||0|828|450|464|PREP|COEXISTS_WITH||473|475|1|1|C0042479|Venoms|bacs,hops,orch|bacs|||venom|||0|888|485|490


SE|152||ti|1|text|16|116|[Spontaneous mortality and vascular lesions in 3 rat strains with different blood pressure levels].
SE|152||ti|1|entity|C0205359|Spontaneous|ftcn|||Spontaneous|||0|694|17|28
SE|152||ti|1|entity|C0005847|Blood Vessels|bpoc|||vascular|||0|888|43|51
SE|152||ti|1|entity|C0221198|Lesion|fndg|||lesions|||0|888|52|59
SE|152||ti|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|888|65|68
SE|152||ti|1|entity|C1547020|*Difference|qnco|||different|||0|837|82|91
SE|152||ti|1|entity|C0005823|Blood Pressure|orgf|||blood pressure|||0|837|92|106
SE|152||ti|1|entity|C0441889|Levels|inpr|||levels|||0|837|107|113
SE|152||ti|1|relation|0|0|C0005847|Blood Vessels|bpoc|bpoc|||vascular|||0|888|43|51|MOD/HEAD|LOCATION_OF||43|59|0|0|C0221198|Lesion|fndg|fndg|||lesions|||0|888|52|59

SE|152||ab|1|text|122|283|We have observed a high and significant mortality in spontaneously hypertensive rats compared to normotensive and hypotensive controls, in the fifth generation.
SE|152||ab|1|entity|C0205250|High|qlco|||high|||0|1000|141|145
SE|152||ab|1|entity|C0750502|Significant|idcn|||significant|||0|694|150|161
SE|152||ab|1|entity|C0034705|Rats, Inbred SHR|mamm|||spontaneously hypertensive rats|||0|1000|175|206
SE|152||ab|1|entity|C0232105|Normal blood pressure|fndg|||normotensive|||0|1000|219|231
SE|152||ab|1|entity|C0857353|Hypotensive|patf|||hypotensive|||0|872|236|247
SE|152||ab|1|entity|C0243148|control|ftcn|||controls|||0|872|248|256
SE|152||ab|1|entity|C0205439|Fifth|qnco|||fifth|||0|872|265|270
SE|152||ab|1|entity|C0079411|Generations|tmco|||generation|||0|872|271|281

SE|152||ab|2|text|283|381|The hypertensive rats exhibited a high frequency of cerebral haemorrhage and periarteritis nodosa.
SE|152||ab|2|entity|C0857121|Hypertensive|fndg|||hypertensive|||0|888|287|299
SE|152||ab|2|entity|C0034693|Rattus norvegicus|mamm|||rats|||0|888|300|304
SE|152||ab|2|entity|C0205212|High frequency|tmco|||high frequency|||0|1000|317|331
SE|152||ab|2|entity|C0007784|Cerebral hemisphere hemorrhage|patf|||cerebral haemorrhage|||0|1000|335|355
SE|152||ab|2|entity|C0031036|Polyarteritis Nodosa|dsyn|||periarteritis nodosa|||0|1000|360|380


SE|153||ti|1|text|16|100|Effects of decreasing arterial blood pressure on cerebral blood flow in the baboon.
SE|153||ti|1|entity|C1280500|Effect|qlco|||Effects|||0|966|16|23
SE|153||ti|1|entity|C0442797|Decreasing|qlco|||decreasing|||0|916|27|37
SE|153||ti|1|entity|C1272641|Systemic arterial pressure|fndg|||arterial blood pressure|||0|916|38|61
SE|153||ti|1|entity|C0007818|Cerebrovascular Circulation|ortf|||cerebral blood flow|||0|1000|65|84
SE|153||ti|1|entity|C0030362|Papio|mamm|||baboon|||0|1000|92|98
SE|153||ti|1|relation|3|1|C0007818|Cerebrovascular Circulation|ortf|ortf|||cerebral blood flow|||0|1000|65|84|PREP|PROCESS_OF||85|87|1|1|C0030362|Papio|mamm|mamm|||baboon|||0|1000|92|98

SE|153||ti|2|text|100|145|Influence of the sympathetic nervous system.
SE|153||ti|2|entity|C0039044|Sympathetic Nervous System|bdsy|||sympathetic nervous system|||0|1000|117|143

SE|153||ab|1|text|151|326|The influence of the sympathetic nervous system on the cerebral circulatory response to graded reductions in mean arterial blood pressure was studied in anesthetized baboons.
SE|153||ab|1|entity|C0039044|Sympathetic Nervous System|bdsy|||sympathetic nervous system|||0|1000|172|198
SE|153||ab|1|entity|C0007818|Cerebrovascular Circulation|ortf|||cerebral circulatory|||0|877|206|226
SE|153||ab|1|entity|C0871261|response|clna|||response|||0|877|227|235
SE|153||ab|1|entity|C0441800|Grade|clas|||graded|||0|661|239|245
SE|153||ab|1|entity|C1272641|Systemic arterial pressure|fndg|||arterial blood pressure|||0|923|265|288
SE|153||ab|1|entity|C0030362|Papio|mamm|||baboons|||0|861|317|324
SE|153||ab|1|relation|4|3|C0039044|Sympathetic Nervous System|bdsy|bdsy|||sympathetic nervous system|||0|1000|172|198|PREP|ASSOCIATED_WITH||257|259|2|1|C1272641|Systemic arterial pressure|fndg|fndg|||arterial blood pressure|||0|923|265|288

SE|153||ab|2|text|326|458|Cerebral blood flow was measured by the 133Xe clearance method, and arterial blood pressure was decreased by controlled hemorrhage.
SE|153||ab|2|entity|C0007818|Cerebrovascular Circulation|ortf|||Cerebral blood flow|||0|1000|326|345
SE|153||ab|2|entity|C0449297|Clearance|qlco|||clearance|||0|790|372|381
SE|153||ab|2|entity|C0025663|Methods|inpr|||method|||0|790|382|388
SE|153||ab|2|entity|C1272641|Systemic arterial pressure|fndg|||arterial blood pressure|||0|1000|394|417
SE|153||ab|2|entity|C0702113|Controlled|ftcn|||controlled|||0|888|435|445
SE|153||ab|2|entity|C0019080|Hemorrhage|fndg|||hemorrhage|||0|888|446|456

SE|153||ab|3|text|458|694|In normal baboons, the constancy of cerebral blood flow was maintained until mean arterial blood pressure was approximately 65% of the base-line value; thereafter, cerebral blood flow decreased when arterial blood pressure was reduced.
SE|153||ab|3|entity|C0205307|Normal|qlco|||normal|||0|888|461|467
SE|153||ab|3|entity|C0030362|Papio|mamm|||baboons|||0|888|468|475
SE|153||ab|3|entity|C0007818|Cerebrovascular Circulation|ortf|||cerebral blood flow|||0|1000|494|513
SE|153||ab|3|entity|C1272641|Systemic arterial pressure|fndg|||arterial blood pressure|||0|923|540|563
SE|153||ab|3|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|861|568|581
SE|153||ab|3|entity|C1442488|BASELINE|qnco|||base-line|||0|734|593|602
SE|153||ab|3|entity|C0007818|Cerebrovascular Circulation|ortf|||cerebral blood flow|||0|1000|622|641
SE|153||ab|3|entity|C1272641|Systemic arterial pressure|fndg|||arterial blood pressure|||0|1000|657|680

SE|153||ab|4|text|694|784|Superior cervical sympathectomy of 2-3 weeks duration did not affect the normal response.
SE|153||ab|4|entity|C1282910|Upper|spco|||Superior|||0|901|694|702
SE|153||ab|4|entity|C0196664|Cervical surgical sympathectomy|topp|||cervical sympathectomy|||0|901|703|725
SE|153||ab|4|entity|C1442457|2 Weeks|tmco|||2-3 weeks|||0|824|729|738
SE|153||ab|4|entity|C0449238|Duration|tmco|||duration|||0|824|739|747
SE|153||ab|4|entity|C1518422|Not|ftcn|||not|||0|1000|752|755
SE|153||ab|4|entity|C0205307|Normal|qlco|||normal|||0|888|767|773
SE|153||ab|4|entity|C0871261|response|clna|||response|||0|888|774|782

SE|153||ab|5|text|784|1130|In contrast, both acute surgical sympathectomy (cervical trunk division) and alpha-receptor blockade (1.5 mg/kg of phenoxybenzamine) enhanced the maintenance of cerebral blood flow in the face of hemorrhagic hypotension in that cerebral blood flow did not decrease until mean arterial blood pressure was approximately 35% of the base-line value.
SE|153||ab|5|entity|C0205178|acute|tmco|||acute|||0|901|802|807
SE|153||ab|5|entity|C0039038|Sympathectomy|topp|||surgical sympathectomy|||0|901|808|830
SE|153||ab|5|entity|C0205064|Cervical|spco|||cervical|||0|623|832|840
SE|153||ab|5|entity|C1280632|Entire trunk|bpoc|||trunk|||0|623|841|846
SE|153||ab|5|entity|C0439095|Alpha|inpr|||alpha|||0|623|861|866
SE|153||ab|5|entity|C0597357|receptor|aapp,rcpt|||receptor|||0|623|867|875
SE|153||ab|5|entity|C0450316|1/5|qnco|||1.5|||0|861|886|889
SE|153||ab|5|entity|C0031441|Phenoxybenzamine|orch,phsu|||phenoxybenzamine|||0|1000|899|915
SE|153||ab|5|entity|C0007818|Cerebrovascular Circulation|ortf|||cerebral blood flow|||0|1000|945|964
SE|153||ab|5|entity|C0333275|Hemorrhagic|ftcn|||hemorrhagic|||0|888|980|991
SE|153||ab|5|entity|C0020649|Hypotension|fndg|||hypotension|||0|888|992|1003
SE|153||ab|5|entity|C0007818|Cerebrovascular Circulation|ortf|||cerebral blood flow|||0|1000|1012|1031
SE|153||ab|5|entity|C1518422|Not|ftcn|||not|||0|1000|1036|1039
SE|153||ab|5|entity|C1272641|Systemic arterial pressure|fndg|||arterial blood pressure|||0|923|1060|1083
SE|153||ab|5|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|861|1088|1101
SE|153||ab|5|entity|C1442488|BASELINE|qnco|||base-line|||0|734|1113|1122

SE|153||ab|6|text|1130|1295|The results indicate that the sympathetic nervous system is not involved in the maintenance of cerebral blood flow in the face of a fall in arterial blood pressure.
SE|153||ab|6|entity|C1274040|result|ftcn|||results|||0|966|1134|1141
SE|153||ab|6|entity|C0039044|Sympathetic Nervous System|bdsy|||sympathetic nervous system|||0|1000|1160|1186
SE|153||ab|6|entity|C1518422|Not|ftcn|||not|||0|1000|1190|1193
SE|153||ab|6|entity|C0007818|Cerebrovascular Circulation|ortf|||cerebral blood flow|||0|1000|1225|1244
SE|153||ab|6|entity|C0085639|Falls|fndg|||fall|||0|1000|1262|1266
SE|153||ab|6|entity|C1272641|Systemic arterial pressure|fndg|||arterial blood pressure|||0|1000|1270|1293
SE|153||ab|6|relation|6|5|C0039044|Sympathetic Nervous System|bdsy|bdsy|||sympathetic nervous system|||0|1000|1160|1186|PREP|ASSOCIATED_WITH||1267|1269|1|1|C1272641|Systemic arterial pressure|fndg|fndg|||arterial blood pressure|||0|1000|1270|1293

SE|153||ab|7|text|1295|1469|Indeed, the implication is that the sympathicoadrenal discharge accompanying hemorrhagic hypotension is detrimental to, rather than responsible for,  cerebral autoregulation.
SE|153||ab|7|entity|C0012621|Discharge, Body Substance|bdsu|||discharge|||0|861|1349|1358
SE|153||ab|7|entity|C0333275|Hemorrhagic|ftcn|||hemorrhagic|||0|888|1372|1383
SE|153||ab|7|entity|C0020649|Hypotension|fndg|||hypotension|||0|888|1384|1395
SE|153||ab|7|entity|C0006104|Brain|bpoc|||cerebral|||0|888|1445|1453
SE|153||ab|7|entity|C0019868|Homeostasis|orgf|||autoregulation|||0|888|1454|1468


SE|154||ti|1|text|16|124|Influence of hematocrit, blood gas tensions, and pH on pressure-flow relations in the isolated canine lung.
SE|154||ti|1|entity|C0018935|Hematocrit procedure|lbpr|||hematocrit|||0|1000|29|39
SE|154||ti|1|entity|C0005800|Blood Gas Analysis|lbpr|||blood gas|||0|890|41|50
SE|154||ti|1|entity|C0233494|Tension|mobd|||tensions|||0|890|51|59
SE|154||ti|1|entity|C0033095|Pressure- physical agent|phpr|||pressure|||0|851|71|79
SE|154||ti|1|entity|C0806140|Flow|orga|||flow|||0|851|80|84
SE|154||ti|1|entity|C0869014|Relations|socb|||relations|||0|851|85|94
SE|154||ti|1|entity|C0205409|Isolated|ftcn|||isolated|||0|851|102|110
SE|154||ti|1|entity|C0012984|Canis familiaris|mamm|||canine|||0|851|111|117
SE|154||ti|1|entity|C0024109|Lung|bpoc|||lung|||0|851|118|122
SE|154||ti|1|relation|0|0|C0024109|Lung|bpoc|bpoc|||lung|||0|851|118|122|MOD/HEAD|PART_OF||111|122|0|0|C0012984|Canis familiaris|mamm|mamm|||canine|||0|851|111|117

SE|154||ab|1|text|130|265|An isolated perfused canine lung preparation in which determinants of vascular caliber could be individually controlled was developed.
SE|154||ab|1|entity|C0205409|Isolated|ftcn|||isolated|||0|815|133|141
SE|154||ab|1|entity|C1549542|Perfuse|ftcn|||perfused|||0|815|142|150
SE|154||ab|1|entity|C0012984|Canis familiaris|mamm|||canine|||0|815|151|157
SE|154||ab|1|entity|C0024109|Lung|bpoc|||lung|||0|815|158|162
SE|154||ab|1|entity|C1521827|Preparation|ftcn|||preparation|||0|815|163|174
SE|154||ab|1|entity|C0005847|Blood Vessels|bpoc|||vascular|||0|888|200|208
SE|154||ab|1|entity|C1301886|Caliber|qnco|||caliber|||0|888|209|216
SE|154||ab|1|relation|0|0|C0024109|Lung|bpoc|bpoc|||lung|||0|815|158|162|MOD/HEAD|PART_OF||151|162|0|0|C0012984|Canis familiaris|mamm|mamm|||canine|||0|815|151|157

SE|154||ab|2|text|265|423|The relation of pulmonary arterial (Pa), venous (PV), and alveolar (PA) pressures was such that Pa greater than PA greater than PV throughout the whole lung.
SE|154||ab|2|entity|C0869014|Relations|socb|||relation|||0|966|269|277
SE|154||ab|2|entity|C0221464|Arterial|spco|||arterial|||0|877|291|299
SE|154||ab|2|entity|C0034090|Pulmonary veins|bpoc|||pulmonary arterial (Pa), venous|||0|877|281|312
SE|154||ab|2|entity|C1440080|Alveolar|bpoc|||alveolar|||0|1000|323|331
SE|154||ab|2|entity|C0033095|Pressure- physical agent|phpr|||pressures|||0|1000|337|346
SE|154||ab|2|entity|C1269026|Entire pulmonary artery|bpoc|||Pa|||0|877|361|363
SE|154||ab|2|entity|C0443228|Largest|qnco|||greater|||0|877|364|371
SE|154||ab|2|entity|C0443228|Largest|qnco|||greater|||0|1000|380|387
SE|154||ab|2|entity|C0444667|Whole|qnco|||whole|||0|888|411|416
SE|154||ab|2|entity|C0024109|Lung|bpoc|||lung|||0|888|417|421

SE|154||ab|3|text|423|500|The addition of isoprenaline to the perfusate abolished vascular reactivity.
SE|154||ab|3|entity|C0442796|Additive|qlco|||addition|||0|928|427|435
SE|154||ab|3|entity|C0022245|Isoproterenol|orch,phsu|||isoprenaline|||0|1000|439|451
SE|154||ab|3|entity|C0005847|Blood Vessels|bpoc|||vascular|||0|853|479|487
SE|154||ab|3|entity|C0205332|Reactive|qlco|||reactivity|||0|853|488|498

SE|154||ab|4|text|500|639|Once stability was reached, vascular cross-sectional area remained acceptably constant for 2.25 hours as judged by normalized conductance.
SE|154||ab|4|entity|C1317741|STABILITY|qlco|||stability|||0|861|505|514
SE|154||ab|4|entity|C0005847|Blood Vessels|bpoc|||vascular|||0|837|528|536
SE|154||ab|4|entity|C0552389|CROSS SECTION|orga|||cross-sectional|||0|837|537|552
SE|154||ab|4|entity|C0205146|Area|spco|||area|||0|837|553|557
SE|154||ab|4|entity|C1547014|*Constant|qnco|||constant|||0|861|578|586
SE|154||ab|4|entity|C1292425|2 Hours|tmco|||2.25 hours|||0|913|591|601

SE|154||ab|5|text|639|778|The influence of perfusate hematocrit, blood gas tensions, and pH on pressure-flow relations was then studied in 15 isolated canine lungs.
SE|154||ab|5|entity|C0018935|Hematocrit procedure|lbpr|||hematocrit|||0|861|666|676
SE|154||ab|5|entity|C0005800|Blood Gas Analysis|lbpr|||blood gas|||0|890|678|687
SE|154||ab|5|entity|C0233494|Tension|mobd|||tensions|||0|890|688|696
SE|154||ab|5|entity|C0033095|Pressure- physical agent|phpr|||pressure|||0|851|708|716
SE|154||ab|5|entity|C0806140|Flow|orga|||flow|||0|851|717|721
SE|154||ab|5|entity|C0869014|Relations|socb|||relations|||0|851|722|731
SE|154||ab|5|entity|C0205409|Isolated|ftcn|||isolated|||0|775|755|763
SE|154||ab|5|entity|C0012984|Canis familiaris|mamm|||canine|||0|775|764|770
SE|154||ab|5|entity|C0024109|Lung|bpoc|||lungs|||0|775|771|776
SE|154||ab|5|relation|0|0|C0024109|Lung|bpoc|bpoc|||lungs|||0|775|771|776|MOD/HEAD|PART_OF||764|776|0|0|C0012984|Canis familiaris|mamm|mamm|||canine|||0|775|764|770

SE|154||ab|6|text|778|867|The hematocrit-vascular conductance relation was derived at constant perfusion pressure.
SE|154||ab|6|entity|C0018935|Hematocrit procedure|lbpr|||hematocrit|||0|764|782|792
SE|154||ab|6|entity|C0005847|Blood Vessels|bpoc|||vascular|||0|764|793|801
SE|154||ab|6|entity|C0869014|Relations|socb|||relation|||0|764|814|822
SE|154||ab|6|entity|C1547014|*Constant|qnco|||constant|||0|802|838|846
SE|154||ab|6|entity|C0033095|Pressure- physical agent|phpr|||pressure|||0|802|857|865

SE|154||ab|7|text|867|942|Conductance varied linearly with hematocrit over a range of 16.5 to 89.5%.
SE|154||ab|7|entity|C0018935|Hematocrit procedure|lbpr|||hematocrit|||0|1000|900|910
SE|154||ab|7|entity|C0205136|Over|spco|||over|||0|1000|911|915
SE|154||ab|7|entity|C1514721|Range|qnco|||range|||0|1000|918|923

SE|154||ab|8|text|942|1040|Mean pulmonary arterial blood gas tensions were: PO2 = 121 mm Hg, PCO2 = 28 mm Hg, and pH = 7.46.
SE|154||ab|8|entity|C0024109|Lung|bpoc|||pulmonary|||0|814|947|956
SE|154||ab|8|entity|C0150411|Blood gases, arterial measurement|diap|||arterial blood gas|||0|814|957|975
SE|154||ab|8|entity|C0233494|Tension|mobd|||tensions|||0|814|976|984
SE|154||ab|8|entity|C0439475|mmHg|qnco|||mm Hg|||0|901|1001|1006
SE|154||ab|8|entity|C0391839|Carbon dioxide, partial pressure|lbtr|||PCO2|||0|1000|1008|1012
SE|154||ab|8|entity|C0439475|mmHg|qnco|||mm Hg|||0|901|1018|1023
SE|154||ab|8|entity|C0020283|Hydrogen-Ion Concentration|qnco|||pH|||0|827|1029|1031

SE|154||ab|9|text|1040|1234|Acute respiratory acidosis (PO2 = 30 mm Hg, PCO2 = 81 mm Hg, pH = 7.17) and lactic acidosis and hypoxemia (PO2 = 32 mm Hg, PCO2 = 21 mm Hg, pH = 6.96) did not significantly alter this relation.
SE|154||ab|9|entity|C0268047|Acute respiratory acidosis|dsyn|||Acute respiratory acidosis|||0|1000|1040|1066
SE|154||ab|9|entity|C0439475|mmHg|qnco|||mm Hg|||0|901|1077|1082
SE|154||ab|9|entity|C0391839|Carbon dioxide, partial pressure|lbtr|||PCO2|||0|1000|1084|1088
SE|154||ab|9|entity|C0439475|mmHg|qnco|||mm Hg|||0|901|1094|1099
SE|154||ab|9|entity|C0020283|Hydrogen-Ion Concentration|qnco|||pH|||0|827|1101|1103
SE|154||ab|9|entity|C0001125|Acidosis, Lactic|dsyn|||lactic acidosis|||0|1000|1116|1131
SE|154||ab|9|entity|C0700292|Hypoxemia|fndg|||hypoxemia|||0|1000|1136|1145
SE|154||ab|9|entity|C0439475|mmHg|qnco|||mm Hg|||0|901|1156|1161
SE|154||ab|9|entity|C0391839|Carbon dioxide, partial pressure|lbtr|||PCO2|||0|1000|1163|1167
SE|154||ab|9|entity|C0439475|mmHg|qnco|||mm Hg|||0|901|1173|1178
SE|154||ab|9|entity|C0020283|Hydrogen-Ion Concentration|qnco|||pH|||0|827|1180|1182
SE|154||ab|9|entity|C1518422|Not|ftcn|||not|||0|1000|1195|1198
SE|154||ab|9|entity|C0869014|Relations|socb|||relation|||0|966|1224|1232

SE|154||ab|10|text|1234|1390|Transformation of the conductance-hematocrit data indicated that hematocrit was the most important determinant of relative apparent viscosity of the blood.
SE|154||ab|10|entity|C0018935|Hematocrit procedure|lbpr|||hematocrit|||0|790|1268|1278
SE|154||ab|10|entity|C1511726|Data|idcn|||data|||0|790|1279|1283
SE|154||ab|10|entity|C0018935|Hematocrit procedure|lbpr|||hematocrit|||0|1000|1299|1309
SE|154||ab|10|entity|C0205393|Most|qnco|||most|||0|660|1318|1322
SE|154||ab|10|entity|C0205345|Relative|qlco|||relative|||0|851|1348|1356
SE|154||ab|10|entity|C0750489|APPARENT|idcn|||apparent|||0|851|1357|1365
SE|154||ab|10|entity|C0042784|Viscosity|npop|||viscosity|||0|851|1366|1375
SE|154||ab|10|entity|C0005767|Blood|tisu|||blood|||0|1000|1383|1388

SE|154||ab|11|text|1390|1556|Both acute respiratory and lactic acidosis failed to significantly increase relative viscosity within the range of hematocrit usually found in secondary polycythemia.
SE|154||ab|11|entity|C0205178|acute|tmco|||acute|||0|888|1395|1400
SE|154||ab|11|entity|C0521346|respiratory|ftcn|||respiratory|||0|888|1401|1412
SE|154||ab|11|entity|C0001125|Acidosis, Lactic|dsyn|||lactic acidosis|||0|1000|1417|1432
SE|154||ab|11|entity|C0205345|Relative|qlco|||relative|||0|888|1466|1474
SE|154||ab|11|entity|C0042784|Viscosity|npop|||viscosity|||0|888|1475|1484
SE|154||ab|11|entity|C1514721|Range|qnco|||range|||0|1000|1496|1501
SE|154||ab|11|entity|C0018935|Hematocrit procedure|lbpr|||hematocrit|||0|1000|1505|1515
SE|154||ab|11|entity|C1318533|Secondary polycythemia NOS|dsyn|||secondary polycythemia|||0|1000|1533|1555
SE|154||ab|11|relation|5|1|C0018935|Hematocrit procedure|lbpr|lbpr|||hematocrit|||0|1000|1505|1515|PREP|DIAGNOSES||1530|1532|1|1|C1318533|Secondary polycythemia NOS|dsyn|dsyn|||secondary polycythemia|||0|1000|1533|1555


SE|155||ti|1|text|16|143|Interaction of the chemoreflex and the pulmonary inflation reflex in the regulation of coronary circulation in conscious dogs.
SE|155||ti|1|entity|C0024109|Lung|bpoc|||pulmonary|||0|890|55|64
SE|155||ti|1|entity|C0232049|Inflation reflexes|ortf|||inflation reflex|||0|890|65|81
SE|155||ti|1|entity|C0851285|Regulation|gora|||regulation|||0|1000|89|99
SE|155||ti|1|entity|C0010067|Coronary Circulation|ortf|||coronary circulation|||0|1000|103|123
SE|155||ti|1|entity|C0234421|Conscious|menp|||conscious|||0|888|127|136
SE|155||ti|1|entity|C0012984|Canis familiaris|mamm|||dogs|||0|888|137|141
SE|155||ti|1|relation|0|0|C0234421|Conscious|menp|menp|||conscious|||0|888|127|136|MOD/HEAD|PROCESS_OF||127|141|0|0|C0012984|Canis familiaris|mamm|mamm|||dogs|||0|888|137|141
SE|155||ti|1|relation|3|1|C0232049|Inflation reflexes|ortf|ortf|||inflation reflex|||0|890|65|81|NOM|AFFECTS||89|99|2|1|C0010067|Coronary Circulation|ortf|ortf|||coronary circulation|||0|1000|103|123
SE|155||ti|1|relation|5|1|C0010067|Coronary Circulation|ortf|ortf|||coronary circulation|||0|1000|103|123|PREP|PROCESS_OF||124|126|1|1|C0012984|Canis familiaris|mamm|mamm|||dogs|||0|888|137|141

SE|155||ab|1|text|149|454|The interaction of chemoreflex and pulmonary inflation reflex control of the coronary circulation was examined in conscious dogs by comparing the responses to chemoreflex stimulation (intracarotid injection of nicotine) when ventilation was allowed to increase with those when ventilation was controlled.
SE|155||ab|1|entity|C0024109|Lung|bpoc|||pulmonary|||0|852|184|193
SE|155||ab|1|entity|C0232049|Inflation reflexes|ortf|||inflation reflex|||0|852|194|210
SE|155||ab|1|entity|C0243148|control|ftcn|||control|||0|852|211|218
SE|155||ab|1|entity|C0010067|Coronary Circulation|ortf|||coronary circulation|||0|1000|226|246
SE|155||ab|1|entity|C0234421|Conscious|menp|||conscious|||0|888|263|272
SE|155||ab|1|entity|C0012984|Canis familiaris|mamm|||dogs|||0|888|273|277
SE|155||ab|1|entity|C0871261|response|clna|||responses|||0|1000|295|304
SE|155||ab|1|entity|C1512915|Intracarotid|blor|||intracarotid|||0|888|333|345
SE|155||ab|1|entity|C1533685|Injection procedure|topp|||injection|||0|888|346|355
SE|155||ab|1|entity|C0028040|Nicotine|hops,orch,phsu|||nicotine|||0|1000|359|367
SE|155||ab|1|entity|C0035203|Respiration|phsf|||ventilation|||0|1000|374|385
SE|155||ab|1|entity|C0035203|Respiration|phsf|||ventilation|||0|1000|426|437
SE|155||ab|1|relation|0|0|C0234421|Conscious|menp|menp|||conscious|||0|888|263|272|MOD/HEAD|PROCESS_OF||263|277|0|0|C0012984|Canis familiaris|mamm|mamm|||dogs|||0|888|273|277
SE|155||ab|1|relation|9|8|C0035203|Respiration|phsf|phsf|||ventilation|||0|1000|374|385|NOM|AFFECTS||211|218|9|1|C0010067|Coronary Circulation|ortf|ortf|||coronary circulation|||0|1000|226|246

SE|155||ab|2|text|454|565|The responses were also compared with those elicited by both forced mechanical and spontaneous hyperinflation.
SE|155||ab|2|entity|C0871261|response|clna|||responses|||0|1000|458|467
SE|155||ab|2|entity|C0443221|Forced|ftcn|||forced|||0|694|515|521
SE|155||ab|2|entity|C0205359|Spontaneous|ftcn|||spontaneous|||0|888|537|548
SE|155||ab|2|entity|C0020449|Hyperdistention|anab|||hyperinflation|||0|888|549|563

SE|155||ab|3|text|565|888|When the heart rate was constant, intracarotidly administered nicotine induced an increase in the depth of respiration followed closely by an increase in late diastolic coronary flow from 48 +/- 2 to 106 +/- 8 ml/min and a reduction in late diastolic coronary resistance from 1.62 +/- 0.08 to 0.78 +/- 0.06 mm Hg/ml min-1.
SE|155||ab|3|entity|C0018810|heart rate|orga|||heart rate|||0|1000|574|584
SE|155||ab|3|entity|C1547014|*Constant|qnco|||constant|||0|791|589|597
SE|155||ab|3|entity|C0028040|Nicotine|hops,orch,phsu|||nicotine|||0|791|627|635
SE|155||ab|3|entity|C0442805|Increase|ftcn|||increase|||0|1000|647|655
SE|155||ab|3|entity|C0205125|Depth|spco|||depth|||0|1000|663|668
SE|155||ab|3|entity|C0035203|Respiration|phsf|||respiration|||0|1000|672|683
SE|155||ab|3|entity|C0442805|Increase|ftcn|||increase|||0|1000|707|715
SE|155||ab|3|entity|C0205087|Late|tmco|||late|||0|861|719|723
SE|155||ab|3|entity|C0018787|Heart|bpoc|||coronary|||0|861|734|742
SE|155||ab|3|entity|C1441384|DIASTOLIC FLOW|ortf|||diastolic coronary flow|||0|861|724|747
SE|155||ab|3|entity|C0439232|Minute of time|tmco|||min|||0|750|778|781
SE|155||ab|3|entity|C0205087|Late|tmco|||late|||0|597|801|805
SE|155||ab|3|entity|C0018787|Heart|bpoc|||coronary|||0|597|816|824
SE|155||ab|3|entity|C0439475|mmHg|qnco|||mm Hg|||0|734|872|877
SE|155||ab|3|entity|C0439232|Minute of time|tmco|||min|||0|734|881|884
SE|155||ab|3|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|ml min-1|||0|734|878|886
SE|155||ab|3|relation|5|4|C0028040|Nicotine|hops,orch,phsu|hops|||nicotine|||0|791|627|635|NOM|AUGMENTS||707|715|4|1|C1441384|DIASTOLIC FLOW|ortf|ortf|||diastolic coronary flow|||0|861|724|747

SE|155||ab|4|text|888|1042|After beta-receptor and cholinergic blockade, a similar coronary dilation in response to nicotine occurred only when ventilation was allowed to increase.
SE|155||ab|4|entity|C0597357|receptor|aapp,rcpt|||receptor|||0|861|899|907
SE|155||ab|4|entity|C0599668|cholinergic|ftcn|||cholinergic|||0|694|912|923
SE|155||ab|4|entity|C0018787|Heart|bpoc|||coronary|||0|828|944|952
SE|155||ab|4|entity|C0012359|Pathological Dilatation|patf|||dilation|||0|828|953|961
SE|155||ab|4|entity|C0028040|Nicotine|hops,orch,phsu|||nicotine|||0|1000|977|985
SE|155||ab|4|entity|C0035203|Respiration|phsf|||ventilation|||0|1000|1005|1016
SE|155||ab|4|relation|0|0|C0018787|Heart|bpoc|bpoc|||coronary|||0|828|944|952|MOD/HEAD|LOCATION_OF||944|961|0|0|C0012359|Pathological Dilatation|patf|patf|||dilation|||0|828|953|961

SE|155||ab|5|text|1042|1206|However, when ventilation was controlled, intracarotidly administered nicotine increased coronary resistance after combined beta-receptor and cholinergic blockade.
SE|155||ab|5|entity|C0035203|Respiration|phsf|||ventilation|||0|1000|1056|1067
SE|155||ab|5|entity|C0028040|Nicotine|hops,orch,phsu|||nicotine|||0|827|1112|1120
SE|155||ab|5|entity|C0018787|Heart|bpoc|||coronary|||0|694|1131|1139
SE|155||ab|5|entity|C0205195|Combined|qlco|||combined|||0|802|1157|1165
SE|155||ab|5|entity|C0597357|receptor|aapp,rcpt|||receptor|||0|802|1171|1179
SE|155||ab|5|entity|C0599668|cholinergic|ftcn|||cholinergic|||0|694|1184|1195
SE|155||ab|5|relation|2|1|C0028040|Nicotine|hops,orch,phsu|orch|||nicotine|||0|827|1112|1120|VERB|AUGMENTS||1121|1130|3|1|C0018787|Heart|bpoc|bpoc|||coronary|||0|694|1131|1139

SE|155||ab|6|text|1206|1320|The reflex coronary dilation was not observed after carotid sinus nerve section or after alpha-receptor blockade.
SE|155||ab|6|entity|C0018787|Heart|bpoc|||coronary|||0|790|1217|1225
SE|155||ab|6|entity|C0012359|Pathological Dilatation|patf|||dilation|||0|790|1226|1234
SE|155||ab|6|entity|C1518422|Not|ftcn|||not|||0|1000|1239|1242
SE|155||ab|6|entity|C0228766|Carotid sinus nerve|bpoc|||carotid sinus nerve|||0|916|1258|1277
SE|155||ab|6|entity|C0439095|Alpha|inpr|||alpha|||0|623|1295|1300
SE|155||ab|6|entity|C0597357|receptor|aapp,rcpt|||receptor|||0|623|1301|1309
SE|155||ab|6|relation|0|0|C0018787|Heart|bpoc|bpoc|||coronary|||0|790|1217|1225|MOD/HEAD|LOCATION_OF||1217|1234|0|0|C0012359|Pathological Dilatation|patf|patf|||dilation|||0|790|1226|1234

SE|155||ab|7|text|1320|1439|Thus, nicotine stimulation of the carotid chemoreflex results in a striking coronary dilation that has two components.
SE|155||ab|7|entity|C0028040|Nicotine|hops,orch,phsu|||nicotine|||0|888|1326|1334
SE|155||ab|7|entity|C0741968|CAROTID|bpoc|||carotid|||0|694|1354|1361
SE|155||ab|7|entity|C0018787|Heart|bpoc|||coronary|||0|790|1396|1404
SE|155||ab|7|entity|C0012359|Pathological Dilatation|patf|||dilation|||0|790|1405|1413
SE|155||ab|7|entity|C0205448|Two|qnco|||two|||0|872|1423|1426
SE|155||ab|7|entity|C1524073|Component, LOINC Axis 1|clas|||components|||0|872|1427|1437
SE|155||ab|7|relation|0|0|C0018787|Heart|bpoc|bpoc|||coronary|||0|790|1396|1404|MOD/HEAD|LOCATION_OF||1396|1413|0|0|C0012359|Pathological Dilatation|patf|patf|||dilation|||0|790|1405|1413

SE|155||ab|8|text|1439|1522|The minor component involves a chemoreflex with its efferent pathway in tthe vagi.
SE|155||ab|8|entity|C1524073|Component, LOINC Axis 1|clas|||component|||0|888|1449|1458
SE|155||ab|8|entity|C0013681|Efferent Pathways|bpoc|||efferent pathway|||0|1000|1491|1507

SE|155||ab|9|text|1522|1707|The major component of coronary dilation follows an increase in the depth of respiration, and its efferent component appears to involve withdrawal of alpha-adrenergic constrictor tone.
SE|155||ab|9|entity|C0205164|Major|qlco|||major|||0|888|1526|1531
SE|155||ab|9|entity|C1524073|Component, LOINC Axis 1|clas|||component|||0|888|1532|1541
SE|155||ab|9|entity|C0018787|Heart|bpoc|||coronary|||0|888|1545|1553
SE|155||ab|9|entity|C0012359|Pathological Dilatation|patf|||dilation|||0|888|1554|1562
SE|155||ab|9|entity|C0442805|Increase|ftcn|||increase|||0|1000|1574|1582
SE|155||ab|9|entity|C0205125|Depth|spco|||depth|||0|1000|1590|1595
SE|155||ab|9|entity|C0035203|Respiration|phsf|||respiration|||0|1000|1599|1610
SE|155||ab|9|entity|C0205116|Efferent|spco|||efferent|||0|888|1620|1628
SE|155||ab|9|entity|C1524073|Component, LOINC Axis 1|clas|||component|||0|888|1629|1638
SE|155||ab|9|entity|C0237955|Withdrawal|menp|||withdrawal|||0|1000|1658|1668
SE|155||ab|9|entity|C0439095|Alpha|inpr|||alpha|||0|742|1672|1677
SE|155||ab|9|entity|C0599756|adrenergic|ftcn|||adrenergic|||0|742|1678|1688
SE|155||ab|9|entity|C0439216|ton|qnco|||tone|||0|742|1701|1705
SE|155||ab|9|relation|0|0|C0018787|Heart|bpoc|bpoc|||coronary|||0|888|1545|1553|MOD/HEAD|LOCATION_OF||1545|1562|0|0|C0012359|Pathological Dilatation|patf|patf|||dilation|||0|888|1554|1562

SE|155||ab|10|text|1707|1847|An almost identical period of reflex coronary dilation followed either forced mechanical or spontaneous hyperinflation in the conscious dog.
SE|155||ab|10|entity|C0205280|Identical|qlco|||identical|||0|790|1717|1726
SE|155||ab|10|entity|C0439531|/period|tmco|||period|||0|790|1727|1733
SE|155||ab|10|entity|C0018787|Heart|bpoc|||coronary|||0|790|1744|1752
SE|155||ab|10|entity|C0012359|Pathological Dilatation|patf|||dilation|||0|790|1753|1761
SE|155||ab|10|entity|C0443221|Forced|ftcn|||forced|||0|660|1778|1784
SE|155||ab|10|entity|C0205359|Spontaneous|ftcn|||spontaneous|||0|888|1799|1810
SE|155||ab|10|entity|C0020449|Hyperdistention|anab|||hyperinflation|||0|888|1811|1825
SE|155||ab|10|entity|C0234421|Conscious|menp|||conscious|||0|888|1833|1842
SE|155||ab|10|entity|C0012984|Canis familiaris|mamm|||dog|||0|888|1843|1846
SE|155||ab|10|relation|0|0|C0018787|Heart|bpoc|bpoc|||coronary|||0|790|1744|1752|MOD/HEAD|LOCATION_OF||1744|1761|0|0|C0012359|Pathological Dilatation|patf|patf|||dilation|||0|790|1753|1761
SE|155||ab|10|relation|0|0|C0234421|Conscious|menp|menp|||conscious|||0|888|1833|1842|MOD/HEAD|PROCESS_OF||1833|1846|0|0|C0012984|Canis familiaris|mamm|mamm|||dog|||0|888|1843|1846
SE|155||ab|10|relation|4|3|C0012359|Pathological Dilatation|patf|patf|||dilation|||0|790|1753|1761|PREP|PROCESS_OF||1826|1828|1|1|C0012984|Canis familiaris|mamm|mamm|||dog|||0|888|1843|1846


SE|156||ti|1|text|16|110|Effect of coronary blood flow on glycolytic flux and intracellular pH in isolated rat hearts.
SE|156||ti|1|entity|C1280500|Effect|qlco|||Effect|||0|1000|16|22
SE|156||ti|1|entity|C0018787|Heart|bpoc|||coronary|||0|901|26|34
SE|156||ti|1|entity|C0232338|Blood flow|orgf|||blood flow|||0|901|35|45
SE|156||ti|1|entity|C0017952|Glycolysis|moft|||glycolytic|||0|623|49|59
SE|156||ti|1|entity|C0175996|Protoplasm|celc|||intracellular|||0|888|69|82
SE|156||ti|1|entity|C0205409|Isolated|ftcn|||isolated|||0|851|89|97
SE|156||ti|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|851|98|101
SE|156||ti|1|entity|C0018787|Heart|bpoc|||hearts|||0|851|102|108
SE|156||ti|1|relation|0|0|C0018787|Heart|bpoc|bpoc|||hearts|||0|851|102|108|MOD/HEAD|PART_OF||98|108|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|851|98|101

SE|156||ab|1|text|116|318|The rate of coronary blood flow was varied in isolated working rat heart preparations to determine its influence on the rate of glocose utilization, tissue high-energy phosphates, and intracellular pH.
SE|156||ab|1|entity|C1521828|Rate|qnco|||rate|||0|1000|120|124
SE|156||ab|1|entity|C0018787|Heart|bpoc|||coronary|||0|901|128|136
SE|156||ab|1|entity|C0232338|Blood flow|orgf|||blood flow|||0|901|137|147
SE|156||ab|1|entity|C0205409|Isolated|ftcn|||isolated|||0|815|162|170
SE|156||ab|1|entity|C0043227|Work|ocac|||working|||0|815|171|178
SE|156||ab|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|815|179|182
SE|156||ab|1|entity|C0018787|Heart|bpoc|||heart|||0|815|183|188
SE|156||ab|1|entity|C1521827|Preparation|ftcn|||preparations|||0|815|189|201
SE|156||ab|1|entity|C1521828|Rate|qnco|||rate|||0|1000|236|240
SE|156||ab|1|entity|C0205250|High|qlco|||high|||0|775|272|276
SE|156||ab|1|entity|C0424589|Vitality|fndg|||energy|||0|775|277|283
SE|156||ab|1|entity|C0031603|inorganic phosphate|inch|||phosphates|||0|775|284|294
SE|156||ab|1|entity|C0175996|Protoplasm|celc|||intracellular|||0|888|300|313
SE|156||ab|1|relation|0|0|C0018787|Heart|bpoc|bpoc|||heart|||0|815|183|188|MOD/HEAD|PART_OF||179|188|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|815|179|182

SE|156||ab|2|text|318|541|A 60% reduction in coronary blood flow resulted in a 30% reduction in oxygen consumption, an accelerated rate of glusoe utilization, lower tissue levels of high-energy phosphate, and higher tissue levels of lactate and H+.
SE|156||ab|2|entity|C0018787|Heart|bpoc|||coronary|||0|901|337|345
SE|156||ab|2|entity|C0232338|Blood flow|orgf|||blood flow|||0|901|346|356
SE|156||ab|2|entity|C0030055|Oxygen Consumption|clna|||oxygen consumption|||0|1000|388|406
SE|156||ab|2|entity|C0521110|Accelerated|ftcn|||accelerated|||0|888|411|422
SE|156||ab|2|entity|C1521828|Rate|qnco|||rate|||0|888|423|427
SE|156||ab|2|entity|C0441889|Levels|inpr|||levels|||0|861|464|470
SE|156||ab|2|entity|C0205250|High|qlco|||high|||0|790|474|478
SE|156||ab|2|entity|C0424589|Vitality|fndg|||energy|||0|790|479|485
SE|156||ab|2|entity|C0205250|High|qlco|||higher|||0|785|501|507
SE|156||ab|2|entity|C0441889|Levels|inpr|||levels|||0|785|515|521
SE|156||ab|2|entity|C0022924|Lactates|orch|||lactate|||0|1000|525|532

SE|156||ab|3|text|541|647|Ventricular performance deteriorated as reflected by a decrease in heart rate and peak systolic pressure.
SE|156||ab|3|entity|C0018827|Heart Ventricle|bpoc|||Ventricular|||0|888|541|552
SE|156||ab|3|entity|C0597198|Performance|inbe|||performance|||0|888|553|564
SE|156||ab|3|entity|C0547047|Decrease|qnco|||decrease|||0|1000|596|604
SE|156||ab|3|entity|C0018810|heart rate|orga|||heart rate|||0|1000|608|618
SE|156||ab|3|entity|C0039155|Systole|tmco|||systolic|||0|901|628|636
SE|156||ab|3|entity|C0445174|Peak pressure|qnco|||peak systolic pressure|||0|901|623|645

SE|156||ab|4|text|647|839|Further reductions in coronary blood flow resulted in inhibition of glycolysis, a greater decrease in tissue levels of high-energy phosphates, and higher tissue levels of both lactate and H+.
SE|156||ab|4|entity|C1517331|Further|spco|||Further|||0|694|647|654
SE|156||ab|4|entity|C0018787|Heart|bpoc|||coronary|||0|901|669|677
SE|156||ab|4|entity|C0232338|Blood flow|orgf|||blood flow|||0|901|678|688
SE|156||ab|4|entity|C0017952|Glycolysis|moft|||glycolysis|||0|1000|715|725
SE|156||ab|4|entity|C0443228|Largest|qnco|||greater|||0|888|729|736
SE|156||ab|4|entity|C0547047|Decrease|qnco|||decrease|||0|888|737|745
SE|156||ab|4|entity|C0441889|Levels|inpr|||levels|||0|861|756|762
SE|156||ab|4|entity|C0205250|High|qlco|||high|||0|851|766|770
SE|156||ab|4|entity|C0424589|Vitality|fndg|||energy|||0|851|771|777
SE|156||ab|4|entity|C0031603|inorganic phosphate|inch|||phosphates|||0|851|778|788
SE|156||ab|4|entity|C0205250|High|qlco|||higher|||0|785|794|800
SE|156||ab|4|entity|C0441889|Levels|inpr|||levels|||0|785|808|814
SE|156||ab|4|entity|C0022924|Lactates|orch|||lactate|||0|1000|823|830

SE|156||ab|5|text|839|992|These changes in glycolytic flux, tissue metabolites, and ventricular performance were proportional to the degree of restriction in coronary blood flow.
SE|156||ab|5|entity|C0017952|Glycolysis|moft|||glycolytic|||0|623|856|866
SE|156||ab|5|entity|C0870883|Metabolites|bacs|||metabolites|||0|861|880|891
SE|156||ab|5|entity|C0018827|Heart Ventricle|bpoc|||ventricular|||0|888|897|908
SE|156||ab|5|entity|C0597198|Performance|inbe|||performance|||0|888|909|920
SE|156||ab|5|entity|C0205351|Proportional|qlco|||proportional|||0|1000|926|938
SE|156||ab|5|entity|C0018787|Heart|bpoc|||coronary|||0|901|971|979
SE|156||ab|5|entity|C0232338|Blood flow|orgf|||blood flow|||0|901|980|990

SE|156||ab|6|text|992|1160|The importance of coronary blood flow and washout of the interstitial space in the maintenance of accelerated glycolytic flux in oxygen-deficient hearts is emphasized.
SE|156||ab|6|entity|C0018787|Heart|bpoc|||coronary|||0|901|1010|1018
SE|156||ab|6|entity|C0232338|Blood flow|orgf|||blood flow|||0|901|1019|1029
SE|156||ab|6|entity|C0225319|Interstitial space|bsoj|||interstitial space|||0|1000|1049|1067
SE|156||ab|6|entity|C0521110|Accelerated|ftcn|||accelerated|||0|587|1090|1101
SE|156||ab|6|entity|C0017952|Glycolysis|moft|||glycolytic|||0|587|1102|1112
SE|156||ab|6|entity|C0030054|Oxygen|elii,phsu|||oxygen|||0|851|1121|1127
SE|156||ab|6|entity|C0011155|Deficiency|ftcn|||deficient|||0|851|1128|1137
SE|156||ab|6|entity|C0018787|Heart|bpoc|||hearts|||0|851|1138|1144
SE|156||ab|6|relation|1|1|C0018787|Heart|bpoc|bpoc|||hearts|||0|851|1138|1144|PREP|LOCATION_OF||1118|1120|6|3|C0225319|Interstitial space|bsoj|bsoj|||interstitial space|||0|1000|1049|1067

SE|156||ab|7|text|1160|1342|It is concluded that acceleration of ATP production from glycolysis can occur only in the marginally ischemic tissue in the peripheral area of tissue supplied by an occluded artery.
SE|156||ab|7|entity|C0000894|Acceleration|phpr|||acceleration|||0|1000|1181|1193
SE|156||ab|7|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|ATP|||0|888|1197|1200
SE|156||ab|7|entity|C0033268|production|ocac|||production|||0|888|1201|1211
SE|156||ab|7|entity|C0017952|Glycolysis|moft|||glycolysis|||0|1000|1217|1227
SE|156||ab|7|entity|C0475224|Ischemic|ftcn|||ischemic|||0|660|1261|1269
SE|156||ab|7|entity|C0205100|Peripheral|spco|||peripheral|||0|888|1284|1294
SE|156||ab|7|entity|C0205146|Area|spco|||area|||0|888|1295|1299
SE|156||ab|7|entity|C0028778|Obstruction|patf|||occluded|||0|888|1325|1333
SE|156||ab|7|entity|C0003842|Arteries|bpoc|||artery|||0|888|1334|1340

SE|156||ab|8|text|1342|1522|The central area of tissue which receives a low rate of coronary blood flow will have a reduced rate of ATP production due to both a lack of oxygen and an inhibition of glycolysis.
SE|156||ab|8|entity|C0205099|Central|spco|||central|||0|888|1346|1353
SE|156||ab|8|entity|C0205146|Area|spco|||area|||0|888|1354|1358
SE|156||ab|8|entity|C0205251|low|qlco|||low|||0|888|1386|1389
SE|156||ab|8|entity|C1521828|Rate|qnco|||rate|||0|888|1390|1394
SE|156||ab|8|entity|C0018787|Heart|bpoc|||coronary|||0|901|1398|1406
SE|156||ab|8|entity|C0232338|Blood flow|orgf|||blood flow|||0|901|1407|1417
SE|156||ab|8|entity|C0392756|Reduced|qlco|||reduced|||0|888|1430|1437
SE|156||ab|8|entity|C1521828|Rate|qnco|||rate|||0|888|1438|1442
SE|156||ab|8|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|ATP|||0|888|1446|1449
SE|156||ab|8|entity|C0033268|production|ocac|||production|||0|888|1450|1460
SE|156||ab|8|entity|C0332268|Lacking|qlco|||lack|||0|1000|1475|1479
SE|156||ab|8|entity|C0030054|Oxygen|elii,phsu|||oxygen|||0|1000|1483|1489
SE|156||ab|8|entity|C0017952|Glycolysis|moft|||glycolysis|||0|1000|1511|1521


SE|157||ti|1|text|16|76|Mechanisms of glycolytic inhibition in ischemic rat hearts.
SE|157||ti|1|entity|C0441712|Mechanisms|ftcn|||Mechanisms|||0|1000|16|26
SE|157||ti|1|entity|C1512232|Glycolysis Inhibition|phsf|||glycolytic inhibition|||0|964|30|51
SE|157||ti|1|entity|C0475224|Ischemic|ftcn|||ischemic|||0|851|55|63
SE|157||ti|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|851|64|67
SE|157||ti|1|entity|C0018787|Heart|bpoc|||hearts|||0|851|68|74
SE|157||ti|1|relation|0|0|C0018787|Heart|bpoc|bpoc|||hearts|||0|851|68|74|MOD/HEAD|PART_OF||64|74|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|851|64|67
SE|157||ti|1|relation|2|1|C1512232|Glycolysis Inhibition|phsf|phsf|||glycolytic inhibition|||0|964|30|51|PREP|PROCESS_OF||52|54|1|1|C0018787|Heart|bpoc|bpoc|||hearts|||0|851|68|74

SE|157||ab|1|text|82|200|The mechanisms of glycolytic inhibition in ischemic myocardium were investigated in the isolated, perfused rat heart.
SE|157||ab|1|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|1000|86|96
SE|157||ab|1|entity|C1512232|Glycolysis Inhibition|phsf|||glycolytic inhibition|||0|964|100|121
SE|157||ab|1|entity|C0151744|Myocardial Ischemia|dsyn|||ischemic myocardium|||0|928|125|144
SE|157||ab|1|entity|C0205409|Isolated|ftcn|||isolated|||0|825|170|178
SE|157||ab|1|entity|C1549542|Perfuse|ftcn|||perfused|||0|825|180|188
SE|157||ab|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|825|189|192
SE|157||ab|1|entity|C0018787|Heart|bpoc|||heart|||0|825|193|198
SE|157||ab|1|relation|0|0|C0018787|Heart|bpoc|bpoc|||heart|||0|825|193|198|MOD/HEAD|PART_OF||189|198|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|825|189|192
SE|157||ab|1|relation|3|2|C1512232|Glycolysis Inhibition|phsf|phsf|||glycolytic inhibition|||0|964|100|121|PREP|PROCESS_OF||163|165|1|1|C0018787|Heart|bpoc|bpoc|||heart|||0|825|193|198

SE|157||ab|2|text|200|283|Glycolysis was inhibited at the level of glyceraldehyde-3-phosphate dehydrogenase.
SE|157||ab|2|entity|C0017952|Glycolysis|moft|||Glycolysis|||0|1000|200|210
SE|157||ab|2|entity|C0017857|Glyceraldehyde-3-Phosphate Dehydrogenases|aapp,enzy|||glyceraldehyde-3-phosphate dehydrogenase|||0|1000|241|281

SE|157||ab|3|text|283|477|The major factors that accounted for the glycolytic inhibition in the ischemic heart compared with the anoxic heart appeared to be higher tissue levels of lactate and H+ in the ischemic tissue.
SE|157||ab|3|entity|C0205164|Major|qlco|||major|||0|872|287|292
SE|157||ab|3|entity|C1521761|Factor|ftcn|||factors|||0|872|293|300
SE|157||ab|3|entity|C1512232|Glycolysis Inhibition|phsf|||glycolytic inhibition|||0|964|324|345
SE|157||ab|3|entity|C0475224|Ischemic|ftcn|||ischemic|||0|888|353|361
SE|157||ab|3|entity|C0018787|Heart|bpoc|||heart|||0|888|362|367
SE|157||ab|3|entity|C0003129|Anoxemia|sosy|||anoxic|||0|853|386|392
SE|157||ab|3|entity|C0018787|Heart|bpoc|||heart|||0|853|393|398
SE|157||ab|3|entity|C0205250|High|qlco|||higher|||0|785|414|420
SE|157||ab|3|entity|C0441889|Levels|inpr|||levels|||0|785|428|434
SE|157||ab|3|entity|C0022924|Lactates|orch|||lactate|||0|1000|438|445
SE|157||ab|3|entity|C0475224|Ischemic|ftcn|||ischemic|||0|694|460|468
SE|157||ab|3|relation|2|1|C1512232|Glycolysis Inhibition|phsf|phsf|||glycolytic inhibition|||0|964|324|345|PREP|PROCESS_OF||346|348|6|1|C0018787|Heart|bpoc|bpoc|||heart|||0|888|362|367

SE|157||ab|4|text|477|603|Increased extracellular pH inhibited glycolysis in anoxic and hypoxic hearts much more readily than it did in aerobic hearts.
SE|157||ab|4|entity|C0205217|Increased|qnco|||Increased|||0|851|477|486
SE|157||ab|4|entity|C0521119|Extracellular|celc|||extracellular|||0|851|487|500
SE|157||ab|4|entity|C0017952|Glycolysis|moft|||glycolysis|||0|1000|514|524
SE|157||ab|4|entity|C0003129|Anoxemia|sosy|||anoxic|||0|928|528|534
SE|157||ab|4|entity|C0242184|Hypoxia|patf|||hypoxic|||0|888|539|546
SE|157||ab|4|entity|C0018787|Heart|bpoc|||hearts|||0|888|547|553
SE|157||ab|4|entity|C0205172|More|ftcn|||more|||0|861|559|563
SE|157||ab|4|entity|C1510824|Aerobic|qlco|||aerobic|||0|888|587|594
SE|157||ab|4|entity|C0018787|Heart|bpoc|||hearts|||0|888|595|601
SE|157||ab|4|relation|1|1|C0018787|Heart|bpoc|bpoc|||hearts|||0|888|595|601|PREP|LOCATION_OF||584|586|4|2|C0003129|Anoxemia|sosy|sosy|||anoxic|||0|928|528|534
SE|157||ab|4|relation|1|1|C0018787|Heart|bpoc|bpoc|||hearts|||0|888|595|601|PREP|LOCATION_OF||584|586|4|2|C0242184|Hypoxia|patf|patf|||hypoxic|||0|888|539|546

SE|157||ab|5|text|603|735|However, maintenance of both extracellular and intracellular pH caused only a modest acceleration of glycolysis in ischemic hearts.
SE|157||ab|5|entity|C0521119|Extracellular|celc|||extracellular|||0|1000|632|645
SE|157||ab|5|entity|C0175996|Protoplasm|celc|||intracellular|||0|888|650|663
SE|157||ab|5|entity|C0000894|Acceleration|phpr|||acceleration|||0|861|688|700
SE|157||ab|5|entity|C0017952|Glycolysis|moft|||glycolysis|||0|1000|704|714
SE|157||ab|5|entity|C0475224|Ischemic|ftcn|||ischemic|||0|888|718|726
SE|157||ab|5|entity|C0018787|Heart|bpoc|||hearts|||0|888|727|733

SE|157||ab|6|text|735|898|Accumulation of tissue lactate and inhibition of glycolysis were directly proportional to the reduction in coronary bloow flow in both anoxic and ischemic hearts.
SE|157||ab|6|entity|C0022924|Lactates|orch|||lactate|||0|861|758|765
SE|157||ab|6|entity|C0017952|Glycolysis|moft|||glycolysis|||0|1000|784|794
SE|157||ab|6|entity|C0205351|Proportional|qlco|||proportional|||0|861|809|821
SE|157||ab|6|entity|C0018787|Heart|bpoc|||coronary|||0|802|842|850
SE|157||ab|6|entity|C0806140|Flow|orga|||flow|||0|802|857|861
SE|157||ab|6|entity|C0003129|Anoxemia|sosy|||anoxic|||0|928|870|876
SE|157||ab|6|entity|C0475224|Ischemic|ftcn|||ischemic|||0|888|881|889
SE|157||ab|6|entity|C0018787|Heart|bpoc|||hearts|||0|888|890|896
SE|157||ab|6|relation|7|6|C0022924|Lactates|orch|orch|||lactate|||0|861|758|765|PREP|TREATS||862|864|2|1|C0003129|Anoxemia|sosy|sosy|||anoxic|||0|928|870|876

SE|157||ab|7|text|898|1008|At intracellular lactate concentrations between 15 and 20 mM, glycolysis was inhibited under both conditions.
SE|157||ab|7|entity|C0175996|Protoplasm|celc|||intracellular|||0|851|901|914
SE|157||ab|7|entity|C0022924|Lactates|orch|||lactate|||0|851|915|922
SE|157||ab|7|entity|C0017952|Glycolysis|moft|||glycolysis|||0|1000|960|970
SE|157||ab|7|entity|C0348080|Condition|qlco|||conditions|||0|966|996|1006
SE|157||ab|7|relation|0|0|C0175996|Protoplasm|celc|celc|||intracellular|||0|851|901|914|MOD/HEAD|LOCATION_OF||901|922|0|0|C0022924|Lactates|orch|orch|||lactate|||0|851|915|922

SE|157||ab|8|text|1008|1131|Addition of either 10, 20, or 40 mM lactate to the perfusate inhibited glycolysis in aerobic, anoxic, and ischemic hearts.
SE|157||ab|8|entity|C0442796|Additive|qlco|||Addition|||0|928|1008|1016
SE|157||ab|8|entity|C0022924|Lactates|orch|||lactate|||0|851|1044|1051
SE|157||ab|8|entity|C0017952|Glycolysis|moft|||glycolysis|||0|1000|1079|1089
SE|157||ab|8|entity|C1510824|Aerobic|qlco|||aerobic|||0|853|1093|1100
SE|157||ab|8|entity|C0003129|Anoxemia|sosy|||anoxic|||0|853|1102|1108
SE|157||ab|8|entity|C0475224|Ischemic|ftcn|||ischemic|||0|888|1114|1122
SE|157||ab|8|entity|C0018787|Heart|bpoc|||hearts|||0|888|1123|1129
SE|157||ab|8|relation|3|2|C0022924|Lactates|orch|orch|||lactate|||0|851|1044|1051|VERB|DISRUPTS||1069|1078|3|1|C0017952|Glycolysis|moft|moft|||glycolysis|||0|1000|1079|1089
SE|157||ab|8|relation|4|3|C0022924|Lactates|orch|orch|||lactate|||0|851|1044|1051|PREP|TREATS||1090|1092|2|1|C0003129|Anoxemia|sosy|sosy|||anoxic|||0|853|1102|1108

SE|157||ab|9|text|1131|1220|The effect of lactate did not appear to be mediated through changes in intracellular pH.
SE|157||ab|9|entity|C1280500|Effect|qlco|||effect|||0|1000|1135|1141
SE|157||ab|9|entity|C0022924|Lactates|orch|||lactate|||0|1000|1145|1152
SE|157||ab|9|entity|C1518422|Not|ftcn|||not|||0|1000|1157|1160
SE|157||ab|9|entity|C0175996|Protoplasm|celc|||intracellular|||0|888|1202|1215

SE|157||ab|10|text|1220|1356|It is concluded that accumulation of lactate represents a major factor in the inhibition of glycolysis that develops in ischemic hearts.
SE|157||ab|10|entity|C0022924|Lactates|orch|||lactate|||0|1000|1257|1264
SE|157||ab|10|entity|C0205164|Major|qlco|||major|||0|888|1278|1283
SE|157||ab|10|entity|C1521761|Factor|ftcn|||factor|||0|888|1284|1290
SE|157||ab|10|entity|C0017952|Glycolysis|moft|||glycolysis|||0|1000|1312|1322
SE|157||ab|10|entity|C0475224|Ischemic|ftcn|||ischemic|||0|888|1340|1348
SE|157||ab|10|entity|C0018787|Heart|bpoc|||hearts|||0|888|1349|1355
SE|157||ab|10|relation|3|2|C0022924|Lactates|orch|orch|||lactate|||0|1000|1257|1264|NOM|DISRUPTS||1298|1308|2|1|C0017952|Glycolysis|moft|moft|||glycolysis|||0|1000|1312|1322


SE|158||ti|1|text|16|96|Comparison of contractile performance of canine atrial and ventricular muscles.
SE|158||ti|1|entity|C0597198|Performance|inbe|||performance|||0|853|42|53
SE|158||ti|1|entity|C0012984|Canis familiaris|mamm|||canine|||0|888|57|63
SE|158||ti|1|entity|C0018792|Heart Atrium|bpoc|||atrial|||0|888|64|70
SE|158||ti|1|entity|C0018827|Heart Ventricle|bpoc|||ventricular|||0|888|75|86
SE|158||ti|1|entity|C0026845|Muscle|tisu|||muscles|||0|888|87|94
SE|158||ti|1|relation|0|0|C0018792|Heart Atrium|bpoc|bpoc|||atrial|||0|888|64|70|MOD/HEAD|PART_OF||57|70|0|0|C0012984|Canis familiaris|mamm|mamm|||canine|||0|888|57|63
SE|158||ti|1|relation|0|0|C0026845|Muscle|tisu|tisu|||muscles|||0|888|87|94|MOD/HEAD|PART_OF||75|94|0|0|C0018827|Heart Ventricle|bpoc|bpoc|||ventricular|||0|888|75|86

SE|158||ab|1|text|102|286|This study compared the contractile performance of a canine right atrial trabecula with that of a macroscopically indistinguishable trabecula isolated from the right ventricular apex.
SE|158||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|107|112
SE|158||ab|1|entity|C0597198|Performance|inbe|||performance|||0|853|138|149
SE|158||ab|1|entity|C0012984|Canis familiaris|mamm|||canine|||0|843|155|161
SE|158||ab|1|entity|C0225844|Right atrial structure|bpoc|||right atrial|||0|843|162|174
SE|158||ab|1|entity|C0222660|Trabecular substance of bone|tisu|||trabecula|||0|843|175|184
SE|158||ab|1|entity|C0222660|Trabecular substance of bone|tisu|||trabecula|||0|827|234|243
SE|158||ab|1|entity|C0225883|Right ventricular structure|bpoc|||right ventricular|||0|877|262|279
SE|158||ab|1|entity|C0140145|APEX1 protein, human|aapp,enzy|328|APEX1|apex|||0|877|280|284
SE|158||ab|1|relation|0|0|C0140145|APEX1 protein, human|aapp,gngm,enzy|aapp|328|APEX1|apex|||0|877|280|284|MOD/HEAD|PART_OF||262|284|0|0|C0225883|Right ventricular structure|bpoc|bpoc|||right ventricular|||0|877|262|279
SE|158||ab|1|relation|0|0|C0222660|Trabecular substance of bone|tisu|tisu|||trabecula|||0|843|175|184|MOD/HEAD|PART_OF||162|184|0|0|C0225844|Right atrial structure|bpoc|bpoc|||right atrial|||0|843|162|174

SE|158||ab|2|text|286|401|The heart was removed from nine mongrel puppies weighing 6-8 kg and placed in Krebs-Ringer's bicarbonate solution.
SE|158||ab|2|entity|C0018787|Heart|bpoc|||heart|||0|1000|290|295
SE|158||ab|2|entity|C0205455|Nine|qnco|||nine|||0|802|313|317
SE|158||ab|2|entity|C0869010|Puppies|mamm|||puppies|||0|802|326|333
SE|158||ab|2|entity|C0005367|Bicarbonates|inch|||bicarbonate|||0|916|379|390
SE|158||ab|2|entity|C0064411|Krebs-Ringer solution|clnd|||Krebs-Ringer's bicarbonate solution|||0|916|364|399

SE|158||ab|3|text|401|507|The bathing solution contained only 1.25 mmoles of Ca2+ and was bubbled with a 95% O2-5% CO2 gas mixture.
SE|158||ab|3|entity|C0150141|Bathing|topp|||bathing|||0|888|405|412
SE|158||ab|3|entity|C0037633|Solutions|sbst|||solution|||0|888|413|421
SE|158||ab|3|entity|C0439190|mmol|qnco|||mmoles|||0|779|442|448
SE|158||ab|3|entity|||gngm|760|CA2|Ca2|||0|1000|452|455
SE|158||ab|3|entity|C0007012|Carbon Dioxide|bacs,inch|||CO2|||0|762|490|493
SE|158||ab|3|entity|C0581444|Gas mixture|chvs|||gas mixture|||0|762|494|505

SE|158||ab|4|text|507|585|Each atrial trabecula was specially selected from the right atrial appendage.
SE|158||ab|4|entity|C0018792|Heart Atrium|bpoc|||atrial|||0|888|512|518
SE|158||ab|4|entity|C0222660|Trabecular substance of bone|tisu|||trabecula|||0|888|519|528
SE|158||ab|4|entity|C0456934|Entire right auricular appendage|bpoc|||right atrial appendage|||0|1000|561|583
SE|158||ab|4|relation|0|0|C0222660|Trabecular substance of bone|tisu|tisu|||trabecula|||0|888|519|528|MOD/HEAD|PART_OF||512|528|0|0|C0018792|Heart Atrium|bpoc|bpoc|||atrial|||0|888|512|518

SE|158||ab|5|text|585|678|Histologically, these trabeculae showed a remarkable longitudinal orientation of the fibers.
SE|158||ab|5|entity|C0205462|Histologic|ftcn|||Histologically|||0|1000|585|599
SE|158||ab|5|entity|C0222660|Trabecular substance of bone|tisu|||trabeculae|||0|966|607|617
SE|158||ab|5|entity|C1550002|Remark|idcn|||remarkable|||0|587|627|637
SE|158||ab|5|entity|C0205127|Longitudinal|spco|||longitudinal|||0|587|638|650
SE|158||ab|5|entity|C1304649|Tissue fiber|tisu|||fibers|||0|1000|670|676

SE|158||ab|6|text|678|988|At Lmax (the length of the muscle at which developed tension was maximum) under identical conditions of temperature, rate of stimulation, ionic milieu, pH, and O2 and CO2 supply, right atrial trabeculae achieved the same developed and total tensions but in a much shorter time than did ventricular trabeculae.
SE|158||ab|6|entity|C1444754|Length|qnco|||length|||0|1000|691|697
SE|158||ab|6|entity|C0026845|Muscle|tisu|||muscle|||0|1000|705|711
SE|158||ab|6|entity|C0233494|Tension|mobd|||tension|||0|1000|731|738
SE|158||ab|6|entity|C0806909|Maximum|fndg|||maximum|||0|1000|743|750
SE|158||ab|6|entity|C0205280|Identical|qlco|||identical|||0|872|758|767
SE|158||ab|6|entity|C0348080|Condition|qlco|||conditions|||0|872|768|778
SE|158||ab|6|entity|C0039476|Temperature|qnco|||temperature|||0|1000|782|793
SE|158||ab|6|entity|C1521828|Rate|qnco|||rate|||0|1000|795|799
SE|158||ab|6|entity|C0022023|Ions|elii|||ionic|||0|623|816|821
SE|158||ab|6|entity|C0007012|Carbon Dioxide|bacs,inch|||CO2|||0|694|845|848
SE|158||ab|6|entity|C0225844|Right atrial structure|bpoc|||right atrial|||0|866|857|869
SE|158||ab|6|entity|C0222660|Trabecular substance of bone|tisu|||trabeculae|||0|866|870|880
SE|158||ab|6|entity|C0445247|Same|qlco|||same|||0|694|894|898
SE|158||ab|6|entity|C0439175|% of total|qnco|||total|||0|872|913|918
SE|158||ab|6|entity|C0233494|Tension|mobd|||tensions|||0|872|919|927
SE|158||ab|6|entity|C0040223|Time|tmco|||time|||0|872|950|954
SE|158||ab|6|entity|C0018827|Heart Ventricle|bpoc|||ventricular|||0|872|964|975
SE|158||ab|6|entity|C0222660|Trabecular substance of bone|tisu|||trabeculae|||0|872|976|986
SE|158||ab|6|relation|0|0|C0222660|Trabecular substance of bone|tisu|tisu|||trabeculae|||0|866|870|880|MOD/HEAD|PART_OF||857|880|0|0|C0225844|Right atrial structure|bpoc|bpoc|||right atrial|||0|866|857|869
SE|158||ab|6|relation|0|0|C0222660|Trabecular substance of bone|tisu|tisu|||trabeculae|||0|872|976|986|MOD/HEAD|PART_OF||964|986|0|0|C0018827|Heart Ventricle|bpoc|bpoc|||ventricular|||0|872|964|975

SE|158||ab|7|text|988|1066|In both muscle groups the maximum developed tension averaged about 2.5 g/mm2.
SE|158||ab|7|entity|C0026845|Muscle|tisu|||muscle|||0|1000|996|1002
SE|158||ab|7|entity|C0806909|Maximum|fndg|||maximum|||0|1000|1014|1021
SE|158||ab|7|entity|C0233494|Tension|mobd|||tension|||0|1000|1032|1039
SE|158||ab|7|entity|C0450346|2/5|qnco|||2.5|||0|824|1055|1058
SE|158||ab|7|entity|C0456786|sq. mm|qnco|||mm2|||0|824|1061|1064

SE|158||ab|8|text|1066|1299|Since Lo (expressed as a fraction of Lmax) was less in atrial muscle than it was in ventribular muscle, we concluded that atrial muscle can be stretched considerably more than can ventricular muscle before optimum length is reached.
SE|158||ab|8|entity|C0018792|Heart Atrium|bpoc|||atrial|||0|888|1121|1127
SE|158||ab|8|entity|C0026845|Muscle|tisu|||muscle|||0|888|1128|1134
SE|158||ab|8|entity|C0026845|Muscle|tisu|||muscle|||0|861|1162|1168
SE|158||ab|8|entity|C0018792|Heart Atrium|bpoc|||atrial|||0|888|1188|1194
SE|158||ab|8|entity|C0026845|Muscle|tisu|||muscle|||0|888|1195|1201
SE|158||ab|8|entity|C0018827|Heart Ventricle|bpoc|||ventricular|||0|888|1246|1257
SE|158||ab|8|entity|C0026845|Muscle|tisu|||muscle|||0|888|1258|1264
SE|158||ab|8|entity|C1444754|Length|qnco|||length|||0|861|1280|1286
SE|158||ab|8|relation|0|0|C0026845|Muscle|tisu|tisu|||muscle|||0|888|1128|1134|MOD/HEAD|PART_OF||1121|1134|0|0|C0018792|Heart Atrium|bpoc|bpoc|||atrial|||0|888|1121|1127
SE|158||ab|8|relation|0|0|C0026845|Muscle|tisu|tisu|||muscle|||0|888|1195|1201|MOD/HEAD|PART_OF||1188|1201|0|0|C0018792|Heart Atrium|bpoc|bpoc|||atrial|||0|888|1188|1194
SE|158||ab|8|relation|0|0|C0026845|Muscle|tisu|tisu|||muscle|||0|888|1258|1264|MOD/HEAD|PART_OF||1246|1264|0|0|C0018827|Heart Ventricle|bpoc|bpoc|||ventricular|||0|888|1246|1257

SE|158||ab|9|text|1299|1445|At any given initial muscle length, the maximum of tension rise for atrial trabeculae amounted to at least twice that for ventricular trabeculae.
SE|158||ab|9|entity|C1442162|GIVEN|cnce|||given|||0|833|1306|1311
SE|158||ab|9|entity|C0205265|Initially|tmco|||initial|||0|833|1312|1319
SE|158||ab|9|entity|C0026845|Muscle|tisu|||muscle|||0|833|1320|1326
SE|158||ab|9|entity|C1444754|Length|qnco|||length|||0|833|1327|1333
SE|158||ab|9|entity|C0806909|Maximum|fndg|||maximum|||0|1000|1339|1346
SE|158||ab|9|entity|C0233494|Tension|mobd|||tension|||0|694|1350|1357
SE|158||ab|9|entity|C0018792|Heart Atrium|bpoc|||atrial|||0|872|1367|1373
SE|158||ab|9|entity|C0222660|Trabecular substance of bone|tisu|||trabeculae|||0|872|1374|1384
SE|158||ab|9|entity|C0018827|Heart Ventricle|bpoc|||ventricular|||0|872|1421|1432
SE|158||ab|9|entity|C0222660|Trabecular substance of bone|tisu|||trabeculae|||0|872|1433|1443
SE|158||ab|9|relation|0|0|C0222660|Trabecular substance of bone|tisu|tisu|||trabeculae|||0|872|1374|1384|MOD/HEAD|PART_OF||1367|1384|0|0|C0018792|Heart Atrium|bpoc|bpoc|||atrial|||0|872|1367|1373
SE|158||ab|9|relation|0|0|C0222660|Trabecular substance of bone|tisu|tisu|||trabeculae|||0|872|1433|1443|MOD/HEAD|PART_OF||1421|1443|0|0|C0018827|Heart Ventricle|bpoc|bpoc|||ventricular|||0|872|1421|1432

SE|158||ab|10|text|1445|1601|At any given load up to 1.5 g/mm2, the maximum velocity of shortening of an atrial trabecula was about three to four times that of a ventricular trabecula.
SE|158||ab|10|entity|C1442162|GIVEN|cnce|||given|||0|888|1452|1457
SE|158||ab|10|entity|C1550025|Load|idcn|||load|||0|888|1458|1462
SE|158||ab|10|entity|C0450316|1/5|qnco|||1.5|||0|824|1469|1472
SE|158||ab|10|entity|C0456786|sq. mm|qnco|||mm2|||0|824|1475|1478
SE|158||ab|10|entity|C0806909|Maximum|fndg|||maximum|||0|888|1484|1491
SE|158||ab|10|entity|C0439830|Velocity|ftcn|||velocity|||0|888|1492|1500
SE|158||ab|10|entity|C0018792|Heart Atrium|bpoc|||atrial|||0|888|1521|1527
SE|158||ab|10|entity|C0222660|Trabecular substance of bone|tisu|||trabecula|||0|888|1528|1537
SE|158||ab|10|entity|C0205449|Three|qnco|||three|||0|861|1548|1553
SE|158||ab|10|entity|C0205450|Four|qnco|||four|||0|872|1557|1561
SE|158||ab|10|entity|C0040223|Time|tmco|||times|||0|872|1562|1567
SE|158||ab|10|entity|C0018827|Heart Ventricle|bpoc|||ventricular|||0|888|1578|1589
SE|158||ab|10|entity|C0222660|Trabecular substance of bone|tisu|||trabecula|||0|888|1590|1599
SE|158||ab|10|relation|0|0|C0222660|Trabecular substance of bone|tisu|tisu|||trabecula|||0|888|1528|1537|MOD/HEAD|PART_OF||1521|1537|0|0|C0018792|Heart Atrium|bpoc|bpoc|||atrial|||0|888|1521|1527
SE|158||ab|10|relation|0|0|C0222660|Trabecular substance of bone|tisu|tisu|||trabecula|||0|888|1590|1599|MOD/HEAD|PART_OF||1578|1599|0|0|C0018827|Heart Ventricle|bpoc|bpoc|||ventricular|||0|888|1578|1589

SE|158||ab|11|text|1601|1809|These results collectively indicate that the contractile performance of the right atrial muscle is in many respects superior to that of the right ventricle, at least under the conditions of these experiments.
SE|158||ab|11|entity|C1274040|result|ftcn|||results|||0|966|1607|1614
SE|158||ab|11|entity|C0597198|Performance|inbe|||performance|||0|853|1658|1669
SE|158||ab|11|entity|C0225844|Right atrial structure|bpoc|||right atrial|||0|877|1677|1689
SE|158||ab|11|entity|C0026845|Muscle|tisu|||muscle|||0|877|1690|1696
SE|158||ab|11|entity|C0679133|RESPECT|socb|||respects|||0|966|1708|1716
SE|158||ab|11|entity|C1282910|Upper|spco|||superior|||0|1000|1717|1725
SE|158||ab|11|entity|C0225883|Right ventricular structure|bpoc|||right ventricle|||0|1000|1741|1756
SE|158||ab|11|entity|C0348080|Condition|qlco|||conditions|||0|966|1777|1787
SE|158||ab|11|entity|C0681814|research study|resa|||experiments|||0|1000|1797|1808
SE|158||ab|11|relation|0|0|C0026845|Muscle|tisu|tisu|||muscle|||0|877|1690|1696|MOD/HEAD|PART_OF||1677|1696|0|0|C0225844|Right atrial structure|bpoc|bpoc|||right atrial|||0|877|1677|1689


SE|159||ti|1|text|16|87|Serum lactate dehydrogenase activity ratios with different substrates.
SE|159||ti|1|entity|C0229671|Serum|bdsu|||Serum|||0|875|16|21
SE|159||ti|1|entity|C1151154|lactate dehydrogenase activity|moft|||lactate dehydrogenase activity|||0|875|22|52
SE|159||ti|1|entity|C0456603|Ratio|inpr|||ratios|||0|875|53|59
SE|159||ti|1|entity|C1547020|*Difference|qnco|||different|||0|623|65|74

SE|159||ab|1|text|93|96|1.

SE|159||ab|2|text|96|362|The lactate dehydrogenase activity of 89 sera from patients suffering myocardial infarction and of 55 sera from patients with hepatocellular damage was assayed under optimal conditions using pyruvate, alpha-oxobutyrate, hydroxypyruvate and glyoxylate as substrates.
SE|159||ab|2|entity|C1151154|lactate dehydrogenase activity|moft|||lactate dehydrogenase activity|||0|1000|100|130
SE|159||ab|2|entity|C0229671|Serum|bdsu|||sera|||0|861|137|141
SE|159||ab|2|entity|C0030705|Patients|podg|||patients|||0|1000|147|155
SE|159||ab|2|entity|C0027051|Myocardial Infarction|dsyn|||myocardial infarction|||0|1000|166|187
SE|159||ab|2|entity|C0229671|Serum|bdsu|||sera|||0|861|198|202
SE|159||ab|2|entity|C0030705|Patients|podg|||patients|||0|1000|208|216
SE|159||ab|2|entity|C0151763|Liver damage|patf|||hepatocellular damage|||0|1000|222|243
SE|159||ab|2|entity|C0348080|Condition|qlco|||conditions|||0|827|270|280
SE|159||ab|2|entity|C0034354|Pyruvates|orch|||pyruvate|||0|1000|287|295
SE|159||ab|2|entity|C0439095|Alpha|inpr|||alpha|||0|888|297|302
SE|159||ab|2|entity|C0134374|oxobutyrate|orch|||oxobutyrate|||0|888|303|314
SE|159||ab|2|entity|C0017996|Glyoxylates|orch|||glyoxylate|||0|1000|336|346
SE|159||ab|2|relation|7|1|C0151763|Liver damage|patf|patf|||hepatocellular damage|||0|1000|222|243|PREP|PROCESS_OF||217|221|6|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|208|216
SE|159||ab|2|relation|8|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|208|216|PREP|LOCATION_OF||203|207|5|1|C0229671|Serum|bdsu|bdsu|||sera|||0|861|198|202
SE|159||ab|2|relation|10|1|C0027051|Myocardial Infarction|dsyn|dsyn|||myocardial infarction|||0|1000|166|187|VERB|PROCESS_OF||156|165|3|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|147|155
SE|159||ab|2|relation|11|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|147|155|PREP|LOCATION_OF||142|146|2|1|C0229671|Serum|bdsu|bdsu|||sera|||0|861|137|141

SE|159||ab|3|text|362|439|Activity was also measured with lactate as substrate at different pH values.
SE|159||ab|3|entity|C0022924|Lactates|orch|||lactate|||0|1000|394|401
SE|159||ab|3|entity|C1547020|*Difference|qnco|||different|||0|828|418|427
SE|159||ab|3|entity|C0042295|Values|qlco|||values|||0|828|431|437

SE|159||ab|4|text|439|442|2.

SE|159||ab|5|text|442|551|The ratios of activities under these different assay conditions were calculated for both series of patients.
SE|159||ab|5|entity|C0456603|Ratio|inpr|||ratios|||0|1000|446|452
SE|159||ab|5|entity|C0441655|Activities|acty|||activities|||0|1000|456|466
SE|159||ab|5|entity|C1547020|*Difference|qnco|||different|||0|816|479|488
SE|159||ab|5|entity|C1510438|Assay|lbpr|||assay|||0|816|489|494
SE|159||ab|5|entity|C0348080|Condition|qlco|||conditions|||0|816|495|505
SE|159||ab|5|entity|C0205549|Series|qnco|||series|||0|1000|531|537
SE|159||ab|5|entity|C0030705|Patients|podg|||patients|||0|1000|541|549

SE|159||ab|6|text|551|754|Correct differentiations for single ratios ranged from virtually nil for hydroxypyruvate/alpha-oxobutyrate to is greater than 93 per cent for glyoxylate/hydroxypyruvate and glyoxylate/alpha-oxobutyrate.
SE|159||ab|6|entity|C0037179|Unmarried person|popg|||single|||0|888|580|586
SE|159||ab|6|entity|C0456603|Ratio|inpr|||ratios|||0|888|587|593
SE|159||ab|6|entity|C0442734|Nil|qnco|||nil|||0|861|616|619
SE|159||ab|6|entity|C0439095|Alpha|inpr|||alpha|||0|790|640|645
SE|159||ab|6|entity|C0134374|oxobutyrate|orch|||oxobutyrate|||0|790|646|657
SE|159||ab|6|entity|C0443228|Largest|qnco|||greater|||0|1000|664|671
SE|159||ab|6|entity|C0562018|cent|qnco|||cent|||0|827|684|688
SE|159||ab|6|entity|C0017996|Glyoxylates|orch|||glyoxylate|||0|694|693|703
SE|159||ab|6|entity|C0017996|Glyoxylates|orch|||glyoxylate|||0|851|724|734
SE|159||ab|6|entity|C0439095|Alpha|inpr|||alpha|||0|851|735|740
SE|159||ab|6|entity|C0134374|oxobutyrate|orch|||oxobutyrate|||0|851|741|752

SE|159||ab|7|text|754|848|This was little improved by the use of multiple ratios involving up to seven separate assays.
SE|159||ab|7|entity|C0023882|Little's Disease|dsyn|||little|||0|1000|763|769
SE|159||ab|7|entity|C0439064|Numerous|qnco|||multiple|||0|888|793|801
SE|159||ab|7|entity|C0456603|Ratio|inpr|||ratios|||0|888|802|808
SE|159||ab|7|entity|C0205453|Seven|qnco|||seven|||0|840|825|830
SE|159||ab|7|entity|C0443299|Separate|spco|||separate|||0|840|831|839
SE|159||ab|7|entity|C1510438|Assay|lbpr|||assays|||0|840|840|846

SE|159||ab|8|text|848|851|3.

SE|159||ab|9|text|851|999|The activity ratio of hydroxypyruvate to pyruvate which is consistently greater than unity was found to be inverted in a case of morphine poisoning.
SE|159||ab|9|entity|C0456603|Ratio|inpr|||ratio|||0|888|864|869
SE|159||ab|9|entity|C0034354|Pyruvates|orch|||pyruvate|||0|1000|892|900
SE|159||ab|9|entity|C0443228|Largest|qnco|||greater|||0|861|923|930
SE|159||ab|9|entity|C0026549|Morphine|orch,phsu|||morphine|||0|888|980|988
SE|159||ab|9|entity|C0032343|Poisoning|inpo|||poisoning|||0|888|989|998


SE|160||ti|1|text|16|61|Fluorometric assay for N-acetylprocainamide.
SE|160||ti|1|entity|C0016352|Fluorometry|lbpr|||Fluorometric|||0|853|16|28
SE|160||ti|1|entity|C1510438|Assay|lbpr|||assay|||0|853|29|34
SE|160||ti|1|entity|C0001061|Acecainide|orch,phsu|||N-acetylprocainamide|||0|1000|39|59
SE|160||ti|1|relation|0|0|C1510438|Assay|lbpr|lbpr|||assay|||0|853|29|34|MOD/HEAD|USES||16|34|0|0|C0016352|Fluorometry|lbpr|lbpr|||Fluorometric|||0|853|16|28

SE|160||ab|1|text|67|203|We describe a simple, rapid fluorometric assay for separate quantitative analysis of procainamide and N-acetylprocainamide in mixtures.
SE|160||ab|1|entity|C0205352|Simple|qlco|||simple|||0|815|81|87
SE|160||ab|1|entity|C0439831|Rapid|qlco|||rapid|||0|815|89|94
SE|160||ab|1|entity|C0016352|Fluorometry|lbpr|||fluorometric|||0|815|95|107
SE|160||ab|1|entity|C1510438|Assay|lbpr|||assay|||0|815|108|113
SE|160||ab|1|entity|C0443299|Separate|spco|||separate|||0|851|118|126
SE|160||ab|1|entity|C0392762|Quantitative|qnco|||quantitative|||0|851|127|139
SE|160||ab|1|entity|C0936012|Analysis|resa|||analysis|||0|851|140|148
SE|160||ab|1|entity|C0033216|Procainamide|orch,phsu|||procainamide|||0|1000|152|164
SE|160||ab|1|entity|C0001061|Acecainide|orch,phsu|||N-acetylprocainamide|||0|1000|169|189
SE|160||ab|1|entity|C0439962|Mixture|sbst|||mixtures|||0|966|193|201
SE|160||ab|1|relation|0|0|C1510438|Assay|lbpr|lbpr|||assay|||0|815|108|113|MOD/HEAD|USES||95|113|0|0|C0016352|Fluorometry|lbpr|lbpr|||fluorometric|||0|815|95|107

SE|160||ab|2|text|203|369|The effective lenear range (fluorescence vs. concentration) in serum is 0.1 to 10.0 mg/liter, regardless of the ratio (by weight) of the two drugs from 1:10 to 10:1.
SE|160||ab|2|entity|C1514721|Range|qnco|||range|||0|802|224|229
SE|160||ab|2|entity|C0016315|Fluorescence|npop|||fluorescence|||0|1000|231|243
SE|160||ab|2|entity|C0229671|Serum|bdsu|||serum|||0|1000|266|271
SE|160||ab|2|entity|C0475211|liter|qnco|||liter|||0|750|290|295
SE|160||ab|2|entity|C0456603|Ratio|inpr|||ratio|||0|1000|315|320
SE|160||ab|2|entity|C0043100|Weight|qnco|||weight|||0|1000|325|331
SE|160||ab|2|entity|C0205448|Two|qnco|||two|||0|888|340|343
SE|160||ab|2|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|888|344|349

SE|160||ab|3|text|369|474|Analytical recoveries by the extraction method used were 100.0 +/- 3.0% and 98.0 +/- 4.0%, respectively.
SE|160||ab|3|entity|C0237820|Recovery|orgf|||recoveries|||0|827|380|390
SE|160||ab|3|entity|C0185115|Extraction|topp|||extraction|||0|888|398|408
SE|160||ab|3|entity|C0025663|Methods|inpr|||method|||0|888|409|415

SE|160||ab|4|text|474|557|For determination of either compound, the maximum coefficient of variation was 10%.
SE|160||ab|4|entity|C0680730|Adjudication|gora|||determination|||0|1000|478|491
SE|160||ab|4|entity|C0205198|Compound|qlco|||compound|||0|861|502|510
SE|160||ab|4|entity|C0806909|Maximum|fndg|||maximum|||0|916|516|523
SE|160||ab|4|entity|C0681921|coefficient of variation|qnco|||coefficient of variation|||0|916|524|548


SE|161||ti|1|text|16|92|Rapid kinetic measurement of lactate in plasma with a centrifugal analyzer.
SE|161||ti|1|entity|C0439831|Rapid|qlco|||Rapid|||0|851|16|21
SE|161||ti|1|entity|C0022702|Kinetics|idcn|||kinetic|||0|851|22|29
SE|161||ti|1|entity|C0242485|Measurement|ftcn|||measurement|||0|851|30|41
SE|161||ti|1|entity|C0022924|Lactates|orch|||lactate|||0|1000|45|52
SE|161||ti|1|entity|C0032105|Plasma|bdsu|||plasma|||0|1000|56|62
SE|161||ti|1|entity|C0179968|Analyzers, Laboratory, Clinical Chemistry, Automated, Centrifugal|medd|||centrifugal analyzer|||0|983|70|90
SE|161||ti|1|relation|2|1|C0032105|Plasma|bdsu|bdsu|||plasma|||0|1000|56|62|PREP|LOCATION_OF||53|55|2|1|C0022924|Lactates|orch|orch|||lactate|||0|1000|45|52

SE|161||ab|1|text|98|276|In this method, blood is collected in ammonium heparinized microhematocrit tubes and lactate is directly determined in the plasma, separated within 15 min from the erythrocytes.
SE|161||ab|1|entity|C0025663|Methods|inpr|||method|||0|1000|106|112
SE|161||ab|1|entity|C0005767|Blood|tisu|||blood|||0|1000|114|119
SE|161||ab|1|entity|C0002611|Ammonium|inch|||ammonium|||0|791|136|144
SE|161||ab|1|entity|C0175730|biomedical tube device|medd|||tubes|||0|791|173|178
SE|161||ab|1|entity|C0022924|Lactates|orch|||lactate|||0|1000|183|190
SE|161||ab|1|entity|C0032105|Plasma|bdsu|||plasma|||0|1000|221|227
SE|161||ab|1|entity|C0439232|Minute of time|tmco|||min|||0|861|249|252
SE|161||ab|1|entity|C0014792|Erythrocytes|cell|||erythrocytes|||0|1000|262|274
SE|161||ab|1|relation|3|1|C0032105|Plasma|bdsu|bdsu|||plasma|||0|1000|221|227|PREP|LOCATION_OF||214|216|4|1|C0022924|Lactates|orch|orch|||lactate|||0|1000|183|190

SE|161||ab|2|text|276|411|Lactate is assayed by mixing 10 mul of sample with NAD+ and lactate dehydrogenase in tris(hydroxymethyl)aminomethane hydrazine buffer.
SE|161||ab|2|entity|C0022924|Lactates|orch|||Lactate|||0|1000|276|283
SE|161||ab|2|entity|C0205430|Mixed|ftcn|||mixing|||0|627|298|304
SE|161||ab|2|entity|||gngm|4591|TRIM37|mul|||0|627|308|311
SE|161||ab|2|entity|C0027270|Nicotinamide adenine dinucleotide (NAD)|bacs,nnon|||NAD|||0|1000|327|330
SE|161||ab|2|entity|C0022917|Lactate Dehydrogenase|aapp,enzy|||lactate dehydrogenase|||0|1000|336|357
SE|161||ab|2|entity|C0814229|Temptation and Restraint Inventory|inpr|||tris|||0|966|361|365
SE|161||ab|2|entity|C0066318|methylamine|orch|||aminomethane|||0|851|380|392
SE|161||ab|2|entity|C0020231|Hydrazine|inch|||hydrazine|||0|851|393|402
SE|161||ab|2|entity|C0006353|Buffers|bacs,irda|||buffer|||0|851|403|409

SE|161||ab|3|text|411|528|The rate of increase in absorbance of the NADH formed, measured at 340 nm, is proportional to lactate concentration.
SE|161||ab|3|entity|C1521828|Rate|qnco|||rate|||0|1000|415|419
SE|161||ab|3|entity|C0442805|Increase|ftcn|||increase|||0|1000|423|431
SE|161||ab|3|entity|C1268822|Optical density function|clna|||absorbance|||0|1000|435|445
SE|161||ab|3|entity|C0027289|NADH|bacs,nnon,phsu|||NADH|||0|1000|453|457
SE|161||ab|3|entity|C0205351|Proportional|qlco|||proportional|||0|1000|489|501
SE|161||ab|3|entity|C0022924|Lactates|orch|||lactate|||0|694|505|512

SE|161||ab|4|text|528|640|The assay is complete in 4 min and absorbance is linearly related to concentration from 0.625 to 15 mmol/liter.
SE|161||ab|4|entity|C1510438|Assay|lbpr|||assay|||0|1000|532|537
SE|161||ab|4|entity|C0205197|Complete|qlco|||complete|||0|1000|541|549
SE|161||ab|4|entity|C0439232|Minute of time|tmco|||min|||0|861|555|558
SE|161||ab|4|entity|C1268822|Optical density function|clna|||absorbance|||0|1000|563|573
SE|161||ab|4|entity|C0439190|mmol|qnco|||mmol|||0|790|628|632
SE|161||ab|4|entity|C0475211|liter|qnco|||liter|||0|790|633|638

SE|161||ab|5|text|640|721|Analytical recoveries of lactate added to plasma averaged 104% (range, 91-116%).
SE|161||ab|5|entity|C0237820|Recovery|orgf|||recoveries|||0|827|651|661
SE|161||ab|5|entity|C0022924|Lactates|orch|||lactate|||0|1000|665|672
SE|161||ab|5|entity|C0032105|Plasma|bdsu|||plasma|||0|1000|682|688
SE|161||ab|5|entity|C1514721|Range|qnco|||range|||0|1000|704|709

SE|161||ab|6|text|721|828|Results compared well for plasma samples analyzed by this method with the CentrifiChem and the Du Pont aca.
SE|161||ab|6|entity|C1274040|result|ftcn|||Results|||0|966|721|728
SE|161||ab|6|entity|C0205170|Good|qlco|||well|||0|1000|738|742
SE|161||ab|6|entity|C0444263|Plasma specimen|bdsu|||plasma samples|||0|983|747|761
SE|161||ab|6|entity|C0025663|Methods|inpr|||method|||0|1000|779|785
SE|161||ab|6|entity|C0699211|Pontal|orch,phsu|||Pont|||0|828|819|823
SE|161||ab|6|entity|C0149561|Structure of anterior cerebral artery|bpoc|||aca|||0|828|824|827


SE|162||ti|1|text|16|127|Improved high-resolution high-voltage paper electrophoresis system for use in screening for aminoacidopathies.
SE|162||ti|1|entity|C0184511|Improved|qlco|||Improved|||0|769|16|24
SE|162||ti|1|entity|C1514893|Resolution|ftcn|||resolution|||0|769|30|40
SE|162||ti|1|entity|C0030351|Paper|mnob|||paper|||0|769|54|59
SE|162||ti|1|entity|C0596705|high voltage electrophoresis|lbpr|||high-voltage paper electrophoresis|||0|769|41|75
SE|162||ti|1|entity|C0449913|System|ftcn|||system|||0|769|76|82
SE|162||ti|1|entity|C0220908|Screening procedure|hlca|||screening|||0|1000|94|103
SE|162||ti|1|entity|C0002514|Amino Acid Metabolism, Inborn Errors|dsyn|||aminoacidopathies|||0|966|108|125
SE|162||ti|1|relation|2|2|C0596705|high voltage electrophoresis|lbpr|lbpr|||high-voltage paper electrophoresis|||0|769|41|75|NOM|DIAGNOSES||94|103|1|1|C0002514|Amino Acid Metabolism, Inborn Errors|dsyn|dsyn|||aminoacidopathies|||0|966|108|125

SE|162||ab|1|text|133|301|High-voltage paper electrophoresis of small samples of serum and urine at pH 6.0 resolves basic and acidic amino acids and separates them from the neutral amino acids.
SE|162||ab|1|entity|C0030351|Paper|mnob|||paper|||0|916|146|151
SE|162||ab|1|entity|C0596705|high voltage electrophoresis|lbpr|||High-voltage paper electrophoresis|||0|916|133|167
SE|162||ab|1|entity|C0700321|Small|qnco|||small|||0|694|171|176
SE|162||ab|1|entity|C0229671|Serum|bdsu|||serum|||0|1000|188|193
SE|162||ab|1|entity|C0042036|Urine|bdsu|||urine|||0|1000|198|203
SE|162||ab|1|entity|C0815040|Amino Acids, Acidic|aapp|||acidic amino acids|||0|1000|233|251
SE|162||ab|1|entity|C0301715|Amino Acids, Neutral|aapp,bacs|||neutral amino acids|||0|1000|280|299

SE|162||ab|2|text|301|478|For separation and identification of the neutral amino acids, the appropriate area of the electrophoretogram is cut out, sewn onto a second sheet of paper, and rerun at pH 1.9.
SE|162||ab|2|entity|C0036679|Diastasis|patf|||separation|||0|1000|305|315
SE|162||ab|2|entity|C0301715|Amino Acids, Neutral|aapp,bacs|||neutral amino acids|||0|1000|342|361
SE|162||ab|2|entity|C1548787|Appropriate|qlco|||appropriate|||0|888|367|378
SE|162||ab|2|entity|C0205146|Area|spco|||area|||0|888|379|383
SE|162||ab|2|entity|C0439787|Out|spco|||out|||0|1000|417|420
SE|162||ab|2|entity|C0457385|seconds|tmco|||second|||0|694|434|440
SE|162||ab|2|entity|C0030351|Paper|mnob|||paper|||0|1000|450|455

SE|162||ab|3|text|478|528|By this method, amino acids are rapidly resolved.
SE|162||ab|3|entity|C0025663|Methods|inpr|||method|||0|1000|486|492
SE|162||ab|3|entity|C0002520|Amino Acids|aapp,bacs,phsu|||amino acids|||0|1000|494|505

SE|162||ab|4|text|528|699|It is suited for use with special procedures such as oxidation of biological fluid with performic acid and specific staining for confirmation of amino acid identification.
SE|162||ab|4|entity|C0025664|Methodology|inpr|||procedures|||0|861|562|572
SE|162||ab|4|entity|C0030011|Oxidation|phpr|||oxidation|||0|1000|581|590
SE|162||ab|4|entity|C0205460|biological|ftcn|||biological|||0|888|594|604
SE|162||ab|4|entity|C0302908|Liquid substance|sbst|||fluid|||0|888|605|610
SE|162||ab|4|entity|C0136106|performic acid|orch|||performic acid|||0|1000|616|630
SE|162||ab|4|entity|C1611825|confirmation|idcn|||confirmation|||0|1000|657|669
SE|162||ab|4|entity|C0002520|Amino Acids|aapp,bacs,phsu|||amino acid|||0|734|673|683


[162]: *** ERROR *** ERROR *** ERROR ***
[163]: *** ERROR *** ERROR *** ERROR ***
SE|165||ti|1|text|16|96|A clinical method for the determination of serum gamma-glutamyl transpeptidase.
SE|165||ti|1|entity|C0205210|Clinical|qlco|||clinical|||0|888|18|26
SE|165||ti|1|entity|C0025663|Methods|inpr|||method|||0|888|27|33
SE|165||ti|1|entity|C0680730|Adjudication|gora|||determination|||0|1000|42|55
SE|165||ti|1|entity|C0229671|Serum|bdsu|||serum|||0|916|59|64
SE|165||ti|1|entity|C0017040|Gamma-glutamyl transferase|aapp,enzy|||gamma-glutamyl transpeptidase|||0|916|65|94
SE|165||ti|1|relation|0|0|C0229671|Serum|bdsu|bdsu|||serum|||0|916|59|64|MOD/HEAD|LOCATION_OF||59|94|0|0|C0017040|Gamma-glutamyl transferase|aapp,gngm,enzy|aapp|||gamma-glutamyl transpeptidase|||0|916|65|94

SE|165||ab|1|text|102|362|A simple, highly sensitive and reproducible method for the assay of gamma-glutamyl transpeptidase (EC 2.3.2-) activity is introduced, using gamma-glutamyl-p-nitroanilide as a substrate and glycylglycine as an acceptor in 50 g/l of polyoxyethylene nonylphenol.
SE|165||ab|1|entity|C0205352|Simple|qlco|||simple|||0|901|104|110
SE|165||ab|1|entity|C0439822|Highly sensitive|qlco|||highly sensitive|||0|901|112|128
SE|165||ab|1|entity|C1514863|Reproducibility|qlco|||reproducible|||0|847|133|145
SE|165||ab|1|entity|C0025663|Methods|inpr|||method|||0|847|146|152
SE|165||ab|1|entity|C1510438|Assay|lbpr|||assay|||0|1000|161|166
SE|165||ab|1|entity|C0017040|Gamma-glutamyl transferase|aapp,enzy|||gamma-glutamyl transpeptidase|||0|1000|170|199
SE|165||ab|1|entity|C0040676|Transferase|aapp,enzy|||EC 2|||0|861|201|205
SE|165||ab|1|entity|C0017984|Glycylglycine|aapp,bacs,phsu|||glycylglycine|||0|1000|291|304
SE|165||ab|1|entity|C0000901|Acceptors|popg|||acceptor|||0|966|311|319
SE|165||ab|1|entity|C0032483|Polyethylene Glycols|bodm,orch,phsu|||polyoxyethylene|||0|888|333|348
SE|165||ab|1|entity|C0068946|nonylphenol|orch|||nonylphenol|||0|888|349|360

SE|165||ab|2|text|362|468|Serum transpeptidase activity was assayed in 1080 healthy adults, the normal mean value being 14.8 mU/ml.
SE|165||ab|2|entity|C0229671|Serum|bdsu|||Serum|||0|840|362|367
SE|165||ab|2|entity|C0030962|Peptidyltransferase|aapp,enzy|||transpeptidase|||0|840|368|382
SE|165||ab|2|entity|C0686750|Well adult|fndg|||healthy adults|||0|884|412|426
SE|165||ab|2|entity|C0086715|Normal Range|qnco|||normal mean value|||0|913|432|449
SE|165||ab|2|relation|0|0|C0229671|Serum|bdsu|bdsu|||Serum|||0|840|362|367|MOD/HEAD|LOCATION_OF||362|382|0|0|C0030962|Peptidyltransferase|aapp,gngm,enzy|aapp|||transpeptidase|||0|840|368|382

SE|165||ab|3|text|468|560|The diagnostic evaluation of the enzyme in various hepatobiliary diseases is also discussed.
SE|165||ab|3|entity|C0920455|diagnosis evaluation|ocdi|||diagnostic evaluation|||0|964|472|493
SE|165||ab|3|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|501|507
SE|165||ab|3|entity|C0744866|Hepatobiliary disease|dsyn|||hepatobiliary diseases|||0|884|519|541
SE|165||ab|3|relation|2|1|C0014442|Enzymes|enzy,orch|enzy|||enzyme|||0|1000|501|507|PREP|ASSOCIATED_WITH||508|510|1|1|C0744866|Hepatobiliary disease|dsyn|dsyn|||hepatobiliary diseases|||0|884|519|541


[165]: *** ERROR *** ERROR *** ERROR ***
SE|167||ti|1|text|16|49|Treatment of renal hypertension.
SE|167||ti|1|entity|C0020544|Hypertension, Renal|dsyn|||renal hypertension|||0|1000|29|47

SE|167||ab|1|text|55|258|There are different types of renal hypertension: hypertension due to parenchymal renal disease, renovascular hypertension, hypertension due to urological disease, hypertension of endstage renal disease.
SE|167||ab|1|entity|C1547020|*Difference|qnco|||different|||0|853|65|74
SE|167||ab|1|entity|C0332307|Type - attribute|qlco|||types|||0|853|75|80
SE|167||ab|1|entity|C0020544|Hypertension, Renal|dsyn|||renal hypertension|||0|1000|84|102
SE|167||ab|1|entity|C0020538|Hypertensive disease|dsyn|||hypertension|||0|1000|104|116
SE|167||ab|1|entity|C0933845|Parenchyma|bpoc|||parenchymal|||0|865|124|135
SE|167||ab|1|entity|C0022658|Kidney Diseases|dsyn|||renal disease|||0|865|136|149
SE|167||ab|1|entity|C0020545|Hypertension, Renovascular|dsyn|||renovascular hypertension|||0|1000|151|176
SE|167||ab|1|entity|C0020538|Hypertensive disease|dsyn|||hypertension|||0|1000|178|190
SE|167||ab|1|entity|C0042075|Urologic Diseases|dsyn|||urological disease|||0|1000|198|216
SE|167||ab|1|entity|C0020538|Hypertensive disease|dsyn|||hypertension|||0|1000|218|230
SE|167||ab|1|entity|C1261469|End stage renal failure|dsyn|||endstage renal disease|||0|1000|234|256
SE|167||ab|1|relation|0|0|C0020545|Hypertension, Renovascular|dsyn|dsyn|||renovascular hypertension|||0|1000|151|176|INFER|CAUSES(SPEC)||136|176|0|0|C0020538|Hypertensive disease|dsyn|dsyn|||hypertension|||0|1000|104|116
SE|167||ab|1|relation|0|0|C0020545|Hypertension, Renovascular|dsyn|dsyn|||renovascular hypertension|||0|1000|151|176|SPEC|ISA||136|176|0|0|C0022658|Kidney Diseases|dsyn|dsyn|||renal disease|||0|865|136|149
SE|167||ab|1|relation|0|0|C0933845|Parenchyma|bpoc|bpoc|||parenchymal|||0|865|124|135|INFER|LOCATION_OF(SPEC)||136|176|0|0|C0020545|Hypertension, Renovascular|dsyn|dsyn|||renovascular hypertension|||0|1000|151|176
SE|167||ab|1|relation|0|0|C0933845|Parenchyma|bpoc|bpoc|||parenchymal|||0|865|124|135|MOD/HEAD|LOCATION_OF||124|149|0|0|C0022658|Kidney Diseases|dsyn|dsyn|||renal disease|||0|865|136|149
SE|167||ab|1|relation|3|1|C0042075|Urologic Diseases|dsyn|dsyn|||urological disease|||0|1000|198|216|PREP|CAUSES||191|197|6|1|C0020538|Hypertensive disease|dsyn|dsyn|||hypertension|||0|1000|178|190
SE|167||ab|1|relation|6|1|C0022658|Kidney Diseases|dsyn|dsyn|||renal disease|||0|865|136|149|PREP|CAUSES||117|123|3|1|C0020538|Hypertensive disease|dsyn|dsyn|||hypertension|||0|1000|104|116

SE|167||ab|2|text|258|395|Treatment has to consider-above all-the possibility of specific, medical or surgical procedures that may cause the underlying condition.
SE|167||ab|2|entity|C0205476|Medical|ftcn|||medical|||0|861|323|330
SE|167||ab|2|entity|C0543467|Operative Surgical Procedures|topp|||surgical procedures|||0|1000|334|353
SE|167||ab|2|entity|C0348080|Condition|qlco|||condition|||0|861|384|393

SE|167||ab|3|text|395|623|If the underlying disease is not amenable to specific therapy, symptomatic medical treatment to lower blood pressure is indicated: besides control of sodium-intake and body weight antihypertensive drugs are generally indicated.
SE|167||ab|3|entity|C0012634|Disease|dsyn|||disease|||0|861|413|420
SE|167||ab|3|entity|C1518422|Not|ftcn|||not|||0|694|424|427
SE|167||ab|3|entity|C0231220|Symptomatic|ftcn|||symptomatic|||0|851|458|469
SE|167||ab|3|entity|C0205476|Medical|ftcn|||medical|||0|851|470|477
SE|167||ab|3|entity|C0005823|Blood Pressure|orgf|||blood pressure|||0|1000|497|511
SE|167||ab|3|entity|C0243148|control|ftcn|||control|||0|1000|534|541
SE|167||ab|3|entity|C0489645|SODIUM INTAKE|orga|||sodium-intake|||0|1000|545|558
SE|167||ab|3|entity|C0005910|Body Weight|orga|||body weight|||0|888|563|574
SE|167||ab|3|entity|C0003364|Antihypertensive Agents|phsu|||antihypertensive drugs|||0|888|575|597
SE|167||ab|3|relation|5|1|C0005823|Blood Pressure|orgf|orgf|||blood pressure|||0|1000|497|511|NOM|AFFECTS||534|541|2|1|C0005910|Body Weight|orga|orga|||body weight|||0|888|563|574
SE|167||ab|3|relation|5|1|C0005823|Blood Pressure|orgf|orgf|||blood pressure|||0|1000|497|511|NOM|AFFECTS||534|541|2|1|C0489645|SODIUM INTAKE|orga|orga|||sodium-intake|||0|1000|545|558

SE|167||ab|4|text|623|798|We use them, alone or in combination, in the following line of order: diuretics, beta-adrenergic blockers, dihydralazine, reserpine, clonidine, alpha-methyldopa, guanethidine.
SE|167||ab|4|entity|C0205195|Combined|qlco|||combination|||0|1000|648|659
SE|167||ab|4|entity|C0332282|Following|tmco|||following|||0|888|668|677
SE|167||ab|4|entity|C0205132|Linear|spco|||line|||0|888|678|682
SE|167||ab|4|entity|C0012798|Diuretics|phsu|||diuretics|||0|1000|693|702
SE|167||ab|4|entity|C0001645|Adrenergic beta-Antagonists|phsu|||beta-adrenergic blockers|||0|1000|704|728
SE|167||ab|4|entity|C0012271|Dihydralazine|orch,phsu|||dihydralazine|||0|1000|730|743
SE|167||ab|4|entity|C0035179|Reserpine|orch,phsu|||reserpine|||0|1000|745|754
SE|167||ab|4|entity|C0009014|Clonidine|orch,phsu|||clonidine|||0|1000|756|765
SE|167||ab|4|entity|C0025741|Methyldopa|aapp,nsba,phsu|||alpha-methyldopa|||0|1000|767|783
SE|167||ab|4|entity|C0018318|Guanethidine|orch,phsu|||guanethidine|||0|1000|785|797


SE|168||ti|1|text|16|129|Effects of graded infusions of monomethylmethacrylate on coagulation, blood lipids, respiration and circulation.
SE|168||ti|1|entity|C1280500|Effect|qlco|||Effects|||0|966|16|23
SE|168||ti|1|entity|C0441800|Grade|clas|||graded|||0|855|27|33
SE|168||ti|1|entity|C0574032|Infusion procedures|topp|||infusions|||0|855|34|43
SE|168||ti|1|entity|C0441509|Coagulation procedure|topp|||coagulation|||0|1000|73|84
SE|168||ti|1|entity|C0596192|blood lipid|lipd|||blood lipids|||0|983|86|98
SE|168||ti|1|entity|C0035203|Respiration|phsf|||respiration|||0|1000|100|111

SE|168||ti|2|text|129|160|An experimental study in dogs.
SE|168||ti|2|entity|C0681814|research study|resa|||experimental study|||0|1000|132|150
SE|168||ti|2|entity|C0012984|Canis familiaris|mamm|||dogs|||0|1000|154|158

SE|168||ab|1|text|166|720|In 4 dogs injected intravenously (i.v.) with 125I labeled fibrinogen, 51Cr labeled platelets and 99mTc labeled albumin, and subjected to successively increasing amounts of i.v. infused monomethylmethacrylate, doses corresponding to the amounts released into the blood stream following implantation of acrylic cement during total hip replacements did not affect the clotting mechanism, did not cause trapping of platelets and fibrin in the lungs, did not generate fat emboli, and did not cause depression of the arterial oxygen tension or blood pressure.
SE|168||ab|1|entity|C0012984|Canis familiaris|mamm|||dogs|||0|861|171|175
SE|168||ab|1|entity|C0016006|Fibrinogen|aapp,bacs|||fibrinogen|||0|1000|224|234
SE|168||ab|1|entity|C0181496|Labels|mnob|||labeled|||0|627|241|248
SE|168||ab|1|entity|C0001924|Albumins|aapp,bacs|||albumin|||0|1000|277|284
SE|168||ab|1|entity|C0442808|Increasing|ftcn|||increasing|||0|733|316|326
SE|168||ab|1|entity|C1265611|Quantity|qnco|||amounts|||0|733|327|334
SE|168||ab|1|entity|C1446466|Dose|qnco|||doses|||0|1000|375|380
SE|168||ab|1|entity|C1265611|Quantity|qnco|||amounts|||0|966|402|409
SE|168||ab|1|entity|C0005775|Blood Circulation|phsf|||blood stream|||0|1000|428|440
SE|168||ab|1|entity|C0021107|Implantation procedure|topp|||implantation|||0|1000|451|463
SE|168||ab|1|entity|C0011343|Dental Cementum|bpoc|||cement|||0|861|475|481
SE|168||ab|1|entity|C0040508|Hip Replacement, Total|topp|||total hip replacements|||0|1000|489|511
SE|168||ab|1|entity|C1518422|Not|ftcn|||not|||0|1000|516|519
SE|168||ab|1|entity|C0005778|Blood coagulation|ortf|||clotting|||0|888|531|539
SE|168||ab|1|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|888|540|549
SE|168||ab|1|entity|C1518422|Not|ftcn|||not|||0|1000|555|558
SE|168||ab|1|entity|C0015982|Fibrin|aapp,bacs,phsu|||fibrin|||0|1000|591|597
SE|168||ab|1|entity|C0024109|Lung|bpoc|||lungs|||0|1000|605|610
SE|168||ab|1|entity|C1518422|Not|ftcn|||not|||0|1000|616|619
SE|168||ab|1|entity|C0013928|Embolism, Fat|dsyn|||fat emboli|||0|1000|629|639
SE|168||ab|1|entity|C1518422|Not|ftcn|||not|||0|1000|649|652
SE|168||ab|1|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|659|669
SE|168||ab|1|entity|C0202155|Oxygen measurement, partial pressure, arterial|lbpr|||arterial oxygen tension|||0|1000|677|700
SE|168||ab|1|entity|C0005823|Blood Pressure|orgf|||blood pressure|||0|1000|704|718
SE|168||ab|1|relation|5|1|C0024109|Lung|bpoc|bpoc|||lungs|||0|1000|605|610|PREP|LOCATION_OF||598|600|19|1|C0015982|Fibrin|aapp,gngm,bacs,phsu|aapp|||fibrin|||0|1000|591|597
SE|168||ab|1|relation|7|1|C0001924|Albumins|aapp,gngm,bacs|aapp|||albumin|||0|1000|277|284|ADJ|STIMULATES||316|326|16|11|C0015982|Fibrin|aapp,gngm,bacs,phsu|gngm|||fibrin|||0|1000|591|597
SE|168||ab|1|relation|15|1|C0040508|Hip Replacement, Total|topp|topp|||total hip replacements|||0|1000|489|511|VERB|AFFECTS|negation|520|526|9|1|C0005778|Blood coagulation|ortf|ortf|||clotting|||0|888|531|539
SE|168||ab|1|relation|20|17|C0016006|Fibrinogen|aapp,gngm,bacs|aapp|||fibrinogen|||0|1000|224|234|VERB|CAUSES|negation|620|628|4|1|C0013928|Embolism, Fat|dsyn|dsyn|||fat emboli|||0|1000|629|639

SE|168||ab|2|text|720|806|Monomethylmethacrylate in whole blood was associated with both blood cells and plasma.
SE|168||ab|2|entity|C0370231|whole blood|bdsu|||whole blood|||0|1000|746|757
SE|168||ab|2|entity|C0005773|Blood Cells|cell|||blood cells|||0|1000|783|794
SE|168||ab|2|entity|C0032105|Plasma|bdsu|||plasma|||0|1000|799|805


[168]: *** ERROR *** ERROR *** ERROR ***
SE|170||ti|1|text|16|109|Anaerobic glycolysis in normal human erythrocytes incubated in vitro with sodium salicylate.
SE|170||ti|1|entity|C0872016|anaerobic glycolysis|moft|||Anaerobic glycolysis|||0|1000|16|36
SE|170||ti|1|entity|C0205307|Normal|qlco|||normal|||0|851|40|46
SE|170||ti|1|entity|C0020114|Human|humn|||human|||0|851|47|52
SE|170||ti|1|entity|C0014792|Erythrocytes|cell|||erythrocytes|||0|851|53|65
SE|170||ti|1|entity|C1533691|in vitro|qlco|||in vitro|||0|1000|76|84
SE|170||ti|1|entity|C0037549|Sodium Salicylate|orch,phsu|||sodium salicylate|||0|1000|90|107
SE|170||ti|1|relation|0|0|C0014792|Erythrocytes|cell|cell|||erythrocytes|||0|851|53|65|MOD/HEAD|PART_OF||47|65|0|0|C0020114|Human|grup,humn|humn|||human|||0|851|47|52
SE|170||ti|1|relation|1|1|C0872016|anaerobic glycolysis|moft|moft|||Anaerobic glycolysis|||0|1000|16|36|PREP|PROCESS_OF||37|39|3|1|C0014792|Erythrocytes|cell|cell|||erythrocytes|||0|851|53|65

SE|170||ab|1|text|115|118|1.

SE|170||ab|2|text|118|285|Some effects of sodium salicylate upon anaerobic glycolysis have been studied in normal human erythrocytes incubated for up to 6 h at 37 degrees C in autologous sera.
SE|170||ab|2|entity|C1280500|Effect|qlco|||effects|||0|966|123|130
SE|170||ab|2|entity|C0037549|Sodium Salicylate|orch,phsu|||sodium salicylate|||0|1000|134|151
SE|170||ab|2|entity|C0872016|anaerobic glycolysis|moft|||anaerobic glycolysis|||0|1000|157|177
SE|170||ab|2|entity|C0205307|Normal|qlco|||normal|||0|851|199|205
SE|170||ab|2|entity|C0020114|Human|humn|||human|||0|851|206|211
SE|170||ab|2|entity|C0014792|Erythrocytes|cell|||erythrocytes|||0|851|212|224
SE|170||ab|2|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|255|264
SE|170||ab|2|entity|C0439859|Autologous|qlco|||autologous|||0|888|268|278
SE|170||ab|2|entity|C0229671|Serum|bdsu|||sera|||0|888|279|283
SE|170||ab|2|relation|0|0|C0014792|Erythrocytes|cell|cell|||erythrocytes|||0|851|212|224|MOD/HEAD|PART_OF||206|224|0|0|C0020114|Human|grup,humn|humn|||human|||0|851|206|211
SE|170||ab|2|relation|6|1|C0037549|Sodium Salicylate|orch,phsu|phsu|||sodium salicylate|||0|1000|134|151|NOM|AFFECTS||123|130|6|2|C0872016|anaerobic glycolysis|moft|moft|||anaerobic glycolysis|||0|1000|157|177

SE|170||ab|3|text|285|288|2.

SE|170||ab|4|text|288|512|Both glucose consumption and lactate production were stimulated by concentrations of salicylate up to 60 mmol/l but at the highest concentration used (90 mmol/l) an initial stimulus was followed by inhibition of glycolysis.
SE|170||ab|4|entity|C0017725|Glucose|bacs,carb,phsu|||glucose|||0|888|293|300
SE|170||ab|4|entity|C0022924|Lactates|orch|||lactate|||0|888|317|324
SE|170||ab|4|entity|C0033268|production|ocac|||production|||0|888|325|335
SE|170||ab|4|entity|C0036075|salicylate|orch,phsu|||salicylate|||0|1000|373|383
SE|170||ab|4|entity|C0439190|mmol|qnco|||mmol|||0|773|393|397
SE|170||ab|4|entity|C1522410|Highest|qlco|||highest|||0|694|411|418
SE|170||ab|4|entity|C0439190|mmol|qnco|||mmol|||0|840|442|446
SE|170||ab|4|entity|C0205265|Initially|tmco|||initial|||0|888|453|460
SE|170||ab|4|entity|C0234402|Stimulus|phpr|||stimulus|||0|888|461|469
SE|170||ab|4|entity|C0017952|Glycolysis|moft|||glycolysis|||0|1000|500|510
SE|170||ab|4|relation|2|1|C0022924|Lactates|orch|orch|||lactate|||0|888|317|324|VERB|STIMULATES||341|351|8|2|C0036075|salicylate|orch,phsu|orch|||salicylate|||0|1000|373|383
SE|170||ab|4|relation|8|5|C0036075|salicylate|orch,phsu|orch|||salicylate|||0|1000|373|383|NOM|DISRUPTS||486|496|1|1|C0017952|Glycolysis|moft|moft|||glycolysis|||0|1000|500|510

SE|170||ab|5|text|512|515|3.

SE|170||ab|6|text|515|729|Losses occurred of adenosine 5'-triphosphate (ATP), adenosine 5'-diphosphate (ADP) and adenosine 5'-phosphate(AMP)at higher concentrations of salicylate and there was a concomitant increase of inorganic phosphate.
SE|170||ab|6|entity|C1517945|Loss|qnco|||Losses|||0|966|515|521
SE|170||ab|6|entity|C0001480|Adenosine Triphosphate|bacs,nnon,phsu|||adenosine 5'-triphosphate|||0|1000|534|559
SE|170||ab|6|entity|C0001459|Adenosine Diphosphate|bacs,nnon|||adenosine 5'-diphosphate|||0|913|567|591
SE|170||ab|6|entity|C0877812|Adenosine 5'-Phosphate|bacs,nnon|||adenosine 5'-phosphate|||0|1000|602|624
SE|170||ab|6|entity|C0457243|Ampere|qnco|||AMP|||0|966|625|628
SE|170||ab|6|entity|C0205250|High|qlco|||higher|||0|872|632|638
SE|170||ab|6|entity|C0036075|salicylate|orch,phsu|||salicylate|||0|1000|657|667
SE|170||ab|6|entity|C1516780|Concomitant|qlco|||concomitant|||0|888|684|695
SE|170||ab|6|entity|C0442805|Increase|ftcn|||increase|||0|888|696|704
SE|170||ab|6|entity|C0031603|inorganic phosphate|inch|||inorganic phosphate|||0|1000|708|727
SE|170||ab|6|relation|7|1|C0036075|salicylate|orch,phsu|orch|||salicylate|||0|1000|657|667|NOM|STIMULATES||696|704|1|1|C0031603|inorganic phosphate|inch|inch|||inorganic phosphate|||0|1000|708|727

SE|170||ab|7|text|729|732|4.

SE|170||ab|8|text|732|890|Other phosphate esters underwent concentration changes at higher concentrations of salicylate that reflected inadequate concentrations of ATP for glycolysis.
SE|170||ab|8|entity|C0599126|phosphate ester|opco|||phosphate esters|||0|983|738|754
SE|170||ab|8|entity|C0205250|High|qlco|||higher|||0|872|790|796
SE|170||ab|8|entity|C0036075|salicylate|orch,phsu|||salicylate|||0|1000|815|825
SE|170||ab|8|entity|C0558058|Reflecting|menp|||reflected|||0|840|831|840
SE|170||ab|8|entity|C0205412|Inadequate|qlco|||inadequate|||0|840|841|851
SE|170||ab|8|entity|C0001480|Adenosine Triphosphate|bacs,nnon,phsu|||ATP|||0|1000|870|873
SE|170||ab|8|entity|C0017952|Glycolysis|moft|||glycolysis|||0|1000|878|888

SE|170||ab|9|text|890|893|5.

SE|170||ab|10|text|893|1065|The rates of sodium efflux from, and potassium influx into, erythrocytes were unaffected by the presence of salicylate at concentrations sufficient to stimulate glycolysis.
SE|170||ab|10|entity|C1521828|Rate|qnco|||rates|||0|966|897|902
SE|170||ab|10|entity|C0037473|Sodium|bacs,elii|||sodium|||0|694|906|912
SE|170||ab|10|entity|C0032821|Potassium|bacs,elii|||potassium|||0|694|930|939
SE|170||ab|10|entity|C0014792|Erythrocytes|cell|||erythrocytes|||0|1000|953|965
SE|170||ab|10|entity|C0036075|salicylate|orch,phsu|||salicylate|||0|1000|1001|1011
SE|170||ab|10|entity|C0205410|Sufficient|qlco|||sufficient|||0|1000|1030|1040
SE|170||ab|10|entity|C0017952|Glycolysis|moft|||glycolysis|||0|1000|1054|1064
SE|170||ab|10|relation|9|3|C0036075|salicylate|orch,phsu|phsu|||salicylate|||0|1000|1001|1011|VERB|AUGMENTS||1044|1053|1|1|C0017952|Glycolysis|moft|moft|||glycolysis|||0|1000|1054|1064


SE|171||ti|1|text|16|68|Arterial catecholamines in hypoxic exercise in man.
SE|171||ti|1|entity|C0221464|Arterial|spco|||Arterial|||0|888|16|24
SE|171||ti|1|entity|C0007412|Catecholamines|nsba,orch|||catecholamines|||0|888|25|39
SE|171||ti|1|entity|C0242184|Hypoxia|patf|||hypoxic|||0|888|43|50
SE|171||ti|1|entity|C0015259|Exercise|dora|||exercise|||0|888|51|59

SE|171||ab|1|text|74|77|1.

SE|171||ab|2|text|77|266|We measured the minute ventilation and arterial blood catecholamine concentrations in four normal men standing and at two levels of moderate treadmill exercise breathing 14% oxygen or air.
SE|171||ab|2|entity|C1301655|Minute ventilation|fndg|||minute ventilation|||0|1000|93|111
SE|171||ab|2|entity|C0229665|Blood arterial|tisu|||arterial blood|||0|861|116|130
SE|171||ab|2|entity|C0007412|Catecholamines|nsba,orch|||catecholamine|||0|861|131|144
SE|171||ab|2|entity|C0205450|Four|qnco|||four|||0|851|163|167
SE|171||ab|2|entity|C0205307|Normal|qlco|||normal|||0|851|168|174
SE|171||ab|2|entity|C0025266|Male population group|popg|||men|||0|851|175|178
SE|171||ab|2|entity|C0205448|Two|qnco|||two|||0|888|195|198
SE|171||ab|2|entity|C0441889|Levels|inpr|||levels|||0|888|199|205
SE|171||ab|2|entity|C0184069|Treadmill|medd|||treadmill|||0|901|218|227
SE|171||ab|2|entity|C1513375|Moderate Exercise|dora|||moderate treadmill exercise|||0|901|209|236
SE|171||ab|2|entity|C0030054|Oxygen|elii,phsu|||oxygen|||0|861|251|257
SE|171||ab|2|entity|C0001861|Air|sbst|||air|||0|1000|261|264
SE|171||ab|2|relation|0|0|C0007412|Catecholamines|nsba,orch|nsba|||catecholamine|||0|861|131|144|MOD/HEAD|PART_OF||116|144|0|0|C0229665|Blood arterial|tisu|tisu|||arterial blood|||0|861|116|130
SE|171||ab|2|relation|2|2|C1301655|Minute ventilation|fndg|fndg|||minute ventilation|||0|1000|93|111|PREP|PROCESS_OF||160|162|5|1|C0025266|Male population group|popg,humn|humn|||men|||0|851|175|178

SE|171||ab|3|text|266|269|2.

SE|171||ab|4|text|269|403|Minute ventilation was significantly higher during hypoxic exercise than during normoxic exercise at an oxygen uptake of 1500 ml/min.
SE|171||ab|4|entity|C1301655|Minute ventilation|fndg|||Minute ventilation|||0|1000|269|287
SE|171||ab|4|entity|C0205250|High|qlco|||higher|||0|827|306|312
SE|171||ab|4|entity|C0242184|Hypoxia|patf|||hypoxic|||0|888|320|327
SE|171||ab|4|entity|C0015259|Exercise|dora|||exercise|||0|888|328|336
SE|171||ab|4|entity|C0015259|Exercise|dora|||exercise|||0|861|358|366
SE|171||ab|4|entity|C0429627|Oxygen uptake|fndg|||oxygen uptake|||0|1000|373|386
SE|171||ab|4|entity|C0439232|Minute of time|tmco|||min|||0|790|398|401

SE|171||ab|5|text|403|406|3.

SE|171||ab|6|text|406|535|Arterial plasma noradrenaline during hypoxic exercise at an oxygen uptake of 1500 ml/min was significantly greater than at rest.
SE|171||ab|6|entity|C0221464|Arterial|spco|||Arterial|||0|851|406|414
SE|171||ab|6|entity|C0032105|Plasma|bdsu|||plasma|||0|851|415|421
SE|171||ab|6|entity|C0028351|Norepinephrine|nsba,orch,phsu|||noradrenaline|||0|851|422|435
SE|171||ab|6|entity|C0242184|Hypoxia|patf|||hypoxic|||0|888|443|450
SE|171||ab|6|entity|C0015259|Exercise|dora|||exercise|||0|888|451|459
SE|171||ab|6|entity|C0429627|Oxygen uptake|fndg|||oxygen uptake|||0|1000|466|479
SE|171||ab|6|entity|C0439232|Minute of time|tmco|||min|||0|790|491|494
SE|171||ab|6|entity|C0443228|Largest|qnco|||greater|||0|861|513|520
SE|171||ab|6|entity|C0035253|Rest|dora|||rest|||0|1000|529|533
SE|171||ab|6|relation|0|0|C0032105|Plasma|bdsu|bdsu|||plasma|||0|851|415|421|MOD/HEAD|LOCATION_OF||415|435|0|0|C0028351|Norepinephrine|nsba,orch,phsu|orch|||noradrenaline|||0|851|422|435

SE|171||ab|7|text|535|538|4.

SE|171||ab|8|text|538|678|Arterial plasma noradrenaline during normoxic exercise at an oxygen uptake of 1500 ml/min was not elevated above the resting concentration.
SE|171||ab|8|entity|C0221464|Arterial|spco|||Arterial|||0|851|538|546
SE|171||ab|8|entity|C0032105|Plasma|bdsu|||plasma|||0|851|547|553
SE|171||ab|8|entity|C0028351|Norepinephrine|nsba,orch,phsu|||noradrenaline|||0|851|554|567
SE|171||ab|8|entity|C0015259|Exercise|dora|||exercise|||0|861|584|592
SE|171||ab|8|entity|C0429627|Oxygen uptake|fndg|||oxygen uptake|||0|1000|599|612
SE|171||ab|8|entity|C0439232|Minute of time|tmco|||min|||0|790|624|627
SE|171||ab|8|entity|C1518422|Not|ftcn|||not|||0|1000|632|635
SE|171||ab|8|entity|C0035253|Rest|dora|||resting|||0|694|655|662
SE|171||ab|8|relation|0|0|C0032105|Plasma|bdsu|bdsu|||plasma|||0|851|547|553|MOD/HEAD|LOCATION_OF||547|567|0|0|C0028351|Norepinephrine|nsba,orch,phsu|orch|||noradrenaline|||0|851|554|567

SE|171||ab|9|text|678|681|5.

SE|171||ab|10|text|681|879|The results are compatible with the suggestion that increased concentrations of arterial plasma noradrenaline contribute to the hypoxic potentiation of the respiratory response to moderate exercise.
SE|171||ab|10|entity|C1274040|result|ftcn|||results|||0|966|685|692
SE|171||ab|10|entity|C1524057|Compatible|qlco|||compatible|||0|1000|697|707
SE|171||ab|10|entity|C0205217|Increased|qnco|||increased|||0|888|733|742
SE|171||ab|10|entity|C0221464|Arterial|spco|||arterial|||0|851|761|769
SE|171||ab|10|entity|C0032105|Plasma|bdsu|||plasma|||0|851|770|776
SE|171||ab|10|entity|C0028351|Norepinephrine|nsba,orch,phsu|||noradrenaline|||0|851|777|790
SE|171||ab|10|entity|C0242184|Hypoxia|patf|||hypoxic|||0|888|809|816
SE|171||ab|10|entity|C0279023|chemosensitization/potentiation|topp|||potentiation|||0|888|817|829
SE|171||ab|10|entity|C0521346|respiratory|ftcn|||respiratory|||0|888|837|848
SE|171||ab|10|entity|C0871261|response|clna|||response|||0|888|849|857
SE|171||ab|10|entity|C0015259|Exercise|dora|||exercise|||0|1000|870|878
SE|171||ab|10|relation|0|0|C0032105|Plasma|bdsu|bdsu|||plasma|||0|851|770|776|MOD/HEAD|LOCATION_OF||770|790|0|0|C0028351|Norepinephrine|nsba,orch,phsu|orch|||noradrenaline|||0|851|777|790


[171]: *** ERROR *** ERROR *** ERROR ***
[172]: *** ERROR *** ERROR *** ERROR ***
[173]: *** ERROR *** ERROR *** ERROR ***
[174]: *** ERROR *** ERROR *** ERROR ***
[175]: *** ERROR *** ERROR *** ERROR ***
[176]: *** ERROR *** ERROR *** ERROR ***
[177]: *** ERROR *** ERROR *** ERROR ***
[178]: *** ERROR *** ERROR *** ERROR ***
[179]: *** ERROR *** ERROR *** ERROR ***
[180]: *** ERROR *** ERROR *** ERROR ***
[181]: *** ERROR *** ERROR *** ERROR ***
[182]: *** ERROR *** ERROR *** ERROR ***
[183]: *** ERROR *** ERROR *** ERROR ***
[184]: *** ERROR *** ERROR *** ERROR ***
[185]: *** ERROR *** ERROR *** ERROR ***
[186]: *** ERROR *** ERROR *** ERROR ***
[187]: *** ERROR *** ERROR *** ERROR ***
[188]: *** ERROR *** ERROR *** ERROR ***
[189]: *** ERROR *** ERROR *** ERROR ***
[190]: *** ERROR *** ERROR *** ERROR ***
[191]: *** ERROR *** ERROR *** ERROR ***
[192]: *** ERROR *** ERROR *** ERROR ***
[193]: *** ERROR *** ERROR *** ERROR ***
[194]: *** ERROR *** ERROR *** ERROR ***
[195]: *** ERROR *** ERROR *** ERROR ***
[196]: *** ERROR *** ERROR *** ERROR ***
[197]: *** ERROR *** ERROR *** ERROR ***
[198]: *** ERROR *** ERROR *** ERROR ***
[199]: *** ERROR *** ERROR *** ERROR ***
[200]: *** ERROR *** ERROR *** ERROR ***
[201]: *** ERROR *** ERROR *** ERROR ***
[202]: *** ERROR *** ERROR *** ERROR ***
[203]: *** ERROR *** ERROR *** ERROR ***
[204]: *** ERROR *** ERROR *** ERROR ***
[205]: *** ERROR *** ERROR *** ERROR ***
[206]: *** ERROR *** ERROR *** ERROR ***
[207]: *** ERROR *** ERROR *** ERROR ***
[208]: *** ERROR *** ERROR *** ERROR ***
[209]: *** ERROR *** ERROR *** ERROR ***
[210]: *** ERROR *** ERROR *** ERROR ***
[211]: *** ERROR *** ERROR *** ERROR ***
[212]: *** ERROR *** ERROR *** ERROR ***
[213]: *** ERROR *** ERROR *** ERROR ***
[214]: *** ERROR *** ERROR *** ERROR ***
[215]: *** ERROR *** ERROR *** ERROR ***
[216]: *** ERROR *** ERROR *** ERROR ***
[217]: *** ERROR *** ERROR *** ERROR ***
[218]: *** ERROR *** ERROR *** ERROR ***
[219]: *** ERROR *** ERROR *** ERROR ***
[220]: *** ERROR *** ERROR *** ERROR ***
[221]: *** ERROR *** ERROR *** ERROR ***
[222]: *** ERROR *** ERROR *** ERROR ***
[223]: *** ERROR *** ERROR *** ERROR ***
[224]: *** ERROR *** ERROR *** ERROR ***
[225]: *** ERROR *** ERROR *** ERROR ***
[226]: *** ERROR *** ERROR *** ERROR ***
[227]: *** ERROR *** ERROR *** ERROR ***
[228]: *** ERROR *** ERROR *** ERROR ***
[229]: *** ERROR *** ERROR *** ERROR ***
[230]: *** ERROR *** ERROR *** ERROR ***
[231]: *** ERROR *** ERROR *** ERROR ***
[232]: *** ERROR *** ERROR *** ERROR ***
[233]: *** ERROR *** ERROR *** ERROR ***
SE|235||ti|1|text|16|78|Hydroxylation of p-Coumaric acid by illuminated chloroplasts.
SE|235||ti|1|entity|C0020365|Hydroxylation|npop|||Hydroxylation|||0|1000|16|29
SE|235||ti|1|entity|C0048207|4-coumaric acid|orch,phsu|||p-Coumaric acid|||0|1000|33|48
SE|235||ti|1|entity|C0008266|Chloroplasts|celc|||chloroplasts|||0|861|64|76

SE|235||ti|2|text|78|102|The role of superoxide.
SE|235||ti|2|entity|C0035820|Role|socb|||role|||0|1000|82|86
SE|235||ti|2|entity|C0038836|Superoxides|elii|||superoxide|||0|1000|90|100

SE|235||ab|1|text|108|111|1.

SE|235||ab|2|text|111|323|Chloroplasts isolated from leaves of spinach-beet (Beta vulgaris L. ssp. vulgaris) do not catalyse the hydroxylation of p-coumaric acid in the dark unless a reductant (such as ascorbate, NADH or NADPH) is added.
SE|235||ab|2|entity|C0008266|Chloroplasts|celc|||Chloroplasts|||0|1000|111|123
SE|235||ab|2|entity|C0600054|Beets|food|||beet|||0|861|156|160
SE|235||ab|2|entity|C0330391|Beta vulgaris|plnt|||Beta vulgaris|||0|602|162|175
SE|235||ab|2|entity|C1518422|Not|ftcn|||not|||0|1000|197|200
SE|235||ab|2|entity|C0020365|Hydroxylation|npop|||hydroxylation|||0|1000|214|227
SE|235||ab|2|entity|C0048207|4-coumaric acid|orch,phsu|||p-coumaric acid|||0|1000|231|246
SE|235||ab|2|entity|C0376446|Reducing Agents|irda|||reductant|||0|966|268|277
SE|235||ab|2|entity|C0178487|ascorbate|orch,phsu,vita|||ascorbate|||0|1000|287|296
SE|235||ab|2|entity|C0027289|NADH|bacs,nnon,phsu|||NADH|||0|1000|298|302
SE|235||ab|2|entity|C0027303|NADP|bacs,nnon|||NADPH|||0|1000|306|311

SE|235||ab|3|text|323|376|Superoxide dismutase has no effect on this reaction.
SE|235||ab|3|entity|C0038838|Superoxide Dismutase|aapp,enzy,phsu|||Superoxide dismutase|||0|1000|323|343
SE|235||ab|3|entity|C1280500|Effect|qlco|||effect|||0|1000|351|357
SE|235||ab|3|entity|C0443286|Reaction|ftcn|||reaction|||0|1000|366|374

SE|235||ab|4|text|376|379|2.

SE|235||ab|5|text|379|466|Illuminated chloroplasts catalyse the hydroxylation in the absence of added reductant.
SE|235||ab|5|entity|C0008266|Chloroplasts|celc|||chloroplasts|||0|861|391|403
SE|235||ab|5|entity|C0020365|Hydroxylation|npop|||hydroxylation|||0|1000|417|430
SE|235||ab|5|entity|C1524062|Additional|ftcn|||added|||0|855|449|454
SE|235||ab|5|entity|C0376446|Reducing Agents|irda|||reductant|||0|855|455|464

SE|235||ab|6|text|466|561|This reaction is completely inhibited by superoxide dismutase, but catalase has little effect.
SE|235||ab|6|entity|C0443286|Reaction|ftcn|||reaction|||0|1000|471|479
SE|235||ab|6|entity|C0038838|Superoxide Dismutase|aapp,enzy,phsu|||superoxide dismutase|||0|1000|507|527
SE|235||ab|6|entity|C0007367|CATALASE|aapp,enzy|||catalase|||0|1000|533|541
SE|235||ab|6|entity|C0023882|Little's Disease|dsyn|||little|||0|888|546|552
SE|235||ab|6|entity|C1280500|Effect|qlco|||effect|||0|888|553|559
SE|235||ab|6|relation|3|1|C0007367|CATALASE|aapp,gngm,enzy|aapp|||catalase|||0|1000|533|541|NOM|AFFECTS||553|559|3|0|C0023882|Little's Disease|dsyn|dsyn|||little|||0|888|546|552

SE|235||ab|7|text|561|564|3.

SE|235||ab|8|text|564|734|Both hydroxylation in the light and hydroxylation in the dark in the presence of reductants are inhibited by diethyldithiocarbamate, EDTA, cyanide and 2-mercaptoethanol.
SE|235||ab|8|entity|C0020365|Hydroxylation|npop|||hydroxylation|||0|1000|569|582
SE|235||ab|8|entity|C0020365|Hydroxylation|npop|||hydroxylation|||0|1000|600|613
SE|235||ab|8|entity|C0376446|Reducing Agents|irda|||reductants|||0|1000|645|655
SE|235||ab|8|entity|C0086154|Diethyldithiocarbamate|orch,phsu|||diethyldithiocarbamate|||0|1000|673|695
SE|235||ab|8|entity|C0013618|Edetic Acid|irda,orch,phsu|||EDTA|||0|1000|697|701
SE|235||ab|8|entity|C0010505|Cyanides|inch|||cyanide|||0|1000|703|710
SE|235||ab|8|entity|C0025402|2-Mercaptoethanol|orch|||2-mercaptoethanol|||0|1000|715|732
SE|235||ab|8|relation|4|1|C0010505|Cyanides|inch|inch|||cyanide|||0|1000|703|710|VERB|DISRUPTS||660|669|6|4|C0020365|Hydroxylation|npop|npop|||hydroxylation|||0|1000|600|613
SE|235||ab|8|relation|4|1|C0013618|Edetic Acid|irda,orch,phsu|orch|||EDTA|||0|1000|697|701|VERB|DISRUPTS||660|669|6|4|C0020365|Hydroxylation|npop|npop|||hydroxylation|||0|1000|600|613
SE|235||ab|8|relation|4|1|C0025402|2-Mercaptoethanol|orch|orch|||2-mercaptoethanol|||0|1000|715|732|VERB|DISRUPTS||660|669|6|4|C0020365|Hydroxylation|npop|npop|||hydroxylation|||0|1000|600|613
SE|235||ab|8|relation|4|1|C0086154|Diethyldithiocarbamate|orch,phsu|orch|||diethyldithiocarbamate|||0|1000|673|695|VERB|DISRUPTS||660|669|6|4|C0020365|Hydroxylation|npop|npop|||hydroxylation|||0|1000|600|613

SE|235||ab|9|text|734|737|4.

SE|235||ab|10|text|737|868|It is proposed that O-2- generated by illuminated chloroplasts is involved in the provision of a reductant to the enzyme phenolase.
SE|235||ab|10|entity|C0008266|Chloroplasts|celc|||chloroplasts|||0|861|787|799
SE|235||ab|10|entity|C1549071|Provisional|idcn|||provision|||0|928|819|828
SE|235||ab|10|entity|C0376446|Reducing Agents|irda|||reductant|||0|966|834|843
SE|235||ab|10|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|888|851|857
SE|235||ab|10|entity|C0598897|phenolase|aapp,enzy|||phenolase|||0|888|858|867


SE|236||ti|1|text|16|154|Identification of chloride-binding sites in hemoglobin by nuclear-magnetic-resonance quadrupole-relaxation studies of hemoglobin digests.
SE|236||ti|1|entity|C0008203|Chlorides|inch|||chloride|||0|901|34|42
SE|236||ti|1|entity|C0005456|Binding Sites|rcpt|||binding sites|||0|901|43|56
SE|236||ti|1|entity|C0019046|Hemoglobin|aapp,bacs|||hemoglobin|||0|1000|60|70
SE|236||ti|1|entity|C0024485|Magnetic Resonance Imaging|diap|||nuclear-magnetic-resonance|||0|850|74|100
SE|236||ti|1|entity|C0035028|Relaxation|dora,topp|||relaxation|||0|850|112|122
SE|236||ti|1|entity|C0019046|Hemoglobin|aapp,bacs|||hemoglobin|||0|888|134|144
SE|236||ti|1|entity|C0868946|Digests|phsf|||digests|||0|888|145|152
SE|236||ti|1|relation|2|1|C0005456|Binding Sites|rcpt|rcpt|||binding sites|||0|901|43|56|PREP|COEXISTS_WITH||57|59|3|1|C0019046|Hemoglobin|aapp,gngm,bacs|aapp|||hemoglobin|||0|1000|60|70

SE|236||ab|1|text|160|384|35Cl minus-nuclear magnetic resonance (NMR) studies indicate that various digests of human hemoglobin with carboxypeptidase A and B, or a combination of the two, may be used for the identification of chloride binding sites.
SE|236||ab|1|entity|C0521447|Nuclear|spco|||nuclear|||0|806|171|178
SE|236||ab|1|entity|C0024485|Magnetic Resonance Imaging|diap|||magnetic resonance (NMR) studies|||0|806|179|211
SE|236||ab|1|entity|C0868946|Digests|phsf|||digests|||0|861|234|241
SE|236||ab|1|entity|C0020114|Human|humn|||human|||0|888|245|250
SE|236||ab|1|entity|C0019046|Hemoglobin|aapp,bacs|||hemoglobin|||0|888|251|261
SE|236||ab|1|entity|C0054755|Carboxypeptidase A|aapp,enzy|||carboxypeptidase A|||0|1000|267|285
SE|236||ab|1|entity|C0205195|Combined|qlco|||combination|||0|1000|298|309
SE|236||ab|1|entity|C0205448|Two|qnco|||two|||0|1000|317|320
SE|236||ab|1|entity|C0008203|Chlorides|inch|||chloride|||0|901|360|368
SE|236||ab|1|entity|C0005456|Binding Sites|rcpt|||binding sites|||0|901|369|382
SE|236||ab|1|relation|0|0|C0019046|Hemoglobin|aapp,gngm,bacs|aapp|||hemoglobin|||0|888|251|261|MOD/HEAD|PART_OF||245|261|0|0|C0020114|Human|grup,humn|humn|||human|||0|888|245|250

SE|236||ab|2|text|384|524|All the digestion products contain, like hemoglobin itself, at least two classes of binding sites, one of high, the others of low affinity.
SE|236||ab|2|entity|C0012238|Digestion|orgf|||digestion|||0|872|392|401
SE|236||ab|2|entity|C1514468|product|qnco|||products|||0|872|402|410
SE|236||ab|2|entity|C0019046|Hemoglobin|aapp,bacs|||hemoglobin|||0|1000|425|435
SE|236||ab|2|entity|C0205448|Two|qnco|||two|||0|790|453|456
SE|236||ab|2|entity|C0456387|Class|inpr|||classes|||0|790|457|464
SE|236||ab|2|entity|C0005456|Binding Sites|rcpt|||binding sites|||0|1000|468|481
SE|236||ab|2|entity|C0205447|One|qnco|||one|||0|1000|483|486
SE|236||ab|2|entity|C0205250|High|qlco|||high|||0|1000|490|494
SE|236||ab|2|entity|C0205394|Other|qlco|||others|||0|966|500|506
SE|236||ab|2|entity|C0205251|low|qlco|||low|||0|888|510|513

SE|236||ab|3|text|524|780|The pH dependence of the excess linewidth of the 35Cl minus NMR signal indicates that in the simple digests with either carboxypeptidase A or B, chloride is bound with high affinity at or near His-beta146-Asp-beta94 and at or near Val-alpha1-Arg-alpha141.
SE|236||ab|3|entity|C0439857|Dependence|mobd|||dependence|||0|888|531|541
SE|236||ab|3|entity|C0442802|Excessive|qlco|||excess|||0|623|549|555
SE|236||ab|3|entity|C0024485|Magnetic Resonance Imaging|diap|||NMR|||0|694|584|587
SE|236||ab|3|entity|C0205352|Simple|qlco|||simple|||0|888|617|623
SE|236||ab|3|entity|C0868946|Digests|phsf|||digests|||0|888|624|631
SE|236||ab|3|entity|C0054755|Carboxypeptidase A|aapp,enzy|||carboxypeptidase A|||0|901|644|662
SE|236||ab|3|entity|C0008203|Chlorides|inch|||chloride|||0|1000|669|677
SE|236||ab|3|entity|C0205250|High|qlco|||high|||0|888|692|696
SE|236||ab|3|entity|C0085845|Aspartate|aapp,bacs|434,443,718,9474,29974,83853,259266|ASIP,ASPA,C3,ATG5,A1CF,ROPN1L,ASPM|Asp|||0|660|729|732
SE|236||ab|3|entity|C0475806|1/3 meter|fndg|||near|||0|562|750|754
SE|236||ab|3|entity|C0042285|Valine|aapp,bacs,phsu|||Val|||0|562|755|758
SE|236||ab|3|entity|||gngm|146|ADRA1D|alpha1|||0|562|759|765
SE|236||ab|3|entity|||gngm|27,473|ABL2,RERE|Arg|||0|562|766|769

SE|236||ab|4|text|780|1020|The high-affinity sites show, in the case of the simple digests, a strong oxygen linkage which is lost in the forms digested with both carboxypeptidase A and B; this linkage may thus be correlated to the presence of conformational changes.
SE|236||ab|4|entity|C0205250|High|qlco|||high|||0|851|784|788
SE|236||ab|4|entity|C0205145|Site|spco|||sites|||0|851|798|803
SE|236||ab|4|entity|C0205352|Simple|qlco|||simple|||0|888|829|835
SE|236||ab|4|entity|C0868946|Digests|phsf|||digests|||0|888|836|843
SE|236||ab|4|entity|C0442821|Strong|qlco|||strong|||0|623|847|853
SE|236||ab|4|entity|C0030054|Oxygen|elii,phsu|||oxygen|||0|623|854|860
SE|236||ab|4|entity|C0054755|Carboxypeptidase A|aapp,enzy|||carboxypeptidase A|||0|1000|915|933
SE|236||ab|4|entity|C0301641|Macromolecular alteration|moft|||conformational changes|||0|983|996|1018
SE|236||ab|4|relation|3|1|C0868946|Digests|phsf|phsf|||digests|||0|888|836|843|NOM|ASSOCIATED_WITH||861|868|3|0|C0030054|Oxygen|elii,phsu|phsu|||oxygen|||0|623|854|860

SE|236||ab|5|text|1020|1180|Organic phosphates, like inositol hexaphosphate, show competition for some of the high-affinity chloride binding sites in hemoglobin and in the simple digests.
SE|236||ab|5|entity|C0031701|Phosphoric Acid Esters|opco|||Organic phosphates|||0|1000|1020|1038
SE|236||ab|5|entity|C0031855|Phytic Acid|bacs,carb,irda,phsu|||inositol hexaphosphate|||0|1000|1045|1067
SE|236||ab|5|entity|C0679932|competition|socb|||competition|||0|1000|1074|1085
SE|236||ab|5|entity|C0205250|High|qlco|||high|||0|840|1102|1106
SE|236||ab|5|entity|C0008203|Chlorides|inch|||chloride|||0|840|1116|1124
SE|236||ab|5|entity|C0005456|Binding Sites|rcpt|||binding sites|||0|840|1125|1138
SE|236||ab|5|entity|C0019046|Hemoglobin|aapp,bacs|||hemoglobin|||0|1000|1142|1152
SE|236||ab|5|entity|C0205352|Simple|qlco|||simple|||0|888|1164|1170
SE|236||ab|5|entity|C0868946|Digests|phsf|||digests|||0|888|1171|1178
SE|236||ab|5|relation|4|1|C0005456|Binding Sites|rcpt|rcpt|||binding sites|||0|840|1125|1138|PREP|COEXISTS_WITH||1139|1141|2|1|C0019046|Hemoglobin|aapp,gngm,bacs|aapp|||hemoglobin|||0|1000|1142|1152

SE|236||ab|6|text|1180|1249|This competition is likewise lost in the doubly digested hemoglobins.
SE|236||ab|6|entity|C0679932|competition|socb|||competition|||0|1000|1185|1196
SE|236||ab|6|entity|C0868946|Digests|phsf|||digested|||0|773|1228|1236
SE|236||ab|6|entity|C0019046|Hemoglobin|aapp,bacs|||hemoglobins|||0|773|1237|1248


SE|237||ti|1|text|16|133|The internal-alkaline pH gradient, sensitive to uncoupler and ATPase inhibitor, in growing Clostridium pasteurianum.
SE|237||ti|1|entity|C0205102|Intrinsic|spco|||internal|||0|843|20|28
SE|237||ti|1|entity|C0002055|Alkalies|inch|||alkaline|||0|843|29|37
SE|237||ti|1|entity|C1138565|delta pH|qnco|||pH gradient|||0|843|38|49
SE|237||ti|1|entity|C0332324|Sensitive|ftcn|||sensitive|||0|1000|51|60
SE|237||ti|1|entity|C0001473|ATP phosphohydrolase|aapp,enzy|1769|DNAH8|ATPase|||0|872|78|84
SE|237||ti|1|entity|C0243077|inhibitors|chvf|||inhibitor|||0|872|85|94
SE|237||ti|1|entity|C0315068|Clostridium pasteurianum|bact|||Clostridium pasteurianum|||0|901|107|131

SE|237||ab|1|text|139|142|1.

SE|237||ab|2|text|142|264|The intracellular pH was measured in growing Clostridium pasteurianum with and acid-base equilibrium distribution method.
SE|237||ab|2|entity|C0175996|Protoplasm|celc|||intracellular|||0|888|146|159
SE|237||ab|2|entity|C0315068|Clostridium pasteurianum|bact|||Clostridium pasteurianum|||0|901|187|211
SE|237||ab|2|entity|C0001117|Acid-Base Equilibrium|ortf|||acid-base equilibrium|||0|875|221|242
SE|237||ab|2|entity|C0520511|Distributing|idcn|||distribution|||0|875|243|255
SE|237||ab|2|entity|C0025663|Methods|inpr|||method|||0|875|256|262

SE|237||ab|3|text|264|367|[14C]Dimethyloxazolidinedione, [14]methylamine and [14C]acetic acid were used as "deltapH-indicators".
SE|237||ab|3|entity|C0012386|Dimethadione|orch,phsu|||Dimethyloxazolidinedione|||0|1000|269|293
SE|237||ab|3|entity|C0066318|methylamine|orch|||methylamine|||0|1000|299|310
SE|237||ab|3|entity|C0000983|Acetic Acid|irda,orch,phsu|||acetic acid|||0|1000|320|331
SE|237||ab|3|entity|C1138565|delta pH|qnco|||deltapH|||0|888|346|353
SE|237||ab|3|entity|C0021212|Indicators|irda|||indicators|||0|888|354|364

SE|237||ab|4|text|367|490|During growth the extracellular pH decreased from 7.1 to 5.1; simultaneously the intracellular pH changed from 7.5 to 5.9.
SE|237||ab|4|entity|C0018270|Growth|orgf|||growth|||0|1000|374|380
SE|237||ab|4|entity|C0521119|Extracellular|celc|||extracellular|||0|888|385|398
SE|237||ab|4|entity|C0175996|Protoplasm|celc|||intracellular|||0|888|448|461

SE|237||ab|5|text|490|585|Thus, the intracellular pH was more alkaline than the extracellular pH by 0.4 to 0.8 pH-units.
SE|237||ab|5|entity|C0175996|Protoplasm|celc|||intracellular|||0|888|500|513
SE|237||ab|5|entity|C0205172|More|ftcn|||more|||0|853|521|525
SE|237||ab|5|entity|C0002055|Alkalies|inch|||alkaline|||0|853|526|534
SE|237||ab|5|entity|C0521119|Extracellular|celc|||extracellular|||0|888|544|557
SE|237||ab|5|entity|C0439148|Unit|qnco|||units|||0|750|578|583

SE|237||ab|6|text|585|588|2.

SE|237||ab|7|text|588|759|This pH gradient (interior alkaline) was abolished by the proton conductor carbonylcyanide m-chlorophenylhydrazone and the ATPase inhibitor N,N'-dicyclohexylcarbodiimide.
SE|237||ab|7|entity|C1138565|delta pH|qnco|||pH gradient|||0|1000|593|604
SE|237||ab|7|entity|C0002055|Alkalies|inch|||alkaline|||0|789|615|623
SE|237||ab|7|entity|C0033727|Protons|elii|||proton|||0|574|646|652
SE|237||ab|7|entity|C0684021|conductor|prog|||conductor|||0|574|653|662
SE|237||ab|7|entity|C0001473|ATP phosphohydrolase|aapp,enzy|1769|DNAH8|ATPase|||0|829|711|717
SE|237||ab|7|entity|C0243077|inhibitors|chvf|||inhibitor|||0|829|718|727
SE|237||ab|7|entity|C0012124|Dicyclohexylcarbodiimide|irda,orch|||dicyclohexylcarbodiimide|||0|888|733|757

SE|237||ab|8|text|759|843|The pH gradient could not be demonstrated in cells depleted of an energy substrate.
SE|237||ab|8|entity|C1138565|delta pH|qnco|||pH gradient|||0|1000|763|774
SE|237||ab|8|entity|C1518422|Not|ftcn|||not|||0|1000|781|784
SE|237||ab|8|entity|C0007634|Cells|cell|||cells|||0|1000|804|809
SE|237||ab|8|entity|C0424589|Vitality|fndg|||energy|||0|694|825|831

SE|237||ab|9|text|843|987|These results suggest that the pH gradient is formed by an ATPase-driven extrusion of protons from the cells rather than by a Donnan potential.
SE|237||ab|9|entity|C1274040|result|ftcn|||results|||0|966|849|856
SE|237||ab|9|entity|C1138565|delta pH|qnco|||pH gradient|||0|1000|874|885
SE|237||ab|9|entity|C0001473|ATP phosphohydrolase|aapp,enzy|1769|DNAH8|ATPase|||0|1000|902|908
SE|237||ab|9|entity|C0443213|Extrusion|qlco|||extrusion|||0|1000|916|925
SE|237||ab|9|entity|C0033727|Protons|elii|||protons|||0|1000|929|936
SE|237||ab|9|entity|C0007634|Cells|cell|||cells|||0|1000|946|951
SE|237||ab|9|entity|C0237399|Potential|qlco|||potential|||0|861|976|985
SE|237||ab|9|relation|2|1|C0007634|Cells|cell|cell|||cells|||0|1000|946|951|PREP|LOCATION_OF||937|941|5|1|C0033727|Protons|elii|elii|||protons|||0|1000|929|936

SE|237||ab|10|text|987|990|3.

SE|237||ab|11|text|990|1143|Growth of the organism was inhibited by low concentrations of both carbonylcyanide m-chlorophenylhydrazone (5 muM) and dicyclohexylcarbodiimide (5 muM).
SE|237||ab|11|entity|C0018270|Growth|orgf|||Growth|||0|1000|990|996
SE|237||ab|11|entity|C0029235|Organism|orgm|||organism|||0|1000|1004|1012
SE|237||ab|11|entity|C0205251|low|qlco|||low|||0|888|1030|1033
SE|237||ab|11|entity|C1009574|Chrysanthemum x morifolium|plnt|||muM|||0|888|1100|1103
SE|237||ab|11|entity|C0012124|Dicyclohexylcarbodiimide|irda,orch|||dicyclohexylcarbodiimide|||0|1000|1109|1133
SE|237||ab|11|entity|C1009574|Chrysanthemum x morifolium|plnt|||muM|||0|888|1137|1140

SE|237||ab|12|text|1143|1308|This finding suggests that the pH gradient is essential for the growing cell as it may be required for substrate accumulation and other types of transport processes.
SE|237||ab|12|entity|C0037088|Signs and Symptoms|sosy|||finding|||0|1000|1148|1155
SE|237||ab|12|entity|C1138565|delta pH|qnco|||pH gradient|||0|1000|1174|1185
SE|237||ab|12|entity|C0205224|Essential|qlco|||essential|||0|1000|1189|1198
SE|237||ab|12|entity|C0007634|Cells|cell|||cell|||0|861|1215|1219
SE|237||ab|12|entity|C0332307|Type - attribute|qlco|||types|||0|1000|1279|1284
SE|237||ab|12|entity|C1519628|Transport Process|moft|||transport processes|||0|983|1288|1307


SE|238||ti|1|text|16|107|D-alanyl-D-alanine carboxypeptidase in the bacterial form and L-form of Proteus mirabilis.
SE|238||ti|1|entity|C0660025|serine-type D-Ala-D-Ala carboxypeptidase|aapp,enzy|||D-alanyl-D-alanine carboxypeptidase|||0|1000|16|51
SE|238||ti|1|entity|C0521009|Bacterial|ftcn|||bacterial|||0|888|59|68
SE|238||ti|1|entity|C1522492|Formation|ftcn|||form|||0|888|69|73
SE|238||ti|1|entity|C0022828|L Forms|bact|||L-form|||0|983|78|84
SE|238||ti|1|entity|C0033701|Proteus mirabilis|bact|||Proteus mirabilis|||0|1000|88|105

SE|238||ab|1|text|113|238|Membranes of the bacterial form and the stable and unstable L-forms of Proteus mirabilis contain LD and DD-carboxypeptidase.
SE|238||ab|1|entity|C0025255|Tissue membrane|tisu|||Membranes|||0|1000|113|122
SE|238||ab|1|entity|C0521009|Bacterial|ftcn|||bacterial|||0|888|130|139
SE|238||ab|1|entity|C1522492|Formation|ftcn|||form|||0|888|140|144
SE|238||ab|1|entity|C0376315|Manufactured form|mnob|||forms|||0|773|175|180
SE|238||ab|1|entity|C0033701|Proteus mirabilis|bact|||Proteus mirabilis|||0|1000|184|201
SE|238||ab|1|entity|C0007075|Carboxypeptidase|aapp,enzy|||carboxypeptidase|||0|888|220|236

SE|238||ab|2|text|238|310|The DD-carboxypeptidase is inhibited non-competitively by penicillin G.
SE|238||ab|2|entity|C0007075|Carboxypeptidase|aapp,enzy|||carboxypeptidase|||0|888|245|261
SE|238||ab|2|entity|C0030827|Penicillin G|antb,orch|||penicillin G|||0|1000|296|308
SE|238||ab|2|relation|1|1|C0030827|Penicillin G|antb,orch|antb|||penicillin G|||0|1000|296|308|VERB|INHIBITS||265|274|1|1|C0007075|Carboxypeptidase|aapp,gngm,enzy|gngm|||carboxypeptidase|||0|888|245|261

SE|238||ab|3|text|310|408|The enzyme of the bacterial form is highly penicillin-sensitive (Ki - 4 X 10(-9) M penicillin G).
SE|238||ab|3|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|314|320
SE|238||ab|3|entity|C0521009|Bacterial|ftcn|||bacterial|||0|888|328|337
SE|238||ab|3|entity|C1522492|Formation|ftcn|||form|||0|888|338|342
SE|238||ab|3|entity|C0030842|Penicillins|antb,orch|||penicillin|||0|901|353|363
SE|238||ab|3|entity|C0439822|Highly sensitive|qlco|||highly penicillin-sensitive|||0|901|346|373
SE|238||ab|3|entity|C0030827|Penicillin G|antb,orch|||penicillin G|||0|901|393|405

SE|238||ab|4|text|408|508|Inhibition is only partly reversible by treatment with penicillinase or by dialysis against buffer.
SE|238||ab|4|entity|C0205343|Reversible|ftcn|||reversible|||0|827|434|444
SE|238||ab|4|entity|C0030841|Penicillinase|aapp,enzy|||penicillinase|||0|1000|463|476
SE|238||ab|4|entity|C0011946|Dialysis procedure|topp|||dialysis|||0|1000|483|491
SE|238||ab|4|entity|C0006353|Buffers|bacs,irda|||buffer|||0|1000|500|506

SE|238||ab|5|text|508|677|In contrast, the DD-carboxypeptidase of the unstable L-form, grown in the presence of penicillin, is 175-fold less penicillin-sensitive (Ki = 7 X 10(7) M penicillin G).
SE|238||ab|5|entity|C0007075|Carboxypeptidase|aapp,enzy|||carboxypeptidase|||0|888|528|544
SE|238||ab|5|entity|C1522492|Formation|ftcn|||form|||0|773|563|567
SE|238||ab|5|entity|C0030842|Penicillins|antb,orch|||penicillin|||0|1000|594|604
SE|238||ab|5|entity|C0332462|Fold|spco|||fold|||0|766|613|617
SE|238||ab|5|entity|C0747422|PENICILLIN SENSITIVITY|dsyn|||penicillin-sensitive|||0|766|623|643
SE|238||ab|5|entity|C0030827|Penicillin G|antb,orch|||penicillin G|||0|901|662|674
SE|238||ab|5|relation|3|2|C0007075|Carboxypeptidase|aapp,gngm,enzy|aapp|||carboxypeptidase|||0|888|528|544|NOM|COEXISTS_WITH||582|590|4|1|C0030842|Penicillins|antb,orch|antb|||penicillin|||0|1000|594|604

SE|238||ab|6|text|677|741|Inhibition is completely reversed by penicillinase or dialysis.
SE|238||ab|6|entity|C0030841|Penicillinase|aapp,enzy|||penicillinase|||0|1000|714|727
SE|238||ab|6|entity|C0011946|Dialysis procedure|topp|||dialysis|||0|1000|731|739

SE|238||ab|7|text|741|932|After inhibition by penicillin and subsequent reactivation the penicillin sensitivity of the bacterial DD-carboxtpeptidase is similar to the sensitivity of the enzyme of the unstable L-form.
SE|238||ab|7|entity|C0030842|Penicillins|antb,orch|||penicillin|||0|1000|761|771
SE|238||ab|7|entity|C0750530|SUBSEQUENT|idcn|||subsequent|||0|694|776|786
SE|238||ab|7|entity|C0747422|PENICILLIN SENSITIVITY|dsyn|||penicillin sensitivity|||0|1000|804|826
SE|238||ab|7|entity|C0521009|Bacterial|ftcn|||bacterial|||0|623|834|843
SE|238||ab|7|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|901|907
SE|238||ab|7|entity|C1522492|Formation|ftcn|||form|||0|773|926|930
SE|238||ab|7|relation|6|5|C0030842|Penicillins|antb,orch|antb|||penicillin|||0|1000|761|771|NOM|INTERACTS_WITH||882|893|2|1|C0014442|Enzymes|enzy,orch|enzy|||enzyme|||0|1000|901|907

SE|238||ab|8|text|932|1100|The hypothesis is proposed that P. mirabilis contains two DD-carboxypeptidases of different penicillin sensitivity and with different mechanisms of penicillin binding.
SE|238||ab|8|entity|C1512571|Hypothesis|idcn|||hypothesis|||0|1000|936|946
SE|238||ab|8|entity|C0330338|Mirabilis|plnt|||mirabilis|||0|888|967|976
SE|238||ab|8|entity|C0205448|Two|qnco|||two|||0|851|986|989
SE|238||ab|8|entity|C0007075|Carboxypeptidase|aapp,enzy|||carboxypeptidases|||0|851|993|1010
SE|238||ab|8|entity|C1547020|*Difference|qnco|||different|||0|877|1014|1023
SE|238||ab|8|entity|C0747422|PENICILLIN SENSITIVITY|dsyn|||penicillin sensitivity|||0|877|1024|1046
SE|238||ab|8|entity|C1547020|*Difference|qnco|||different|||0|853|1056|1065
SE|238||ab|8|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|853|1066|1076
SE|238||ab|8|entity|C1149096|penicillin binding|moft|||penicillin binding|||0|1000|1080|1098

SE|238||ab|9|text|1100|1315|Peptidoglycan synthesis in the cell walls of the unstable L-form is probably carried out with the help of only one DD-carboxypeptidase, viz. the completely reactivatable enzyme with the lower penicillin sensitivity.
SE|238||ab|9|entity|C0030958|Peptidoglycan|bacs,orch|||Peptidoglycan|||0|888|1100|1113
SE|238||ab|9|entity|C0869032|Synthesis|phpr|||synthesis|||0|888|1114|1123
SE|238||ab|9|entity|C0007623|Cell Wall|celc|||cell walls|||0|1000|1131|1141
SE|238||ab|9|entity|C1522492|Formation|ftcn|||form|||0|773|1160|1164
SE|238||ab|9|entity|C0332148|Probable diagnosis|qlco|||probably|||0|1000|1168|1176
SE|238||ab|9|entity|C0439787|Out|spco|||out|||0|1000|1185|1188
SE|238||ab|9|entity|C0205447|One|qnco|||one|||0|775|1211|1214
SE|238||ab|9|entity|C0007075|Carboxypeptidase|aapp,enzy|||carboxypeptidase|||0|775|1218|1234
SE|238||ab|9|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|827|1270|1276
SE|238||ab|9|entity|C0441994|Lower|ftcn|||lower|||0|901|1286|1291
SE|238||ab|9|entity|C0747422|PENICILLIN SENSITIVITY|dsyn|||penicillin sensitivity|||0|901|1292|1314
SE|238||ab|9|relation|5|1|C0007623|Cell Wall|celc|celc|||cell walls|||0|1000|1131|1141|PREP|LOCATION_OF||1124|1126|1|1|C0030958|Peptidoglycan|bacs,orch|orch|||Peptidoglycan|||0|888|1100|1113


SE|239||ti|1|text|16|41|Pigeon-liver NAD kinase.
SE|239||ti|1|entity|C0325912|Columbidae|bird|||Pigeon|||0|861|16|22
SE|239||ti|1|entity|C0023884|Liver|bpoc|||liver|||0|861|23|28
SE|239||ti|1|entity|C0068337|NAD+ kinase|aapp,enzy|||NAD kinase|||0|861|29|39

SE|239||ti|2|text|41|98|The structural and kinetic basis of regulation of NADPH.
SE|239||ti|2|entity|C0022702|Kinetics|idcn|||kinetic|||0|888|60|67
SE|239||ti|2|entity|C1527178|Basis|ftcn|||basis|||0|888|68|73
SE|239||ti|2|entity|C0851285|Regulation|gora|||regulation|||0|1000|77|87
SE|239||ti|2|entity|C0027303|NADP|bacs,nnon|||NADPH|||0|1000|91|96

SE|239||ab|1|text|104|222|NAD kinase was purified from pigeon liver by an improved procedure which included chromatography on phosphocellulose.
SE|239||ab|1|entity|C0068337|NAD+ kinase|aapp,enzy|||NAD kinase|||0|1000|104|114
SE|239||ab|1|entity|C0325912|Columbidae|bird|||pigeon|||0|888|133|139
SE|239||ab|1|entity|C0023884|Liver|bpoc|||liver|||0|888|140|145
SE|239||ab|1|entity|C0184511|Improved|qlco|||improved|||0|888|152|160
SE|239||ab|1|entity|C0184661|Procedures|hlca|||procedure|||0|888|161|170
SE|239||ab|1|entity|C0008550|Chromatography|lbpr|||chromatography|||0|1000|186|200
SE|239||ab|1|entity|C0070824|phosphocellulose|irda,orch|||phosphocellulose|||0|1000|204|220

SE|239||ab|2|text|222|353|The resultant preparation was homogeneous as judged by gel electrophoresis, but electrofocusing gave indications of heterogeneity.
SE|239||ab|2|entity|C1521827|Preparation|ftcn|||preparation|||0|861|236|247
SE|239||ab|2|entity|C0596607|Gel Electrophoresis|lbpr|||gel electrophoresis|||0|1000|277|296
SE|239||ab|2|entity|C0022169|Isoelectric Focusing|lbpr|||electrofocusing|||0|1000|302|317
SE|239||ab|2|entity|C0392360|Reason for|idcn|||indications|||0|1000|323|334
SE|239||ab|2|entity|C0019409|Heterogeneity|grpa|||heterogeneity|||0|1000|338|351

SE|239||ab|3|text|353|493|The enzyme appeared to be of molecular weight 270000, and to consist of subunits of molecular weight 34000; it may therefore be an octomer.
SE|239||ab|3|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|357|363
SE|239||ab|3|entity|C0026385|Molecular Weight|qnco|||molecular weight|||0|901|382|398
SE|239||ab|3|entity|C0026385|Molecular Weight|qnco|||molecular weight|||0|901|437|453

SE|239||ab|4|text|493|856|Kinetic studies over a wide range of substrate concentrations revealed departures from Michaelis-Menten behaviour with the substrate NAD+; these were interpreted tentatively in terms of negative homotropic interactions between identical binding sites, since thermal and chemical inactivation studies revealed no evidence for more than one type of catalytic site.
SE|239||ab|4|entity|C0022702|Kinetics|idcn|||Kinetic|||0|872|493|500
SE|239||ab|4|entity|C0008972|Clinical Research|resa|||studies|||0|872|501|508
SE|239||ab|4|entity|C0205136|Over|spco|||over|||0|1000|509|513
SE|239||ab|4|entity|C0332464|Widening|spco|||wide|||0|888|516|520
SE|239||ab|4|entity|C1514721|Range|qnco|||range|||0|888|521|526
SE|239||ab|4|entity|C0004927|Behavior|inbe|||behaviour|||0|827|597|606
SE|239||ab|4|entity|C0027270|Nicotinamide adenine dinucleotide (NAD)|bacs,nnon|||NAD|||0|861|626|629
SE|239||ab|4|entity|C0205160|Negative|qlco|||negative|||0|660|679|687
SE|239||ab|4|entity|C0205280|Identical|qlco|||identical|||0|901|720|729
SE|239||ab|4|entity|C0005456|Binding Sites|rcpt|||binding sites|||0|901|730|743
SE|239||ab|4|entity|C0441501|Chemical inactivation|topp|||chemical inactivation|||0|890|763|784
SE|239||ab|4|entity|C0008972|Clinical Research|resa|||studies|||0|890|785|792
SE|239||ab|4|entity|C0205172|More|ftcn|||more|||0|1000|818|822
SE|239||ab|4|entity|C0205447|One|qnco|||one|||0|888|828|831
SE|239||ab|4|entity|C1547052|*Type|qnco|||type|||0|888|832|836
SE|239||ab|4|entity|C0600499|Catalytic Domain|amas|||catalytic site|||0|1000|840|854
SE|239||ab|4|relation|0|0|C0008972|Clinical Research|resa|resa|||studies|||0|890|785|792|MOD/HEAD|USES||763|792|0|0|C0441501|Chemical inactivation|topp|topp|||chemical inactivation|||0|890|763|784

SE|239||ab|5|text|856|1008|The significance of the kinetics and of the type of inhibition produced by NADPH is discussed in terms of the regulation of NAD kinase activity in vivo.
SE|239||ab|5|entity|C0750502|Significant|idcn|||significance|||0|928|860|872
SE|239||ab|5|entity|C0022702|Kinetics|idcn|||kinetics|||0|1000|880|888
SE|239||ab|5|entity|C1547052|*Type|qnco|||type|||0|1000|900|904
SE|239||ab|5|entity|C0027303|NADP|bacs,nnon|||NADPH|||0|1000|931|936
SE|239||ab|5|entity|C0851285|Regulation|gora|||regulation|||0|1000|966|976
SE|239||ab|5|entity|C1150497|NAD+ kinase activity|moft|||NAD kinase activity|||0|1000|980|999
SE|239||ab|5|entity|C1515655|in vivo|spco|||in vivo|||0|1000|1000|1007
SE|239||ab|5|relation|6|2|C0027303|NADP|bacs,nnon|bacs|||NADPH|||0|1000|931|936|NOM|AFFECTS||966|976|2|1|C1150497|NAD+ kinase activity|moft|moft|||NAD kinase activity|||0|1000|980|999


SE|240||ti|1|text|16|89|Hydrogen ion changes and contractile behavior in the perfused rat heart.
SE|240||ti|1|entity|C0033727|Protons|elii|||Hydrogen ion|||0|884|16|28
SE|240||ti|1|entity|C0004927|Behavior|inbe|||behavior|||0|853|53|61
SE|240||ti|1|entity|C1549542|Perfuse|ftcn|||perfused|||0|840|69|77
SE|240||ti|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|840|78|81
SE|240||ti|1|entity|C0018787|Heart|bpoc|||heart|||0|840|82|87
SE|240||ti|1|relation|0|0|C0018787|Heart|bpoc|bpoc|||heart|||0|840|82|87|MOD/HEAD|PART_OF||78|87|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|840|78|81
SE|240||ti|1|relation|1|1|C0018787|Heart|bpoc|bpoc|||heart|||0|840|82|87|PREP|LOCATION_OF||62|64|2|2|C0033727|Protons|elii|elii|||Hydrogen ion|||0|884|16|28

SE|240||ab|1|text|95|264|The effect of acid-base alterations was analyzed using isolated rat hearts perfused at constant coronary perfusion pressure, and stimulated to contract at constant rat.
SE|240||ab|1|entity|C1280500|Effect|qlco|||effect|||0|1000|99|105
SE|240||ab|1|entity|C0001128|Acids|chem|||acid|||0|840|109|113
SE|240||ab|1|entity|C1515926|Alteration|idcn|||alterations|||0|840|119|130
SE|240||ab|1|entity|C0205409|Isolated|ftcn|||isolated|||0|851|150|158
SE|240||ab|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|851|159|162
SE|240||ab|1|entity|C0018787|Heart|bpoc|||hearts|||0|851|163|169
SE|240||ab|1|entity|C1547014|*Constant|qnco|||constant|||0|775|182|190
SE|240||ab|1|entity|C0018787|Heart|bpoc|||coronary|||0|775|191|199
SE|240||ab|1|entity|C0033095|Pressure- physical agent|phpr|||pressure|||0|775|210|218
SE|240||ab|1|entity|C1547014|*Constant|qnco|||constant|||0|888|250|258
SE|240||ab|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|888|259|262
SE|240||ab|1|relation|0|0|C0018787|Heart|bpoc|bpoc|||hearts|||0|851|163|169|MOD/HEAD|PART_OF||159|169|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|851|159|162

SE|240||ab|2|text|264|376|The amount of shortening in the major axis and its derivative were measured to assess myocardial contractility.
SE|240||ab|2|entity|C1265611|Quantity|qnco|||amount|||0|1000|268|274
SE|240||ab|2|entity|C1295723|Major Axis|spco|||major axis|||0|1000|296|306
SE|240||ab|2|entity|C1527240|Derivative|ftcn|||derivative|||0|1000|315|325
SE|240||ab|2|entity|C0027045|Myocardial Contraction|ortf|||myocardial contractility|||0|950|350|374

SE|240||ab|3|text|376|481|Both the 'respiratory' and 'metabolic' alterations affected the contractile behavior to the same extent.
SE|240||ab|3|entity|C0521346|respiratory|ftcn|||respiratory|||0|1000|386|397
SE|240||ab|3|entity|C0311400|Metabolic|ftcn|||metabolic|||0|872|404|413
SE|240||ab|3|entity|C1515926|Alteration|idcn|||alterations|||0|872|415|426
SE|240||ab|3|entity|C0004927|Behavior|inbe|||behavior|||0|853|452|460
SE|240||ab|3|entity|C0445247|Same|qlco|||same|||0|888|468|472
SE|240||ab|3|entity|C0439792|Extent|spco|||extent|||0|888|473|479

SE|240||ab|4|text|481|590|In the physiological range studied by us, acidosis depresses and alkalosis increases myocardial contraction.
SE|240||ab|4|entity|C0205463|Physiological|ftcn|||physiological|||0|888|488|501
SE|240||ab|4|entity|C1514721|Range|qnco|||range|||0|888|502|507
SE|240||ab|4|entity|C0001122|Acidosis|patf|||acidosis|||0|1000|523|531
SE|240||ab|4|entity|C0002063|Alkalosis|dsyn|||alkalosis|||0|1000|546|555
SE|240||ab|4|entity|C0027045|Myocardial Contraction|ortf|||myocardial contraction|||0|1000|566|588

SE|240||ab|5|text|590|726|However acidosis seems to depress contractility more than the enhancement produced by the same change in pH towards the alkalotic side.
SE|240||ab|5|entity|C0001122|Acidosis|patf|||acidosis|||0|861|598|606
SE|240||ab|5|entity|C1140999|Contraction|patf|||contractility|||0|761|624|637
SE|240||ab|5|entity|C0445247|Same|qlco|||same|||0|888|680|684
SE|240||ab|5|entity|C0002063|Alkalosis|dsyn|||alkalotic|||0|853|710|719
SE|240||ab|5|entity|C0441987|Side|spco|||side|||0|853|720|724
SE|240||ab|5|relation|1|1|C0001122|Acidosis|patf|patf|||acidosis|||0|861|598|606|VERB|AFFECTS||616|623|5|1|C1140999|Contraction|patf|patf|||contractility|||0|761|624|637

SE|240||ab|6|text|726|1002|When either amount of shortening or max dl/dt was plotted as a function of hydrogen ion acitvity (aH+) a linear correlation was obtained, either with pure 'metabolic' or 'respiratory' acid-base induced alterations (correlation coefficients higher than -.95; P less than .01).
SE|240||ab|6|entity|C1265611|Quantity|qnco|||amount|||0|861|738|744
SE|240||ab|6|entity|C0031843|physiological aspects|phsf|||function|||0|1000|789|797
SE|240||ab|6|entity|C0033727|Protons|elii|||hydrogen ion|||0|734|801|813
SE|240||ab|6|entity|C0205132|Linear|spco|||linear|||0|694|831|837
SE|240||ab|6|entity|C0311400|Metabolic|ftcn|||metabolic|||0|861|882|891
SE|240||ab|6|entity|C0001128|Acids|chem|||acid|||0|833|910|914
SE|240||ab|6|entity|C0205263|Induced|ftcn|||induced|||0|833|920|927
SE|240||ab|6|entity|C1268764|Respiratory alteration|fndg|||respiratory' acid-base induced alterations|||0|833|897|939
SE|240||ab|6|entity|C1547015|*Coefficient|qnco|||coefficients|||0|827|953|965
SE|240||ab|6|entity|C0205250|High|qlco|||higher|||0|966|966|972

SE|240||ab|7|text|1002|1173|Our findings suggest that in the range studied by us, contraction of the perfused rat heart following acid-base alterations, is a linear function of hydrogen ion activity.
SE|240||ab|7|entity|C0243095|Finding|ftcn|||findings|||0|1000|1006|1014
SE|240||ab|7|entity|C1514721|Range|qnco|||range|||0|1000|1035|1040
SE|240||ab|7|entity|C1140999|Contraction|patf|||contraction|||0|1000|1056|1067
SE|240||ab|7|entity|C1549542|Perfuse|ftcn|||perfused|||0|840|1075|1083
SE|240||ab|7|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|840|1084|1087
SE|240||ab|7|entity|C0018787|Heart|bpoc|||heart|||0|840|1088|1093
SE|240||ab|7|entity|C0001128|Acids|chem|||acid|||0|840|1104|1108
SE|240||ab|7|entity|C1515926|Alteration|idcn|||alterations|||0|840|1114|1125
SE|240||ab|7|entity|C0205132|Linear|spco|||linear|||0|888|1132|1138
SE|240||ab|7|entity|C0031843|physiological aspects|phsf|||function|||0|888|1139|1147
SE|240||ab|7|entity|C0033727|Protons|elii|||hydrogen ion|||0|901|1151|1163
SE|240||ab|7|relation|0|0|C0018787|Heart|bpoc|bpoc|||heart|||0|840|1088|1093|MOD/HEAD|PART_OF||1084|1093|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|840|1084|1087
SE|240||ab|7|relation|4|1|C0018787|Heart|bpoc|bpoc|||heart|||0|840|1088|1093|PREP|LOCATION_OF||1068|1070|3|1|C1140999|Contraction|patf|patf|||contraction|||0|1000|1056|1067


SE|241||ti|1|text|16|112|Changes of EEG and pulmonary venous admixture during a protein load in patients with cirrhosis.
SE|241||ti|1|entity|C0013819|Electroencephalography|diap|||EEG|||0|1000|27|30
SE|241||ti|1|entity|C0034090|Pulmonary veins|bpoc|||pulmonary venous|||0|877|35|51
SE|241||ti|1|entity|C1510816|Admixture|qlco|||admixture|||0|877|52|61
SE|241||ti|1|entity|C0033684|Proteins|aapp,bacs|||protein|||0|888|71|78
SE|241||ti|1|entity|C1550025|Load|idcn|||load|||0|888|79|83
SE|241||ti|1|entity|C0030705|Patients|podg|||patients|||0|1000|87|95
SE|241||ti|1|entity|C0016059|Fibrosis|patf|||cirrhosis|||0|1000|101|110
SE|241||ti|1|relation|1|1|C0016059|Fibrosis|patf|patf|||cirrhosis|||0|1000|101|110|PREP|PROCESS_OF||96|100|5|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|87|95

SE|241||ab|1|text|118|268|21 patients with cirrhosis of the liver and 24 control patients were studied before and after a protein load (120 g protein per day during one week).
SE|241||ab|1|entity|C0030705|Patients|podg|||patients|||0|861|121|129
SE|241||ab|1|entity|C0016059|Fibrosis|patf|||cirrhosis|||0|1000|135|144
SE|241||ab|1|entity|C0023884|Liver|bpoc|||liver|||0|1000|152|157
SE|241||ab|1|entity|C0243148|control|ftcn|||control|||0|790|165|172
SE|241||ab|1|entity|C0030705|Patients|podg|||patients|||0|790|173|181
SE|241||ab|1|entity|C0033684|Proteins|aapp,bacs|||protein|||0|888|214|221
SE|241||ab|1|entity|C1550025|Load|idcn|||load|||0|888|222|226
SE|241||ab|1|entity|C0086376|GTP-Binding Proteins|aapp,enzy|||g protein|||0|901|232|241
SE|241||ab|1|entity|C0439228|day|tmco|||day|||0|1000|246|249
SE|241||ab|1|entity|C0205447|One|qnco|||one|||0|888|257|260
SE|241||ab|1|entity|C0439230|week|tmco|||week|||0|888|261|265
SE|241||ab|1|relation|6|1|C0023884|Liver|bpoc|bpoc|||liver|||0|1000|152|157|PREP|LOCATION_OF||145|147|2|1|C0016059|Fibrosis|patf|patf|||cirrhosis|||0|1000|135|144
SE|241||ab|1|relation|7|1|C0016059|Fibrosis|patf|patf|||cirrhosis|||0|1000|135|144|PREP|PROCESS_OF||130|134|1|1|C0030705|Patients|podg,humn|humn|||patients|||0|861|121|129

SE|241||ab|2|text|268|348|An EEG was recorded and a visual assessment of frequency pattern was performed.
SE|241||ab|2|entity|C0013819|Electroencephalography|diap|||EEG|||0|1000|271|274
SE|241||ab|2|entity|C0234621|Visual|ftcn|||visual|||0|888|294|300
SE|241||ab|2|entity|C0220825|Evaluation|ftcn|||assessment|||0|888|301|311
SE|241||ab|2|entity|C0439603|Frequencies (time pattern)|tmco|||frequency|||0|888|315|324
SE|241||ab|2|entity|C0449774|Patterns|spco|||pattern|||0|888|325|332

SE|241||ab|3|text|348|397|Venous admixture was estimated during hyperoxia.
SE|241||ab|3|entity|C0348013|Venous|spco|||Venous|||0|888|348|354
SE|241||ab|3|entity|C1510816|Admixture|qlco|||admixture|||0|888|355|364
SE|241||ab|3|entity|C0242706|Hyperoxia|sosy|||hyperoxia|||0|1000|386|395

SE|241||ab|4|text|397|571|According to the EEG frequency pattern the patient group with cirrhosis was subdivided into those with EEG slowing after the protein load (n = 7) and those without (n = 14).
SE|241||ab|4|entity|C0013819|Electroencephalography|diap|||EEG|||0|888|414|417
SE|241||ab|4|entity|C0439603|Frequencies (time pattern)|tmco|||frequency|||0|888|418|427
SE|241||ab|4|entity|C0030705|Patients|podg|||patient|||0|888|440|447
SE|241||ab|4|entity|C0441833|Groups|inpr|||group|||0|888|448|453
SE|241||ab|4|entity|C0016059|Fibrosis|patf|||cirrhosis|||0|1000|459|468
SE|241||ab|4|entity|C0013819|Electroencephalography|diap|||EEG|||0|773|500|503
SE|241||ab|4|entity|C0439834|Slow|qlco|||slowing|||0|773|504|511
SE|241||ab|4|entity|C0033684|Proteins|aapp,bacs|||protein|||0|888|522|529
SE|241||ab|4|entity|C1550025|Load|idcn|||load|||0|888|530|534

SE|241||ab|5|text|571|672|The following results were obtained: 1) Resting arterial blood gases did not change in either group.
SE|241||ab|5|entity|C0332282|Following|tmco|||following|||0|872|575|584
SE|241||ab|5|entity|C1274040|result|ftcn|||results|||0|872|585|592
SE|241||ab|5|entity|C0150411|Blood gases, arterial measurement|diap|||arterial blood gases|||0|1000|619|639
SE|241||ab|5|entity|C1518422|Not|ftcn|||not|||0|1000|644|647
SE|241||ab|5|entity|C0441833|Groups|inpr|||group|||0|861|665|670

SE|241||ab|6|text|672|811|2) There was a significant increase of the AaD02 (difference between alveolar p02 and peripheral arterial p02) in cirrhotics and controls.
SE|241||ab|6|entity|C0750502|Significant|idcn|||significant|||0|888|687|698
SE|241||ab|6|entity|C0442805|Increase|ftcn|||increase|||0|888|699|707
SE|241||ab|6|entity|C1547020|*Difference|qnco|||difference|||0|1000|722|732
SE|241||ab|6|entity|C1440080|Alveolar|bpoc|||alveolar|||0|888|741|749
SE|241||ab|6|entity|C1548699|P02|inpr|||p02|||0|888|750|753
SE|241||ab|6|entity|C0489868|PERIPHERAL ARTERIES|bpoc|||peripheral arterial|||0|877|758|777
SE|241||ab|6|entity|C1548699|P02|inpr|||p02|||0|877|778|781
SE|241||ab|6|entity|C0439686|Cirrhotic|qlco|||cirrhotics|||0|966|786|796
SE|241||ab|6|entity|C0243148|control|ftcn|||controls|||0|966|801|809

SE|241||ab|7|text|811|961|3) The increase in AaD02 was significantly larger in those cirrhotics showing EEG slowing compared to those without EEG - slowing or to the controls.
SE|241||ab|7|entity|C0442805|Increase|ftcn|||increase|||0|1000|818|826
SE|241||ab|7|entity|C0443228|Largest|qnco|||larger|||0|861|854|860
SE|241||ab|7|entity|C0439686|Cirrhotic|qlco|||cirrhotics|||0|966|870|880
SE|241||ab|7|entity|C0013819|Electroencephalography|diap|||EEG|||0|872|889|892
SE|241||ab|7|entity|C0439834|Slow|qlco|||slowing|||0|872|893|900
SE|241||ab|7|entity|C0013819|Electroencephalography|diap|||EEG|||0|773|927|930
SE|241||ab|7|entity|C0439834|Slow|qlco|||slowing|||0|773|933|940
SE|241||ab|7|entity|C0243148|control|ftcn|||controls|||0|966|951|959

SE|241||ab|8|text|961|1057|4) Fractional venous admisture increased significantly in those cirrhotics showing EEG slowing.
SE|241||ab|8|entity|C1264633|Fraction of|qnco|||Fractional|||0|587|964|974
SE|241||ab|8|entity|C0348013|Venous|spco|||venous|||0|587|975|981
SE|241||ab|8|entity|C0439686|Cirrhotic|qlco|||cirrhotics|||0|966|1025|1035
SE|241||ab|8|entity|C0013819|Electroencephalography|diap|||EEG|||0|872|1044|1047
SE|241||ab|8|entity|C0439834|Slow|qlco|||slowing|||0|872|1048|1055

SE|241||ab|9|text|1057|1155|There was no significant change in those patients who did not show EEG changes or in the controls.
SE|241||ab|9|entity|C0750502|Significant|idcn|||significant|||0|888|1070|1081
SE|241||ab|9|entity|C0030705|Patients|podg|||patients|||0|1000|1098|1106
SE|241||ab|9|entity|C1518422|Not|ftcn|||not|||0|1000|1115|1118
SE|241||ab|9|entity|C0013819|Electroencephalography|diap|||EEG|||0|872|1124|1127
SE|241||ab|9|entity|C0243148|control|ftcn|||controls|||0|966|1146|1154


[241]: *** ERROR *** ERROR *** ERROR ***
[242]: *** ERROR *** ERROR *** ERROR ***
[243]: *** ERROR *** ERROR *** ERROR ***
[244]: *** ERROR *** ERROR *** ERROR ***
[245]: *** ERROR *** ERROR *** ERROR ***
[246]: *** ERROR *** ERROR *** ERROR ***
[247]: *** ERROR *** ERROR *** ERROR ***
[248]: *** ERROR *** ERROR *** ERROR ***
SE|250||ti|1|text|16|93|An evaluation of factors affecting the in vitro bioassay for erythropoietin.
SE|250||ti|1|entity|C0220825|Evaluation|ftcn|||evaluation|||0|1000|19|29
SE|250||ti|1|entity|C1521761|Factor|ftcn|||factors|||0|966|33|40
SE|250||ti|1|entity|C1533691|in vitro|qlco|||in vitro|||0|901|55|63
SE|250||ti|1|entity|C0005507|Biological Assay|lbpr|||bioassay|||0|901|64|72
SE|250||ti|1|entity|C0014822|Erythropoietin|aapp,horm|||erythropoietin|||0|1000|77|91

SE|250||ab|1|text|99|239|Two main aspects of the in vitro mouse foetal liver cell assay for Erythroid Stimulating Factor (ESF) in human sera have been investigated.
SE|250||ab|1|entity|C0205448|Two|qnco|||Two|||0|840|99|102
SE|250||ab|1|entity|C0205225|Primary|qlco|||main|||0|840|103|107
SE|250||ab|1|entity|C1547011|Aspect|qnco|||aspects|||0|840|108|115
SE|250||ab|1|entity|C1533691|in vitro|qlco|||in vitro|||0|827|123|131
SE|250||ab|1|entity|C0025914|House mice|mamm|||mouse|||0|827|132|137
SE|250||ab|1|entity|C1517162|Fetal Liver|emst|||foetal liver|||0|827|138|150
SE|250||ab|1|entity|C0007634|Cells|cell|||cell|||0|827|151|155
SE|250||ab|1|entity|C1510438|Assay|lbpr|||assay|||0|827|156|161
SE|250||ab|1|entity|C1516960|Erythroid|qlco|||Erythroid|||0|802|166|175
SE|250||ab|1|entity|C1521761|Factor|ftcn|||Factor|||0|802|188|194
SE|250||ab|1|entity|C0020114|Human|humn|||human|||0|888|204|209
SE|250||ab|1|entity|C0229671|Serum|bdsu|||sera|||0|888|210|214
SE|250||ab|1|relation|0|0|C0229671|Serum|bdsu|bdsu|||sera|||0|888|210|214|MOD/HEAD|PART_OF||204|214|0|0|C0020114|Human|grup,humn|humn|||human|||0|888|204|209

SE|250||ab|2|text|239|466|The haem extraction process has been shown to give specific and quantitative recovery of 59Fe labelled haem from haemoglobin thus confirming that the material assayed in human sera is stimulating the synthesis of this protein.
SE|250||ab|2|entity|C0018966|Heme|bacs,orch|||haem|||0|851|243|247
SE|250||ab|2|entity|C0185115|Extraction|topp|||extraction|||0|851|248|258
SE|250||ab|2|entity|C1522240|Process|phpr|||process|||0|851|259|266
SE|250||ab|2|entity|C0392762|Quantitative|qnco|||quantitative|||0|888|303|315
SE|250||ab|2|entity|C0237820|Recovery|orgf|||recovery|||0|888|316|324
SE|250||ab|2|entity|C0018966|Heme|bacs,orch|||haem|||0|1000|342|346
SE|250||ab|2|entity|C0019046|Hemoglobin|aapp,bacs|||haemoglobin|||0|1000|352|363
SE|250||ab|2|entity|C0520510|Materials|sbst|||material|||0|1000|389|397
SE|250||ab|2|entity|C0020114|Human|humn|||human|||0|888|409|414
SE|250||ab|2|entity|C0229671|Serum|bdsu|||sera|||0|888|415|419
SE|250||ab|2|entity|C0869032|Synthesis|phpr|||synthesis|||0|1000|439|448
SE|250||ab|2|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|457|464
SE|250||ab|2|relation|0|0|C0229671|Serum|bdsu|bdsu|||sera|||0|888|415|419|MOD/HEAD|PART_OF||409|419|0|0|C0020114|Human|grup,humn|humn|||human|||0|888|409|414
SE|250||ab|2|relation|3|1|C0229671|Serum|bdsu|bdsu|||sera|||0|888|415|419|PREP|LOCATION_OF||406|408|7|2|C0019046|Hemoglobin|aapp,gngm,bacs|aapp|||haemoglobin|||0|1000|352|363
SE|250||ab|2|relation|8|4|C0018966|Heme|bacs,orch|bacs|||haem|||0|1000|342|346|VERB|STIMULATES||423|434|2|2|C0033684|Proteins|aapp,gngm,bacs|gngm|||protein|||0|1000|457|464

SE|250||ab|3|text|466|601|The extraction procedure can be simplified considerably by prior mixing of the reagents without significantly influencing the results.
SE|250||ab|3|entity|C0185115|Extraction|topp|||extraction|||0|888|470|480
SE|250||ab|3|entity|C0184661|Procedures|hlca|||procedure|||0|888|481|490
SE|250||ab|3|entity|C0332152|Status pre-|tmco|||prior|||0|872|525|530
SE|250||ab|3|entity|C0205430|Mixed|ftcn|||mixing|||0|872|531|537
SE|250||ab|3|entity|C0034760|Reagents|irda|||reagents|||0|1000|545|553
SE|250||ab|3|entity|C1274040|result|ftcn|||results|||0|966|592|599

SE|250||ab|4|text|601|770|Several serum constituents (citrate, testosterone, B12, folic acid and iron) have been investigated over a range of concentrations for possible effects on the cultures.
SE|250||ab|4|entity|C0443302|Several|qnco|||Several|||0|851|601|608
SE|250||ab|4|entity|C0229671|Serum|bdsu|||serum|||0|851|609|614
SE|250||ab|4|entity|C0729650|Constituents|sbst|||constituents|||0|851|615|627
SE|250||ab|4|entity|C0008857|Citrates|orch|||citrate|||0|1000|629|636
SE|250||ab|4|entity|C0039601|Testosterone|horm,phsu,strd|||testosterone|||0|1000|638|650
SE|250||ab|4|entity|||gngm|4709,7126|NDUFB3,TNFAIP1|B12|||0|1000|652|655
SE|250||ab|4|entity|C0016410|Folic Acid|orch,phsu,vita|||folic acid|||0|1000|657|667
SE|250||ab|4|entity|C0302583|Iron|bacs,elii,phsu|||iron|||0|1000|672|676
SE|250||ab|4|entity|C0205136|Over|spco|||over|||0|1000|701|705
SE|250||ab|4|entity|C1514721|Range|qnco|||range|||0|1000|708|713
SE|250||ab|4|entity|C0332149|Possible|qlco|||possible|||0|872|736|744
SE|250||ab|4|entity|C1280500|Effect|qlco|||effects|||0|872|745|752
SE|250||ab|4|entity|C0010453|Anthropological Culture|idcn|||cultures|||0|1000|760|768

SE|250||ab|5|text|770|832|Generally only small effects on haem synthesis were observed.
SE|250||ab|5|entity|C0700321|Small|qnco|||small|||0|733|785|790
SE|250||ab|5|entity|C1280500|Effect|qlco|||effects|||0|733|791|798
SE|250||ab|5|entity|C0018966|Heme|bacs,orch|||haem|||0|888|802|806
SE|250||ab|5|entity|C0869032|Synthesis|phpr|||synthesis|||0|888|807|816

SE|250||ab|6|text|832|1006|It is concluded that variations in the levels of these factors in sera from treated patients will not produce any significant alterations in the estimated ESF concentrations.
SE|250||ab|6|entity|C0205419|Variant|qlco|||variations|||0|966|853|863
SE|250||ab|6|entity|C0441889|Levels|inpr|||levels|||0|1000|871|877
SE|250||ab|6|entity|C1521761|Factor|ftcn|||factors|||0|966|887|894
SE|250||ab|6|entity|C0229671|Serum|bdsu|||sera|||0|1000|898|902
SE|250||ab|6|entity|C1292734|Treats|clas|||treated|||0|872|908|915
SE|250||ab|6|entity|C0030705|Patients|podg|||patients|||0|872|916|924
SE|250||ab|6|entity|C1518422|Not|ftcn|||not|||0|1000|930|933
SE|250||ab|6|entity|C0750502|Significant|idcn|||significant|||0|872|946|957
SE|250||ab|6|entity|C1515926|Alteration|idcn|||alterations|||0|872|958|969
SE|250||ab|6|entity|C0750572|Estimated|qnco|||estimated|||0|757|977|986
SE|250||ab|6|entity|C1516960|Erythroid|qlco|||ESF|||0|757|987|990
SE|250||ab|6|entity|C1521761|Factor|ftcn|||ESF|||0|757|987|990
SE|250||ab|6|relation|3|1|C0030705|Patients|podg,humn|humn|||patients|||0|872|916|924|PREP|LOCATION_OF||903|907|4|1|C0229671|Serum|bdsu|bdsu|||sera|||0|1000|898|902


SE|251||ti|1|text|16|59|[Synthesis of N-substituted isoindolines].
SE|251||ti|1|entity|C0869032|Synthesis|phpr|||Synthesis|||0|1000|17|26

SE|251||ab|1|text|65|159|Some derivatives of isoindoline were prepared in order to test their cardiovascular activity.
SE|251||ab|1|entity|C0243072|derivatives|chvs|||derivatives|||0|1000|70|81

SE|251||ab|2|text|159|323|Pharmacological tests showed that some of the compounds had moderate alpha-blocking and coronarodilatory activity whereas others had some local anesthetic activity.
SE|251||ab|2|entity|C0205464|pharmacological|ftcn|||Pharmacological|||0|888|159|174
SE|251||ab|2|entity|C0392366|Tests|inpr|||tests|||0|888|175|180
SE|251||ab|2|entity|C0205198|Compound|qlco|||compounds|||0|966|205|214
SE|251||ab|2|entity|C0439095|Alpha|inpr|||alpha|||0|790|228|233
SE|251||ab|2|entity|C0332206|Blocking|ftcn|||blocking|||0|790|234|242
SE|251||ab|2|entity|C0205394|Other|qlco|||others|||0|966|281|287
SE|251||ab|2|entity|C0002921|Local anesthesia|topp|||local anesthetic|||0|901|297|313


[251]: *** ERROR *** ERROR *** ERROR ***
[252]: *** ERROR *** ERROR *** ERROR ***
[253]: *** ERROR *** ERROR *** ERROR ***
[254]: *** ERROR *** ERROR *** ERROR ***
[255]: *** ERROR *** ERROR *** ERROR ***
SE|257||ti|1|text|16|99|[Mechanisms of the thermogenic action of noradrenaline during adaptation to cold].
SE|257||ti|1|entity|C0441712|Mechanisms|ftcn|||Mechanisms|||0|1000|17|27
SE|257||ti|1|entity|C0028351|Norepinephrine|nsba,orch,phsu|||noradrenaline|||0|1000|57|70
SE|257||ti|1|entity|C0000934|Acclimatization|orgf|||adaptation|||0|1000|78|88

SE|257||ab|1|text|105|265|In white rats both adapted and unadapted to cold, the RQ dynamics during cold exposure, noradrenaline and ganglion blocking agent administration, were studied.
SE|257||ab|1|entity|C0684072|albino rat|mamm|||white rats|||0|1000|108|118
SE|257||ab|1|entity|C0231275|Cold exposure|inpo|||cold exposure|||0|1000|178|191
SE|257||ab|1|entity|C0028351|Norepinephrine|nsba,orch,phsu|||noradrenaline|||0|1000|193|206
SE|257||ab|1|entity|C0017076|Ganglionic Blockers|phsu|||ganglion blocking agent|||0|916|211|234

SE|257||ab|2|text|265|491|The adapted animals' RQ in thermoneutral conditions was shown to be a little higher than in the control rats; 0.5 mg/kg noradrenaline injections induced a clear RQ decrease in the former and did not influence the latters' RQ.
SE|257||ab|2|entity|C0003062|Animals|anim|||animals|||0|660|277|284
SE|257||ab|2|entity|C0348080|Condition|qlco|||conditions|||0|827|306|316
SE|257||ab|2|entity|C0023882|Little's Disease|dsyn|||little|||0|872|335|341
SE|257||ab|2|entity|C0205250|High|qlco|||higher|||0|872|342|348
SE|257||ab|2|entity|C0243148|control|ftcn|||control|||0|888|361|368
SE|257||ab|2|entity|C0034693|Rattus norvegicus|mamm|||rats|||0|888|369|373
SE|257||ab|2|entity|C0444499|0/5|qnco|||0.5|||0|827|375|378
SE|257||ab|2|entity|C0028351|Norepinephrine|nsba,orch,phsu|||noradrenaline|||0|827|385|398
SE|257||ab|2|entity|C1533685|Injection procedure|topp|||injections|||0|827|399|409
SE|257||ab|2|entity|C0522503|Translucent|qlco|||clear|||0|802|420|425
SE|257||ab|2|entity|C0547047|Decrease|qnco|||decrease|||0|802|429|437
SE|257||ab|2|entity|C0750523|FORMER|idcn|||former|||0|1000|445|451
SE|257||ab|2|entity|C1518422|Not|ftcn|||not|||0|1000|460|463
SE|257||ab|2|relation|0|0|C0028351|Norepinephrine|nsba,orch,phsu|nsba|||noradrenaline|||0|827|385|398|MOD/HEAD|ISA||385|409|0|0|C1533685|Injection procedure|topp|topp|||injections|||0|827|399|409
SE|257||ab|2|relation|0|0|C1533685|Injection procedure|topp|topp|||injections|||0|827|399|409|MOD/HEAD|USES||385|409|0|0|C0028351|Norepinephrine|nsba,orch,phsu|phsu|||noradrenaline|||0|827|385|398

SE|257||ab|3|text|491|544|Cold exposure was followed by a RQ decrease in both.
SE|257||ab|3|entity|C0231275|Cold exposure|inpo|||Cold exposure|||0|1000|491|504
SE|257||ab|3|entity|C0547047|Decrease|qnco|||decrease|||0|861|526|534

SE|257||ab|4|text|544|675|Ganglion blocking agent administration decreased the RQ in the adapted animals and prevented it from falling in the control those.
SE|257||ab|4|entity|C0017076|Ganglionic Blockers|phsu|||Ganglion blocking agent|||0|916|544|567
SE|257||ab|4|entity|C0003062|Animals|anim|||animals|||0|861|615|622
SE|257||ab|4|entity|C0085639|Falls|fndg|||falling|||0|1000|645|652

SE|257||ab|5|text|675|789|Noradrenaline is supposed to be the main but not the only factor activating lipolysis in the cold adapted animals.
SE|257||ab|5|entity|C0028351|Norepinephrine|nsba,orch,phsu|||Noradrenaline|||0|1000|675|688
SE|257||ab|5|entity|C0205225|Primary|qlco|||main|||0|1000|711|715
SE|257||ab|5|entity|C1518422|Not|ftcn|||not|||0|1000|720|723
SE|257||ab|5|entity|C1521761|Factor|ftcn|||factor|||0|764|733|739
SE|257||ab|5|entity|C1515877|Activate|ftcn|||activating|||0|764|740|750
SE|257||ab|5|entity|C0023796|Lipolysis|orgf|||lipolysis|||0|764|751|760
SE|257||ab|5|entity|C0003062|Animals|anim|||animals|||0|827|781|788
SE|257||ab|5|relation|1|1|C0003062|Animals|anim|anim|||animals|||0|827|781|788|PREP|LOCATION_OF|negation|761|763|3|3|C0028351|Norepinephrine|nsba,orch,phsu|orch|||Noradrenaline|||0|1000|675|688


[257]: *** ERROR *** ERROR *** ERROR ***
[258]: *** ERROR *** ERROR *** ERROR ***
[259]: *** ERROR *** ERROR *** ERROR ***
[260]: *** ERROR *** ERROR *** ERROR ***
[261]: *** ERROR *** ERROR *** ERROR ***
[262]: *** ERROR *** ERROR *** ERROR ***
[263]: *** ERROR *** ERROR *** ERROR ***
[264]: *** ERROR *** ERROR *** ERROR ***
[265]: *** ERROR *** ERROR *** ERROR ***
[266]: *** ERROR *** ERROR *** ERROR ***
[267]: *** ERROR *** ERROR *** ERROR ***
[268]: *** ERROR *** ERROR *** ERROR ***
SE|270||ti|1|text|16|101|Chromosomal basis of the merozygosity in a partially deploid mutant of Pneumococcus.
SE|270||ti|1|entity|C0008633|Chromosomes|celc|||Chromosomal|||0|853|16|27
SE|270||ti|1|entity|C1527178|Basis|ftcn|||basis|||0|853|28|33
SE|270||ti|1|entity|C0596988|Mutant|comd|||mutant|||0|827|77|83
SE|270||ti|1|entity|C0038410|Streptococcus pneumoniae|bact|||Pneumococcus|||0|1000|87|99

SE|270||ab|1|text|107|231|A sulfonamide-resistant mutant of pneumococcus, sulr-c, displays a genetic instability, regularly segregating to wild type.
SE|270||ab|1|entity|C0038760|Sulfonamides|orch,phsu|||sulfonamide|||0|851|109|120
SE|270||ab|1|entity|C0332325|Resistant|ftcn|||resistant|||0|851|121|130
SE|270||ab|1|entity|C0596988|Mutant|comd|||mutant|||0|851|131|137
SE|270||ab|1|entity|C0038410|Streptococcus pneumoniae|bact|||pneumococcus|||0|1000|141|153
SE|270||ab|1|entity|C0314603|Genetic|ftcn|||genetic|||0|888|174|181
SE|270||ab|1|entity|C1444783|Instability|fndg|||instability|||0|888|182|193
SE|270||ab|1|entity|C0445392|Wild|inpr|||wild|||0|888|220|224
SE|270||ab|1|entity|C1547052|*Type|qnco|||type|||0|888|225|229

SE|270||ab|2|text|231|399|DNA extracts of derivatives of the strain possess transforming activities for both the mutant and wild-type alleles, establishing that the strain is a partial diploid.
SE|270||ab|2|entity|C0012854|DNA|bacs,nnon|||DNA|||0|1000|231|234
SE|270||ab|2|entity|C0243072|derivatives|chvs|||derivatives|||0|1000|247|258
SE|270||ab|2|entity|C0456178|Microbiology subtype strains|inpr|||strain|||0|1000|266|272
SE|270||ab|2|entity|C0441655|Activities|acty|||activities|||0|861|294|304
SE|270||ab|2|entity|C0596988|Mutant|comd|||mutant|||0|1000|318|324
SE|270||ab|2|entity|C0445392|Wild|inpr|||wild|||0|851|329|333
SE|270||ab|2|entity|C1547052|*Type|qnco|||type|||0|851|334|338
SE|270||ab|2|entity|C0002085|Alleles|gngm|||alleles|||0|851|339|346
SE|270||ab|2|entity|C0456178|Microbiology subtype strains|inpr|||strain|||0|1000|370|376
SE|270||ab|2|entity|C0728938|Partial|qnco|||partial|||0|888|382|389
SE|270||ab|2|entity|C0012568|Diploidy|orga|||diploid|||0|888|390|397

SE|270||ab|3|text|399|525|The linkage of sulr-c to strr-61, a stable chromosomal marker, was established, thus defining a chromosomal locus for sulr-c.
SE|270||ab|3|entity|C0008631|Chromosome Markers|lbtr,sosy|||chromosomal marker|||0|865|442|460
SE|270||ab|3|entity|C0008633|Chromosomes|celc|||chromosomal|||0|623|495|506

SE|270||ab|4|text|525|831|DNA isolated from sulr-c cells transforms two mutant recipient strains at the same low efficiency as it does a wild-type recipient, although the mutant property of these strains makes them capable of integrating classical "low-efficiency" donor markers equally as efficiently as "high efficiency" markers.
SE|270||ab|4|entity|C0012854|DNA|bacs,nnon|||DNA|||0|1000|525|528
SE|270||ab|4|entity|C0007634|Cells|cell|||cells|||0|773|550|555
SE|270||ab|4|entity|C0205448|Two|qnco|||two|||0|623|567|570
SE|270||ab|4|entity|C0596988|Mutant|comd|||mutant|||0|623|571|577
SE|270||ab|4|entity|C0445247|Same|qlco|||same|||0|851|603|607
SE|270||ab|4|entity|C0205251|low|qlco|||low|||0|851|608|611
SE|270||ab|4|entity|C0013682|Efficiency|qnco|||efficiency|||0|851|612|622
SE|270||ab|4|entity|C0445392|Wild|inpr|||wild|||0|623|636|640
SE|270||ab|4|entity|C1547052|*Type|qnco|||type|||0|623|641|645
SE|270||ab|4|entity|C0596988|Mutant|comd|||mutant|||0|888|670|676
SE|270||ab|4|entity|C0871161|Property|qlco|||property|||0|888|677|685
SE|270||ab|4|entity|C0443177|Classical|ftcn|||classical|||0|530|737|746
SE|270||ab|4|entity|C0205251|low|qlco|||low|||0|530|748|751
SE|270||ab|4|entity|C0013682|Efficiency|qnco|||efficiency|||0|530|752|762
SE|270||ab|4|entity|C0205250|High|qlco|||high|||0|623|805|809
SE|270||ab|4|entity|C0013682|Efficiency|qnco|||efficiency|||0|623|810|820

SE|270||ab|5|text|831|945|Hence sulr-c must have a different basis for its low efficiency than do classical low efficiency point mutations.
SE|270||ab|5|entity|C1547020|*Difference|qnco|||different|||0|853|856|865
SE|270||ab|5|entity|C1527178|Basis|ftcn|||basis|||0|853|866|871
SE|270||ab|5|entity|C0205251|low|qlco|||low|||0|888|880|883
SE|270||ab|5|entity|C0013682|Efficiency|qnco|||efficiency|||0|888|884|894
SE|270||ab|5|entity|C0443177|Classical|ftcn|||classical|||0|840|903|912
SE|270||ab|5|entity|C0205251|low|qlco|||low|||0|840|913|916
SE|270||ab|5|entity|C0013682|Efficiency|qnco|||efficiency|||0|840|917|927
SE|270||ab|5|entity|C0162735|Point Mutation|genf|||point mutations|||0|840|928|943

SE|270||ab|6|text|945|1161|We suggest that the DNA in the region of the sulr-c mutation has a structural abnormality which leads both to its frequent segregation during growth and its difficulty in efficiently mediating genetic transformation.
SE|270||ab|6|entity|C0012854|DNA|bacs,nnon|||DNA|||0|1000|965|968
SE|270||ab|6|entity|C0205147|Region|spco|||region|||0|1000|976|982
SE|270||ab|6|entity|C0026882|Mutation|genf|||mutation|||0|827|997|1005
SE|270||ab|6|entity|C0332183|Frequent|tmco|||frequent|||0|888|1059|1067
SE|270||ab|6|entity|C0080141|Segregation|inbe,socb|||segregation|||0|888|1068|1079
SE|270||ab|6|entity|C0018270|Growth|orgf|||growth|||0|1000|1087|1093
SE|270||ab|6|entity|C0040684|Transformation, Genetic|genf|||genetic transformation|||0|1000|1138|1160
SE|270||ab|6|relation|7|2|C0018270|Growth|orgf|orgf|||growth|||0|1000|1087|1093|VERB|AFFECTS||1128|1137|1|1|C0040684|Transformation, Genetic|genf|genf|||genetic transformation|||0|1000|1138|1160


SE|271||ti|1|text|16|110|Recombination as a requirement for segregation of a partially diploid mutant of Pneumococcus.
SE|271||ti|1|entity|C0034865|Recombination, Genetic|genf|||Recombination|||0|1000|16|29
SE|271||ti|1|entity|C1514873|Requirement|idcn|||requirement|||0|1000|35|46
SE|271||ti|1|entity|C0080141|Segregation|inbe,socb|||segregation|||0|1000|51|62
SE|271||ti|1|entity|C0012568|Diploidy|orga|||diploid|||0|790|78|85
SE|271||ti|1|entity|C0596988|Mutant|comd|||mutant|||0|790|86|92
SE|271||ti|1|entity|C0038410|Streptococcus pneumoniae|bact|||Pneumococcus|||0|1000|96|108

SE|271||ab|1|text|116|327|Conditions are described in which the pneumococcal mutant strain sulr-c, resistant to the drug sulfanilamide, gives rise to sensitive segregants resistant to nitrobenzoic acid at a frequency constant with time.
SE|271||ab|1|entity|C0348080|Condition|qlco|||Conditions|||0|966|116|126
SE|271||ab|1|entity|C0038410|Streptococcus pneumoniae|bact|||pneumococcal|||0|758|154|166
SE|271||ab|1|entity|C0596988|Mutant|comd|||mutant|||0|758|167|173
SE|271||ab|1|entity|C0456178|Microbiology subtype strains|inpr|||strain|||0|758|174|180
SE|271||ab|1|entity|C0332325|Resistant|ftcn|||resistant|||0|1000|189|198
SE|271||ab|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug|||0|888|206|210
SE|271||ab|1|entity|C0038702|Sulfanilamide|antb,orch|||sulfanilamide|||0|888|211|224
SE|271||ab|1|entity|C0332324|Sensitive|ftcn|||sensitive|||0|694|240|249
SE|271||ab|1|entity|C0332325|Resistant|ftcn|||resistant|||0|1000|261|270
SE|271||ab|1|entity|C0260053|Nitrobenzoic acid|orch|||nitrobenzoic acid|||0|1000|274|291
SE|271||ab|1|entity|C0439603|Frequencies (time pattern)|tmco|||frequency|||0|888|297|306
SE|271||ab|1|entity|C1547014|*Constant|qnco|||constant|||0|888|307|315
SE|271||ab|1|entity|C0040223|Time|tmco|||time|||0|1000|321|325
SE|271||ab|1|relation|0|0|C0038702|Sulfanilamide|antb,orch|antb|||sulfanilamide|||0|888|211|224|MOD/HEAD|ISA||206|224|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug|||0|888|206|210
SE|271||ab|1|relation|7|1|C0038702|Sulfanilamide|antb,orch|orch|||sulfanilamide|||0|888|211|224|ADJ|TREATS|negation|189|198|2|1|C0038410|Streptococcus pneumoniae|bact|bact|||pneumococcal|||0|758|154|166

SE|271||ab|2|text|327|494|This segregant frequency is markedly enhanced upon exposure of the cells to doses of ultraviolet light or mitomycin C that permit survival of 50% to 90% of the cells.
SE|271||ab|2|entity|C0439603|Frequencies (time pattern)|tmco|||frequency|||0|861|342|351
SE|271||ab|2|entity|C0522501|Massive|qlco|||markedly|||0|1000|355|363
SE|271||ab|2|entity|C0007634|Cells|cell|||cells|||0|1000|394|399
SE|271||ab|2|entity|C1446466|Dose|qnco|||doses|||0|1000|403|408
SE|271||ab|2|entity|C0041625|Ultraviolet Rays|npop|||ultraviolet light|||0|1000|412|429
SE|271||ab|2|entity|C0002475|Mitomycin|antb,orch|||mitomycin C|||0|1000|433|444
SE|271||ab|2|entity|C0038952|Continuance of life|acty|||survival|||0|1000|457|465
SE|271||ab|2|entity|C0439083|>90|qnco|||90|||0|1000|476|478
SE|271||ab|2|entity|C0007634|Cells|cell|||cells|||0|1000|487|492

SE|271||ab|3|text|494|561|Treatment with acridine orange diminishes the segregant frequency.
SE|271||ab|3|entity|C0001185|Acridine Orange|irda,orch|||acridine orange|||0|1000|509|524
SE|271||ab|3|entity|C0439603|Frequencies (time pattern)|tmco|||frequency|||0|861|550|559

SE|271||ab|4|text|561|881|From the known influences of these three agents on genetic recombination, we propose that a recombination event is necessary in the generation of segregants.--During a period of incubation following treatment with ultraviolet light or mitomycin C, cell division resumes and the original segregant frequency is restored.
SE|271||ab|4|entity|C0205309|Known|qlco|||known|||0|694|570|575
SE|271||ab|4|entity|C0205449|Three|qnco|||three|||0|872|596|601
SE|271||ab|4|entity|C0450442|Agent|chvf|||agents|||0|872|602|608
SE|271||ab|4|entity|C0034865|Recombination, Genetic|genf|||genetic recombination|||0|1000|612|633
SE|271||ab|4|entity|C0034865|Recombination, Genetic|genf|||recombination|||0|888|653|666
SE|271||ab|4|entity|C0441471|Events|evnt|||event|||0|888|667|672
SE|271||ab|4|entity|C0079411|Generations|tmco|||generation|||0|966|693|703
SE|271||ab|4|entity|C0439531|/period|tmco|||period|||0|1000|729|735
SE|271||ab|4|entity|C0041625|Ultraviolet Rays|npop|||ultraviolet light|||0|1000|775|792
SE|271||ab|4|entity|C0002475|Mitomycin|antb,orch|||mitomycin C|||0|1000|796|807
SE|271||ab|4|entity|C0007590|Cell division|celf|||cell division|||0|884|809|822
SE|271||ab|4|entity|C1550028|Resume|idcn|||resumes|||0|884|823|830
SE|271||ab|4|entity|C0205313|Original|idcn|||original|||0|802|839|847
SE|271||ab|4|entity|C0439603|Frequencies (time pattern)|tmco|||frequency|||0|802|858|867
SE|271||ab|4|relation|13|11|C0002475|Mitomycin|antb,orch|antb|||mitomycin C|||0|1000|796|807|NOM|AFFECTS||576|586|13|2|C0034865|Recombination, Genetic|genf|genf|||genetic recombination|||0|1000|612|633

SE|271||ab|5|text|881|1254|Thus potential segregants are either unable to replicate in the absence of selection, or they are under-represented among the cells dividing soon after treatment.--If the sulr-c mutation is introduced into a mutant pneumococcal strain lacking an ATP-dependent exonuclease activity and deficient in recombination with transforming DNA, segregant frequencies are unaffected.
SE|271||ab|5|entity|C0237399|Potential|qlco|||potential|||0|660|886|895
SE|271||ab|5|entity|C0007634|Cells|cell|||cells|||0|1000|1007|1012
SE|271||ab|5|entity|C0026882|Mutation|genf|||mutation|||0|827|1059|1067
SE|271||ab|5|entity|C0596988|Mutant|comd|||mutant|||0|851|1089|1095
SE|271||ab|5|entity|C0038410|Streptococcus pneumoniae|bact|||pneumococcal|||0|851|1096|1108
SE|271||ab|5|entity|C0456178|Microbiology subtype strains|inpr|||strain|||0|851|1109|1115
SE|271||ab|5|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|ATP|||0|861|1127|1130
SE|271||ab|5|entity|C1148824|exonuclease activity|genf|||exonuclease activity|||0|861|1141|1161
SE|271||ab|5|entity|C0011155|Deficiency|ftcn|||deficient|||0|1000|1166|1175
SE|271||ab|5|entity|C0034865|Recombination, Genetic|genf|||recombination|||0|1000|1179|1192
SE|271||ab|5|entity|C0012854|DNA|bacs,nnon|||DNA|||0|861|1211|1214
SE|271||ab|5|relation|8|0|C1366628|ATP8A2 gene|gngm,aapp|gngm|51761|ATP8A2|ATP|||0|861|1127|1130|ADJ|AUGMENTS||1131|1140|8|0|C1148824|exonuclease activity|genf|genf|||exonuclease activity|||0|861|1141|1161
SE|271||ab|5|relation|8|4|C0007634|Cells|cell|cell|||cells|||0|1000|1007|1012|VERB|LOCATION_OF|negation|1116|1123|6|1|C1148824|exonuclease activity|genf|genf|||exonuclease activity|||0|861|1141|1161

SE|271||ab|6|text|1254|1349|This fact may indicate limits upon the type of recombination event responsible for segregation.
SE|271||ab|6|entity|C1549649|Limit|idcn|||limits|||0|966|1277|1283
SE|271||ab|6|entity|C1547052|*Type|qnco|||type|||0|1000|1293|1297
SE|271||ab|6|entity|C0034865|Recombination, Genetic|genf|||recombination|||0|888|1301|1314
SE|271||ab|6|entity|C0441471|Events|evnt|||event|||0|888|1315|1320
SE|271||ab|6|entity|C0080141|Segregation|inbe,socb|||segregation|||0|1000|1337|1348


[271]: *** ERROR *** ERROR *** ERROR ***
SE|273||ti|1|text|16|82|Involvement of the small intestine in systemic mast cell disease.
SE|273||ti|1|entity|C0021852|Intestines, Small|bpoc|||small intestine|||0|1000|35|50
SE|273||ti|1|entity|C0221013|Mastocytosis, Systemic|dsyn|||systemic mast cell disease|||0|1000|54|80

SE|273||ab|1|text|88|237|A patient is reported with mast cell infiltration of the small intestine in the absence of the skin involvement characteristic of mast cell disease.
SE|273||ab|1|entity|C0030705|Patients|podg|||patient|||0|1000|90|97
SE|273||ab|1|entity|C0024880|mast cell|cell|||mast cell|||0|901|115|124
SE|273||ab|1|entity|C0332448|Infiltration|patf|||infiltration|||0|901|125|137
SE|273||ab|1|entity|C0021852|Intestines, Small|bpoc|||small intestine|||0|1000|145|160
SE|273||ab|1|entity|C1511567|Cutaneous Involvement|fndg|||skin involvement|||0|972|183|199
SE|273||ab|1|entity|C1521970|Characteristics|grpa|||characteristic|||0|966|200|214
SE|273||ab|1|entity|C0024899|mastocytosis|dsyn|||mast cell disease|||0|1000|218|235
SE|273||ab|1|relation|5|1|C0021852|Intestines, Small|bpoc|bpoc|||small intestine|||0|1000|145|160|PREP|LOCATION_OF||138|140|2|1|C0332448|Infiltration|patf|patf|||infiltration|||0|901|125|137

SE|273||ab|2|text|237|309|She also had subtotal villous atrophy responsive to a gluten-free diet.
SE|273||ab|2|entity|C1519984|Villous|qlco|||villous|||0|901|259|266
SE|273||ab|2|entity|C1265893|Subtotal atrophy|patf|||subtotal villous atrophy|||0|901|250|274
SE|273||ab|2|entity|C0205342|Responsive|ftcn|||responsive|||0|1000|275|285
SE|273||ab|2|entity|C0344351|Gluten free diet|fndg|||gluten-free diet|||0|1000|291|307

SE|273||ab|3|text|309|388|Criteria for diagnosing mast cell disease of the small intestine are proposed.
SE|273||ab|3|entity|C0243161|criteria|inpr|||Criteria|||0|1000|309|317
SE|273||ab|3|entity|C0011900|Diagnosis|hlca|||diagnosing|||0|900|322|332
SE|273||ab|3|entity|C0024899|mastocytosis|dsyn|||mast cell disease|||0|900|333|350
SE|273||ab|3|entity|C0021852|Intestines, Small|bpoc|||small intestine|||0|1000|358|373
SE|273||ab|3|relation|1|1|C0021852|Intestines, Small|bpoc|bpoc|||small intestine|||0|1000|358|373|PREP|LOCATION_OF||351|353|2|1|C0024899|mastocytosis|dsyn|dsyn|||mast cell disease|||0|900|333|350

SE|273||ab|4|text|388|506|The literature of small intestinal mast cell disease is reviewed and the relationship to coeliac disease is discussed.
SE|273||ab|4|entity|C0023866|Literature|inpr|||literature|||0|1000|392|402
SE|273||ab|4|entity|C0021852|Intestines, Small|bpoc|||small intestinal|||0|893|406|422
SE|273||ab|4|entity|C0024899|mastocytosis|dsyn|||mast cell disease|||0|893|423|440
SE|273||ab|4|entity|C0439849|Relationships|qlco|||relationship|||0|1000|461|473
SE|273||ab|4|entity|C0007570|Celiac Disease|dsyn|||coeliac disease|||0|1000|477|492
SE|273||ab|4|relation|0|0|C0021852|Intestines, Small|bpoc|bpoc|||small intestinal|||0|893|406|422|MOD/HEAD|LOCATION_OF||406|440|0|0|C0024899|mastocytosis|dsyn|dsyn|||mast cell disease|||0|893|423|440


[273]: *** ERROR *** ERROR *** ERROR ***
